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Abstract 
Globally cancer remains one of the leading causes of mortality.  Overall, it has been esti-
mated that one in three people will develop cancer in their lifetime, and one in four will die 
from it. While a curative intent will always be the aim of any surgical or oncological 
treatment a significant proportion of patients will go on to develop locally advanced or 
metastatic disease.  Patient outcomes are not solely determined by host or tumour factors but 
rather by a complex interaction of both.  Indeed, the systemic changes associated with cancer 
including reduced appetite, weight loss and poorer performance can significantly impact on 
both the quality and quantity of life in patients with cancer. As a result, accurate and realistic 
prognostication is vitally important and can guide clinical decision making. 
In its simplest form the systemic inflammatory response is a reaction to tissue injury brought 
on by ischaemia, necrosis, trauma, hypoxia or cancer. It is increasingly clear that cancer 
progression and outcomes are dependent on a complex interaction between both tumour and 
host characteristics including the systemic inflammatory response. Clinically, the 
commonest means of measuring the systemic inflammatory response in patients with cancer 
is with the use of biochemical or haematological markers. In practice this means an elevated 
C-reactive protein (CRP), hypoalbuminaemia or increased white cells (WCC), neutrophil 
and platelet counts.  
The work presented in this thesis further examines the relationship between the systemic 
inflammatory response, body composition, tumour metabolic activity and outcomes in 
patients with cancer. The effect of the systemic inflammatory response on outcomes in 
patients with cancer was examined directly. The relationship between the systemic 
inflammatory response and changes in body composition and their relationship to outcomes 
was then examined with cross-sectional and longitudinal studies. Finally, the question of the 
driving force behind the relationship between the systemic inflammatory response and 
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changes in body composition was examined by looking at tumour metabolic activity in 
patients with cancer.  
The results of the two large meta-analyses in both operable and advanced cancers can be 
seen in Chapter 3 and 4.  In operable cancer the systemic inflammatory response had 
independent prognostic value, across tumour types and geographical locations. On meta-
analysis there was a significant relationship between an elevated Neutrophil Lymphocyte 
Ratio (NLR) and both overall (p<0.00001) and cancer specific survival (p<0.00001), 
between an elevated Lymphocyte Monocyte Ratio (LMR) and both overall (p<0.00001) and 
cancer specific survival (p<0.00001), between an elevated Platelet Lymphocyte Ratio (PLR) 
and both overall (p<0.00001) and cancer specific survival (p=0.005) and between an 
elevated Glasgow Prognostic Score (GPS)/modified Glasgow Prognostic Score (mGPS) and 
both overall (p<0.00001) and cancer specific survival (p<0.00001).  In advanced cancer the 
systemic inflammatory response also had prognostic value, across tumour types and 
geographical locations. On meta-analysis there was a significant relationship between an 
elevated NLR and both overall survival (p<0.00001) and cancer specific survival (CSS) 
(p<0.00001), between an elevated PLR and overall survival (p=0.0003) and between an 
elevated GPS/mGPS and both overall (p<0.00001) and cancer specific survival (p=0.0001).  
The majority of studies in these two meta-analyses were retrospective in nature, however the 
results of a further large systematic review focusing solely on randomised control trials can 
be seen in Chapter 5. In this review the GPS/mGPS was shown to have prognostic value in 
Non-Small Cell Lung Cancer (NSCLC), oesophageal cancer, pancreatic cancer, prostate 
cancer and breast cancer. While the NLR was shown to have prognostic value in 
nasopharyngeal cancer, oesophageal cancer, pancreatic cancer, biliary cancer, prostate 
cancer and multiple cancer types. Therefore, the prognostic strength of the systemic 
inflammatory response has been confirmed across over 400 papers including 36 prospective 
randomised control trials.  
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However, the question still remained about the level of systemic inflammation in cancer 
patients as a whole. In order to answer this a further systematic review was undertaken in 
Chapter 6. This examined the prevalence of cancer associated systemic inflammation as 
measured by the GPS/mGPS and its implications for the ongoing care of patients with 
cancer. In this review which contained 140 studies including 40,893 patients the percentage 
of patients who were systemically inflamed varied from 28% to 63% according to tumour 
type. The most commonly studied cancer overall was colorectal cancer in which 40% of 
patients were systemically inflamed. In operable disease the percentage of patients who were 
systemically inflamed varied from 21% to 38% in gastroesophageal and colorectal cancer 
respectively. Again, the most commonly studied cancer was colorectal cancer and 38% were 
systemically inflamed. In inoperable disease the percentage of patients who were 
systemically inflamed varied from 29% to 79% in prostate and haematological cancers 
respectively.  This confirmed that the systemic inflammatory response was common in both 
operable and inoperable cancers and could prove to be a fruitful target for therapeutic 
interventions in the future. 
The results of Chapter 3-5 show that the two most widely validated methods of monitoring 
the systemic inflammatory response are the GPS/mGPS and NLR. These are considered to 
be cumulative scores and composite ratios respectively.  The results of Chapter 7 focuses on 
comparing the prognostic value of both cumulative scores and composite ratios in patients 
undergoing surgery for colon cancer (n=801). When adjusted for Tumour Node Metastasis 
(TNM) stage, NLR>5 (p<0.001), Neutrophil Lymphocyte Score (NLS, p<0.01), Platelet 
Lymphocyte Score (PLS, p<0.001), LMR<2.4 (p<0.001), Lymphocyte Monocyte Score 
(LMS, p<0.001), Neutrophil Platelet Score (NPS, p<0.001), CRP Albumin Ratio (CAR, 
p<0.001) and mGPS (p<0.001) were significantly associated with cancer specific survival.  
In patients undergoing elective surgery (n=689) the majority of the composite ratios/scores 
correlated with age (p<0.01), BMI (p<0.01), T-stage (p<0.01), venous invasion (p<0.01) and 
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peritoneal involvement (p<0.01). When NPS (myeloid) and mGPS (liver) were directly 
compared their relationship with both overall and cancer specific survival was similar. These 
results suggest that both composite ratios and cumulative scores had prognostic value, 
independent of TNM stage, in patients with colon cancer. However, cumulative scores, 
based on normal reference ranges, were simpler and more consistent for clinical use. 
The importance of the relationship between the systemic inflammatory response and changes 
in physical function have long been reported particularly in the setting of patients with 
advanced cancer. This relationship was examined further in Chapter 8 which was a post hoc 
analysis of a previously completed randomised control trial assessing the effect of 
corticosteroid use on analgesic requirements in patients with advanced disease (n=40). It 
showed that patients with an Eastern Cooperative Oncology Group Performance Status 
(ECOG-PS) of 2 and an mGPS of 2 had a higher Interleukin-6 (IL-6, p=0.017) level and 
poorer overall survival (p<0.001) when compared to patients with an ECOG-PS of 0/1 and 
an mGPS of 0.  This work provides supporting evidence for the potential therapeutic 
targeting of IL-6 in patients with advanced cancer which is currently being explored with 
the use of immunomodulatory agents such as tocilizumab.    
These results suggest that there is considerable merit in combining monitoring of the 
systemic inflammatory response using acute phase proteins and other factors such as 
performance status in patients with cancer. Indeed this method of prognostication is given 
greater weight by the results of Chapter 10 which show in 730 patients with advanced cancer 
that on multivariate cox regression analysis ECOG-PS (HR 1.61 95%CI 1.42-1.83, 
p<0.001), mGPS (HR 1.53, 95%CI 1.39-1.69, p<0.001) and Body mass index/Weight Loss 
(BMI/WL) grade (HR 1.41, 95%CI 1.25-1.60, p<0.001) remained independently associated 
with overall survival. In patients with a BMI/WL grade 0/1 both ECOG and mGPS remained 
independently associated with overall survival. This further suggests that the ECOG/mGPS 
 6 
framework may form the basis of risk stratification of survival in patients with advanced 
cancer.  
The use of CT scanning to determine the quantity and quality of skeletal muscle in patients 
with cancer is an increasing area of research and clinical interest.  The two most commonly 
used software packages for image analysis are ImageJ and Slice-O-Matic. In Chapter 2 the 
differential impact of the use of these software packages is examined in patients undergoing 
surgery for colorectal cancer (n=341). In this study, Bland-Altman analysis showed that 
ImageJ gave consistently higher values for all body composition parameters (p<0.001), 
resulting in more patients classified as having a high subcutaneous fat index (SFI, p<0.001) 
and visceral fat index (VFI, p<0.001) and fewer patients being classified as having a low 
skeletal muscle index (SMI, p<.0001) and skeletal muscle density (SMD, p<0.001). In 
addition, SFI, VFI, SMI and SMD were significantly associated with shorter overall survival 
when calculated with ImageJ (all p<0.05). These results suggest that with the drive towards 
the incorporation of CT derived body composition analysis to standard clinical practice there 
must be a concurrent drive towards standardisation irrespective of the software package 
used.   
Skeletal muscle is a very physiologically active tissue and the quantity and quality of skeletal 
muscle can have a direct impact on outcomes in patients with cancer. In Chapter 9 the effect 
of the systemic inflammatory response on body composition and outcomes in patients with 
operable colorectal cancer (n=650) is examined. In this study on univariate survival analysis, 
age, ASA, TNM stage, mGPS, BMI, SFI, visceral obesity (VO), SMI and SMD were 
significantly associated with overall survival (all p<0.05). Furthermore, a low SMI and SMD 
were significantly associated with an elevated mGPS (<0.05). On multivariate analysis, SMI 
(HR 1.50, 95%CI 1.04-2.18, p=0.031), SMD (HR 1.42, 95%CI 0.98-2.05, p=0.061) and 
mGPS (HR 1.44, 95%CI 1.15-1.79, p=0.001) remained independently associated with 
overall survival. This study therefore delineates the relationship between the loss of quantity 
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and quality of skeletal muscle mass, the systemic inflammatory response and survival in 
patients with operable colorectal cancer.     
The results of Chapter 11 add further weight to the prognostic relationship between markers 
of the systemic inflammatory response, physical function and body composition in patients 
with advanced cancer (n=289). In this study ECOG-PS, mGPS, timed up and go (TUG), 2 
minute walk test (2MWT), hand grip strength (HGS), combined objective performance tests 
(COPT), SMI and SMD had prognostic value (all p<0.05). However, none of these factors, 
with the exception of HGS (HR 1.63, 95%CI 1.03–2.59, p=0.04), displaced the prognostic 
value of ECOG-PS within the ECOG-PS/mGPS framework. These results validate the 
clinical utility of the ECOG-PS/mGPS framework in the assessment of patients with 
advanced cancer.  
Furthermore, in Chapter 12 the results of the longitudinal monitor of body composition in 
patients with operable colorectal cancer (n=470) have shown that the majority of patients 
did not change their SMI (81%) or SMD (72%) status on follow-up. In male patients those 
who maintained a low SMI were older (p<0.001), received less adjuvant chemotherapy 
(p<0.05), had a higher mGPS/NLR (both p<0.05), had a BMI≥25, had pre-op VO and follow 
up VO (all p<0.01). In female patients those who maintained a low SMI were older (p<0.01), 
had more open surgery (p<0.05), had a higher mGPS (p<0.05), had a BMI≥25, had pre-op 
VO and follow up VO (all p<0.01). On Cox-regression analysis patients who maintained a 
low SMI and SMD on follow up had worse overall survival (p<0.05). However, when 
adjusted for age, sex, TNM stage and mGPS neither a maintained low SMI nor SMD was 
independently associated with survival. This suggests that a low skeletal muscle mass and 
quality are established early in the disease course, maintained following resection of the 
primary tumour and associated with VO and the presence of a systemic inflammatory 
response.   
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The relationship between tumour metabolic activity and the systemic inflammatory response 
was examined in Chapter 13. This systematic review contained twelve studies including  
2,588 patients and showed that the majority of studies showed a direct relationship between 
the tumour and bone marrow glucose uptake as measured by positron emission tomography 
CT (PET-CT) scanning and the host systemic inflammatory responses as measured by CRP 
(n=2), albumin (n=2), WCC (n=3), neutrophils (n=2) and platelets (n=2). The majority of 
the studies (n=8) also showed a direct relationship between tumour and bone marrow glucose 
uptake and poor outcomes. This suggests a direct relationship between the tumour and bone 
marrow glucose uptake and host systemic inflammation.  This may suggest new approaches 
for more optimal therapeutic targeting and monitoring strategies in patients with cancer. 
Furthermore, Chapter 14 showed in patients undergoing curative radiotherapy for lung 
cancer (n=119) that on univariate survival analysis, lung cancer stage (p<0.01), mGPS 
(p<0.05), NLR (p<0.01), SMD (p<0.05) and Total Lesion Glycolysis (TLG, p<0.001) were 
associated with overall survival.  An elevated TLG was associated with sex (p<0.05), TNM 
stage (p<0.001), mGPS (p<0.01) and maximized standardised uptake values (SUVmax, 
p<0.001). On multivariate survival analysis only a TLG>68.89 (HR:2.03, 95%CI 1.35-3.07, 
p<0.001) remained independently associated with OS. This suggests that Tumour glucose 
uptake was associated with activation of the systemic inflammatory response but not lower 
skeletal muscle mass in patients with lung cancer.  This suggests that the early targeting of 
the systemic inflammatory response could provide a fruitful treatment strategy aimed at 
maintaining skeletal muscle mass and function while also improving quality of life and 
outcomes in patients with cancer.   
In summary, the systemic inflammatory response has a direct relationship with changes in 
body composition and outcomes in patients with cancer. Interestingly this association would 
seem to be independent of tumour metabolic activity and potentially tumour stage. Cancer 
related changes in body composition and their associated effect on performance status seem 
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to be established early in the disease process and maintained despite treatments targeting the 
tumour specifically, be they oncological or surgical. Given that an elevated systemic 
inflammatory response is not currently targeted, the present results would suggest that the 
die is cast in these patients.  However, it may be that new treatment strategies targeting the 
inflammatory response as early as possible in the disease progression may arrest or  reverse 
any skeletal muscle loss and improve outcomes in patients with cancer. 
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NSAIDS Non-Steroidal Anti-Inflammatory Drugs  
NSCLC Non-Small Cell Lung Cancer  
mGPS Modified Glasgow Prognostic Score  
MIF Macrophage Inhibitory Factor  
MTV Metabolic Tumour Volume  
OS Overall Survival  
PET Positron Emission Tomography  
PFS Progression Free Survival  
PINI Prognostic Inflammatory and Nutritional Index 
PLR Platelet Lymphocyte Ratio  
PLS Platelet Lymphocyte Score  
PS Performance Status  
US Ultrasound Scan  
RCT Randomised Control Trial  
RECIST Response evaluation criteria in solid tumors 
ROI Region Of Interest 
SAT Subcutaneous Adipose Tissue 
SIR Systemic Inflammatory Response 
SFA Skeletal Fat Area 
SFI Subcutaneous Fat Index 
SMA Skeletal Muscle Area 
SMD Skeletal Muscle Density 
SMI Skeletal Muscle Index 
BMSUV Bone Marrow Standardized Uptake Value 
SUV Standardized Uptake Value 
TSUV Tumour Standardized Uptake Value  
TFA Total Fat Area 
TFI Total Fat Index 
TLG Total Lesion Glycolysis 
TGF Transforming Growth Factor  
TNF Tumour Necrosis Factor  
TME Tumour Microenvironment 
TNM Tumour, Node, Metastasis 
TUG Timed Up and Go  
TSP Tumour Stroma Percentage 
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VAT Visceral Adipose Tissue 
VFA Visceral Fat Area 
VFI Visceral Fat Index 
VAT Visceral Adipose Tissue 
VO Visceral Obesity 
WCC White Cell Count 
WHO World Health Organization 
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1. INTRODUCTION 
 HOST IMMUNE RESPONSE 
The immune response is the protective mechanism of detecting and removing organisms 
such as bacteria, yeasts, fungi, and helminths identified as non-self. In addition, it targets 
host cells which are displaying non-self antigens including those infected with viruses and 
cancer cells. However, at times the immune surveillance and destruction of cancer cells is 
not complete. In this case the cancer cells can reach a stable equilibrium with the host 
immune system (1, 2). Subsequent evasion of the immune system allows growth of the 
primary cancer and eventual development of disseminated disease (1, 2). The immune 
system is divided into two broad constituent parts: the innate or non-specific immune system 
and the adaptive or acquired immune system. 
The innate immune system generates a non-specific response to pathogens and tissue injury. 
The initial barrier defence consists of epithelium lined body surfaces including the skin, 
gastrointestinal tract, respiratory tract and genitourinary tract. Should this be breached then 
the innate non-specific immune system is activated. Specifically, this consists of circulating 
humoral factors in the complement cascade, and cellular components including phagocytes 
(neutrophils and macrophages), granulocytes (basophils, eosinophils, and mast cells), and 
directly cytotoxic natural killer cells (NK).  
The innate immune response is initiated and coordinated by the interaction of pro and anti-
inflammatory cytokines and chemokines (3, 4). In the initial acute response, pro-
inflammatory cytokines such as IL-1 and IL-6 predominate (4). Once the acute insult is dealt 
with anti-inflammatory cytokines such as IL-10 and TGF-β begin to predominate allowing 
restoration of normal tissue structure and function (4).  
 44 
In the majority of cases activation of the innate response in turn leads to activation of the 
adaptive immune response through the presentation of antigens by phagocytic cells. The 
adaptive immune system provides a more specific response to pathogens and other non-self 
antigens/cancer cells which can be stored providing immunological memory.  
Lymphocytes are the predominant cell of the adaptive immune response. Lymphocytes 
mature in the bone marrow (B cells) or thymus (T cells) and become activated by 
presentation of non-self antigens by antigen presenting cells such as neutrophils and 
macrophages. B cells form part of the humoral immune system and, following activation, 
produce antibodies against the specific antigens. Antibodies can directly target pathogens 
while also recruiting and potentiating the innate immune response following antibody-
antigen binding through the compliment cascade and by encouraging phagocytosis. The 
action of T cells is mediated by the binding of non-self antigens to T cell receptors. Cytotoxic 
T cells (CD8+) are the predominant cell of the T-cell mediated adaptive immune response 
and act via the production of cytotoxins. In addition, several other subsets of T cells exist, 
each with specific roles including antigen presentation (CD4+ helper T cells), antigen 
memory (CD45R0+ memory T cells), and regulation of the adaptive immune response 
(FOXP3+ T regs). 
Generally, the adaptive immune system is regarded as the most important for cancer 
immunoediting. Indeed, it is thought that innate immune response related inflammation 
promotes tumour progression at least in part by suppression of the adaptive immune response 
(5). 
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 THE LOCAL INFLAMMATORY RESPONSE 
It is now recognised that the pathogenicity of cancer is due to a complex interaction between 
both host and tumour factors (6, 7). For a considerable amount of time the importance of the 
extent and specific type of intra and peri-tumour infiltration has been recognised in patients 
with cancer (8). Recently, there has been an increasing appreciation of the importance of the 
interaction between tumour cells, the local inflammatory infiltrate, and the tumour 
microenvironment in terms of both prognosis and as a potential therapeutic target. It has 
been reported that a high level of lymphocytic tumour infiltrate is associated with better 
outcomes in patients with cancer (9). Interestingly and in contrast to the above, local 
infiltration by cells of the innate response such as macrophages and neutrophils produce a 
local pro-tumour environment which aids in tumour progression and is associated with a 
poorer outcome (10). 
 THE SYSTEMIC INFLAMMATORY RESPONSE  
Inflammation in its simplest form is a reaction to tissue injury brought on by ischaemia, 
necrosis, trauma, hypoxia or cancer or as a response to an active infection. The acute phase 
of inflammation may resolve after the removal of the causal stimulus or it may persist and 
become chronic. There are multiple inflammatory stimuli including prostaglandins, and 
leukotrienes released by damaged cells and pro-inflammatory cytokines (IL-1. IL-6 and 
TNF-α) released by macrophages and neutrophils. These pro-inflammatory factors act on 
target cells to release a cascade of mediators which initiate and maintain the inflammatory 
response. The acute phase of the inflammatory response is characterised by local and 
systemic changes in vasculature, metabolism and plasma protein composition and the 
promotion of the initial non-specific immune response with the influx of neutrophils, 
complement and antibodies. 
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Acute phase proteins whose concentration changes by at least 25% in the presence of an 
inflammatory stimuli are produced within the liver (11). These proteins undergo substantial 
metabolic alterations across several organ systems resulting in the behavioural, 
psychological, biochemical and nutritional changes associated with systemic inflammation 
(12).  Pro-inflammatory cytokines, in particular IL-6 which acts on hepatocytes, are believed 
to mediate the acute phase response and both serum C-reactive protein and amyloid have 
been shown to be highly specific markers of the systemic inflammation(13). If the causative 
inflammatory stimulus is not removed inflammation can become chronic with profound 
multisystemic consequences including alteration in the protein production of hepatic cells, 
hematopoietic changes, metabolic changes and alterations in the hypothalamic-pituitary-
adrenal axis.  
1.3.1 The Systemic Inflammatory Response and Cancer:  
It is increasingly clear that cancer progression is dependent in a complex interaction between 
both tumour and host characteristics and in particular the host systemic inflammatory 
response(14-16). Indeed, there is increasing evidence that in addition to an elevated systemic 
inflammatory response that other host factors such as weight loss and performance status 
have an impact on outcomes in patients with cancer (17-24). In particular the systemic 
inflammatory response has been associated with increased weight loss and reduced 
performance status and may be an important contributing factor in the nutritional and 
functional decline seen in patients with advanced cancer (17, 25).  
Indeed, recently there has been an increase in interest in the prognostic impact of the 
systemic inflammatory response in patients with advanced and metastatic disease. This 
interest was further heightened by recent cohort studies which show that inappropriate 
anticancer treatment in patients with metastatic disease does not improve quality of life or 
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survival, has increased costs associated with end-of-life care, and has been directly related 
to death within 30 days of initiating treatment (26-28). As mentioned above Temel and co-
workers have further validated these results in a recent randomised control trial reporting 
longer median survival and improved quality of life in patients with metastatic non-small 
cell lung cancer who received early best supportive care (29). These studies have reported 
that markers of the systemic inflammatory response have an independent prognostic value, 
across tumour types and geographical locations, in patients with advanced cancer (30, 31). 
Indeed, the mGPS has been shown in several studies to provide additional prognostic 
determination when combined performance status in patients with advanced cancer (17, 32). 
In healthy patients the inflammatory response is short lived however in patients with cancer 
the presence of the systemic inflammatory response bears striking similarities to chronic 
inflammation. In his setting the normal inflammatory homeostasis is altered in favour of a 
pro-inflammatory phenotype. In this setting the normal endogenous anti-inflammatory 
mechanisms mediated by interleukin- 10 (IL-10), transforming growth factor (TGF) -β, 
prostaglandins and lipoxins are impaired by pro-inflammatory cytokines such as IL-1, IL-6, 
tumour necrosis factor (TNF) α and IGF-1(33). This alteration of haemostasis increased the 
likelihood of the development of malignancy. Indeed, in animal models it has been shown 
the inhibition of IL-6 by TGF-β inhibits tumour growth (34). In addition, the deletion of IL-
10 in mice has been shown to lead to the development of colorectal cancers (35).  
Furthermore, the importance of the systemic inflammatory response in patients with cancer 
can be seen by the effect that targeting it has on patient care. Indeed, clinical studies 
including RTCs have shown that NSAIDs improve global quality of life scores in patients 
with advanced cancer (23). Additionally, more targeted therapy with the JAK inhibitor 
ruxolitinib in patients with myeloproliferative disease, has been shown to improve quality 
of life (36). 
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1.3.2 Measurement of the systemic inflammatory response 
Clinically, the most common means of measuring the systemic inflammatory response in 
patients with cancer is with the use of biochemical or haematological markers. In practice 
this means an elevated C-reactive protein, hypoalbuminaemia or increased white cells, 
neutrophils and platelet counts. A clear relationship between individual markers of the 
systemic inflammatory response and outcomes has been demonstrated in both inoperable 
and inoperable disease (37, 38). In addition these individual factors can be used to construct 
cumulative scores and composite ratios such as the modified Glasgow Prognostic score 
(mGPS), Neutrophil Lymphocyte Ratio (NLR) and Platelet Lymphocyte ratio (PLR) (37, 
38). The prognostic value of these individual factors and the scores and ratios constructed 
from them in both operable and inoperable cancers and in the setting of randomised control 
trials are outlined below.  
1.3.2.1 C-reactive protein 
C-reactive protein (CRP) is a pentraxin protein which was discovered in 1930 and received 
its name due to its reactivity with the pneumococcal C-polysaccharide (12). It is classed as 
a positive acute phase protein and its prevalence in the acute phase response is seen in Figure 
1.1.  CRP is produced by hepatocytes after pathogen induced IL 6 secretion by both 
macrophages and T cells.  Its physiological role is to bind to lysophosphatidylcholine 
expressed on the surface of dying or damaged cells and some bacterial cell membranes. It 
acts as an opsonin while also potentiating the action of the complement cascade and the 
innate immune response. The presence of a raised CRP has been shown to be a poor 
prognostic indicator in patients with both operable and inoperable cancers (37, 38). 
Furthermore, its close association with IL-6 production has led to its use as a surrogate 
marker of IL-6 production and activation of the JAK/STAT signalling pathway in patients 
with cancer.  
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1.3.2.2 Albumin 
Albumin is globular protein produced in the liver. It is the most prevalent plasma transport 
protein and has a negative impact on the acute phase response as can be seen in Figure 1.1. 
Low serum albumin levels are associated with activation of the acute phase of the innate 
immune response. Furthermore, low serum albumin concentrations have been shown to be 
poor prognostic indicator in patients with both operable and inoperable cancers (37, 38).  
1.3.2.3 The Glasgow Prognostic Scores 
A combination of both CRP and albumin readings in the form of the Glasgow Prognostic 
Scores (GPS) and the modified Glasgow Prognostic Score (mGPS) have been shown to be 
prognostic in patients with cancer independent of stage and tumour type (37, 38). The 
makeup of both the GPS and mGPS is summarised in Table 1.1. Both use the widely 
accepted cut of values of >10mg/L for CRP and <35g/L for albumin to build a cumulative 
prognostic score. The basis of the prognostic value of both the GPS and mGPS is in their 
relationship to the innate immune response and the acute phase of it in particular. As can be 
seen in Figure 1.1 a high CRP and a low albumin are associated with the initial acute 
response and the activation of the JAK/STAT pathway with its potentiation of the innate 
immune response. In the case of patients with cancer this response can become established 
chronically leading to the alteration of both local and systemic homeostasis in favour of 
disease progression.  
1.3.2.4 The Differential White Cell Count and Associated Cumulative Scores and 
Composite Ratios  
The total count of white blood cells is a common laboratory measure of the systemic 
inflammatory response and has been shown to be prognostic in patients with cancer (37, 38). 
In addition, the different constituent part of the white cell count have been shown to be 
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prognostic in patients with cancer while also directly relating back to activation of the 
immune response. Neutrophils make up the majority of the circulating white cell population 
and are the key effector cells of the innate immune system. Furthermore, platelets and 
monocytes have been shown to be important markers of acute inflammation. Lymphocytes 
are the predominant cell type of the adaptive immune system. As a result, ratios and scores 
comparing neutrophils, platelets, monocytes and lymphocytes can show the preponderance 
of the innate immune response over the adaptive immune response in patients with cancer 
(Table 1.1). The most commonly used composite ratio in both operable and inoperable 
disease is the Neutrophil Lymphocyte Ratio (NLR) (37, 38). While several cumulative 
scores using different components of the differential white cell count have been constructed 
including the Neutrophil Platelet Score (NPS) and the Neutrophil Lymphocyte Score (NLS) 
both of which have been shown to be prognostic in patients with cancer (39, 40).   
 THE SYSTEMIC INFLAMMATORY RESPONSE, BODY COMPOSITION 
AND TUMOUR METABOLIC ACTIVITY IN PATIENTS WITH CANCER 
1.4.1 The Systemic Inflammatory Response and Anorexia, Weight Loss and Physical 
Function in Patients with Cancer 
The progression of cancer is often associated with anorexia, weight loss and loss of skeletal 
muscle (cancer cachexia) all of which are associated with poor outcomes (41) (42). However, 
the basis for this change in body composition is not fully understood. Indeed, the level of 
cancer cachexia varies according to tumour type with lung and gastrointestinal cancers being 
particularly associated with weight loss and a loss of muscle mass. 
The presence of an elevated systemic inflammatory response has been shown to be 
associated with lower quantity and quality of skeletal muscle in patients with cancer. Indeed 
in some longitudinal studies it has been shown that an elevated inflammatory response can 
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lead to a progressive decline in skeletal muscle even after treatment has been instigated  (20, 
43, 44). As a result it has been speculated that the systemic inflammation may be a key 
underlying mechanism driving skeletal muscle catabolism in patients with cancer (45). 
Preservation of skeletal muscle quantity and quality has been shown to have a central role in 
maintaining physical function and outcomes in patients with cancer. Furthermore, the  
central role for the systemic inflammatory response in driving cancer related catabolism can 
be seen in a recent randomised clinical trial by Lundholm and co-workers which showed a 
significant improvement in ECOG-PS in patients treated with the NSAID indomethacin, 
when compared to placebo (46). Indeed this association between the control of the systemic 
inflammatory response and physical function was given further weight by Maddedu and co-
workers who showed in the setting of another randomised control trial a significant 
improvement in 6min walk test performance and an improvement in ECOG-PS in patients 
treated with celecoxib, when compared to baseline (47).  
 
Figure 1.1: Change in plasma concentrations of some acute phase proteins after a moderate inflammatory 
stimulus (adapted from Gabay and Kushner 1999) (12) 
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Table 1.1: Systemic inflammation based prognostic ratios and scores based of acute phase proteins and the 
constituent part of the differential white blood cell count 
 
1.4.2 Body Composition Assessment in Patients with Cancer 
In the past, body mass index (BMI) was used as a means of assessing malnutrition and cancer 
cachexia. However, BMI is a very non-specific means of assessing body composition and 
does not take account the amount of adipose tissue or lean muscle mass. As a result, various 
Ratio/ Score Ratio/Score 
Neutrophil Lymphocyte Ratio (NLR):  
Neutrophil count: lymphocyte count ≤3 
Neutrophil count: lymphocyte count 3-5 
Neutrophil count: lymphocyte count >5 
Platelet Lymphocyte Ratio (PLR):  
Platelet count: lymphocyte count  ≤150 
Platelet count: lymphocyte count >150  
Lymphocyte Monocyte Ratio (LMR):  
lymphocyte count: monocyte count ≥2.40 
lymphocyte count: monocyte count <2.40 
Neutrophil Platelet Score (NPS):  
Neutrophil Count ≤ 7.5 x 109/l and platelet count < 400 x 109/l 0 
Neutrophil Count > 7.5 x 109/l and platelet count < 400 x 109/l  1 
Neutrophil Count ≤ 7.5 x 109/l and platelet count > 400 x 109/l  1 
Neutrophil Count > 7.5 x 109/l and platelet count > 400 x 109/l  2 
Glasgow Prognostic Score (GPS):  
C-reactive protein ≤ 10mg/l and Albumin ≥35 g/l 0 
C-reactive protein > 10mg/l and Albumin ≥35 g/l 1 
C-reactive protein ≤ 10mg/l and Albumin <35 g/l 1 
C-reactive protein > 10mg/l and Albumin <35 g/l 2 
modified Glasgow Prognostic Score (mGPS):  
C-reactive protein ≤ 10mg/l and Albumin ≥35 g/l 0 
C-reactive protein > 10mg/l and Albumin ≥35 g/l 1 
C-reactive protein > 10mg/l and Albumin <35 g/l 2 
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techniques have been used to better define body composition in patients with cancer 
including as bioelectric impedance analysis, whole body potassium, and air displacement 
plethysmography.  
These techniques had some merit in the research setting but their application to clinical work 
was fraught with difficulties. As a result, image-based approaches such as Dual-energy X-
ray absorptiometry (DEXA), magnetic resonance imaging (MRI), ultrasound scan (USS) and 
computed tomography (CT), have been increasingly utilized. In particular due to its routine 
used in cancer staging, CT is now being widely used to measure body composition, 
providing new clinically useful information about both pre and post treatment body 
composition in patients with cancer.  
There are currently several software packages available which allow for the calculation of 
body composition based on staging or post treatment CT scans. These are both manual and 
semi-automated depending on the package used. The majority of studies use a single CT 
slice at the L3 level to calculate the quantity and quality of skeletal muscle as well as the 
quantity of visceral, intra-muscular and subcutaneous fat in patients with cancer (48).  These 
can then be related to specific outcomes such as post-operative complications, performance 
status and survival in patients with cancer.  
1.4.3 Tumour Metabolic Activity in Patients with Cancer 
Prognostication in patients with cancer involves a close interaction between host factors such 
as the systemic inflammatory response and tumour factors. Indeed, the importance of both 
has been highlighted in recent studies by Park and co-workers on the importance of staging 
both the tumour and the host (7).  
The driving force behind the skeletal muscle loss seen in patients with cancer with the 
associated loss in physical function and poorer outcomes is likely to follow a similar pattern. 
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The metabolic activity of both the primary tumour and metastatic deposits are now being 
assessed using Positron Emission Tomography (PET) scanning in patients with multiple 
solid organ tumours including lung, gastro-oesophageal and colorectal cancers. This often 
forms part of the standard pre-operative or pre-oncological treatment workup for patients to 
assess the size and metabolic activity of the primary tumour as well as for the presence of 
any metastatic disease.  
PET is an established nuclear imaging technique based on the uptake of glucose using the 
tracer18F-2-fluoro-2-deoxy-d-glucose (18FDG) in order to examine the metabolic activities 
of tumours (49). Recently PET scanning has been combined with CT imaging to give 
information about the anatomical location as well as tumour physiological activity (49).   In 
addition to highlighting the primary tumour or any metastatic deposits PET-CT scanning has 
highlighted areas of increased metabolic activity in patients with cancer including the bone 
marrow. This provides invaluable information about the potential connections between 
tumour physiological activity, the host systemic inflammatory response and body 
composition in patients with cancer.  
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 Summary and Aims 
1.5.1 Summary 
Cancer remains one of the leading causes of mortality worldwide and  while a curative intent 
is the aim of any surgical or oncological treatment many patients either present with or go 
onto develop disseminated disease requiring systemic anti-cancer therapy and best 
supportive care (38). In this case and given that patients with advanced cancer have a limited 
life expectancy, appropriate treatment selection becomes of the utmost importance.  Indeed, 
there is increasing evidence that inappropriate anti-cancer treatments can negatively affect 
both the quality and quantity of life of patients with cancer (50).  
The systemic inflammatory response has been implicated as a unifying mechanism for the 
systemic symptoms associated with cancer such as pain, nausea, anorexia, weight loss and 
reduced physical function (51). Furthermore, the systemic inflammatory response has been 
implicated as the driving force behind the deterioration in both skeletal muscle quantity and 
quality in patients with both operable and advanced cancers (52). This loss of skeletal muscle 
mass is associated with both poorer outcomes in patients with operable and inoperable 
cancers and with increased complications of both surgical and oncological treatments.   
The driving force behind this physiological and functional decline seen in patients with 
cancer is of some debate. It has been postulated that the tumour itself is the primary furnace 
behind this deterioration. However, recent studies have shown that the host factors including 
the systemic inflammatory response in particular are equally as important at predicting 
outcomes in patients with cancer. Indeed, recent studies using PET-CT scanning have shown 
a direct relationship between tumour and bone marrow metabolic activity and the systemic 
inflammatory response in patients with cancer (53). However, it remains to be seen if tumour 
metabolic activity has a direct impact on skeletal muscle loss or if the systemic inflammatory 
response is driving this physiological and functional decline. Taken together these proposed 
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relationships, if proven, could provide novel therapeutic targets and monitoring strategies to 
improve outcomes for patients with both operable and inoperable cancers.  
 
1.5.2 Aims 
1. To definitively establish the relationship between the systemic inflammatory 
response and outcomes in patients with both operable and inoperable cancer. 
2. To compare the prognostic value of systemic inflammatory response markers, in 
particular that of composite ratios and cumulative scores, in patients with cancer. 
3. To determine the effect of software packages on CT derived body composition. 
4. To determine the relationship between the systemic inflammatory response and CT 
derived body composition measurements and outcomes in patients with cancer 
5.  To determine the relationship between longitudinal changes in CT derived body 
composition, clinicopathological characteristics, the systemic inflammatory 
response and outcomes in patients with cancer. 
6. To compare and contrast the clinical utility of the ECOG-PS/ mGPS framework 
and the BMI/WL grade in patients with cancer. 
7. To determine the relationship between the ECOG-PS/ mGPS framework, CT-
derived body composition, physical function tests and outcomes in patients with 
advanced cancer 
8. To determine the relationship between imaging derived tumour metabolic activity, 
body composition, the systemic inflammatory response and outcomes in patients 
with cancer.
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2. METHODS FOR ASSESSMENT OF THE SYSTEMIC INFLAMMATORY     
RESPONSE, CT-DERIVED BODY COMPOSITION AND PET-CT DERIVED 
TUMOUR METABOLIC ACTIVITY   
 Assessment of the Systemic Inflammatory Response 
The monitoring of the systemic inflammatory response in this thesis was carried out by using 
either acute phase proteins i.e. CRP and albumin or the constituent parts of the differential 
white blood cell count i.e. neutrophils, lymphocytes, platelets and monocytes (37, 38, 54, 
55).  The results of two recent systematic reviews and meta-analyses have shown that the 
majority of studies now use composite ratios constructed from the differential white blood 
cell count such as the Neutrophil Lymphocyte Ratio (NLR), Platelet Lymphocyte Ratio 
(PLR) and the Lymphocyte Monocyte Ratio (LMR) or acute phase proteins such as the 
CRP/Albumin Ratio (CAR) (37, 38).  
In addition, cumulative scores constructed using normal reference ranges of the different 
components of the white blood cell count such as the neutrophil lymphocyte score (NLS), 
platelet lymphocyte score (PLS), lymphocyte monocyte score (LMS), Neutrophil Platelet 
Score (NPS) or acute phase proteins such as the Glasgow Prognostic Score/modified 
Glasgow Prognostic Score (GPS/mGPS) are widely used (37, 38, 40, 55). Both methods 
have been shown to be prognostic in patients with both operable and advanced cancer and 
their means of construction is given in Table 2.1 below.  
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2.1.1 Tables and Footnotes  
Table 2.1: Systemic inflammation based prognostic ratios and scores 
Ratio/ Score Ratio/Score 
Neutrophil Lymphocyte Ratio (NLR):  
Neutrophil count: lymphocyte count ≤3 
Neutrophil count: lymphocyte count 3-5 
Neutrophil count: lymphocyte count >5 
Neutrophil Lymphocyte Score (NLS):  
Neutrophil Count ≤ 7.5 x 109/l and lymphocyte count ≥1.5 x 109/l 0 
Neutrophil Count > 7.5 x 109/l and lymphocyte count ≥1.5 x 109/l 1 
Neutrophil Count ≤ 7.5 x 109/l and lymphocyte count <1.5 x 109/l 1 
Neutrophil Count > 7.5 x 109/l and lymphocyte count <1.5 x 109/l 2 
Platelet Lymphocyte Ratio (PLR):  
Platelet count: lymphocyte count  ≤150 
Platelet count: lymphocyte count >150  
Platelet Lymphocyte Score (PLS):  
Platelet Count ≤ 400 x 109/l and lymphocyte count ≥1.5 x 109/l 0 
Platelet Count > 400 x 109/l and lymphocyte count ≥1.5 x 109/l 1 
Platelet Count ≤ 400 x 109/l and lymphocyte count <1.5 x 109/l 1 
Platelet Count > 400 x 109/l and lymphocyte count <1.5 x 109/l 2 
Lymphocyte Monocyte Ratio (LMR):  
Lymphocyte count: monocyte count ≥2.40 
Lymphocyte count: monocyte count <2.40 
 Lymphocyte Monocyte Score (LMS):  
Lymphocyte count ≥1.5 x 109/l and monocyte count ≤ 0.80 x 109/l 0 
Lymphocyte count <1.5 x 109/l and monocyte count ≤ 0.80 x 109/l 1 
Lymphocyte count ≥1.5 x 109/l and monocyte count > 0.80 x 109/l 1 
Lymphocyte count <1.5 x 109/l and monocyte count > 0.80 x 109/l 2 
Neutrophil Platelet Score (NPS):  
Neutrophil Count ≤ 7.5 x 109/l and platelet count < 400 x 109/l 0 
Neutrophil Count > 7.5 x 109/l and platelet count < 400 x 109/l  1 
Neutrophil Count ≤ 7.5 x 109/l and platelet count > 400 x 109/l  1 
Neutrophil Count > 7.5 x 109/l and platelet count > 400 x 109/l  2 
C-reactive protein Albumin Ratio (CAR):  
C-reactive protein: Albumin ≤0.22 
C-reactive protein: Albumin >0.22 
Glasgow Prognostic Score (GPS):  
C-reactive protein ≤ 10mg/l and Albumin ≥35 g/l 0 
C-reactive protein > 10mg/l and Albumin ≥35 g/l 1 
C-reactive protein ≤ 10mg/l and Albumin <35 g/l 1 
C-reactive protein > 10mg/l and Albumin <35 g/l 2 
modified Glasgow Prognostic Score (mGPS):  
C-reactive protein ≤ 10mg/l and Albumin ≥35 g/l 0 
C-reactive protein > 10mg/l and Albumin ≥35 g/l 1 
C-reactive protein > 10mg/l and Albumin <35 g/l 2 
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 Systematic Review and Meta-analysis methods 
2.2.1 Systematic Review 
All systematic reviews and meta-analysis of published literature in this thesis were 
undertaken according to a pre-defined protocol described in the PRISMA-P statement. The 
primary outcomes to be assessed are defined in individual Chapters.  Wide-ranging literature 
searches were carried out using specified medical subject heading (MeSH) terms defined in 
each Chapter in the US National Library of Medicine (MEDLINE), the Excerpta Medica 
database (EMBASE) and the Cochrane Database of Systematic Reviews (CDSR) to identify 
articles. 
On completion of the online search, the title and abstract of each identified study was 
examined for relevance. Studies not in cancer patients, studies not available in English and 
those published in abstract form only were excluded. Where there were multiple publications 
from the same cohort the most recent paper was included.  Full texts were obtained for all 
studies deemed potentially relevant. Once further exclusions outlined below were carried 
out, the bibliographies of all included articles were subsequently hand searched to identify 
any additional studies. 
Only articles that reported survival analysis and gave hazard ratios (HR) with associated 
confidence intervals were included in any final meta-analysis. Articles reporting survival 
analysis in relative risk (RR) and odds ratio (OR) were also included but not in the meta-
analysis. All potentially eligible papers were reviewed in full by two authors independently 
and graded according to GRADE recommendations. 
2.2.2 Meta-analysis:  
The HRs and 95 % CIs were directly retrieved from the article. If several estimates were 
reported for the same marker, the multivariate estimate was used in preference to the 
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univariate analysis. Data was assessed for heterogeneity using the I2 statistic and χ2 test 
interpreted using the guidance from the Cochrane Handbook for Systematic Reviews of 
Interventions (56). The degrees of heterogeneity were defined as minimal between 0% and 
30%, moderate between 30% and 50%, substantial between 50% and 80% and considerable 
between 80% and 100%.  Given the likely differences in methodology of the studies 
included, meta-analysis was performed using the random- effects (DerSimonian – Laird 
method) model unless stated otherwise. The Z test was used to assess the overall impact of 
systemic inflammation based scores on overall and cancer specific survival.  All P values 
were 2-sided and P < 0.05 were considered statistically significant. Evidence of publication 
bias was evaluated using visual inspection of funnel plots. All analyses were performed 
using Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The 
Nordic Cochrane Centre, the Cochrane Collaboration, 2014. 
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 CT-Derived Body Composition 
2.3.1 Definitions and Nomenclature 
Cancer is predominantly a disease of old age. As a result, often cancer related muscle loss 
may be a combination of age-related muscle decline or sarcopenia and disease related 
cachexia.  Age related muscle loss or sarcopenia can begin from the age of 40 and can 
progress at a rate of 6% per decade until the age of 70 when it can increase to 25-40% per 
decade (57-59). The precise definition of sarcopenia remains the subject of some debate. 
However it has generally been accepted to constitute a level of loss of muscle mass greater 
than two standard deviations below that of a healthy young reference population (59, 60). 
Cancer cachexia is a multifactorial syndrome which is characterised by the loss of muscle 
mass either with or without the loss of adipose tissue leading to a progressive functional and 
physiological decline (61). Systemic inflammation is one of the central components of 
cancer cachexia and can increase the baseline metabolic rate and catabolic rate of muscle 
tissue while also supressing food intake, therefore driving weight loss (61-63).  
Skeletal muscle is a highly physiologically active organ and accounts for about 40-45% of 
body weight. Skeletal muscle is highly plastic and can respond to a variety of stimuli. As a 
result, skeletal muscle mass has been closely related to morbidity and mortality leading to a 
significant increase in interest in skeletal muscle when investigating frailty and cachexia (59, 
64).  
In addition to skeletal muscle mass and fat mass, their respective densities have been 
associated with outcomes in patients with cancer. Two recent studies reported that patients 
with elevated visceral fat had lower functional capacity, greater treatment-related toxicities 
and poorer overall survival (65, 66).  
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The recent advent of CT-derived measurements of muscle radiodensity have potentially 
allowed for assessment of muscle quality (i.e. the degree of fat infiltration) to be assessed 
without the need for tissue sampling (59). Such muscle radiodensity has been associated 
with myopenia or a clinically relevant muscle wasting associated with reduced performance 
status (67).  
While muscle wasting in cancer may be due to a combination of both sarcopenia and cancer 
cachexia the term sarcopenia is now widely used to define low CT-derived muscle mass in 
patients with cancer (59).  Similarly, low skeletal muscle radiodensity and myosteatosis have 
been used interchangeably.  The variation in this nomenclature was highlighted in a recent 
editorial by Skipworth and needs to be standardised along with the assessment for CT-
derived measurement of muscle quantity and quality to enter routine clinical practice (68). 
For the purpose of this thesis the abbreviation SMI has been used interchangeably with 
sarcopenia. Specifically, this refers to height and/or BMI and sex adjusted measurement of 
CT derived skeletal muscle volume (66). Similarly, the abbreviation SMD has been used 
interchangeably with myosteatosis. Specifically, this refers to height and/or BMI and sex 
adjusted measurement of CT-derived skeletal muscle radiodensity (66). The abbreviation 
SFI has been used to refer to sub cutaneous fat. Specifically, this refers to sex adjusted 
measurement of CT derived subcutaneous fat mass (69). Finally, visceral obesity refers to 
sex adjusted measurements of CT-derived visceral fat mass (66, 70). 
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2.3.2 CT Images Analysis 
CT scans were conducted at a tube voltage of 120kV, with 5mm slice thickness, and a 512 
× 512 image resolution (71). An individual CT slice was acquired at the level of the third 
lumbar vertebra. Patients whose scans were taken 3 months or more prior to their 
surgery/treatment were excluded from the study. The two most commonly used image 
analysis software packages are ImageJ and Slice-O-Matic. The specific methodology for 
using both software packages is described below. Measurements were performed by two 
individuals for each Chapter. Initial training was undertaken on a cohort of training scans 
before test measurement of 30 scans was carried out with each scorer being blinded to the 
others results. Inter-rater reliability was assessed using inter-class correlation coefficients 
with a correlation of ≥0.8 being required before joint scoring could be commenced. The 
investigators were blind to patient’s demographic and clinico-pathological status 
ImageJ 
ImageJ is a Java-based image processing and analysis program developed by NIH and is free 
to be downloaded from their website (version 1.52, 
https://imagej.nih.gov/ij/download.html). ImageJ is able to evaluate the density of each 
pixel, and with the latest advances in the package, density has been calibrated to reflect true 
HU values (72). Region of interest measurements include Total Fat Area (TFA), Visceral 
Fat Area (VFA) and Skeletal Muscle Area (SMA) with an attenuation threshold from -190 
to +150 HU (i.e. -190 to -30 for adipose tissue, -29 to +150 for skeletal muscle).  Specifically, 
TFA was quantified by depicting the outer contours of the abdominal wall, while VFA was 
performed by outlining the inner contour of the psoas and abdominal wall muscles (Figure 
2.1). Similarly, SMA was measured by manually delineating muscle areas included 
quadratus lumborum, psoas, rectus abdominus, erector spinae muscles, internal transverse 
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and external oblique muscle groups (Figure 2.2). SFA calculated by subtracting VFA from 
TFA (Figure 2.1). Skeletal muscle radiodensity (SMD) was measured from the same region 
of interest used to calculate SMI, as its mean HU (Figure 2.2).  
Slice-O-Matic 
Slice-O-Matic version 5.0 (TomoVision, Magog, Canada; 64 bit; available at 
https://www.tomovision.com/index.html) was used to perform CT image segmentation 
process within different body composition regions. The adipose tissue was segmented to 
distinguish between intramuscular adipose tissue (IMAT), visceral (intra-abdominal) 
adipose tissue (VAT) and subcutaneous adipose tissue (SAT) using pre-defined thresholds. 
Skeletal muscle areas included quadratus lumborum, psoas, rectus abdominus, erector spinae 
muscles, internal transverse and external oblique muscle groups (Figure 2.3). Every tissue 
cross-sectional area was initially tagged with standard HU ranges using set thresholds for 
IMAT of -190 to -30HU, for VAT of -150 to -50 HU, for SAT of -190 to -30 HU and for 
SMA of -29 to +150 HU (Figure 2.3). Once the appropriate threshold HU ranges were set, 
compartmental segmentation was computed.  
Body composition measurements 
All results of body composition parameters (TFA, VFA, SFA, SMA) were later divided by 
the patient’s height in meters squared to generate total fat index (TFI, cm2/m2), visceral fat 
index (VFI, cm2/m2), subcutaneous fat index (SFI, cm2/m2) and skeletal muscle index (SMI, 
cm2/m2). These indices were then adjusted for sex and BMI and compared with established 
thresholds for body composition status (Table 2.2).  Skeletal muscle radiodensity (SMD, 
HU) was measured from the same region of interest used to calculate SMI, as its mean HU 
(Table 2.2).  These radiodensities were then adjusted for sex and BMI and compared with 
established thresholds for body composition status (Table 2.2). 
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2.3.3 Tables and Footnotes  
Table 2.2: CT derived body composition measures and thresholds used  
Body Composition Measurement  
High SFI (69): 
 Males>50.0 cm2m2 and Females>42.0 cm2m2  
Visceral obesity (66, 70):  
VFA: Males >160 cm2  and Females >80 cm2 
Sarcopenia  
SMI (Dolan) (52): 
Males: BMI≤25kg/m2 and SMI<45 cm2m2 or BMI>25kg/m2 and SMI<53 cm2m2 
Females: BMI≤25kg/m2 and SMI<39 cm2m2 or BMI>25kg/m2 and SMI<41 cm2m2 
SMI (Martin) (66): 
Males: BMI≤25kg/m2 and SMI<43 cm2m2 or BMI>25kg/m2 and SMI<53 cm2m2 
Females: BMI≤25kg/m2 and SMI<41 cm2m2 or BMI>25kg/m2 and SMI<41 cm2m2 
Myosteatosis  
SMD (Dolan) (52): 
BMI≤25kg/m2 and SMD<34 HU or BMI>25kg/m2 and SMD<32HU 
SMD (Martin) (66):  
BMI≤25kg/m2 and SMD<41 HU or BMI>25kg/m2 and SMD<33HU  
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2.3.4 Figures and Legends 
 
Figure 2.1: Example of selection of CT body composition fat areas using ImageJ software; (A) mid-L3 vertebra 
axial slice from preoperative portal venous phase CT, (B) threshold selection of adipose tissue using automatic 
selection of pixels of radiodensity ranging -190 to -30 Hounsfield units (HU), (C) region of interest (ROI) 
selection for total fat area (TFA,cm2), (D) ROI selection for visceral fat area (VFA, cm2). Adapted from 
McSorley et al 2017 (71) . 
 
 
Figure 2.2: Example of selection of CT body composition skeletal muscle area using ImageJ software; (A) 
mid-L3 vertebra axial slice from preoperative portal venous phase CT, (B) threshold selection of skeletal 
muscle tissue using automatic selection of pixels of radiodensity ranging _29 to 150 Hounsfield units (HU), 
(C) region of interest (ROI) selection for skeletal muscle area (SMA, cm2). Adapted from McSorley et al 2017 
(71). 
 
  
Figure 2.3: Example of selection of CT body composition fat areas using Slice-O-Matic; (A) mid-L3 vertebra 
axial slice from preoperative portal venous phase CT, (B)threshold selection of intramuscular adipose tissue 
(IMAT, -190 to -30 Hounsfield units (HU), green), visceral (intra-abdominal) adipose tissue (VAT, -150 to -
50 Hounsfield units (HU), yellow), subcutaneous adipose tissue (SAT,  -190 to -30 Hounsfield units (HU), 
blue) and skeletal muscle area (SMA, -29 to +150 Hounsfield units (HU), red) (73).  
A B 
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 Direct comparison of Image J and Slice-O-Matic CT-derived body 
composition in patients with colorectal cancer  
2.4.1 Introduction  
Currently there are several software programs that calculate CT derived body composition 
at the 3rd lumbar vertebrae. The two most commonly used software packages are ImageJ 
(National Institutes of Health, Bethesda, USA) and Slice-O-Matic 5.0 (TomoVision, 
Montreal, Canada). ImageJ requires the manual analysis of areas of interest including the 
quadratus lumborum, psoas, rectus abdominus, erector spinae muscles, internal transverse 
and external oblique muscle groups whereas Slice-O-Matic carried out the same analysis in 
a semi-automated manner. Irving and co-workers directly compared the values generated for 
adipose tissue and skeletal muscle cross-sectional areas from these software packages in 26 
patients with a mean percentage difference of less than 2% (72). Teigen and co-workers 
directly compared the values generated from these software packages in 51 patients with a 
mean percentage difference of less than 1% (74).  
Therefore, in small cohort studies CT-derived body composition parameters analyzed by 
ImageJ and Slice-O-Matic give similar but not identical results. The aim of this direct 
comparison was, for the first time, to compare body composition analysis using both ImageJ 
and Slice-O-Matic and their relationship with survival in a large cohort of patients 
undergoing surgery for colorectal cancer.   
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2.4.2 Patients and Methods 
CT-derived body composition was carried out using both Image J and Slice-O-Matic as 
outlined above in Section 2.3. For each parameter comparison, normality of the data was 
assessed by Shapiro-Wilk normality tests. Spearman’s rank correlation coefficient was used 
to examine the strength of the inter-relationship between ImageJ and Slice-O-Matic for each 
body composition parameter. In addition, the difference between ImageJ and Slice-O-Matic 
for each body composition parameter was tested using Wilcoxon-test. The determination of 
proportional bias between two software programs (ImageJ and Slice-O-Matic) was carried 
out using Bland-Altman analysis. 
Mortality within 30 days of the index procedure or during the index admission results in 
exclusion from subsequent survival analysis.  The time between the date of surgery and the 
date of death of any cause was used to define overall survival (OS).  Survival data were 
analysed using univariate and multivariate Cox regression.  Those variables associated to a 
degree of p<0.1 were entered into a backward conditional multivariate model. Kaplan-Meier 
curves for overall survival were constructed over a 60-month period. Missing data were 
excluded from analysis on a variable by variable basis.  Two tailed p values <0.05 were 
considered statistically significant.  Statistical analysis was performed using SPSS software 
(Version 21.0. SPSS Inc., Chicago, IL, USA). 
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2.4.3 Results  
A total of 341 colorectal cancer patients were selected for CT scans  
Association between ImageJ and Slice-O-Matic 
The overall mean TFI was significantly correlated between ImageJ and Slice-O-Matic (R2 = 
0.996, p<0.001). The overall mean SFI was significantly correlated between ImageJ and 
Slice-O-Matic (R2 = 0.969, p<0.001, Table 2.3). The overall mean VFI was significantly 
correlated between ImageJ and Slice-O-Matic (R2 = 0.919, p<0.001, Table 2.3). The overall 
mean SMI was significantly correlated between ImageJ and Slice-O-Matic (R2 = 0.927, 
p<0.001, Table 2.3). The overall mean SMD was significantly correlated between ImageJ 
and Slice-O-Matic (R2 = 0.971, p<0.001, Table 2.3).  
The mean percentage difference for TFI calculated using ImageJ and Slice-O-Matic (+9.3% 
(0.56), p<0.001). The mean percentage difference for SFI calculated using ImageJ and Slice-
O-Matic (+7.9% (0.17), p<0.001, Table 2.3). The mean percentage difference for VFI 
calculated using ImageJ and Slice-O-Matic (+20.3% (0.21), p<0.001, Table 2.3). The mean 
percentage difference for SMI calculated using ImageJ and Slice-O-Matic (+2.9% (0.49), 
p<0.001, Table 2.3). The mean percentage difference for SMD calculated using ImageJ and 
Slice-O-Matic (+1.2% (0.09), p<0.001, Table 2.3). 
Bland-Altman analysis between ImageJ and Slice-O-Matic 
The mean difference of TFI using ImageJ and Slice-O-Matic was 13.1 (-10.1% to +36.3%) 
respectively and 1.17% (4/341) of patients were outside the 95% CI (p<0.001). The mean 
difference of VFI using ImageJ and Slice-O-Matic was 5.4 (-22.9% to +48.9) respectively 
and 3.23% (11/341) of patients were outside the 95% CI (p<0.001). The mean difference of 
SFI using ImageJ and Slice-O-Matic was 5.4 (-39.5% to +50.3%) respectively and 3.23% 
(11/341) of patients were outside the 95% CI (p<0.001). The mean difference of SMI using 
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ImageJ and Slice-O-Matic was 2.3 (-6.5% +11.7%) respectively and 2.64% (9/341) of 
patients were outside the 95% CI (p<0.001). The mean difference of SMD using ImageJ and 
Slice-O-Matic was 0.5 (-3.8% to +4.8%) respectively and 1.76% (6/341) of patients were 
outside the 95% CI (p<0.001). 
Body composition and overall survival between ImageJ and Slice-O-Matic 
In total 256 (75.1%) patients were classified as having visceral obesity using ImageJ 
compared to 210 (61.6%) patients using Slice-O-Matic (Table 2.3). In total 271 (79.5%) 
were classified as having an elevated SFI using ImageJ compared to 245 patients (71.8%) 
using Slice-O-Matic.  
In total 157 (46%) were classified as sarcopenic (Dolan) using Image J compared to 209 
(61.3%) using Slice-O-Matic. In total 131 (38.4%) were classified as having myosteatosis 
(Dolan) using Image J compared to 141 (41.3%) using Slice-O-Matic. In total 157 (46%) 
were classified as sarcopenic (Martin) using Image J compared to 203 (59.5%) using Slice-
O-Matic. In total 191 (56%) were classified as having myosteatosis (Martin) using Image J 
compared to 1813 (53.1%) using Slice-O-Matic.  
On univariate Cox regression survival analysis, visceral obesity (VO) when analysed with 
Image J, was significantly associated with overall survival (HR: 0.58, 95%CI 0.40-0.86, p = 
0.007, Table 2.4). In contrast, on univariate Cox regression survival analysis, VO when 
analysed with Slice-O-Matic was not significantly associated with overall survival (p=0.084, 
Table 2.4). On multivariate Cox regression analysis VO when analysed with Image J 
remained independently associated with overall survival (HR: 0.58, 95%CI 0.40-0.86, 
p=0.007, Table 2.4) 
On univariate Cox regression survival analysis SFI was significantly associated with overall 
survival when analysed with Image J (HR: 0.48, 95%CI 0.32-0.70, p<0.001, Table 2.4). On 
 71 
univariate Cox regression survival analysis SFI was significantly associated with overall 
survival when analysed with Slice-O-Matic (HR: 0.54, 95%CI 0.37-0.79, p<0.001, Table 
2.4). On multivariate Cox regression analysis SFI when analysed with Image J remained 
independently associated with overall survival (HR: 0.48, 95%CI 0.32-0.70, p<0.001, Table 
2.4). 
On univariate Cox regression analysis Sarcopenia (Dolan) was significantly associated with 
overall survival when analysed with Image J (HR: 1.92, 95%CI 1.32-2.80, p=0.001, Table 
2.4). On univariate Cox regression analysis Sarcopenia (Dolan) was significantly associated 
with overall survival when analysed with Slice-O-Matic (HR: 2.04, 95%CI 1.34-3.10, 
p=0.001, Table 2.4). On multivariate Cox regression analysis Sarcopenia (Dolan) when 
analysed with Slice-O-Matic remained independently associated with overall survival (HR: 
2.04, 95%CI 1.34-3.10, p=0.001, Table 2.4). 
On univariate Cox regression analysis Sarcopenia (Martin) was significantly associated with 
overall survival when analysed with Image J (HR: 1.75, 95%CI 1.21-2.55, p=0.003, Table 
2.4). On univariate Cox regression analysis Sarcopenia (Martin) was significantly associated 
with overall survival when analysed with Slice-O-Matic (HR: 1.66, 95%CI 1.11-2.48, 
p=0.012, Table 2.4). On multivariate Cox regression analysis Sarcopenia (Martin) when 
analysed with Image J remained independently associated with overall survival (HR: 1.75, 
95%CI 1.21-2.55, p=0.003, Table 2.4). 
On univariate Cox regression analysis Myosteatosis (Dolan) was significantly associated 
with overall survival when analysed with Image J (HR: 1.62, 95%CI 1.12-2.34, p=0.01, 
Table 2.4). On univariate Cox regression analysis Myosteatosis (Dolan) was significantly 
associated with overall survival when analysed with Slice-O-Matic (HR: 1.73, 95%CI 1.20-
2.50, p=0.004, Table 2.4). On multivariate Cox regression analysis Myosteatosis (Martin) 
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when analysed with Slice-O-Matic remained independently associated with overall survival 
(HR: 1.73, 95%CI 1.20-2.50, p=0.004, Table 2.4).  
On univariate Cox regression analysis Myosteatosis (Martin) was not significantly 
associated with overall survival when analysed with Image J (p=0.689, Table 2.4). On 
univariate Cox regression analysis Myosteatosis (Martin) was significantly associated with 
overall survival when analysed with Slice-O-Matic (HR: 2.07, 95%CI 1.40-3.06, p<0.001, 
Table 2.4). On multivariate Cox regression analysis Myosteatosis (Martin) when analysed 
with Slice-O-Matic remained independently associated with overall survival (HR: 2.07, 
95%CI 1.40-3.06, p<0.001, Table 2.4).  
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2.4.4 Discussion 
The present study showed that ImageJ and Slice-O-Matic derived values for TFI, SFI, VFI 
and SMI were strongly associated. However, ImageJ consistently gave higher values for all 
body composition parameters. As a consequence, these higher values resulted in more 
patients being classified as viscerally obese (~14%) and fewer patients being classified as 
sarcopenic (~14%) using standard thresholds previously described. Finally, such differences 
between the software packages’ estimates altered the relationship of the body composition 
indices with overall survival. Therefore, CT-derived body composition is not only dependent 
on the age, sex, BMI and the systemic inflammatory response- it would appear to be also 
dependent on the software package used (75).   
There was a consistent proportional systematic bias in the values calculated by the two 
software packages for TFI, VFI, SFI and SMI. The lower values from the Slice-O-Matic 
analysis may be explained by the semi-automated procedure such that there was an 
underestimation relative to the manual Image J procedure.  For example, Image J requires 
the user to draw around the areas of interest on the CT scan whereas Slice-O-Matic 
automatically selects the areas of interest to calculate the total area.  With reference to fat 
and muscle tissue, Slice-O-Matic may classify areas as part of adjacent structures. Indeed, 
this limitation is acknowledged for some CT scans in the Slice-O-Matic manual and an 
additional image editing component to the software is included to allow for fine tuning of 
automated images based on expert clinical and anatomical knowledge (74).     
Several limitations associated with this study should be acknowledged. This study was 
carried out on retrospectively collected CT-scans and both ImageJ and Slice-O-Matic image 
analysis was carried out once for each scan. Nevertheless, the present study reflects the real-
world use of these software packages.   
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In conclusion, the present study showed that ImageJ, compared with Slice-o-Matic, gave 
higher values of different body composition parameters. The impact of different software 
programs on the appropriate classification thresholds should be taken into account when 
carrying out CT-derived body composition analysis in patients with colorectal cancer.   As 
a result of this study a decision was made to use ImageJ for all CT-derived body composition 
analysis in this thesis. 
  . 
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2.4.5 Tables and Footnotes  
Table 2.3: Mean (SD) CT body composition parameters measurements and correlation coefficient test using ImageJ and Slice-O-Matic. Body composition parameters included VFI, SFI, 
SMI.  
Body composition 
parameters 
Software program N Mean (SD) R2 
(P-value) 
Mean Percentage 
Difference (SD) 
P-value 
VFI (cm2/m2) ImageJ 341 70.6 (39.6) 0.919 
(<0.001a) 
+20.3% (0.21) <0.001b 
Slice-O-Matic 341 57.7 (36.4)  
SFI (cm2/m2) ImageJ 341 86.1 (50.2) 0.969 
(<0.001a) 
+7.9% (0.17) <0.001b 
Slice-O-Matic 341 81.0 (54.8)  
SMI (cm2/m2) ImageJ 341 46.5 (9.7) 0.927 
(<0.001a) 
+2.9% (0.49) <0.001b 
Slice-O-Matic 341 44.0 (9.6)  
SMD (cm2/m2) ImageJ 
Slice-O-Matic 
341 
341 
34.5 (8.3) 
34.1 (8.3) 
0.971 
(<0.001a) 
+1.2% (0.09) <0.001b 
Abbreviations: SD, standard deviation; CT, computed tomography; VFI, visceral fat index; SFI, subcutaneous fat index; SMI; skeletal muscle index.a. Calculated with one sample t-test. b. Calculated with Wilcoxon-test. 
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Table 2.4: The relationship between body composition and overall survival in patients with colorectal cancer using ImageJ and Slice-O-Matic. 
Body composition Software program Threshold value (N, %) Univariate Cox Regression Multivariate Cox regression    
HR (95% CI) P-value  HR (95% CI) P-value  
Visceral obesity ImageJ 256 (75.1) 0.58 (0.40-0.86) 0.007 0.58 (0.40-0.86) 0.007 
Slice-O-Matic 210 (61.6) 0.72 (0.50-1.04) 0.084 _ 0.636 
High SFI ImageJ 271 (79.5) 0.48 (0.32-0.70) <0.001 0.48 (0.32-0.70) <0.001 
Slice-O-Matic 245 (71.8) 0.54 (0.37-0.79) 0.001 _ 0.683 
Sarcopenia (Dolan) ImageJ 157 (46.0) 1.92 (1.32-2.80) 0.001 _ 0.154 
Slice-O-Matic 209 (61.3) 2.04 (1.34-3.10) 0.001 2.04 (1.34-3.10) 0.001 
Sarcopenia (Martin) ImageJ 157 (46.0) 1.75 (1.21-2.55) 0.003 1.75 (1.21-2.55) 0.003 
Slice-O-Matic 203 (59.5) 1.66 (1.11-2.48) 0.012 _ 0.595 
Myosteatosis (Dolan) ImageJ 131 (38.4) 1.62 (1.12-2.34) 0.010 _ 0.992 
Slice-O-Matic 141 (41.3) 1.73 (1.20-2.50) 0.004 1.73 (1.20-2.50) 0.004 
Myosteatosis (Martin) ImageJ 191 (56.0) 0.93 (0.64-1.34) 0.689 _ 0.474 
Slice-O-Matic 181 (53.1) 2.07 (1.40-3.06) <0.001 2.07 (1.40-3.06) <0.001 
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 PET-CT Images Analysis 
2.5.1 PET-CT 
Positron Emission Tomography (PET) is an established nuclear imaging technique based on 
the uptake of glucose that reflects the metabolic activity of tumours and combined with CT 
scanning gives both anatomic and metabolic assessment of the tumour and metastases (49), 
commonly using the tracer 18F-2-fluoro-2-deoxy-D-glucose (18FDG) (76). The PET-CT 
parameters included in this thesis were maximum standardised tumour uptake value 
(SUVmax), mean standardized tumour uptake (SUVmean) and metabolic tumour volume 
(MTV). Tumour derived glucose uptake was then calculated as total lesion glycolysis (TLG) 
using the following formula: TLG= SUVmean x MTV. An example of a PET-CT scan in a 
patients with squamous cell lung cancer is included below (Figure 2.4) (77). 
 
2.5.2 18F FDG-PETCT 
18F FDG-PETCT scanning was performed according to departmental standard procedures 
based on the EANM guidelines (78) on one of the two multimodality PETCT scanners 
(Discovery-690 or 710, General Electric System, Milwaukee, WI, USA). Patients were 
fasted for at least 6 hours before and 1 hour after the IV injection of 400MBq 18F-FDG. 
Blood glucose levels were measured before 18F-FDG injection to ensure concentrations 
<11mmol/l. Unenhanced CT images were acquired using a 120kV automatic mA modulation 
range of 15-240mAs. The torso CT covered from the skull base to the mid-thigh, with 
reconstructions performed at 2.5 mm increments. This was followed by PET images, 
encompassing the same transverse field of view as the CT. PET acquisition time was 3-4 
minutes per bed position. PET attenuation correction was based on the CT data and images 
were corrected for scatter and iteratively reconstructed using Time of Flight and SharpIR on 
a 192x192 matrix. 
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PETCT images were analysed on GE Advantage Workstation using a SUVmax of 7g/ml 
threshold level to view the PET images. SUVmean and MTV were obtained from 3D 
isocontour at 42% of the maximal pixel value (VOL42). TLG was calculated according to 
the following formula: TLG= SUVmean x MTV. PETCT data were measured from the 
region of interest (ROI) placed over the dominant sites. 
2.5.3 Figures and Legends 
 
Figure 2.4: Squamous cell carcinoma in left upper lobe with associated atelectasis. Adapted from Lee et al 
2012 (77) 
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3. THE ROLE OF THE SYSTEMIC INFLAMMATORY RESPONSE IN 
PREDICTING OUTCOMES IN PATIENTS WITH ADVANCED INOPERABLE 
CANCER: SYSTEMATIC REVIEW AND META-ANALYSIS   
 Introduction  
As mentioned above in Chapter 2 cancer is a leading cause of both morbidity and mortality 
globally (79). Furthermore, while a curative intent is the aim of any surgical treatment many 
patients either present with or go onto develop disseminated disease requiring systemic anti-
cancer therapy with a palliative intent. Given that patients with advanced cancer have a 
limited life expectancy appropriate treatment selection becomes vital. Indeed, the paradigm 
of precision medicine (right treatment, right patient, right time) is in the vanguard of 
oncology treatment, and if applied outcomes for all patients would improve irrespective of 
new treatment availability.(80) 
However, optimal allocation of treatment remains elusive.  There is increasing evidence that 
inappropriate anti-cancer treatment does not improve quality of life or survival (26-28, 50).  
A National Clinical Enquiry into Patient Outcome and Death (NCEPOD) reported that 
chemotherapy hastened or directly caused the death of over 25% of patients who died within 
30 days of receiving treatment (26). This need for caution has been further illustrated by a 
randomised control trial comparing early palliative and standard oncological care in patients 
with metastatic non-small cell lung cancer conducted by Temel et al (50). In this randomised 
trial patients who received palliative care early not only maintained better quality of life 
scores but also had a significantly longer median survival (50).  These reports provide a 
persuasive argument for optimising the stratification of anti-cancer therapy in patients with 
advanced cancer.  Therefore, it is important to examine the criteria that may be used to 
effectively stratify patients as to their likely survival prior to the allocation of treatment in 
patients with advanced cancer. 
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In the setting of patients with advanced cancer, Tumour, Node, Metastasis (TNM) staging 
has little discriminatory prognostic value and other patient related measures such as weight 
loss, performance status and quality of life have superior prognostic value.  Therefore, the 
decision to proceed with systemic therapy is frequently based on these parameters by an 
oncologist and primarily on the basis of subjective clinical observation.  More recently, 
measurement of skeletal muscle mass made from CT scans has been proposed to be useful 
in this context (66).   Nevertheless, it is clear that the potential for sub-optimal allocation of 
anti-cancer therapy is considerable. 
Recently, in a systematic review of prognostic tools in patients with advanced cancer, it was 
reported that a number of prognostic tools had been validated in different centres (32). It was 
striking that the majority of these validated tools were based on subjective criteria, in 
particular the assessment of physical function. Only one validated prognostic tool the GPS, 
assessing the magnitude of the systemic inflammatory response, was based exclusively on 
objective criteria. Indeed, there is now strong evidence that the chronic systemic 
inflammatory response results in classical features of cancer cachexia, including the 
preferential loss of lean muscle mass (81-83). Indeed, studies have shown a direct 
relationship between systemic inflammation measured by the GPS and NLR and elevation 
of inflammatory cytokines, adipokines and other biochemical disturbances associated with 
loss of lean muscle mass and reduced performance status (81, 84-87). Recently, Laird and 
co-workers showed that in a large cohort study in two international bio banks, the 
combination of performance status and the systemic inflammatory response as measured by 
the mGPS improved the prediction of outcomes of patients with advanced cancer (17).  
Furthermore, they showed that quality of life was independently associated with both 
performance and the GPS (25). 
Therefore, from the above and with the introduction of immunotherapeutic agents for 
advanced inoperable cancer the aim on this systematic review and meta-analysis is to assess 
 81 
the role of the markers of systemic inflammatory response in predicting outcomes in patients 
with advanced inoperable cancer.  
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 Patients and Methods  
The present systematic review and meta-analysis of published literature was undertaken as 
outlined in Chapter 2. The primary outcome was to assess the prognostic value of the 
systemic inflammatory response in patients with advanced inoperable cancer treated with 
chemotherapy, immunotherapy, radiotherapy, best supportive care or a combination of these 
treatment strategies. This was carried out by a wide-ranging literature search to identify 
studies carried out up to December 2015. The medical subject heading (MeSH) terms used 
were Advanced Cancer, CRP, Albumin, White Cell Count, Neutrophil Count, Lymphocyte 
Count, Monocyte Count, Platelet Count and Red Blood Cell Count. As stated in Chapter 2 
only articles that reported survival analysis were included in the review.  Studies with 
patients who had failed resections and patients who underwent palliative symptom control 
procedures were also included. 
Statistical Analysis  
A meta-analysis was carried out as outlined in Chapter 2.  
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 Results  
Study selection process 
Initial search strategy identified 9546 articles whose titles and abstracts were reviewed 
(Figure 3.1). Articles were excluded if initial curative surgery formed part of the treatment 
regimen (n=3114), where survival was not the primary outcome measure (n=1225), full 
articles were not available (n=1195), articles examining response to bacterial and viral 
infection (n=924), articles not carried out in humans (n=2021), articles not published in 
English (n=219), and those that were a systematic review/meta-analysis (n=149).  
This led to a review of the full text of 699 articles. Further articles were excluded if surgery 
was part of the treatment regimen being examined (n=421), progression free survival (PFS) 
was the only outcome measured (n=62) and if survival was not expressed as HR (95%CI; 
n=47). The remaining 169 articles had their bibliographies reviewed in a systematic manner 
and this identified a further 29 articles to be included in the final analysis leading to a final 
total of 198 articles.   
 
Studies of the prognostic value of C-reactive protein (CRP) in patients with advanced 
cancer: 
Sixty-three articles with both OS and/or CSS as their primary outcome measures were 
identified comprising data on 13,498 patients (8,466 deaths) (Table 17.1). Fifty-four studies 
were carried out in a retrospective manner while eight were prospective with one study 
having both prospective and retrospective arms (Table 17.1). Fifty-four studies used 
multivariate and nine used univariate survival analysis (Table 17.1). On meta-analysis of the 
55 retrospective studies including 11,761 patients (7,316 deaths) there was a significant 
association between elevated CRP and survival (HR: 1.97 95%CI 1.76-2.21, p<0.00001) 
with a considerable degree of heterogeneity (I2=92%). On meta-analysis of the 9 prospective 
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studies including 1,598 patients (1,009 deaths) there was a significant association between 
elevated CRP and survival (HR: 1.72 95%CI1.31-2.26, p<0.00001) with a considerable 
degree of heterogeneity (I2=88%). 
Fifty-six studies examined the relationship with overall survival including 11,787 patients 
(7,477 deaths), as the primary outcome measure. On meta-analysis, there was a significant 
association between CRP and overall survival (HR: 1.47 95%CI 1.40-1.54, p<0.00001) with 
a considerable degree of heterogeneity (I2=90%,Figure 3.2).  There was variation in the 
threshold of CRP used in the studies, the most common being >10 mg/L (n=19) followed by 
>5 mg/L (n=5). Other thresholds (n=32) were used in <5 studies and therefore meta-analysis 
was not carried out.  
On meta-analysis those studies with a threshold of >10mg/L (n=19), including 3,883 patients 
(3,458 deaths), there was a significant association between CRP and overall survival (HR: 
1.73 95%CI 1.55-1.93, p<0.00001) with a moderate degree of heterogeneity (I2 = 35%). 
These included studies on cancer of the pancreas (n=6), lung (n=5), lymphoma (n=2), HCC 
(n=1), osteosarcoma (n=1), prostate (n=1), oesophagus (n=1), multiple cancers (n=1) and 
renal cells (n=1).  
On meta-analysis of those studies with a threshold of >10mg/L and pancreatic cancer (n=6) 
1,510 patients (1,446 deaths) there was a significant association between CRP and overall 
survival (HR: 1.64 95%CI 1.28-2.10, p<0.0001) with substantial heterogeneity (I2=73%). In 
these six studies, there was a variation in their geographical locations including Japan (n=2), 
Korea (n=2), Germany (n=1) and Australia (n=1).  The proportion of patients who had a 
CRP level >10mg/L with pancreatic cancer was 90% in Japan, 65% in Korea, 63% in 
Australia and 19% in Germany. 
On meta-analysis of those studies with a threshold of >10mg/L and lung cancer (n=5) 
including 996 patients (960 deaths) there was a significant association between CRP and 
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overall survival (HR: 1.58 95%CI 1.37-1.84, p<0.00001) with no heterogeneity (I2=0%). In 
these 5 studies, there was a wide variation in their geographical locations including the Czech 
Rep (n=1), UK (n=1), Sweden (n=1), China (n=1) and Japan (n=1).  The proportion of 
patients who had a CRP level >10mg/L and lung cancer was 98% in the Czech Rep, 80% in 
the UK, 71% in Sweden, 43% in China and 33% in Japan.  Remaining cancer types and 
geographical locations had <5 studies therefore further meta-analysis was not carried out. 
On meta-analysis those studies with a threshold of >5mg/L (n=5), including 961 patients 
(515 deaths), there was a significant association between CRP and overall survival (HR: 1.66 
95%CI 1.15-2.38, p=0.007) with a substantial degree of heterogeneity (I2 = 83%). These 
included studies on cancer of the pancreas (n=2), prostate (n=1), renal cells (n=1) and 
colorectal (n=1).  These included studies carried out in Japan (n=3), Belgium (n=1) and 
Sweden (n=1). The proportion of patients who had a CRP>5mg/L was 100% in Sweden, 
66% in Belgium and 50% in Japan.  Remaining cancer types and geographical locations had 
<5 studies therefore further meta-analysis was not carried out. 
Ten studies examined the relationship with cancer specific survival including 1711 patients 
(989 deaths), as its primary outcome measure. On meta-analysis, there was a significant 
association between CRP and cancer specific survival (HR: 2.93 95%CI 2.14-4.01, 
p<0.00001) with a substantial degree of heterogeneity (I2=66%). The most common 
thresholds used on the CSS group were >10 mg/L (n=4) including cancer of the prostate 
(n=1), breast (n=1), renal cells (n=1) and urothelial (n=1). All thresholds had <5 studies and 
therefore meta-analysis was not carried out. In the >10mg/L group studies were carried out 
in the UK (n=3) and Italy (n=1). The proportion of patients who had a CRP level >10mg/L 
was 64% in the UK and 50% in Italy.  
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 Studies of the prognostic value of albumin (Alb) in patients with advanced cancer: 
Thirty-three articles with both OS (n=29) and/or CSS (n=5) as their primary outcome 
measures were identified comprising data on 10,288 patients (8,740 deaths) (Table 17.2). 
Twenty-eight studies were conducted in a retrospective manner while five were prospective. 
Twenty-nine articles used multivariate and four univariate survival analysis (Table 17.2). 
Thirty-one studies examined the relationship with overall survival including 9,753 patients 
(8,493 deaths), as its primary outcome measure. On meta-analysis, there was a significant 
association between low albumin and overall survival (HR: 1.77 95%CI 1.54-2.03, 
p<0.00001) with a considerable degree of heterogeneity (I2=84%, Figure 3.3).  There was 
variation in the threshold of albumin examined. The most common thresholds examined 
were <35g/L (n=13) and <30 mg/L (n=5). Other thresholds were used in <5 studies (n=15) 
and therefore meta-analysis was not carried out.  
On meta-analysis those studies with a threshold of <35g/L (n=13), including 2,127 patients 
(1,831 deaths), there was a significant association between low albumin and overall survival 
(HR: 2.21 95%CI 1.60-3.06, p<0.00001) with a considerable degree of heterogeneity (I2 = 
79%). These included studies on cancer of the pancreas (n=5), biliary tract (n=2), multi 
anatomical sites (n=1), breast (n=1), lung (n=1), HCC (n=1), colorectal (n=1) and multiple 
myeloma (n=1).  These included studies carried out in Korea (n=6), Japan (n=3), Singapore 
(n=1), Canada (n=1), Belgium (n=1), France (n=1), Spain (n=1), Australia (n=1), and the 
UK (n=1). The proportion of patients who had an albumin <35g/L was 51% in Korea, 49% 
in Spain, 31% in Belgium, 26% in the UK and 16% in France.   
On meta-analysis of those studies with a threshold of <35g/L and pancreatic cancer (n=5) 
910 patients (834 deaths) there was a significant association between reduced albumin and 
overall survival (HR: 1.96 95%CI 1.04-3.69, p=0.04) with substantial heterogeneity 
(I2=85%). In these five studies, there was a variation in their geographical locations including 
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Korea (n=2), Japan (n=1), Australia (n=1) and Belgium (n=1).  The proportion of patients 
who had an albumin level <35g/L with pancreatic cancer was 31% in Belgium and 42% in 
Australia.  
On meta-analysis of those studies with a threshold of <30g/L (n=5), including 1,319 patients 
(1,192 deaths), there was a significant association between low albumin and overall survival 
(HR: 1.57 95%CI 1.26-1.95, p<0.0001) with a minimal degree of heterogeneity (I2 =14%).  
These included studies on cancer of the lung (n=2), gastric (n=1), renal cells (n=1), and 
multiple anatomical sites (n=1).  These included studies carried out in the US (n=1), Taiwan 
(n=1), Japan (n=1), Turkey (n=1) and Sweden (n=1). The proportion of patients who had an 
albumin <30g/L was 49% in Taiwan, 39% in Japan, 20% in Turkey and 17% in Sweden.   
 
Studies of the prognostic value of white cell count (WCC) in patients with advanced cancer: 
Four articles with both OS (n=3) and/or CSS (n=1) as their primary outcome measures were 
identified comprising data on 1,593 patients (1,440 deaths) (Table 17.3).  All four were 
retrospective multivariate survival studies carried out in cancer of the lung (n=2), renal cells 
(n=1) and multiple anatomical sites (n=1). There was variation in the level of WCC used 
between different papers including >10x109/L (n=2), >10.2x109/L for males and >10.6x109 
/L for females (n=1), and >11 x 109 /L for both sexes (n=1). Geographically studies were 
carried out in the UK (n=2), US (n=1) and Italy (n=1). The proportion of patients who had 
an elevated WCC was 24% in the US, 28% in the UK and 28% in Italy. Due to the small 
number of studies, meta-analysis was not carried out.  
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 Studies of the prognostic value of neutrophils in patients with advanced cancer: 
Nine articles with both OS (n=7) and/or CSS (n=2) as their primary outcome measures were 
identified comprising data on 2,870 patients (2,266 deaths) (Table 17.4). Seven studies were 
conducted in a retrospective manner while two were prospective. (Table 17.4).  Five articles 
reported significance on multivariate and two articles reported significance on univariate 
survival analysis. There was variation in the levels of neutrophils used in individual papers 
including neutrophil count ≥ upper limit of normal (ULN) without defining it explicitly 
(n=3), neutrophil count >7.5x109 cells/ml (n=1), neutrophil count >3.41x109 cells/ml (n=1), 
absolute neutrophil count (ANL) >4.7 x 109 L (n=1), ANC≥7500 (n=1), log of readings 
above normal which was defined as >7x109/L (n=1) and >8x109/L (n=1).   
Seven studies examined the relationship with overall survival including 2,364 patients 
(1,999 deaths), as its primary outcome measure.  On meta-analysis, there was a significant 
association between elevated neutrophils and overall survival (HR: 1.89 95%CI 1.25-2.85, 
p=0.002) with a considerable degree of heterogeneity (I2=87%).  Studies were in melanoma 
(n=2), renal (n=1), lung (n=1), breast (n=1), mesothelioma (n=1) and lung (n=1) cancer. 
Geographically studies were carried out in France (n=2) and Italy (n=2), USA (n=1), China 
(n=1) and Australia (n=1). The proportion of patients who had elevated Neutrophils was 
32% in Australia, 28% in France, 19% in the USA and 12% in Italy.  
Two studies examined the relationship with cancer specific survival including 506 patients 
(267 deaths), as its primary outcome measure. Due to the small number of studies, meta-
analysis was not carried out.  
 
Studies of the prognostic value of lymphocytes in patients with advanced cancer: 
Eleven articles with OS as their primary outcome measures were identified comprising data 
on 2,517 patients (2,148 deaths) (Table 17.5). Ten studies were conducted in a retrospective 
 89 
manner and one prospectively. Nine studies reported significance on multivariate survival 
analysis and two on univariate survival analysis. (Table 17.5). On meta-analysis, there was 
a significant association between lower lymphocyte levels and overall survival (HR: 1.68 
95%CI 1.35-2.09, p<0.00001) with a substantial degree of heterogeneity (I2=68%).   
There was considerable variation in the lymphocyte thresholds used in each study including 
continuous readings (n=1), <0.5x109/L (n=1), <0.7x109/L (n=1), >2x109/L (n=2), <1x109/L 
(n=2), ≥0.45x109/L (n=1), <2.25x109/L (n=1), <1.4x1x109/L (n=1), and 2.70x109/L (n=1). 
These included studies on cancer of the pancreas (n=3), lymphoma (n=1), lung (n=1), 
nasopharyngeal (n=1), mesothelioma (n=1), colorectal (n=1), cervical (n=1), melanoma 
(n=1) and multiple cancer types (n=1). Geographically studies were carried out in China 
(n=3), US (n=3), France (n=2), Japan (n=2) and Korea (n=1), The proportion of patients who 
had low lymphocytes was 75% in Korea, 48% in US, 47% in China, 45% in Japan and 32% 
in France. All eleven studies used chemotherapy as the treatment modality. No specific 
lymphocyte thresholds had more than four studies and therefore no further meta-analysis 
was carried out. 
 
Studies of the prognostic value of monocytes in patients with advanced cancer: 
Five articles with OS as their primary outcome measures were identified comprising data on 
1,367 patients (1,152 deaths) (Table 17.6). All five studies were conducted in a retrospective 
multivariate manner, used chemotherapy as the treatment regime of choice and conducted 
their analysis in a multivariate manner. On meta-analysis of there was a significant 
association between elevated monocytes and survival (HR: 1.40 95%CI 1.05-1.87, p=0.02) 
with a substantial degree of heterogeneity (I2=66%).  There was considerable variation in 
the levels of monocytes used including >0.8x109/L (n=1), ≥0.64x109/L (n=1), ≥0.45x109/L 
(n=1), ≥0.35x109/L (n=1) and ≥0.55x109/L (n=1). There was also variation in the types of 
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cancer examined including lung (n=2), lymphoma (n=1), nasopharyngeal (n=1) and 
colorectal metastasis (n=1).  In terms of geographical locations, the studies were carried out 
in China (n=3), Korea (n=1) and Italy (n=1).  The proportion of patients who had high 
monocytes was 57% in China, 50% in Korea, and 23% in Italy. No specific monocyte 
thresholds had more than four studies and therefore no further meta-analysis was carried out. 
 
Studies of the prognostic value of platelets in patients with advanced cancer: 
Eight articles with both OS (n=7) and/or CSS (n=1) as their primary outcome measures were 
identified comprising data on 4,850 patients (2,422 deaths) (Table 17.7). Seven studies were 
conducted in a retrospective manner while one was prospective (Table 17.7).  All eight 
articles reported multivariate survival analysis. 
Seven studies examined the relationship with overall survival including 4,653 patients 
(2,293 deaths), as its primary outcome measure. On meta-analysis of there was a significant 
association between elevated platelets and survival (HR: 1.47 95%CI 1.12-1.93, p=0.006) 
with a considerable degree of heterogeneity (I2=92%).  There was variation in the thresholds 
of platelets examined including a platelet count >300 × 109 /L (n=1), >360 x 109 /L (n=1), 
<130 g/L (n=1), >350 × 109 /L (n=1), >450 × 109 /L (n=1), ≥ULN (n=1) and continuous 
readings (n=1). There was also variation in the type of cancers being examined including 
lung (n=1), oropharyngeal (n=1), pleural mesothelioma (n=1), nasopharyngeal (n=1), 
pancreatic (n=1), renal (n=1) and multiple cancers (n=1). Geographically studies were 
carried out in US (n=3), China (n=2), France (n=1) and Sweden (n=1). The proportion of 
patients who had elevated platelet counts was 30% in Sweden, 24% in the US, 15% in China 
and 11% in France.  However, no specific platelet thresholds had more than four studies and 
therefore no further meta-analysis was carried out. 
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Studies of the prognostic value of the Glasgow Prognostic Score (GPS/mGPS) in patients 
with advanced cancer: 
Forty-four articles with both OS (n=37) and/or CSS (n=9) as their primary outcome 
measures were identified comprising data on 12,578 patients (10,745 deaths) (Table 17.8).  
Thirty-two studies were conducted in a retrospective manner while twelve were prospective 
(Table 17.8).  Forty studies reported multivariate and four reported univariate survival 
analysis (Table 17.8).  On meta-analysis of the 32 retrospective studies including 9,472 
patients (7,936 deaths) there was a significant association between elevated GPS/mGPS and 
survival (HR: 1.93 95%CI 1.76-2.13, p<0.00001) with a moderate degree of heterogeneity 
(I2=42%).  On meta-analysis of the 12 prospective studies including 3,244 patients (2,809 
deaths) there was a significant association between elevated GPS/mGPS and survival (HR: 
2.09 95%CI 1.69-2.57, p=0.0001) with a substantial degree of heterogeneity (I2=69%).  
Thirty-six studies examined the relationship with overall survival including 11,441 patients 
(10,022 deaths), as its primary outcome measure.  On meta-analysis, there was a significant 
association between GPS and overall survival (HR: 2.06 95%CI 1.86-2.28, p<0.00001) with 
a substantial degree of heterogeneity (I2=56%, Figure 3.4).  These included studies on cancer 
of multiple anatomical sites (n=7), gastric (n=7), lung (n=5), pancreas (n=5), colon (n=3), 
lymphoma (n=1), biliary tract (n=1), bladder (n=1), haematological (n=1), prostate (n=1), 
renal cell (n=1), oesophagus (n=1), HCC (n=1) and cervix (n=1). 
On meta-analysis those studies carried out in multiple anatomical sites (n=7), including 
5,804 patients (5,139 deaths), there was a significant association between elevated 
GPS/mGPS and overall survival (HR: 2.22 95%CI 1.81-2.71, p<0.00001) with a moderate 
degree of heterogeneity (I2 = 65%). These included studies carried out in the UK (n=2), 
Australia (n=2), Japan (n=1), Norway (n=1) and Brazil (n=1). The proportion of patients 
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who had an elevated GPS was 93% in Japan, 77% in the UK, 69% in Norway, 46% in 
Australia and 20% in Brazil.  
On meta-analysis those studies carried out in gastric cancer (n=7), including 1,283 patients 
(5139 deaths), there was a significant association between elevated GPS/mGPS and overall 
survival (HR: 2.08 95%CI 1.58-2.74, p<0.00001) with a moderate degree of heterogeneity 
(I2 = 40%). These included studies carried out in the Japan (n=2), Korea (n=2), Taiwan 
(n=1), UK (n=1) and Czech Rep (n=1).  The proportion of patients who had an elevated GPS 
was 74% in Taiwan, 73% in the UK, 52% in the Czech Rep, 49% in Japan and 42% in Korea. 
On meta-analysis those studies carried out in lung cancer (n=5), including 1,104 patients 
(708 deaths), there was a significant association between elevated GPS and overall survival 
(HR: 2.05 95%CI 1.52-2.77, p<0.00001) with a substantial degree of heterogeneity (I2 = 
55%). These included studies carried out in the UK (n=2), China (n=2) and Greece (n=1). 
The proportion of patients who had an elevated GPS was 76% in the UK, 33% in China and 
29% in Greece.  
On meta-analysis those studies carried out in pancreatic cancer (n=5), including 735 patients 
(719 deaths), there was a significant association between elevated GPS and overall survival 
(HR: 1.91 95%CI 1.29-2.83, p=0.001) with a substantial degree of heterogeneity (I2 = 70%). 
These included studies carried out in the Japan (n=3), Australia (n=1) and the UK (n=1). The 
proportion of patients who had an elevated GPS was 70% in the UK, 63% in Australia and 
36% in Japan.   
Nine studies examined cancer specific survival including 1,137 patients (723 deaths), as its 
primary outcome measure. On meta-analysis, there was a significant association between 
elevated GPS and cancer specific survival (HR: 1.69 95%CI 1.48-1.92, p<0.00001) with a 
minimal degree of heterogeneity (I2=4%).  These included studies on cancer of the colon 
(n=3), lung (n=2), gastro-oesophageal (n=2), breast (n=1) and renal cells (n=1). These 
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included studies carried out in the UK (n=5), Japan (n=2) and China (n=2). The proportion 
of patients who had an elevated GPS was 77% in China, 65% in the UK and 43% in Japan.  
However, since no cancer type or country had more than four studies further meta-analysis 
was not carried out.   
 
Studies of the prognostic value of Neutrophil Lymphocyte Ratio (NLR) in patients with 
advanced cancer: 
Fifty-nine articles with both OS (n=58) and/or CSS (n=2) as their primary outcome measures 
were identified comprising data on 16,921 patients (12,801 deaths) (Table 17.9).  Forty-three 
of these were conducted in a retrospective manner while sixteen were prospective. Fifty-five 
studies reported multivariate and four reported univariate survival analysis (Table 17.9). On 
meta-analysis of the 43 retrospective studies including 10,870 patients (8,044 deaths) there 
was a significant association between elevated NLR and survival (HR: 1.78 95%CI 1.59-
1.98, p<0.00001) with a considerable degree of heterogeneity (I2=77%; Figure 3.5). On 
meta-analysis of the 16 prospective studies including 5,898 patients (4,733 deaths) there was 
a significant association between elevated NLR and survival (HR: 1.63 95%CI 1.41-1.88, 
p<0.00001) with a substantial degree of heterogeneity (I2=67%; Figure 3.5).  
Fifty-eight studies examined the relationship with overall survival including 16,405 patients 
(12,675 deaths) as its primary outcome measure. On meta-analysis, there was a significant 
association between NLR and overall survival (HR: 1.71 95%CI 1.57-1.86, p<0.00001) with 
a substantial degree of heterogeneity (I2=79%, Figure 3.5). The most common NLR 
thresholds used were ≥5 (n=19), ≥4 (n=5) and ≥3 (n=12). Other thresholds were used in <5 
studies and therefore meta-analysis was not carried out (n=23).  
On meta-analysis those studies with a threshold of ≥5 (n=19), including 5,506 patients (4,613 
deaths) there was a significant association between elevated NLR and overall survival (HR: 
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1.64 95%CI 1.42-1.89, p<0.00001) with a substantial degree of heterogeneity (I2 = 57%). 
These included cancer of the pancreas (n=5), lung (n=4), colorectal (n=3), multiple 
anatomical sites (n=2), mesothelioma (n=1), prostate (n=2), cholangiocarcinoma (n=1) and 
HCC (n=1).  
On meta-analysis of those studies with a threshold of ≥5 and pancreatic cancer (n=5) 1009 
patients (942 deaths) there was a significant association between an NLR≥5 and overall 
survival (HR: 1.78 95%CI 1.30-2.44, p=0.0003) with substantial heterogeneity (I2=56%). In 
these five studies, there was a variation in their geographical locations including Japan (n=2), 
Australia (n=1), Korea (n=1) and China (n=1).  The proportion of patients who had an 
NLR≥5 with pancreatic cancer 48% in Australia, 29% in Korea, and 20% in Japan. No 
country had more than 4 studies and therefore no further meta-analysis was carried out.    
On meta-analysis those studies with a threshold of ≥4 (n=5), including 834 patients (588 
deaths), there was a significant association between elevated NLR and overall survival (HR: 
2.08 95%CI 1.45-3.00, p<0.0001) with a substantial degree of heterogeneity (I2 = 57%). 
These included cancer of the lung (n=1), colorectal (n=1), B-cell lymphoma (n=1), T-cell 
lymphoma (n=1) and gastric (n=1).  In these five studies, there was a variation in their 
geographical locations including Japan (n=2), UK (n=1), Peru (n=1) and Austria (n=1).  The 
proportion of patients who had an NLR≥4 was 40% in Japan, 35% in Peru, 32% in the UK 
and 19% in Austria. 
On meta-analysis those studies with a threshold of ≥3 (n=12), including 4,195 patients (3,130 
deaths), there was a significant association between elevated NLR and overall survival (HR: 
1.75 95%CI 1.53-2.01, p<0.00001) with a substantial degree of heterogeneity (I2=56%). 
These included cancer of the renal cells (n=3), prostate (n=3), gastric (n=3), melanoma 
(n=1), colorectal (n=1) and multiple anatomical sites (n=1). These included studies carried 
out in the Korea (n=2), US/Israel (n=2), China (n=2), Italy (n=2), Australia (n=1), Canada 
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(n=1), Taiwan (n=1) and the UK (n=1). The proportion of patients who had an NLR≥3 was 
71% in the US/Israel, 53% in Korea, 52% in Australia, 51% in Taiwan, 47% in the UK, 42% 
in China and 30% in Italy. No tumour site had more than four studies and therefore no further 
meta-analysis was carried out. 
 
Studies of the prognostic value of lymphocyte monocyte ratio (LMR) in patients with 
advanced cancer: 
Eleven articles with both OS (n=11) and/or CSS (n=1) as their primary outcome measures 
were identified comprising data on 5,043 patients (3,842 deaths) (Table 17.10).  All 11 
studies were retrospective and multivariate analysis was carried out.  On meta-analysis, there 
was a significant association between a low LMR and overall survival (HR: 1.84 95%CI 
1.64-2.07, p<0.00001) with minimal heterogeneity (I2=8%, Figure 3.6). There was a variety 
of LMR thresholds used in each study including ≤2.6 (n=1), <2.8 (n=1), ≥2.475 (n=1), <2.11 
(n=1), >5.22 (n=1), ≤4.56 (n=1), ≤5.07 (n=1), ≤3.4 (n=1), ≤2.11 (n=1), ≤3.11 (n=1) and low 
LMR but no figures given (n=1).  These included studies on lung cancer (n=2), lymphoma 
(n=2), nasopharyngeal cancer (n=3) Hodgkin’s lymphoma (n=2), and colorectal (n=2). 
Geographically the studies were carried out in China (n=5), Korea (n=3), Taiwan (n=1), 
Hungary (n=1) and Italy (n=1). The proportion of patients who had low LMRs was 53% in 
Italy, 52% in Korea 45% in China and 41% in Taiwan. No specific LMR thresholds had 
more than four studies and therefore no further meta-analysis was carried out. 
 
Studies of the prognostic value of platelet lymphocyte ratio (PLR) in patients with advanced 
cancer: 
Twelve articles with both OS (n=12) and/or CSS (n=2) as their primary outcome measures 
were identified comprising data on 5,733 patients (2,611 deaths) (Table 17.11).  Ten studies 
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were conducted in a retrospective manner and two prospectively. Eleven studies were also 
conducted in a multivariate and one in a univariate manner (Table 17.11).  On meta-analysis, 
there was a significant association between an elevated PLR on overall survival (HR: 1.49 
95%CI 2.10-1.84, p=0.0003) with considerable heterogeneity (I2=82%, Figure 3.7). There 
was a variety of PLR thresholds used in each study including >111.23 (n=1), ≥190 (n=1), 
>153.44 (n=1), >322 (n=1), >146 (n=1), >200 (n=1), ≥152.6 (n=1), ≥250 (n=1), >119.50 
(n=1), ≥150 (n=1), >162 (n=1) and one study which simply stated elevated PLR without 
given a numerical value. These included studies on cancer of the lung (n=5), nasopharynx 
(n=1), cervix (n=1), prostate (n=1), pancreas (n=2), colorectal (n=1) and liver (n=1). 
Geographically studies were located in China (n=6), Japan (n=2), Turkey (n=1), Austria 
(n=1), Australia (n=1) and the US (n=1). The proportion of patients who had an elevated 
PLR was 61% in Australia, 59% in Japan, 50% in Turkey, 31% in China, 29% in Austria 
and 20% in the US. No specific PLR thresholds had more than four studies and therefore no 
further meta-analysis was carried out. 
 
Studies of the prognostic value of other markers/scores of the systemic inflammatory 
response in patients with advanced cancer: 
During the course of this review several studies (n=6) were identified which could not be 
assigned to one of the above groupings (Table 17.12). Two studies focused on the 
CRP/Albumin ratio (CAR). The first such study was by Zhou et al(88) from China. In this 
multivariate survival analysis on patients with small cell lung cancer a CRP/Alb ratio ≥0.441 
was shown to be related to a statistically significant worse OS (HR: 1.34 95%CI 1.04-1.73 
p=0.025).  The second such study by Yamashita et al(89) from Japan. In this multivariate 
survival analysis on patients with prostate cancer a CRP/Alb ratio ≥7 was shown to be related 
to a statistically non-significant worse overall survival (HR: 2.34 95%CI 0.91-6.05 p=0.08).  
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Two further studies focused on the relationship between globulin, albumin and survival. 
Shibutani et al(90) in Japan reported that the albumin/globulin ratio predicted overall 
survival (HR: 2.247, 95%CI 1.069-4.722, p=0.033) independent of the NLR. Yao et al(91) 
in China reported that in patients with advanced NSCLC, the globulin/albumin ratio (GAR) 
>0.58 and an Alb<35g/L was associated with poorer OS (GAR HR: 1.65, 95%CI  1.20-2.26, 
p=0.002, Alb HR 1.92, 95%CI ,1.10-3.36, p=0.022). Chan et al(92) in China reported that, 
in patients with HCC, the albumin-to-alkaline phosphatase ratio (AAPR) >0.68 predicted 
poorer OS (HR 2.185, 95%CI, 1.780-2.683, p<0.001).  
Finally, Zhou et al(88) in China reported that, in patients with SCLC, the CRP/Globulin ratio 
≥1.29 predicted poorer OS in both the testing (HR: 1.35, 95%CI, 1.61-1.81, p=0.046) and 
validated (HR: 1.43, 95%CI, 1.052-1.95, p=0.022) cohorts. Due to the small number of these 
studies meta-analysis was not carried out.      
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  Discussion   
The results of the present systematic review and meta-analysis show clearly that the systemic 
inflammatory response, as evidenced by a number of markers at clinical thresholds, have 
independent prognostic value, across tumour types and geographical locations, in patients 
with advanced cancer.  In particular, CRP, albumin and neutrophil count and the scores 
derived from them (GPS and NLR) have been consistently validated worldwide. There was 
considerable variation in the thresholds reported to have prognostic value when CRP, 
albumin and neutrophil counts were examined. There was less variation in the thresholds 
reported for NLR and still less for the GPS. The majority of studies were retrospective and 
therefore further prospective studies are warranted.  In particular, there is a need to determine 
their clinical utility in the context of randomised clinical trials and thereby inform the 
appropriate treatment selection for patients with advanced cancer.  
In the present review, the majority of studies reported overall survival as the endpoint.  
However, for some markers of the systemic inflammatory response such as CRP and GPS 
there were also multiple studies using cancer specific survival as an endpoint.  It was of 
interest therefore that, on meta-analysis, the degree of heterogeneity appeared to be greater 
for overall survival as an endpoint compared with cancer specific survival (CRP 90% vs. 
66% and GPS 56% vs. 4% respectively).  This observation may be explained by previous 
observations that markers of the systemic inflammatory response have a stronger 
relationship with the cancer survival compared with the overall survival (93, 94).  Therefore, 
the optimal prognostic utility of markers of the systemic inflammatory response such as CRP 
and the GPS are in the prediction of cancer specific survival. 
With reference to overall survival as an end-point, heterogeneity was greater in studies with 
a variety of thresholds compared to those with a standard threshold (e.g. CRP 90% (all) vs. 
35% (>10mg/l), albumin 84% (all) vs. 79% (<35g/l) and NLR 79% (all) vs. 57% (>5) 
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respectively).  In studies with these specific thresholds (e.g. in CRP threshold >10mg/l), 
compared with all tumour types, heterogeneity was less in specific tumour types (e.g. lung 
cancer heterogeneity was lower, 0% vs. 35% for all).  Therefore, the threshold used, and the 
specific cancer studied influence the consistency of the association between markers of the 
systemic inflammatory response and overall survival in patients with advanced cancer.  This 
has implications for the routine clinical application of markers such as CRP and NLR where 
several different thresholds have been reported in the literature.  However, the GPS/mGPS 
have internationally recognised thresholds and are the preferred measure of the systemic 
inflammatory response amongst those investigators active in the field (95) and therefore are 
likely to have reproducible clinical utility in the context of randomised trials in patients with 
advanced cancer. 
In the present review it was of interest that, across different markers of the systemic 
inflammatory response, when comparing using the same threshold and tumour type, the 
geographical prevalence of an elevated systemic inflammatory response varied.  There was 
a trend towards a greater proportion of patients who had elevated markers in Western 
countries compared with Eastern Asian countries.  Given the objective nature of these 
measurements there may be genetic or environmental causes of such a consistent difference.  
Indeed, as was mentioned in Chapter 2 there are well known ethnic differences in the normal 
range of neutrophils and lymphocytes (96-98).   Given that the most common thresholds 
used for NLR were >5 and >3 it is likely that a combination of genetic and environmental 
factors are responsible for such consistent East/West differences.  To date, similar data for 
the GPS/mGPS has not appeared in the literature.  Therefore, differences in the magnitude 
of systemic inflammatory responses may explain, in part, the East/West split often observed 
in overall survival independent of tumour stage alone.  Irrespective, the present results point 
to the value of not only staging the tumour but also the host systemic inflammatory response 
(99) in patients with advanced disease.  
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As mentioned above while IL-6 would appear to be an ideal marker for the systemic 
inflammatory response its strong correlation with CRP, and the relative expense of IL-6 
measurement has resulted in IL-6 not being routinely measured despite its central position 
in the systemic inflammatory cascade.  Furthermore, IL-6 is produced in most tissues 
including the tumour meaning that compared with CRP and albumin (produced in the liver 
only) and neutrophils and platelets (myeloid tissue only), its use as a marker of the systemic 
inflammatory responses is perhaps suboptimal.   
While little work has focused on the use of systemic inflammatory response monitoring to 
track treatment response in the setting of advanced disease this is not the case in the 
neoadjuvant and adjuvant settings (100-102).  Carruthers et al (2012) showed a direct 
relationship between an NLR ≥ 5  and decreased time to local recurrence (HR: 3.8 95%CI 
1.3–11.2 p=0.014) in patients with locally advanced rectal cancers receiving 
chemoradiotherapy (102). Dreyer et al (2016) showed that an elevated mGPS was associated 
with a poorer pathological response (p=0.022) in patients treated with neoadjuvant 
chemoradiotherapy (101), while Crozier et al (2006) showed that a CRP≥10mg/l was 
associated with worse survival in patients receiving adjuvant chemotherapy following 
surgery for colorectal cancer (HR: 5.57 95%CI 1.32–23.51 p=0.019) (100).  It has been 
widely reported that the  toxicity caused by chemotherapy and/or radiotherapy has its basis 
in the inflammatory response (51). This suggests that immune system modulation could be 
the key mechanism in their therapeutic activity and a potential therapeutic target (51, 103, 
104).  
Furthermore, there is increasing evidence that the systemic inflammatory response is a 
central mediator of the negative symptoms associated with both chemotherapy and 
radiotherapy (51, 105). Animal models have suggested that the administration of 
chemotherapeutic agents induces IL-6 production and illness behaviours in mice (51, 106). 
Several common chemotherapeutic agents have been shown to be associated with the 
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production of proinflammatory cytokines and the presence of natural killer (NK) cells, and 
activated T cell in patients with cancer (51, 107-109). In a recent observational study in 
patients being treated with chemoradiotherapy for advanced disease there was a dose-
dependent rise in IL 6, IL 10, and TNF, correlating with symptoms such as pain, fatigue, and 
anorexia (51, 110).  
The development of immune-oncology medications such as ipilimumab provides a potential 
means to target the activated inflammatory cascades to treat patients (111, 112). Indeed in a 
recent study in pancreatic cancer ruxolitinib, a strong down regulator of the inflammatory 
JAK/STAT pathway, was shown to increase median survival from 1.8 to 2.7 months in 
patients with high CRP readings (113).  This suggests a possible innovative means to treat 
patients with advanced cancers (113). 
The present systematic review and meta-analysis has a number of limitations. While it was 
the aim to only include the most recent paper where multiple publications from the same 
cohort where available, due to the practice of combining databases from different 
geographical locations under different lead institutions some double counting has occurred.  
Intrinsic to the process and the high proportion of retrospective studies is the potential for 
publication bias.  However, the volume of studies examined in the present review would 
mitigate, in part, against such publication bias.  In the meta-analysis there was considerable 
heterogeneity that could be accounted for in part by differing thresholds and tumour type.  It 
may be that as there is greater threshold standardisation in prospective studies the degree of 
heterogeneity will be reduced in subsequent meta-analysis of prospective studies.    
In summary, the present systematic review and meta-analysis shows clearly that the systemic 
inflammatory response, as evidenced by a number of markers, has independent prognostic 
value in patients with advanced cancer.  Of these markers, the GPS and NLR have been 
consistently validated worldwide.  Therefore, it can be concluded that the systemic 
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inflammatory response is an important predictor of outcome and is likely to inform treatment 
decisions in patients with advanced cancer.  Further prospective studies are warranted.
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 Figures and Legends  
 
Figure 3.1: PRISMA flowchart demonstrating study selection 
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Figure 3.2: Forrest Plot of Studies investigating the prognostic value of CRP in an unselected cohort of patients 
with advanced cancer  
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Figure 3.3: Forrest Plot of Studies investigating the prognostic value of Albumin in an unselected cohort of 
patients with advanced cancer   
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Figure 3.4: Forrest Plot of Studies investigating the prognostic value of GPS/mGPS in an unselected cohort of 
patients with advanced cancer 
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Figure 3.5: Forrest Plot of Studies investigating the prognostic value of NLR in an unselected cohort of patients 
with advanced cancer 
 108 
 
Figure 3.6: Forrest Plot of Studies investigating the prognostic value of LMR in an unselected cohort of patients 
with advanced cancer   
 
Figure 3.7: Forrest Plot of Studies investigating the prognostic value of PLR in an unselected cohort of patients 
with advanced cancer  
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4. THE ROLE OF THE SYSTEMIC INFLAMMATORY RESPONSE IN 
PREDICTING OUTCOMES IN PATIENTS WITH OPERABLE CANCER: 
SYTEMATIC REVIEW AND META-ANALYSIS  
 Introduction 
Cancer remains one of the leading causes of mortality worldwide and is responsible for  8.8 
million deaths per year (79). Overall, it has been estimated that one in three people will 
develop cancer in their lifetime, and one in four will die from it (114, 115).Indeed, in the UK 
alone it is estimated that 150,000 people die because of cancer each year (79, 115). Such a 
large burden of disease accounts for a significant proportion of the healthcare budgets of the 
UK, US and worldwide medical care (79, 115, 116).  
Four cancers: lung, colorectal, breast and prostate account for approximately half of all new 
cases and deaths (114). For a range of solid organ malignancies including colorectal, lung, 
breast and prostate cancers, definitive local therapy in the form of surgical resection remains 
the cornerstone of treatment (114). 
The genetic composition of many different types of cancer has been widely reported, 
however there is also increasing evidence that the host inflammatory response plays an 
important role in the development and progression of cancer (7, 14, 115, 117). In 2010 
Roxburgh and McMillan published the first comprehensive review of the role of the systemic 
inflammatory response in predicting survival in patients with primary operable cancer (114). 
They identified 80 studies where the systemic inflammatory response was related to either 
overall, and cancer specific survival (114). However the majority of studies used singular 
markers of the inflammatory response such as CRP, albumin neutrophil, lymphocyte and 
platelet counts, indeed just 18 studies reported combined prognostic scores to improve 
prediction of survival (114). These included eight that reported the prognostic value of the 
GPS, and nine studies that reported the prognostic value of NLR. While these studies 
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reported a significant relationship between the systemic inflammatory response and survival 
there were variable thresholds used for the single or combined markers resulting in 
considerable variability in the magnitude of the effect reported (114).  
However, since this review there has been a marked increase in the number of studies 
reporting the prognostic value of combined scoring systems based on the systemic 
inflammatory response. The majority reported have principally been ratios of components 
of the white cell count such as the neutrophil lymphocyte ratio (NLR), platelet lymphocyte 
ratio (PLR), lymphocyte monocyte ratio (LMR) but also acute phase proteins such as C-
reactive protein/albumin ratio (CAR). Another approach is to combine scores of the acute 
phase proteins such as GPS/mGPS (85, 115, 118). The presence of an elevated systemic 
inflammatory response as shown by the presence of circulating white cells and acute phase 
proteins is an important unifying host characteristic in patients with cancer. The prognostic 
ability of the combined scores has been widely reported and there have been reviews of NLR 
(85) and mGPS (87) and in advanced cancer (38). The present review is the first since 2010 
to focus on primarily operable cancer and to include all recognised systemic inflammation 
based prognostic scores. This will rationalise the evidence for the role of systemic 
inflammation based prognostic scores in patients with primary operable cancers.  
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 Patients and Methods 
The present systematic review and meta-analysis of published literature was undertaken as 
outlined in Chapter 2. The primary outcome was to assess the prognostic value of the 
validated combined scores of the systemic inflammatory response (NLR, PLR, LMR, GPS 
and mGPS) in patients with primary operable cancer. This was carried out by a wide-ranging 
literature search to identify studies carried out up to December 2016. The medical subject 
heading (MeSH) terms used were Cancer, GPS, Glasgow Prognostic Score, mGPS, modified 
Glasgow Prognostic Score, NLR, Neutrophil Lymphocyte Ratio, LMR, Leucocyte 
Monocyte Ratio, PLR and Platelet Lymphocyte Ratio. As stated in Chapter 2 only articles 
that reported survival analysis were included in the review.  Studies that did not follow the 
majority of other studies in terms of score or ratio direction interpretation were excluded 
from the final meta-analysis. Studies with patients who had chemotherapy and/ or 
radiotherapy before or after surgery were also included. 
Statistical Analysis  
A meta-analysis was carried out as outlined in Chapter 2. 
.  
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 Results 
Study selection process 
The study selection process is summarised in Figure 4.1. Initial search strategy identified 
4780 articles whose titles and abstracts were reviewed. Articles were excluded if the 
treatment regime was chemotherapy/ radiotherapy only (n=659), where survival was not the 
primary outcome measure (n=2811), full articles were not available (n=372), and those that 
were a systematic review/meta-analysis (n=374).  
This led to a review of the full text of 564 articles. A further 351 articles were excluded if 
progression free survival (PFS) was the only outcome measured (n=112), if the treatment 
regime was chemotherapy/ radiotherapy only (n=58) and if survival was not expressed as 
HR/ OR/ RR (95%CI; n=181). The remaining 213 articles had their bibliographies reviewed 
in a systematic manner and this identified a further 31 articles to be included in the final 
analysis leading to final figure of 244 articles considered in the present systematic review 
and meta-analysis.   
 
Studies of the prognostic value of Glasgow Prognostic Score (GPS) or modified Glasgow 
Prognostic Score (mGPS) in patients with primary operable cancer: 
Eighty articles with both overall survival (OS) and/or cancer specific survival (CSS) as their 
primary outcome measures were identified (Table 18.1). This comprised data on 25,207 
patients (9,361 deaths) reporting the significant prognostic value of GPS/mGPS in cohorts 
of patients with primary operable cancer (Table 18.1).  Seventy two studies were carried out 
in a retrospective manner while eight were prospective (Table 18.1). Seventy two studies 
used multivariate and eight used univariate survival analysis (Table 18.1).  
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After exclusion forty eight studies examined the relationship with overall survival including 
16,160 patients (6,051 deaths), as the primary outcome measure. On meta-analysis there was 
a significant association between GPS/mGPS and overall survival (HR 1.86 95%CI 1.68-
2.07, p<0.00001) with a substantial degree of heterogeneity (I2=61%, Figure 4.2). These 
included studies on colorectal (n=12), oesophageal (n=7), liver (n=6), gastric (n=6), 
pancreatic (n=5), lung (n=4), gallbladder (n=2), colorectal liver metastases (n=1), renal 
(n=1), bladder (n=1), cholangiocarcinoma (n=1), oral (n=1) and vulval cancers (n=1).  
On meta-analysis of those studies carried out in colorectal cancer (n=12), including 4,739 
patients (1,883 deaths), there was a significant association between elevated GPS/ mGPS 
and overall survival (HR: 1.62 95%CI 1.42-1.84, p< 0.00001) with a substantial degree of 
heterogeneity (I2 = 51%, Figure 4.3). These included studies carried out in the UK (n=8), 
Japan (n=2), Korea (n=1) and Australia (n=1). The proportion of patients who had an 
elevated GPS/ mGPS was 60% in Australia, 39% in Japan, 37% in the UK and 21% in Korea.  
On meta-analysis of studies involving oesophageal cancer (n=7), including 1,918 patients 
(669 deaths), there was a significant association between GPS/mGPS and overall survival 
(HR: 1.73 95%CI 1.31-2.29, p<0.0001) with a minimal degree of heterogeneity (I2 = 34%, 
Figure 4.4). These included studies carried out in Japan (n=4), Germany (n=1), China (n=1) 
and Ireland (n=1). The proportion of patients who had an elevated GPS/mGPS was 19% in 
Japan, 46% in Germany, 28% in China and 22% in Ireland.  
On meta-analysis of studies involving liver cancer (n=6), including 2,142 patients (801 
deaths), there was a significant association between GPS/mGPS and overall survival (HR: 
2.87 95%CI 1.79-4.60, p<0.0001) with a substantial degree of heterogeneity (I2 = 71%, 
Figure 4.5). These included studies carried out in Japan (n=3) and China (n=3). The 
proportion of patients who had an elevated GPS/ mGPS was 20% in Japan and 12% in China. 
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On meta-analysis of studies involving gastric cancer (n=6), including 2,471 patients (753 
deaths), there was a significant association between GPS/mGPS and overall survival (HR: 
1.95 95%CI 1.36-2.79, p=0.0003) with a substantial degree of heterogeneity (I2 = 70%, 
Figure 4.6). These included studies carried out in Japan (n=4), China (n=1) and Italy (n=1). 
The proportion of patients who had an elevated GPS/mGPS was, 30% in Japan, 23% in 
China and 52% in Italy. 
On meta-analysis those studies carried out in pancreatic cancer (n=5), including 549 patients 
(501 deaths), there was a significant association between GPS/ mGPS and overall survival 
(HR: 1.70 95%CI 1.21-2.38, p=0.002) with a substantial degree of heterogeneity (I2 = 60%, 
Figure 4.7). These included studies carried out in the UK (n=2), Japan (n=1), Italy (n=1) and 
Austria (n=1). The proportion of patients who had an elevated GPS/mGPS was 45% in the 
UK, 23% in Japan, 68% in Italy and 34% in Austria. 
After exclusion twenty nine studies examined CSS including 9,053 patients (2,686 deaths), 
as its primary outcome measure. On meta-analysis there was a significant association 
between GPS/mGPS and cancer specific survival (HR 2.08 95%CI 1.82-2.39, p<0.00001) 
with a substantial degree of heterogeneity (I2=68%, Figure 4.8). These included studies on 
colorectal (n=16), oesophageal (n=4), oesophago-gastric (n=2), gastric (n=2), renal cell 
(n=2), colorectal liver metastases (n=1), oral (n=1) and bladder cancers (n=1). 
On meta-analysis of studies involving colorectal cancer (n=16), including 5121 patients 
(1300 deaths), there was a significant association between GPS/mGPS and cancer specific 
survival (HR: 1.75 95%CI 1.55-1.98, p<0.00001) with a moderate degree of heterogeneity 
(I2 = 42%, Figure 4.9). These included studies carried out in the UK (n=15) and Japan (n=1). 
The proportion of patients who had an elevated GPS/mGPS was 39% in the UK and 8% in 
Japan. 
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Studies of the prognostic value of Neutrophil Lymphocyte Ratio (NLR) in patients with 
primary operable cancer: 
One hundred and fifty eight articles with both OS and/or CSS as their primary outcome 
measures were identified (Table 18.2). This comprised data on 63,837 patients (22,681 
deaths) reporting the significant prognostic value of NLR in cohorts of patients with primary 
operable cancer.  All one hundred and fifty eight studies were carried out in a retrospective 
manner (Table 18.2). One hundred and twenty eight studies used multivariate and thirty used 
univariate survival analysis (Table 18.2).  After exclusion one hundred and nineteen studies 
examined the relationship with overall survival including 49,664 patients (18,542 deaths), 
as the primary outcome measure. On meta-analysis there was a significant association 
between NLR and overall survival (HR 1.73 95%CI 1.56-1.91, p<0.00001) with a 
considerable degree of heterogeneity (I2=98%, Figure 4.10). The most common NLR 
threshold examined was ≥5 (n=29). Other thresholds were ≥3 (n=9), ≥2.5 (n=7), NLR as 
continuous variable (n=7), ≥4 (n=7) and ≥2 (n=5). Other thresholds were used in <5 studies 
and thus, meta-analysis was not carried out (n=55). 
On meta-analysis of those studies with a threshold of ≥5 (n=29), including 9,997 patients 
(4,012 deaths) there was a significant association between elevated NLR and overall survival 
(HR: 1.92 95%CI 1.67-2.20, p<0.00001) with a moderate degree of heterogeneity (I2 = 47%, 
Figure 4.11). These included colorectal (n=8), lung (n=4), colorectal liver metastases (n=4), 
oesophageal (n=3), gastric (n=2), soft tissue sarcoma (n=2), liver (n=2), pancreatic (n=1), 
renal (n=1), pleural mesothelioma (n=1) and hepato-pancreatico-biliary cancers (n=1). 
On meta-analysis of those studies with a threshold of ≥5 and colorectal cancer (n=8), 
including 3,379 patients (825 deaths) there was a significant association between an NLR≥5 
and overall survival (HR: 1.80 95%CI 1.37-2.37, p<0.0001) with moderate heterogeneity 
(I2=45%, Figure 4.12). In these eight studies, there was a variation in their geographical 
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locations including the UK (n=2), Korea (n=2), Taiwan (n=1), Austria (n=1), US (n=1) and 
Australia (n=1). The proportion of patients who had an NLR≥5 with colorectal cancer was 
25% in the UK, 5% in Korea, 25% in Taiwan, 11% in US and 30% in Australia. 29% in 
Korea and 20% in Japan. No country had more than 4 studies and therefore no further meta-
analysis was carried out.  
On meta-analysis of those studies with a threshold of ≥3 (n=9), including 2,638 patients (835 
deaths) there was a significant association between elevated NLR and overall survival (HR: 
1.83 95%CI 1.48-2.27, p<0.00001) with a moderate degree of heterogeneity (I2 = 44%, 
Figure 4.13). These included gastric (n=2), liver (n=1), biliary tract (n=1), bladder (n=1), 
breast (n=1), colorectal (n=1), pleural mesothelioma (n=1) and endometrial cancers (n=1). 
In these nine studies, there was a variation in their geographical locations including Japan 
(n=4), Canada (n=2), China (n=1), Belgium (n=1) and Australia (n=1). The proportion of 
patients who had an NLR≥3 was 28% in Japan, 47% in Canada, 33% in China, 31% in 
Belgium and 52% in Australia. No tumour site had more than four studies and therefore no 
further meta-analysis was carried out. 
On meta-analysis of those studies with a threshold of ≥2.5 (n=7), including 1,888 patients 
(475 deaths) there was a significant association between elevated NLR and overall survival 
(HR: 1.78 95%CI 1.29-2.44, p=0.0004) with a moderate degree of heterogeneity (I2 = 42%, 
Figure 4.14). These included lung (n=3), oesophageal (n=1), colorectal (n=1), soft tissue 
sarcoma (n=1) and liver cancers (n=1). In these seven studies, there was a variation in their 
geographical locations including Japan (n=5), China (n=1) and US (n=1). The proportion of 
patients who had an NLR≥2.5 was 30% in Japan, 28% in China and 50% in US. No tumour 
site had more than four studies and therefore no further meta-analysis was carried out. 
On meta-analysis those studies with NLR as continuous variable (n=7), including 2,472 
patients (1,466 deaths) there was a moderate association between elevated NLR and overall 
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survival (HR: 1.05 95%CI 1.02-1.08, p=0.001) with a substantial degree of heterogeneity (I2 
= 63%, Figure 4.15). These included pancreatic (n=2), renal (n=2), colorectal (n=1), lung 
(n=1) and bladder cancers (n=1). In these seven studies, there was a variation in their 
geographical locations including the UK (n=2), US (n=2), China (n=1), Austria (n=1) and 
Australia (n=1). No tumour site had more than four studies and therefore no further meta-
analysis was carried out.  
On meta-analysis those studies with a threshold of ≥4 (n=7), including 2,195 patients (697 
deaths) there was a significant association between elevated NLR and overall survival (HR: 
1.36 95%CI 1.01-1.84, p=0.04) with a substantial degree of heterogeneity (I2 = 73%, Figure 
4.16). These included glioblastoma (n=2), gastric (n=1), oesophageal (n=1), ovarian (n=1), 
breast (n=1) and colon cancers (n=1). In these seven studies, there was a variation in their 
geographical locations including Japan (n=2), China (n=1), the UK (n=1), Belgium (n=1), 
Austria (n=1) and Ireland (n=1). The proportion of patients who had an NLR≥4 was 15% in 
Japan, 32% in China, 22% in Belgium and 36% in Ireland. No tumour site had more than 
four studies and therefore no further meta-analysis was carried out. 
On meta-analysis those studies with a threshold of ≥2 (n=5), including 3,065 patients (1,068 
deaths) there was a significant association between elevated NLR and overall survival (HR: 
1.48 95%CI 1.28-1.72, p<0.00001) with minimal heterogeneity (I2 = 0%, Figure 4.17). These 
cancers included gastric (n=2), colorectal (n=1), liver (n=1) and pancreatic (n=1). In these 
five studies, there was a variation in their geographical locations including China (n=3) and 
Korea (n=2). The proportion of patients who had an NLR≥2 was 60% in China and 39% in 
Korea. No tumour site had more than four studies and therefore no further meta-analysis was 
carried out. 
After exclusion forty one studies examined the relationship with cancer specific survival 
including 17,539 patients (4,617 deaths), as its primary outcome measure. On meta-analysis 
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there was a significant association between NLR and cancer specific survival (HR 1.32 
95%CI 1.24-1.41, p<0.00001) with a considerable degree of heterogeneity (I2=81%, Figure 
4.18). The most common NLR thresholds used was≥5 (n=7), ≥3 (n=6) and NLR as 
continuous variable (n=5). Other thresholds did not have more than four studies and 
therefore meta-analysis was not carried out (n=19). 
On meta-analysis those studies with a threshold of ≥5 (n=7), including 1,283 patients (531 
deaths) there was a significant association between elevated NLR and cancer specific 
survival (HR: 1.89 95%CI 1.53-2.34, p<0.00001) with minimal heterogeneity (I2 = 0%, 
Figure 4.19). These included colorectal (n=2), liver only colorectal metastases (n=1) and soft 
tissue sarcoma (n=1), adrenal (n=1), pancreatic (n=1) and renal cancers (n=1).  In these seven 
studies, there was a variation in their geographical locations including the UK (n=3), Austria 
(n=2), US (n=1) and South Korea (n=1). The proportion of patients who had an NLR≥5 was 
19% in the UK, 35% in US and 7% in South Korea. No tumour site had more than four 
studies and therefore no further meta-analysis was carried out. 
On meta-analysis those studies with a threshold of ≥3 (n=6), including 2,367 patients (525 
deaths) there was a significant association between elevated NLR and cancer specific 
survival (HR: 1.81 95%CI 1.42-2.30, p<0.00001) with a moderate degree of heterogeneity 
(I2 = 32%, Figure 4.20). These included renal (n=2), bladder (n=1), colorectal (n=1), 
oesophageal (n=1) and gastric cancers (n=1). In these six studies, there was a variation in 
their geographical locations including Japan (n=2), Korea (n=1), China (n=1), Taiwan (n=1) 
and Canada (n=1). The proportion of patients who had an NLR≥3 was 25% in Japan, 20% 
in Korea, 20% in China, 40% in Taiwan and 51% in Canada. No tumour site had more than 
four studies and therefore no further meta-analysis was carried out. 
On meta-analysis those studies with NLR as continuous variable (n=5), including 3,686 
patients (1,312 deaths) there was a significant association between elevated NLR and cancer 
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specific survival (HR: 1.06 95%CI 1.01-1.10, p=0.008) with a substantial degree of 
heterogeneity (I2 = 80%, Figure 4.21). These included renal (n=1), bladder (n=1), colorectal 
(n=1), liver only colorectal metastases (n=1) and gastric cancers (n=1). In these six studies, 
there was a variation in their geographical locations including the US (n=3), the UK (n=1) 
and Australia (n=1). No tumour site had more than four studies and therefore no further 
meta-analysis was carried out. 
 
Studies of the prognostic value of platelet lymphocyte ratio (PLR) in patients with primary 
operable cancer: 
Sixty eight articles with both OS and/or CSS as their primary outcome measures were 
identified (Table 18.3). This comprised data on 29,273 patients (10,729 deaths) reporting the 
significant prognostic value of PLR in cohorts of patients with primary operable cancer 
(Table 18.3).  All sixty eight studies were conducted in a retrospective manner. Forty three 
studies were conducted in a multivariate and twenty five in a univariate manner (Table 18.3).  
After exclusions fifty five studies examined the relationship with overall survival including 
25,601 patients (9,258 deaths), as the primary outcome measure. On meta-analysis there was 
a significant association between an elevated PLR and overall survival (HR 1.09 95%CI 
1.06-1.11, p<0.00001) with a substantial degree of heterogeneity (I2=80%, Figure 4.22). The 
most common PLR thresholds examined were ≥300 (n=10) and ≥150 (n=7). Other 
thresholds did not have more than four studies and therefore meta-analysis was not carried 
out (n=58). 
On meta-analysis those studies with a threshold of ≥300 (n=10), including 3,713 patients 
(HR: 1.61 95%CI 1.20-2.18, p=0.002) with a substantial degree of heterogeneity (I2 = 75%, 
Figure 4.23). These included colorectal (n=3), lung (n=2), gastric (n=2), colorectal liver 
metastases (n=1), oesophageal (n=1) and ovarian cancers (n=1). In these ten studies, there 
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was a variation in their geographical locations including the UK (n=3), Korea (n=2), China 
(n=2), Hungary (n=1), Italy (n=1) and Japan (n=1). The proportion of patients who had a 
PLR≥300 was 20% in the UK, 4% in Korea, 10% in China, 13% in Italy and 5% in Japan. 
No tumour site had more than four studies and therefore no further meta-analysis was carried 
out. 
On meta-analysis those studies with a threshold of ≥150 (n=7), including 1,315 patients (667 
deaths) there was a significant association between elevated PLR and overall survival (HR: 
1.59 95%CI 1.29-1.97, p<0.0001) with a minimal degree of heterogeneity (I2 = 29%, Figure 
4.24). These included oesophageal (n=2), pancreatic (n=2), liver (n=1), colorectal liver 
metastases (n=1) and colorectal cancers (n=1). In these seven studies, there was a variation 
in their geographical locations including China (n=2), Japan (n=2), the UK (n=1), Hong 
Kong (n=1) and Australia (n=1). The proportion of patients who had a PLR≥150 was 43% 
in China, 49% in Japan, 41% in the UK, 27% in Hong Kong and 75% in Australia. No 
tumour site had more than four studies and therefore no further meta-analysis was carried 
out. 
After exclusions fifteen studies examined the relationship with cancer specific survival 
including 4,489 patients (1,769 deaths), as the primary outcome measure. On meta-analysis 
there was a significant association between an elevated PLR and cancer specific survival 
(HR 1.21 95%CI 1.06-1.38, p=0.005) with a substantial degree of heterogeneity (I2=63%, 
Figure 4.25). The most common PLR threshold examined was ≥300 (n=4). Other thresholds 
used were >150 (n=1), ≥25.4 (n=1), >103 (n=1), ≥132 (n=1), ≥176 (n=1), >190 (n=1), ≥200 
(n=1), ≥240 (n=1), ≥292 (n=1), PLR as continuous variable (n=1) and PLR per 100 units 
(n=1). These included studies on oesophageal (n=3), colorectal (n=3), gastric (n=2), 
colorectal liver metastases (n=1), adrenal (n=1), renal (n=1), endometrial (n=1), bladder 
(n=1), soft tissue sarcoma (n=1) and breast cancers (n=1). Geographically studies were 
located in the UK (n=5), China (n=4), Austria (n=2), Japan (n=1), US (n=1), South Korea 
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(n=1) and Canada (n=1). The proportion of patients who had an elevated PLR was 12% in 
the UK, 55% in China, 23% in Japan, 38% in US and 3% in South Korea. No specific PLR 
thresholds had more than four studies and therefore no further meta-analysis was carried out. 
 
Studies of the prognostic value of lymphocyte monocyte ratio (LMR) in patients with primary 
operable cancer: 
Twenty one articles with both OS and/or CSS as their primary outcome measures were 
identified (Table 18.4). This comprised data on 15,386 patients (4,298 deaths) reporting the 
significant prognostic value of LMR in cohorts of patients with primary operable cancer 
(Table 18.4).  All 21 studies were retrospective. Nineteen studies used multivariate and two 
used univariate survival analysis (Table 18.4).  
After exclusion twelve studies examined the relationship with overall survival including 
11,913 patients (3,106 deaths), as the primary outcome measure. On meta-analysis there was 
a significant association between an elevated LMR and overall survival (HR 0.69 95%CI 
0.63-0.74, p<0.00001) with a substantial degree of heterogeneity (I2=61%, Figure 4.26). 
There was a variety of LMR cut-offs used in each study including ≥2, (n=1), ≥2.14 (n=1), 
>2.35 (n=1), >2.38 (n=1), >2.83 (n=1),  ≥2.85 (n=1), >2.87 (n=1), >3.23 (n=1), ≥3.80 (n=1), 
≥4 (n=1), ≥4.32 (n=1) and ≥4.95 (n=1). These included studies on colorectal (n=3), bladder 
(n=2), liver only colorectal metastases (n=1), gastric (n=1), renal (n=1), liver (n=1), breast 
(n=1), soft tissue sarcoma (n=1) and cervical cancers (n=1).  Geographically the studies were 
carried out in China (n=6), Austria (n=3), the UK (n=1), Canada (n=1) and Australia (n=1). 
The proportion of patients who had high LMRs was 71% in China, 68% in Japan, 64% in 
the UK, 49% in Australia and 48% in Austria. No specific LMR thresholds had more than 
four studies and therefore no further meta-analysis was carried out. 
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After exclusion five studies examined the relationship with cancer specific survival 
including 1,627 patients (697 deaths), as the primary outcome measure. On meta-analysis 
there was a significant association between an elevated LMR and cancer specific survival 
(HR 0.70 95%CI 0.60-0.82, p<0.00001) with a moderate degree of heterogeneity (I2=47%, 
Figure 4.27). There was a variety of LMR cut-offs used in each study including >2.35 (n=1), 
≥2.85 (n=1), >2.93 (n=1) and ≥4.95 (n=1). One study expressed LMR in terms of log. These 
included studies on liver only colorectal metastases (n=1), gastric cancer (n=1), oesophageal 
cancer (n=1), bladder cancer (n=1) and soft tissue sarcoma (n=1). Geographically the studies 
were carried out in the China (n=2), UK (n=1), Austria (n=1), and Canada (n=1). The 
proportion of patients who had high LMRs was 68% in Japan, 64% in the UK, 50% in 
Austria and 40% in China. No specific LMR thresholds had more than four studies and 
therefore no further meta-analysis was carried out. 
 
Studies of the prognostic value of other scores of the systemic inflammatory response in 
patients with primary operable cancer: 
Thirty five articles reported a variety of other scores reported in less than 10 studies each. 
These included the PNI (Prognostic Nutritional Index), COP-NLR (combined platelet count 
and NLR), NLR/PLR combination, CAR (CRP/albumin ratio), SI (systemic inflammatory 
score), SII (systemic inflammatory index), NLR/CRP combination, (HALP) haemoglobin, 
albumin, lymphocyte and platelet, NLR/ESR (erythrocyte sedimentation rate) combination, 
(WLR) white cell count to lymphocyte count ratio, (APRI) AST-platelet ratio index,  
PI/CRP/WCC combination, Canton score, (AGR) albumin/ globulin ratio, CRP/Neutrophil 
combination, (PIS) Prognostic Inflammation Score, and the CONUT score. 
Eight articles with both OS and/or CSS as their primary outcome measures were identified 
(Table 18.5). This comprised data on 2,666 patients (1,387 deaths) reporting the significant 
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prognostic value of PNI in cohorts of patients with primary operable cancer.  All eight 
studies were carried out in a retrospective manner (Table 18.5). Six studies used multivariate 
and two used univariate survival analysis (Table 18.5).  
After exclusion seven studies examined the relationship with overall survival including 
2,087 patients (1,087 deaths), as the primary outcome measure. On meta-analysis there was 
a significant association between PNI and overall survival (HR 1.76 95%CI 1.52-2.04, 
p<0.00001) with minimal heterogeneity (I2=0%, Figure 4.28). The most common PNI 
threshold examined was ≤45 (n=3), ≤50 (n=1), ≤50.5 (n=1), 48.5 (n=1), 48.2 (n=1). These 
included hepatocellular (n=3), gastric (n=2), lung (n=1) and colorectal liver metastases 
(n=1). In these eight studies, there was a variation in their geographical locations including 
Japan (n=2), UK (n=1), Hong Kong (n=1), China (n=1), US (n=1) and Italy (n=1).The 
proportion of patients who with an elevated PNI was 74% in Hong Kong, 59% in Japan, 
59% in Italy, 52% in China and 17% in the UK. No tumour site had more than four studies 
and therefore no further meta-analysis was carried out. Two studies examined the 
relationship with cancer specific survival including 579 patients (300 deaths), as the primary 
outcome measure. Both of these studies used a PNI threshold of ≤45. No threshold was used 
in ≥4 studies and thus, meta-analysis was not carried out. 
Four studies reported the COP-NLR score. The first such study was by Ishizuka and co-
workers(119) from Japan. In this multivariate survival analysis on patients with colorectal 
cancer, low COP-NLR was shown to be related to a statistically better cancer specific 
survival (OR: 0.464 95% CI 0.267-0.807 p=0.007). The second such study was also by 
Ishizuka and co-workers(120) from Japan. In this multivariate survival analysis on patients 
with gastric cancer, elevated COP-NLR was shown to be related to a statistically significant 
worse overall survival (HR: 1.781 95% CI 1.094-2.899 p=0.020). The third such study was 
by Zhang and co-workers(121) from China. In this multivariate survival analysis on patients 
with lung cancer, elevated COP-NLR was shown to be related to a statistically significant 
 124 
worse overall survival (HR: 1.810 95% CI 1.587-2.056 p<0.001). The fourth such study was 
by Neal and co-workers(122) from the UK. In this univariate survival analysis on patients 
with colorectal liver metastases, elevated COP-NLR was shown to be related to a statistically 
significant worse overall survival (HR: 1.230 95% CI 1.005-1.505 p=0.045) and worse 
cancer specific survival (HR: 1.243 95% CI 1.003-1.541 p=0.047). 
Three studies reported the combination of the NLR and PLR. The first such study was by 
Feng and co-workers(123) from China. The combination of NLR and PLR is collectively 
named the CNP. The CNP was calculated based on data obtained on the day of admission, 
where patients with both elevated NLR (>3.45) and PLR (>166.5) were allocated a score of 
2, and patients showing one or neither were allocated a score of 1 or 0, respectively. In this 
multivariate survival analysis on patients with oesophageal cancer, CNP 1 or 2 was shown 
to be related to a statistically worse overall survival (HR: 1.964 95% CI 1.371-2.814 
p<0.001). The second such study was by Cummings and coworkers (124) from the UK. In 
this multivariate survival analysis on patients with endometrial cancer, both high NLR and 
PLR was shown to be related to a statistically significant worse overall survival (HR: 2.54 
95% CI 1.61-4.01 p<0.001) and worse cancer specific survival (HR: 2.26 95% CI 1.24-4.13 
p=0.008). The third such study was by Chuan Li and co-workers(125) from China. In this 
multivariate survival analysis on patients with liver cancer, elevated postoperative NLR-
PLR was shown to be related to a statistically significant worse overall survival (HR: 2.894 
95% CI 1.992-4.2 p<0.001).  
Two studies reported the CAR. The first such study was by Ishizuka and coworkers (126) 
from Japan. In this multivariate survival analysis on patients with colorectal cancer, CAR 
>0.038 was shown to be related to a statistically worse overall survival (HR: 2.613 95% CI 
1.621-4.212 p<0.001). The second such study was by Xu and coworkers (127) from China. 
In this multivariate survival analysis on patients with oesophageal cancer, CRP/ Albumin 
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ratio >0.50 was shown to be related to a statistically significant worse overall survival (HR: 
2.44 95% CI 1.82-3.26 p<0.0001). 
One study reported the SI, a score involving leucocyte count, serum albumin and 
haemoglobin level. High leucocyte count (>9,500 µl), low serum albumin level (3.5 g/dl) 
and low haemoglobin level (<12.5 mg/dl) was each allocated a score of 1.The study was 
conducted by Miyata and coworkers (128) from Japan. In this multivariate survival analysis 
on patients with oesophageal cancer, SI score of 2/3 was shown to be related to a statistically 
significant worse overall survival (HR: 3.17 95% CI 1.74-5.78 p=0.0002).  
One study reported on the SII which was determined as neutrophil x platelet / lymphocyte. 
The study was conducted by Ha and coworkers (129) from South Korea. In this multivariate 
survival analysis on patients with ampulla of vater cancer, SII ≤ 780 was shown to predict 
better overall survival (HR: 0.924 95% CI 0.44-1.93 p=0.833).  
One study reported on the combination of the NLR and CRP. The study was conducted by 
Tomita and coworkers (130) from Japan. In this multivariate survival analysis on patients 
with lung cancer, low NLR and low CRP (compared to both high) was shown to predict 
better overall survival (RR: 0.403 95% CI 0.240-0.689 p=0.0012).  
One study reported on preoperative HALP. The study was conducted by Chen and coworkers 
(131) from China. In this multivariate survival analysis on patients with gastric cancer, 
HALP ≥ 56.8 was shown to predict better overall survival (HR: 0.700 95% CI 0.496-0.987 
p=0.042).  
One study reported on the combination of the NLR and ESR. The study was conducted by 
Hyun and coworkers (132) from Korea. Patients were divided into three groups: those with 
ESR and NLR in the normal range (group 0), those with either elevated ESR or elevated 
NLR (group I), and those with both elevated ESR and elevated NLR (group II). In this 
multivariate survival analysis on patients with renal cancer, both elevated ESR and NLR was 
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shown to predict worse overall survival (HR: 3.521 95% CI 1.888-6.567 p<0.001) and worse 
cancer specific survival (HR: 4.367 95% CI 1.987-9.597 p<0.001). 
One study reported on the WLR. The study was conducted by East and coworkers (133) 
from the UK. In this multivariate survival analysis on patients with colon cancer, WLR ≥ 
3.4 was shown to predict worse overall survival (HR: 4.10 95% CI 3.13-7.42 p=0.03).  
One study reported on the APRI. The study was conducted by Shen and coworkers (134) 
from China. In this multivariate survival analysis on patients with liver cancer, APRI ≥ 0.62 
was shown to predict worse overall survival (HR: 1.508 95% CI 1.127-2.016 p=0.006).  
One study reported on the combination of the PI, CRP and white cell count (0 if both low, 1 
if either high, 2 if both high). The study was conducted by Aurello and co-workers(135) 
from Italy. In this multivariate survival analysis on patients with gastric cancer, PI 2 was 
shown to predict worse overall survival (HR: 0.37 95% CI 0.16-0.82 p=0.01).  
One study reported on the Canton score involving PNI, NLR and platelet. The study was 
conducted by Sun and coworkers (136) from China. In this multivariate survival analysis on 
patients with gastric cancer, elevated Canton score was shown to predict worse overall 
survival (HR: 1.643 95% CI 1.142-2.364 p=0.007).  
One study reported on the AGR. The study was conducted by Li and coworkers (137) from 
China. In this multivariate survival analysis on patients with colorectal cancer, AGR ≥ 1.50 
was shown to predict better overall survival (HR: 0.646 95% CI 0.543-0.767 p<0.001).  
One study reported on the combination of CRP and neutrophils. The study was conducted 
by Christina and coworkers (138) from Austria. In this multivariate survival analysis on 
patients with oral cancer, high CRP/ neutrophil was shown to predict worse overall survival 
(HR: 2.7 95% CI 0.68-10.75 p=0.16).  
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One study reported on the PIS involving a combination of NLR and serum albumin. PIS was 
defined as follows: patients with increased NLR and decreased serum albumin were assigned 
score 0; patients with either increased NLR or decreased serum albumin were assigned score 
1; patients with decreased NLR and increased serum albumin were assigned score 2. The 
study was conducted by Wang and coworkers (139) from China. In this multivariate survival 
analysis on patients with ovarian cancer, PIS 2 was shown to predict better overall survival 
(HR: 0.18 95% CI 0.09-0.38 p<0.001).  
Finally, the last study reported on the CONUT score involving serum albumin concentration, 
total lymphocyte counts and total cholesterol concentration. The study was conducted by 
Toyokawa and coworkers (140) from Japan. In this multivariate survival analysis on patients 
with oesophageal cancer, high CONUT score was shown to predict worse overall survival 
(HR: 2.303 95% CI 1.191-4.455 p=0.013).  
 
Assessment of bias using funnel plot analysis of studies carried out in patients with primary 
operable cancer: 
Funnel plot analysis containing ten or more studies revealed bias towards studies reporting 
a relationship between an increased systemic inflammatory response as evidenced by the 
GPS/GPS (multiple tumour types Figure 4.2 and Figure 4.8; colorectal cancer Figure 4.3 and 
Figure 4.9), NLR (multiple tumour types Figure 4.10 and Figure 4.18; NLR>5 Figure 4.11), 
PLR (multiple tumour types Figure 4.22 and 25; PLR>300 Figure 4.23), LMR (multiple 
tumour types Figure 4.26) and poorer survival. The funnel plots also showed that a clear 
majority of studies had high patient numbers. This is particularly true for studies focusing 
on GPS/mGPS (Figure 4.2 and Figure 4.9), NLR (Figure 4.10 and Figure 4.18), PLR (Figure 
4.22) and LMR (Figure 4.26).
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 Discussion  
In the present review 244 reports of the prognostic value of systemic inflammation based 
prognostic scores were identified.  This is in contrast to the initial review by Roxburgh and 
McMillan (2010) where 18 such studies were identified.  In particular, those scores based on 
the ratio of components of a white cell count have been the subject of intense interest with, 
over the intervening 7 years, 158 studies reporting the value of the NLR, 68 reporting PLR 
and 21 reporting LMR.  Also, the cumulative GPS/mGPS has been the subject of 80 reports. 
The majority of these studies have been carried out in lung and gastrointestinal cancer. For 
example, the GPS/mGPS had prognostic value in lung (5 studies), gastric cancer (7 studies), 
pancreatic (5 studies), and colon cancer (3 studies).  A feature of this up to date review of 
systemic inflammation based prognostic scores is the identification of the proliferation of 
new scores derived from routinely available markers of the systemic inflammatory response. 
Most notable among these that have been validated in several studies are PINI (7 studies), 
COP-NLR (4 studies) and CNP (3 studies). It remains to be established whether any of the 
scores will have prognostic value in addition to the GPS/mGPS and NLR.  Irrespective, there 
is increasing recognition and acceptance of the clinical utility of systemic inflammation 
based prognostic scores prior to surgery for cancer. 
It is perhaps surprising that, given apparent the superior prognostic value of the GPS/ mGPS 
(115) the relatively larger numbers of reports of the prognostic value of ratios based on 
components of the white cell count.  However, the pre-operative differential white cell count 
is part of the standard pre-operative workup for the majority of cancer resections as it is used 
to help identify patients who may have an infection prior to surgery.  Also, the white cell 
count is used to identify any pre-existing conditions that may affect the surgical procedure 
such as the hypercoagulability of thrombocytosis. Thus, these results are routinely available 
for retrospective studies.  This might also explain the variety of prognostic thresholds 
reported for NLR, PLR and LMR. In contrast, reports on the prognostic value of the 
 129 
GPS/mGPS, not routinely assessed as part of the standard pre-operative workup, were more 
likely to be examined in prospective studies.  This might explain the consistent adherence to 
the original thresholds reported for GPS/ mGPS.  From the above there is a strong case for 
the GPS/mGPS to be incorporated into pre-operative workup of patients undergoing surgery 
for cancer. 
It is of interest that while there is general uniformity of thresholds used in the GPS/mGPS 
studies, with most adhering to the original abnormal thresholds (CRP >10mg/l and albumin 
<35g/l), studies in East Asia particularly Japan have used thresholds of 7.5mg/l (141), 5mg/l 
(142, 143) and 3mg/l (144-146).  Such lower CRP thresholds are above the normal reference 
ranges in Japan/ East Asia cohorts and results in fewer patients breaching the CRP>10mg/l 
threshold. This observation of a greater proportion of patients with elevated systemic 
inflammation markers in Western countries compared with Eastern Asian countries is also 
apparent in white cell derived ratios.  Given the objective and reproducible nature of 
systemic inflammation based prognostic scores it is likely that such observations are real.    
Indeed, there are recognized ethnic differences in the normal range of neutrophils and 
lymphocytes (96-98). For example, Azab and co-workers recently reported that, in more than 
9,000 patients in the United States, there were ethnic differences in the NLR (97). 
Specifically, in the cohort as a whole the mean NLR was 2.15.  In contrast, black Americans 
had a mean NLR of 1.76, Hispanic Americans had a mean NLR of 2.08 and white Americans 
had a mean NLR of 2.24 (97). Also, within ethnicities, patients who had diabetes, 
cardiovascular disease, a high BMI and were smokers had a significantly higher NLR (97).   
Although, similar data for the GPS/mGPS has not yet appeared in the literature it is likely 
that there would be a similar effect on the GPS/ mGPS. Therefore, given that the most 
common abnormal thresholds used for NLR are >5 and >3 it is likely that a combination of 
tumour and host genetic and environmental factors are responsible for such consistent 
East/West differences. These and the present results emphasise the importance of not only 
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staging the tumour but also the host systemic inflammatory response in patients with 
operable disease (7).  
Recently, studies have directly compared the prognostic value of the two most common 
combined markers of the systemic inflammatory response, the NLR and the GPS/ mGPS. 
Guthrie and co-workers (2013) reported a comparison in both the preoperative and follow-
up settings in patients with resectable colorectal cancer. In this study of 206 patients 
undergoing a surgical resection at a single institution it was reported that both preoperative 
mGPS (HR: 1.97, CI 1.16-3.34, p<0.005) and NLR (HR: 3.07, CI 1.23-7.63, p<0.05) were 
independently associated with cancer specific survival (147). However, in the postoperative 
follow-up only mGPS (HR: 4.81, CI 2.13-10.83, p<0.001) maintained its significance in 
terms of cancer specific survival (147). In contrast, Wang and co-workers (2012) reported 
that, in 177 patients with pancreatic cancer treated with surgery and palliative chemotherapy, 
although NLR and mGPS predicted overall survival, only NLR was independently 
associated with overall survival (HR: 2.54 CI 1.31-4.90, p=0.006) (148). Finally, Okuno and 
co-workers (2016) reported that, in 534 patients with perihilar cholangiocarcinoma, both the 
NLR and mGPS had prognostic value (149).  However, on multivariate analysis, only the 
mGPS was independently associated with overall survival (HR: 1.58 CI 1.21-2.06, p=0.001) 
(149).    
The present review and meta-analysis has a number of limitations. While it was the aim to 
only include the most recent paper where multiple publications from the same cohort where 
available, due to the practice of combining databases from different geographical locations 
under different lead institutions some double counting has occurred. In addition, funnel plot 
analysis, even after fixed effect analysis, showed that there was for all systemic inflammation 
based prognostic scores some asymmetry.  This would suggest that there may be some 
reporting bias.  The basis of this bias is not clear.  Other than statistically significant results 
being more likely to be published other possible contributors may be that the studies included 
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in the analysis were English language only publication, had small study size, included 
multiple tumour types and included multiple thresholds.  Nevertheless, the consistency of 
prognostic value over a variety of systemic inflammation based prognostic scores and across 
larger studies, single tumour types and single thresholds would indicate that although there 
was evidence of bias in the meta-analysis, such scores do indeed have prognostic value.  
Similarly, when only univariate analysis was available it was entered into the analysis. The 
majority of studies had HR derived from multivariate analysis (181 studies) and therefore 
harmonisation of HR results was not attempted. In the present meta-analysis, there was 
considerable heterogeneity in the HR of some of the markers of the systemic inflammatory 
response.  However, this was less when a consistent threshold for the marker was used. There 
are other potential contributors to such heterogeneity including geographical location. Such 
sub-analysis was limited by the number of studies available for meta-analysis. The strength 
of this present review is its comprehensive nature. 
In summary, the results of this review consolidate the prognostic value of combined markers 
of the systemic inflammatory response including GPS/mGPS NLR, PLR and LMR in 
patients with resectable cancers. This is particularly true for the GPS/mGPS and NLR and 
in lung and GI cancers. These should form part of the routine preoperative workup and 
follow-up for all such patients undergoing resection for cancer. 
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 Figures and Legends  
 
Figure 4.1: PRISMA flowchart demonstrating study selection 
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Figure 4.2: Forrest and Funnel Plot of Studies investigating the prognostic value of GPS/mGPS in terms of OS 
in an unselected cohort of patients with operable cancer 
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Figure 4.3: Forrest and Funnel Plot of Studies investigating the prognostic value of GPS/mGPS in terms of OS 
in patients with operable colorectal cancer 
 
Figure 4.4: Forrest and Funnel Plot of Studies investigating the prognostic value of GPS/mGPS in terms of OS 
in patients with operable oesophageal cancer 
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Figure 4.5: Forrest and Funnel Plot of Studies investigating the prognostic value of GPS/mGPS in terms of OS 
in patients with operable liver cancer 
 
Figure 4.6: Forrest and Funnel Plot of Studies investigating the prognostic value of GPS/mGPS in terms of OS 
in patients with operable gastric cancer 
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Figure 4.7: Forrest and Funnel Plot of Studies investigating the prognostic value of GPS/mGPS in terms of OS 
in patients with operable pancreatic cancer 
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Figure 4.8: Forrest and Funnel Plot of Studies investigating the prognostic value of GPS/mGPS in terms of CSS in an unselected cohort of patients with operable cancer
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Figure 4.9: Forrest and Funnel Plot of Studies investigating the prognostic value of GPS/mGPS in terms of CSS in patients with operable colorectal cancer
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Figure 4.10: Forrest and Funnel Plot of Studies investigating the prognostic value of NLR in terms of OS in an 
unselected cohort of patients with operable cancer 
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Figure 4.11: Forrest and Funnel Plot of Studies investigating the prognostic value of NLR≥5 in terms of OS in 
an unselected cohort of patients with operable cancer 
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Figure 4.12: Forrest and Funnel Plot of Studies investigating the prognostic value of NLR≥5 in terms of OS in 
patients with operable colorectal cancer 
 
Figure 4.13: Forrest and Funnel Plot of Studies investigating the prognostic value of NLR≥3 in terms of OS in 
an unselected cohort of patients with operable cancer 
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Figure 4.14: Forrest and Funnel Plot of Studies investigating the prognostic value of NLR≥2.5 in terms of OS 
in an unselected cohort of patients with operable cancer 
 
Figure 4.15: Forrest and Funnel Plot of Studies investigating the prognostic value of NLR as a continuous 
variable in terms of OS in an unselected cohort of patients with operable cancer 
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Figure 4.16: Forrest and Funnel Plot of Studies investigating the prognostic value of NLR≥4 in terms of OS in 
an unselected cohort of patients with operable cancer 
 
Figure 4.17: Forrest and Funnel Plot of Studies investigating the prognostic value of NLR≥2 in terms of OS in 
an unselected cohort of patients with operable cancer 
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Figure 4.18: Forrest and Funnel Plot of Studies investigating the prognostic value of NLR in terms of CSS in 
an unselected cohort of patients with operable cancer 
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Figure 4.19: Forrest and Funnel Plot of Studies investigating the prognostic value of NLR≥5 in terms of CSS 
in an unselected cohort of patients with operable cancer 
 
Figure 4.20: Forrest and Funnel Plot of Studies investigating the prognostic value of NLR≥3 in terms of CSS 
in an unselected cohort of patients with operable cancer 
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Figure 4.21: Forrest and Funnel Plot of Studies investigating the prognostic value of NLR as a continuous 
variable in terms of CSS in an unselected cohort of patients with operable cancer 
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Figure 4.22: Forrest and Funnel Plot of Studies investigating the prognostic value of PLR in terms of OS in an 
unselected cohort of patients with operable cancer 
 148 
 
Figure 4.23: Forrest and Funnel Plot of Studies investigating the prognostic value of PLR≥300 in terms of OS 
in an unselected cohort of patients with operable cancer 
 
Figure 4.24: Forrest and Funnel Plot of Studies investigating the prognostic value of PLR≥150 in terms of OS 
in an unselected cohort of patients with operable cancer 
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Figure 4.25: Forrest and Funnel Plot of Studies investigating the prognostic value of PLR in terms of CSS in 
an unselected cohort of patients with operable cancer 
 
Figure 4.26: Forrest and Funnel Plot of Studies investigating the prognostic value of LMR in terms of OS in 
an unselected cohort of patients with operable cancer 
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Figure 4.27: Forrest and Funnel Plot of Studies investigating the prognostic value of LMR in terms of CSS in 
an unselected cohort of patients with operable cancer 
 
Figure 4.28: Forrest and Funnel Plot of Studies investigating the prognostic value of PNI in terms of OS in an 
unselected cohort of patients with operable cancer 
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5. THE PROGNOSTIC VALUE OF THE SYSTEMIC INFLAMMATORY 
RESPONSE IN RANDOMISED CLINICAL TRIALS IN CANCER: A 
SYSTEMATIC REVIEW 
 Introduction 
As mentioned above in Chapter 3 and  4 the prognostic value of the systemic inflammatory 
response in cancer has been well established in observational studies.  Over the course of the 
last 30 years multiple markers of the systemic inflammatory response such as CRP, albumin, 
neutrophil count, lymphocyte count and that of other white cells have been reported to have 
prognostic value in patients with cancer, at all stages of disease (85, 87).  In the last 15 years 
there has been a movement towards the use of combined prognostic scores such as the 
GPS/mGPS (CRP and albumin) and ratios such as the NLR (neutrophils and lymphocytes) 
to standardise and maximise prognostic value (37, 38).  
Despite the proven utility of these prognostic tools there has been an ongoing reluctance by 
the oncology community to incorporate these into routine clinical trial design.  In 2012, 
MacDonald commented, “The seminal observation by McMillan and colleagues that the 
presence of a dysregulated state as evidenced by a high CRP connotes a dire prognosis has 
been generally ignored to date and not used to stratify patients in oncology clinical trials. 
Particularly in the more aggressive tumour types (e.g. pancreas and lung), the future of 
patients with elevated mGPS scores is so grim that they should be given precachexia status 
and offered multimodal therapy which may delay the onset of cachexia and/or death (150).”   
More recently, Laird and co-workers in large prospective cohorts of patients with advanced 
cancer have added weight to this assertion (17, 25).  
Based on work to date and the sound rationale for the use of prognostic tools in oncology 
trials, the aim of this systematic review was to examine and rationalise the evidence for the 
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role of systemic inflammation based prognostic scores in the setting of randomised control 
trials.   
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 Patients and Methods 
The present systematic review and meta-analysis of published literature was undertaken as 
outlined in Chapter 2. Inclusion criteria consisted of randomised controlled clinical trials 
carried out in adult patients (aged 18-99) with curable and incurable cancer treated with any 
systemic anti-cancer therapy using validated combined scores of the systemic inflammatory 
response in both prospective and retrospective analysis with a primary outcome measure of 
survival. The primary aim was to assess the prognostic value of the validated combined 
scores of the systemic inflammatory response (NLR, PLR, LMR, GPS and mGPS) in the 
setting of randomised controlled clinical trials. This was carried out by a wide-ranging 
literature search to identify trials carried out from January 1947 to 31st January 2018. The 
medical subject heading (MeSH) terms used were Cancer, Randomised Control Trial, GPS, 
Glasgow Prognostic Score, mGPS, modified Glasgow Prognostic Score, NLR, Neutrophil 
Lymphocyte Ratio, LMR, Leucocyte Monocyte Ratio, PLR and Platelet Lymphocyte Ratio.  
Only articles that reported survival were included. Results were reported in terms of (1) 
cancer type and (2) combined markers of the systemic inflammatory response used.  No 
meta-analysis was carried out.  
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 Results  
The study selection process is summarised in Figure 5.1. Initial search strategy identified 
382 papers and abstracts whose titles and abstracts were reviewed. Trials were excluded as 
they were not clinical trials (n=173) and as survival was not their primary measure (n=72).  
This led to a review of the full text of 137 articles. A further 106 articles were excluded as 
they were not in English (n=51), were animal studies (n=32), were not carried out in patients 
with cancer (n=20) and were carried out in duplicate datasets (n=3).  The remaining 31 
articles, had their bibliographies reviewed in a systematic manner and this identified a further 
5 articles to be included in the final analysis leading to final figure of 36 reports containing 
data on 40,354 patients considered in the present systematic review (Table 5.1 and Table 
5.2).  
There were 28 trials containing data on 36,549 patients presented in full paper form and 8 
trials containing data on 3,805 patients presented in abstract form.  Most trials were 
published within the last three years. Seven trials containing data on 6,044 patients were 
published in 2015. Seven trials containing data on 3,913 patients were published in 2016. 
Twelve trials containing data on 27,228 patients were published in 2017. In all 36 trials the 
predominant treatments being investigated was chemotherapy and radiotherapy. The 
majority of trials were in advanced inoperable cancer and colorectal cancer was most 
common cancer type with 10 articles containing data on 27,438 patients.   
The prognostic utility of the GPS/mGPS was assessed in 7 trials with data on 1,284 patients 
and NLR/dNLR was assessed in 33 trials with data on 39,313 patients. All 36 trials were 
analysed in a post hoc manner. The thresholds used for GPS/mGPS were the same in all 
trials. The GPS/mGPS was shown to have prognostic value in randomised clinical trials in 
NSCLC (151), oesophageal cancer (152), pancreatic cancer (153), prostate cancer (154) and 
breast cancer (155). The thresholds for NLR varied between 3 to 6 and for dNLR between 2 
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to 5. The most common threshold for NLR was ≥3 and was used in 9 trials containing data 
on 4,042 patients. The most common threshold for dNLR was 2 and was used in 3 trials 
containing data on 3,810 patients. The NLR/dNLR was shown to have prognostic value in 
randomised clinical trials in nasopharyngeal cancer (156), oesophageal cancer (157), 
pancreatic cancer (158), biliary cancer (159), prostate cancer (160) and multiple cancer types 
(161). A combination of both GPS/mGPS and NLR/dNLR were measured in 2 trials 
containing data on 461 patients (162, 163). Thomsen and colleagues showed that both mGPS 
(HR: 2.16, 95%CI 1.52-3.06, p<0.001) and dNLR (HR: 1.68, 95%CI 1.35-2.08, p<0.001) 
were prognostic in 68 patients with multiple cancer types (162). Chua and colleagues showed 
that both GPS (HR: 4.1, 95%CI 2.2-7.7, p<0.0001) and NLR (HR: 2.0, 95%CI 1.2-3.3, 
p=0.010) were prognostic in 393 patients with colorectal cancer (163). 
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 Discussion  
The results of the present systematic review are consistent with previous observational 
studies and confirm the clinical utility and prognostic value of systemic inflammation based 
prognostic tools in the randomised control trial setting. Therefore, we propose that the time 
has now come for the universal incorporation of measures of the systemic inflammatory 
response into the design of randomised clinical trials in patients with cancer. Monitoring of 
both tumour and host responses will enable a more reliable estimate of benefit from 
oncological treatment. This will in turn highlight opportunities not only to target the tumour 
but also host systemic inflammatory responses. 
Despite supportive meta-analysis of hundreds of reports of the prognostic value of markers 
of the systemic inflammatory response (37, 38) , one of the main reasons for the lack of 
incorporation on monitoring of the systemic inflammatory response into standard 
randomised control trial protocols has been the apparent lack of prospective data and also 
the lack of a clear biological rationale behind their clinical utility. Therefore, the present 
review has only included prospective randomised trials, and these confirm the prognostic 
value of the systemic inflammatory response. Moreover, with the explosion of interest in 
immunological treatments in patients with cancer, including several dedicated journals, the 
biological rationale for such systemic inflammation based prognostic scores has now become 
clear (164, 165). It remains to be established which of the markers of the systemic 
inflammatory response will be used in the RCT setting. However, compared with a ratio 
such as the NLR with its variable and poorly defined cut-off, a score such as the GPS with 
its well defined cut-off has a clear advantage (40). 
In the present systematic review only two small RCTs reported two measures of the systemic 
inflammatory response and in both trials the GPS/mGPS and the NLR/dNLR were shown to 
have independent prognostic value (162, 163). 
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Therefore, in the context of the large preponderance of RCTs using NLR/dNLR it would 
suggest that NLR/dNLR should become the tool of choice for the measurement of the 
systemic inflammatory response in randomised trials. However, recently the NLR/ dNLR 
ratio approach to combining markers of the systemic inflammatory response as a prognostic 
tool has been questioned (40, 166).   
In particular it is not clear from a ratio what component is abnormal, what component is the 
prognostic value derived from and therefore the optimal threshold for prognostic value. This 
is confirmed in the variety of thresholds that have been reported for NLR/dNLR both in 
observational studies and the RCT setting. In contrast, the cumulative score approach such 
as the GPS/mGPS uses consistent thresholds and have been successfully applied to the RCT 
setting.  Although, in many centres in the USA CRP has not been routinely measured either 
in clinical oncology practice or in the randomised control trial setting, recently CRP, 
albumin, and NLR have been listed as mandatory measurements in the first international 
consensus on mandatory baseline and prognostic characteristics in future trials for the 
treatment of unresectable pancreatic cancer (167).  
The advantage of a differential white cell count on which to base a prognostic score is that 
currently it is universally examined in clinical practice in patients with cancer.  We have 
recently proposed that a number of scores based on the differential white cell count could be 
used to replace the ratios currently used (40). For example, the neutrophil lymphocyte score 
(NLS) could replace the NLR, the platelet lymphocyte score (PLS) could replace the PLR 
and the lymphocyte monocyte score (LMS) could replace the LMR (40).  Indeed, recent 
analysis of the ARCAD database of >22,000 patients with advanced colorectal cancer 
confirms the value of the cumulative score approach compared with the ratio approach (168). 
In summary, the prognostic value of systemic inflammation-based prognostic scores 
established extensively in observational studies over the past two decades has now been 
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confirmed in the randomised controlled setting.  The time has now come for prospective 
incorporation of such scores into randomised controlled trials in patients with cancer.
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 Tables and Footnotes  
Table 5.1: The relationship between the systemic inflammatory response and survival in randomised clinical trials in patients with cancer (published papers) 
Authors Randomised Clinical 
Trial  
Tumour Type Country  Patients (n) Randomised Clinical Trial Systemic 
Inflammation 
Outcome Comment 
Rinehart et al 
2013 (151) 
DEX NSCLC United States 124 Standard chemotherapy vs. Standard 
chemotherapy and Dexamethasone  
GPS OS Univariate analysis: 
GPS: p< 0.05  
Lee et al 2012 
(169) 
First-SIGNAL 
NCT00455936 
Lung Korea 199 Gefitinib plus gemcitabine plus cisplatin 
vs gefitinib monotherapy  
NLR OS Multivariate 
Post treatment 
NLR>2.52 
HR 1.13, 95%CI 
1.06-1.21, p<0.001 
Chua et al 2016 
(156)  
SQNP01 
NCC0901 
 
 
 
 
Naso-pharyngeal Singapore 221 
 
 
 
172 
Two-dimensional radiotherapy vs.  Two-
dimensional radiotherapy and 
chemotherapy 
 
Intensity modulated radiotherapy or 
concurrent chemotherapy vs. Intensity 
modulated radiotherapy and 
chemotherapy  
NLR OS Multivariate: 
NLR≥3: 
HR 1.06, 95%CI 
0.76-1.49, p>0.05 
 
Cox et al 2017 
(157) 
SCOPE1: 
NCT00509561 
Oesophageal UK 258 Chemoradiotherapy vs 
Chemoradiotherapy and cetuximab 
dNLR OS Multivariate 
dNLR≥2  
HR 1.64 95%CI 
1.17-2.29, p<0.01 
Okuno et al 2017 
(152) 
JCOG0303: 
UMIN000000861 
Oesophageal Japan 142 Radiotherapy and standard cisplatin vs. 
Radiotherapy and low dose cisplatin  
GPS OS Univariate 
GPS 2 vs GPS 0 
HR 1.95 95%CI 
1.19-3.18, p<0.01 
Grenader et al 
2016 (170) 
REAL-2 
ISRCTN51678883  
Oesophago-gastric UK  908 Epirubicin and cisplatin and either 
fluorouracil (ECF) or capecitabine (ECX) 
vs Epirubicin and oxaliplatin and either 
fluorouracil (EOF) or capecitabine (EOX) 
NLR OS Multivariate 
NLR>3 
HR 1.67 95% CI 
1.45–1.93 p<0.001 
 
Bruix et al 2017 
(171) 
Sharp 
NCT00105443 
AP: NCT00492752 
Hepatocellular Multinational 827 Sorafenib vs. Placebo NLR OS Multivariate  
NLR>3 (Sorafenib 
group) 
HR 2.356, p<0.0001 
 160 
 
NLR>3.86 (Placebo 
group) 
HR 1.779, p<0.0001  
Grenader et al 
2015 (159) 
ABC-02: 
NCT00262769 
 
BT-22: 
UMIN 000001685 
 
Biliary UK  
 
Japan  
462 Gemcitabine vs. Gemcitabine and 
cisplatin 
Gemcitabine vs. Gemcitabine and 
cisplatin  
dNLR OS Multivariate 
dNLR≥3 
HR 1.62, 95% CI 
1.32–2.01, p<0.001 
Vivaldi et al 2016 
(158) 
FLAP: NCT02351219 Pancreatic  Italy  137 Neoadjuvant FOLFOXIRI and Surgery vs 
Neoadjuvant FOLFOXIRI and 
radiotherapy  
NLR  OS Multivariate 
NLR ≥4 
HR 2.42, 95%CI: 
1.38-4.25, p<0.01 
Hurwitz et al 2015 
(153) 
RECAP: 
NCT01423604 
Pancreatic United States 127 Capecitabine vs Capecitabine and 
ruxolitinib 
mGPS OS Univariate 
mGPS 1/2 vs mGPS 
0 
HR 0.60, 95%CI 
0.35-1.03, p<0.10 
Goldstein et al 
2015 (172) 
MPACT: 
NCT00844649 
Pancreatic Multinational  861 Gemcitabine vs Gemcitabine and nab-
paclitaxel 
NLR OS Multivariate 
NLR≤5 
HR 0.57, 95%CI 
0.48-0.68, p<0.001 
Renfro et al 2017 
(173) 
Multiple in ARCAD 
database  
Colorectal  Multinational  22,654 Multiple chemotherapy trials  dNLR 30 day OS Multivariate 
dNLR≥5 
HR 1.74, 95%CI 
1.25-2.41, p<0.01 
Wood et al 2017 
(174) 
COIN: NCT00182715 Colorectal UK and Ireland 1630 Oxaliplatin/fluoropyrimidine combination 
chemotherapy vs 
oxaliplatin/fluoropyrimidine combination 
chemotherapy and Cetuximab 
dNLR OS Univariate 
dNLR≥2.2 
HR 1.35, 95%CI 
1.20-1.52, p<0.001  
 
Thomsen et al 
2016 (162) 
NORDIC-VII: 
NCT00660582 
Colorectal Norway and 
Denmark  
393 Cetuximab and FLOX vs. Cetuximab and 
intermittent FLOX 
mGPS, dNLR OS Univariate 
mGPS1 vs 0 
HR 1.60, 95%CI 
1.27-2.01, p<0.001 
 
mGPS 0 vs 2 
HR : 2.16, 95%CI 
1.52-3.06, p<0.001 
 
dNLR>2.1 
HR : 1.68, 95%CI 
1.35-2.08, p<0.001  
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Passardi et al 2016 
(175) 
ITACa: 
NCT01878422 
Colorectal Italy 289 Standard chemotherapy vs. either 
FOLFIRI or FOLFOX4 and bevacizumab. 
NLR OS Multivariate 
NLR ≥3 
HR:1.78, 95%CI: 
1.17-2.70, p<0.01 
Correale et al 2014 
(176) 
GOLFIG-2 
EUDRACT: 2005-
003458-81 
Colorectal Italy 124 Gemcitabine, Oxaliplatin, Levofolinate, 
5-Fluorouracil, Granulocyte-Macrophage 
Colony-Stimulating Factor, and 
Interleukin-2 (GOLFIG) Vs. FOLFOX 
Chemotherapy 
NLR OS Univariate 
NLR< 3 
HR 0.44, P< 0.001 
Hazama et al 2014 
(177) 
Phase 1 HLA2402 
matched  
Colorectal  Japan 96 Comparison of five HLA-A*2402-
restricted peptides, three derived from 
oncoantigens and two from vascular 
endothelial growth factor (VEGF)  
NLR OS Univariate analysis: 
NLR≥3: p<0.05 
Lorente et al 2015 
(178) 
Phase III TROPC trial  Prostate UK 755 Cabazitaxel vs. mitoxantrone NLR OS Multivariate 
NLR≥3 
HR 1.55, 95% CI 
1.3– 1.84, p<0.001 
Van Soest et al 
2015 (160) 
VENICE: 
NCT00519285 
 
 
TAX327:  
NCT01487902 
Prostate Multinational  1224 
  
 
 
1006 
 
Docetaxel/ prednisone and placebo vs 
Docetaxel/ prednisone and aflibercept 
 
 
Docetaxel/ prednisone and placebo vs 
Docetaxel/ prednisone and mitoxantrone 
dNLR OS Multivariate 
dNLR ≥2.0 
HR 1.29, 95% CI 
1.11–1.50, p<0.001 
 
dNLR ≥2.0 
HR 1.43, 95% CI 
1.20–1.70, p<0.001 
Sonpavde et al 
2014 (179) 
SUN-1120:  
NCT00676650 
Prostate Multinational  848 Prednisone and sunitinib or placebo 
following docetaxel monotherpy  
NLR OS Multivariate  
NLR Log-
transformed 
HR 1.55, 95%CI 
1.32-1.83, p<0.001  
Linton et al 2013 
(154) 
AT-101-CS-205:  
NCT00571675 
Prostate United States and 
Russia 
220 Docetaxel/prednisone vs Docetaxel/ 
pednisone and AT101 
mGPS 
 
OS Multivariate 
mGPS  
HR 1.87, 95% CI 
1.35-2.59, p<0.001 
 
mGPS 2 vs 0 
HR 3.44, 95%CI 
1.75-6.76, p<0.001 
Fox et al 2013 
(180) 
EGF20001 Renal Multinational  362 
Lapatinib versus hormone therapy 
 
NLR 
 
 
 
PLR 
OS Multivariate: 
NLR>3 
HR 1.42, 95%CI 
1.10-1.84, p=0.008 
 
Univariate: 
PLR>195 
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HR 1.88, 95%CI 
1.48-2.37, p<0.0001 
Ojerholm et al 
2017 (181) 
SWOG8710: 
NCT02756637 
Bladder United States 230 Cystectomy plus neoadjuvant 
chemotherapy vs. cystectomy alone 
NLR OS  Multivariate 
NLR (continuous) 
HR 1.04, 95%CI 
0.98-1.11, p=0.24 
Honecker et al 
2017 (155) 
 
PELICAN:  
NCT00266799 
Breast Germany 210 First-line pegylated liposomal 
doxorubicin (PLD) vs. capecitabine. 
GPS OS Multivariate 
GPS: p<0.10 
Romano et al 2015 
(182) 
Multiple:  GIMEMA 
MMY-3006, 
GIMEMA MM03-05, 
RV-MM-PI209, J0231 
Multiple Myeloma  Italy  309 Multiple trials on newly diagnosed 
multiple myeloma treated with novel 
therapies  
NLR OS Univariate analysis: 
NLR≥2: p=0.0002 
Bigot et al 2017 
(183) 
ICT –Phase 1 trial  Multiple France  155 Standard treatment vs. Immune 
checkpoint treatment 
NLR OS Multivariate 
NLR≥6  
HR 1.75, 95%CI 
1.04-2.94, p<0.05  
Kumar et al 2015 
(161) 
Multiple 
Phase 1 (RMH) 
Multiple UK 1300 Dose and toxicity finding study for 
chemotherapy in multiple phase 1 
chemotherapy trials  
NLR OS Univariate 
Test Cohort, 
NLR>4.45  
HR 1.78, 95%CI 
1.41-2.87, p<.0001 
 
Validation Cohort, 
NLR>4.45 
HR 1.57, 95%CI 
1.42-1.97, p<0.001 
Chua et al 2012 
(163) 
Single Agent Phase 1   Multiple Australia  68 Docetaxel monotherapy vs. standard 
treatment  
GPS 
NLR 
OS Multivariate 
GPS 
HR 4.1, 95%CI 2.2-
7.7, p<0.0001 
 
NLR>5 
HR 2.0, 95%CI 1.2-
3.3, p=0.010 
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Table 5.2: The relationship between the systemic inflammatory response and survival in randomised clinical trials in patients with cancer (published abstracts) 
Authors Randomised Clinical 
Trial  
Tumour Type Country  Patients 
(n) 
Randomised Clinical 
Trial 
Systemic 
Inflammation 
Outcome Comment 
Diakos et al 2016 
(184)  
CO.17 NCT00640471  
 
CO.20 
NCT00079066 
Colorectal Australia and Canada 572 
 
750 
CO.17: Cetuximab vs. 
best 
supportive care, 
 
 
CO.20:  Brivanib (B) vs. 
placebo 
dNLR  OS Multivariate 
dNLR≥2 
CO.17  HR 1.4, 95% 
CI 1.1-1.8, p <0.01 
 
CO.20 HR 1.4, 95% 
CI 1.2-1.6, p<0.0001  
Diakos et al 2016 
(185) 
AGITG MAX Colorectal Australia 471 Capecitabine and 
bevacizumab vs. 
Capecitabine and 
bevacizumab and 
mitomycin C 
NLR OS Multivariate 
NLR≥5 
HR 1.8, 95%CI 1.3-
2.3, p<.0001  
Ce Maio et al 2017 
(186) 
ECRTC 62043/62072 Sarcoma Belgium  333 Pazopanib vs placebo NLR OS Univariate 
NLR>3 
HR 1.86, 95%CI 1.43-
2.41, p<0.001 
Coleman et al 2017 
(187) 
Phase 1 Trial Recurrent Primary 
Malignant Brain 
Tumour 
UK 100 Primary corticosteroid 
vs. best supportive care 
NLR OS Multivariate 
NLR≥4 
HR 1.73, 95%CI 1.02-
2.94, p=0.043 
Wang-Gillam et al 
2017 (188) 
NAPOLI-1: 
NCT01494506 
Pancreatic Multinational  116 Liposomal irinotecan + 
5-fluorouracil and 
leucovorin vs 5-
fluorouracil and 
leucovorin alone 
NLR 
 
 
 
PLR 
OS Univariate 
NLR≤5 
HR 0.62, 95%CI 0.44-
0.86, p=0.005 
 
PLR≤150 
HR 0.52, 95%CI 0.32-
0.84, p=0.008 
Smyth et al 2017 
(189) 
REAL 3: 
NCT00824785 
Oesphagogastric  UK  553 Epirubicin, Oxaliplatin, 
Capecitabine (EOC) vs 
EOC plus panitumumab 
(EOC-P) 
NLR OS Univariate 
NLR: Upper Tertile 
EOC cohort 
HR: 9.97, 95%CI 
7.43-15.43, p<0.001 
 
ECP-P cohort 
HR: 5.26, 95%CI 
4.28-7.17, p<0.001 
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Clarke et al 2018 
(190) 
ASCENT: 
NCT01588990 
Colorectal  Australia 128 First line BEV+XELOX 
or mFOLFOX6 in phase 
A (PhA) with planned 
continuation of 
BEV+FOLFIRI beyond 
1st progression in phase 
B (PhB). 
NLR OS Univariate: 
NLR>5 
HR: 1.6, 95% CI 1.0-
2.7, p = 0.052 
Argiles et al 2018 
(191) 
RECOURSE: 
NCT01607957 
Colorectal  Multinational  782 Trifluridine/tipiracil 
(TAS-102) vs placebo 
NLR OS Multivariate: 
NLR≥3: p = 0.15 
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 Figures and Legends  
 
Figure 5.1: PRISMA flowchart demonstrating study selection  
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6. THE PREVALENCE OF CANCER ASSOCIATED SYSTEMIC 
INFLAMMATION AND ITS IMPLICATIONS: OBSERVATIONS FROM 
PROGNOSTIC STUDIES USING THE GLASGOW PROGNOSTIC SCORE 
 Introduction 
In 2014 McAllister and Weinberg concluded that tumour related systemic inflammation was 
the “seventh hallmark of cancer” and the “tip of the iceberg” in terms of cancer biology and 
treatment (117, 192, 193). Furthermore, as can be seen in Chapter 3 and 4 Dolan and co-
workers showed that widely used clinical markers of the systemic inflammatory response 
(CRP, albumin, neutrophils and platelets) had prognostic value in patients with operable and 
in advanced cancer. Indeed, the activation of the systemic inflammatory response has been 
strongly implicated in the aggressiveness of the disease and development of cachexia with 
associated deleterious outcomes (7, 193, 194). 
The prognostic application of markers of the systemic inflammatory response in patients 
with cancer are usually based around composite ratios or scores of different circulating white 
blood cells or acute phase proteins; representing the systemic responses of two different 
organs, lymphoid/myeloid tissue and liver respectively (40).  The most widely validated 
example of a composite ratio would be the NLR based on the ratio of circulating neutrophil 
and lymphocyte counts (37, 38).  While it is clear that composite ratios such as the NLR 
have prognostic value, there is a large variation in the specific threshold levels used which 
makes comparison of studies difficult (37, 38). The most widely validated example of a 
cumulative scores is the GPS/mGPS based on the acute phase proteins CRP and albumin 
(37, 38).  The advantage of cumulative scores are that they are based on validated laboratory 
reference ranges and the advantage of the GPS/mGPS is that consistent thresholds that allow 
for direct comparison of the systemic inflammatory response across different institutions and 
geographical locations. 
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While the prognostic importance of the systemic inflammatory response in patients with 
both operable and inoperable cancers is widely recognised, the level of systemic 
inflammation in patients with cancer across the literature has not been formally assessed. 
Therefore, the aim of this Chapter was to determine the prevalence of systemic inflammation 
as measured by the GPS/ mGPS in patients with either operable and inoperable cancer.  
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 Patients and Methods 
The present review of published literature was based on that of two previous systematic 
reviews (37, 38) undertaken according to a pre-defined protocol described in the PRISMA-
P statement and outlined in Chapters 2.  Only studies that had greater than 100 observations 
and reported survival were considered in the final analysis.  
Statistical Analysis 
Studies were reviewed and the number of patients with breast, bladder, gynaecological, 
prostate, gastrointestinal, haematological, renal, colorectal, head and neck, 
hepatopancreaticobiliary, pulmonary and multiple types of cancer types were grouped into 
tables for operable, inoperable and combined studies. The individual number of patients with 
elevated CRP and albumin readings were also included. No meta analysis was carried out 
since it could be considered as a narrative review of previous systematic reviews (37, 38).   
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 Results 
Study selection process 
The review of existing systematic reviews (37, 38) led to a review of the full text of 104 
articles. A further 36 articles were identified from bibliographies and were included in this 
narrative review leading to a final total of 140 articles.  The details of the 140 studies 
included in the review are shown in Table 6.1. 
Studies of the GPS/ mGPS in patients with breast cancer 
No articles were identified in patients with operable breast cancer (Table 6.1). Two studies 
including 181 patients were identified in inoperable breast cancer. These studies included 
both retrospective (n=1) and prospective studies (n=1). These included studies carried out in 
the UK (n=1) and Germany (n=1). In total 81 (45%) of patients were systematically inflamed 
(Table 6.1 and Table 6.2). 
Studies of the GPS/ mGPS in patients with bladder cancer 
Two studies including 2133 patients were identified in operable bladder cancer. These 
studies were both retrospective studies (n=2). These included studies carried out in Italy 
(n=1) and Japan (n=1). In total 723 (34%) of patients were systematically inflamed (Table 
6.1 and Table 6.2). A single study was identified in patients with inoperable bladder cancer. 
This contained 67 patients, was prospective, carried out in the Korea and showed that 34 
(51%) of patients were systemically inflamed.  
Studies of the GPS/ mGPS in patients with gynaecological cancer 
Three studies including 724 patients were identified in operable gynaecological cancer. 
These studies included both retrospective (n=2) and prospective studies (n=1). These 
included studies carried out in the Austria (n=1), Japan (n=1) and China (n=1). In total 186 
(26%) of patients were systematically inflamed (Table 6.1 and Table 6.2).  
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 Three studies including 870 patients were identified in inoperable gynaecological cancer. 
These studies included both retrospective (n=2) and prospective studies (n=1). These 
included studies carried out in the multiple countries (n=1), Austria (n=1) and China (n=1). 
In total 309 (36%) of patients were systematically inflamed (Table 6.1 and Table 6.2).  
Studies of the GPS/ mGPS in patients with prostate cancer 
No articles were identified in patients with operable prostate cancer (Table 6.1Table 5.1 and 
Table 6.2). Two studies including 223 patients were identified in inoperable prostate cancer. 
These studies included both retrospective (n=1) and prospective studies (n=1).  These 
included studies carried out in multiple countries (n=1) and Japan (n=1). In total 65 (29%) 
of patients were systematically inflamed (Table 6.1 and Table 6.2).  
Studies of the GPS/ mGPS in patients with gastroesophageal cancer 
Twenty-five studies including 7,693 patients were identified in operable gastroesophageal 
cancer. These studies included both retrospective (n=24) and prospective studies (n=1). 
These included studies carried out in Japan (n=13), UK (n=5), China (n=3), Germany (n=2), 
Ireland (n=1) and Italy (n=1). In total 1,617 (21%) of patients were systematically inflamed 
(Table 6.1 and Table 6.2).  
Eleven studies including 1,897 patients were identified in inoperable gastroesophageal 
cancer. These studies included both retrospective (n=10) and prospective studies (n=1). 
These included studies carried out in the UK (n=3), Japan (n=3), Korea (n=2), China (n=1), 
Czech Rep (n=1) and Taiwan (n=1). In total 1032 (54%) of patients were systematically 
inflamed (Table 6.1 and Table 6.3).  
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Studies of the GPS/ mGPS in patients with haematological cancer 
Two studies including 430 patients were identified in inoperable haematological cancer. All 
studies were retrospective. These included studies carried out in China (n=1) and Korea 
(n=1). In total 340 (79%) of patients were systematically inflamed (Table 6.1 and Table 6.3). 
Studies of the GPS/ mGPS in patients with renal cancer 
Seven studies including 2417 patients were identified in operable renal cancer. These studies 
included both retrospective (n=6) and prospective studies (n=1). These included studies 
carried out in the UK (n=2), Japan (n=4) and Korea (n=1). In total 717 (30%) of patients 
were systematically inflamed (Table 6.1 and Table 6.2). 
Two studies including 142 patients were identified in inoperable renal cancer. These studies 
included both retrospective (n=1) and prospective studies (n=1). These studies were both 
carried out in the UK. In total 101 (45%) of patients were systematically inflamed (Table 6.1 
and Table 6.3).  
Studies of the GPS/ mGPS in patients with colorectal cancer 
Twenty-nine studies including 8,832 patients were identified in operable colorectal cancer. 
These studies included both retrospective (n=26) and prospective studies (n=3). These 
included studies carried out in the UK (n=15), Japan (n=11), China (n=1), Korea (n=1) and 
Australia (n=1). In total 3,356 (38%) of patients were systematically inflamed (Table 6.1 
and Table 6.2).  
Eight studies including 1166 patients were identified in inoperable colorectal cancer. These 
studies included both retrospective (n=6) and prospective studies (n=2). These included 
studies carried out in the UK (n=2), Japan (n=2), France (n=1), Korea (n=1), Australia (n=1) 
and Norway/Denmark (n=1). In total 622 (53%) of patients were systematically inflamed 
(Table 6.1 and Table 6.3).  
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Studies of the systemic inflammatory response in patients with head and neck cancer 
A single study was identified in patients with operable head and neck cancer. This contained 
178 patients, was retrospective, carried out in the UK and showed that 47 (26%) of patients 
were systemically inflamed (Table 6.1 and Table 6.2). Three studies including 531 patients 
were identified in inoperable head and neck cancer. These studies included both 
retrospective (n=1) and prospective studies (n=1). These included studies carried out in 
Taiwan (n=2) and China (n=1).  In total 251 (47%) of patients were systematically inflamed 
( and ).  
Studies of the GPS/ mGPS in patients with Hepatopancreaticobiliary Cancer 
Sixteen studies including 3,587 patients were identified in operable hepatopancreaticobiliary 
cancer. These studies included both retrospective (n=14) and prospective studies (n=2). 
These included studies carried out in Japan (n=8), the UK (n=2), China (n=4), Italy (n=1), 
and Austria (n=1). In total 1,001 (28%) of patients were systematically inflamed (Table 6.1 
and Table 6.2) .  
Seven studies including 920 patients were identified in inoperable hepatopancreaticobiliary 
cancer. These studies included both retrospective (n=5) and prospective studies (n=2). These 
included studies carried out in Japan (n=3), UK (n=1), USA (n=1), China (n=1) and Australia 
(n=1). In total 333 (36%) of patients were systematically inflamed (Table 6.1 and Table 6.3).  
Studies of the GPS/ mGPS in patients with Pulmonary Cancer 
Four studies including 2,579 patients were identified in operable pulmonary cancer. All of 
these studies were retrospective. These included studies carried out in the Japan (n=2), UK 
(n=1) and China (n=1). In total 1,001 (27.9) of patients were systematically inflamed (Table 
6.1 and Table 6.2).  
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Seven studies including 1,456 patients were identified in inoperable pulmonary cancer. 
These studies included were both retrospective (n=4) and prospective studies (n=3). These 
included studies carried out in the UK (n=2), China (n=2), Greece (n=2) and the USA (n=1). 
In total 857 (59%) of patients were systematically inflamed (Table 6.1 and Table 6.3).  
Studies of the GPS/mGPS in patients with Multiple Cancer Types 
No articles were identified in patients with operable multiple types of cancer. Seven studies 
including 4,867 patients were identified in inoperable multiple cancer types. These studies 
included both retrospective (n=3) and prospective studies (n=4). These included studies 
carried out in the UK (n=2), Australia (n=2), USA (n=1), Japan (n=1) and Norway (n=1). In 
total 3,556 (73%) of patients were systematically inflamed (Table 6.1 and Table 6.3).  
Combined Inoperable and Operable Studies:  
Inoperable and operable cancer studies are summarised in Table 6.2 and Table 6.3. The 
percentage of patients (>40,000) who were systemically inflamed varied from 28% to 63% 
according to tumour type (gastroesophageal and multiple cancers respectively). The most 
commonly studied cancer was colorectal cancer (~10,000 patients) and 40% were 
systemically inflamed overall (Table 6.2). The percentage of patients with operable cancer 
(>28,000) who were systemically inflamed varied from 21% to 38% (gastroesophageal and 
colorectal cancer respectively, Table 6.3). The most commonly studied cancer was colorectal 
cancer (>8,500 patients) and 38% were systemically inflamed (Table 6.3). The percentage 
of patients with inoperable cancer (>12,000) who were systemically inflamed varied from 
29% to 79% (prostate and haematological cancers, Table 6.3). Furthermore, a commonly 
studied cancer was colorectal cancer (>1,100 patients) and 53% were systemically inflamed 
(Table 6.3).   
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 Discussion 
In the present narrative review of the prevalence of the systemic inflammatory response (as 
evidenced by GPS/mGPS) in more than 40,000 patients with cancer it was clear that the 
elevation of the GPS/mGPS was common and the prevalence was greater in advanced cancer 
compared with operable cancer. In particular, in patients with operable tumours (>500 
patients) no tumour type had more than 50% of patients with an elevated GPS/mGPS. In 
contrast, in patients with inoperable disease (>500 patients) gastro-oesophageal cancer, 
colorectal cancer, hepatopancreaticobiliary cancer, pulmonary cancer and multiple cancers 
all had more than 50% of patients with an elevated GPS/mGPS. Therefore, it is clear that the 
presence of a systemic inflammatory response is a common prognostic feature of established 
cancer, especially advanced cancer.  
The results of the present review are consistent with the report of Procter and colleagues who 
first studied the prevalence of the mGPS before and after diagnosis in an unselected cohort 
of patients with cancer and reported that “the proportions of mGPS 1 and 2 were greater 
following a diagnosis of cancer (195).”  Taken together these results would indicate that the 
systemic inflammatory response is present at the earliest stages of cancer and increases as 
the cancer progresses. Given the independent prognostic value of the mGPS this may suggest 
that the systemic inflammatory response reflects or promotes tumour progression. 
Irrespective, these results have implications for the future stratification and treatment of both 
operable and inoperable disease in patients with cancer. 
The implications for patient stratification are clear and there is now evidence of the 
GPS/mGPS being used in the randomised clinical trial setting (54). The implications for 
treatment are less clear in patients with operable cancer. For example, there is increasing 
interest in the addition of either aspirin or steroids to pre-operative management regimes 
(196). The implication for treatment in patients with inoperable cancers is likely to focus on 
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the use of anti-inflammatory regimes to improve the response rates for anticancer therapies 
(82).  
In summary, the systemic inflammatory response, as evidenced by the GPS/mGPS, was 
common in both primary operable and advanced inoperable cancers particularly in lung and 
gastrointestinal cancers. Therefore, the systemic inflammation “iceberg” is in plain sight and 
should be factored into future treatment plans of patients with cancer.  
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 Tables and Footnotes  
Table 6.1: Studies using mGPS to stratify patients undergoing operative and non-operative treatment for cancer. 
No: GPS/ 
mGPS 
Study Type of 
Study 
Cancer Country  Patients 
(n) 
Measure of SIR CRP 
>10mg/l 
Albumin 
<35 g/l 
GPS/mGP
S 0 
GPS/mGP
S 1 
GPS/mGP
S 2 
Additional 
Treatment  
Breast cancer 
Operable 
            
1     _    _ _ _  
Breast cancer 
Inoperable 
            
1.  Al Murri et 
al 2006 
(197) 
 
Retrospectiv
e  
Breast cancer UK 96 GPS (0/1/2) 45 (47) 6 (6) 51 (53) 39 (41) 6 (6) Chemotherapy and 
endocrine therapy  
2.  Honecker et 
al 2018 
(198) 
 
Prospective  Breast cancer Germany  85 GPS (0/1/2) 36 17 49 (57.6) 22 (25.9) 14 (16.5) First line 
chemotherapy  
Combined Total     181    100 (55.2) 61 (33.7) 20 (11.1)  
             
Bladder cancer 
Operable 
            
1.  Ferro et al 
2015 (199) 
 
Retrospectiv
e  
Bladder cancer Italy 1037 mGPS (0/1/2)  391 (37.7) 97 (9.4) 646 (62.3) 297 (28.6) 94 (9.1) 77.1% received 
adjuvant 
chemotherapy 
2.  Kimura et 
al 2019 
(200) 
 
Retrospectiv
e  
Bladder cancer Japan  1096 mGPS _ _ 764 (69.7) 299 (27.3) 33 (3.0) 4.0% patients 
received adjuvant 
chemotherapy  
Bladder cancer 
Inoperable 
            
1.  Hwang et al 
2012 (201) 
 
Prospective  Bladder cancer Korea 67 GPS (1&2) 30 (44.8) 
 
 
21 (31.3) 33 (49.3) 17 (25.4) 17 (25.4) Treated with 
chemotherapy  
Combined Total     2200    1443 (65.6) 613 (27.9) 144 (6.5)  
             
Gynaecological 
cancer Operable 
            
1.  Hefler-
Frischmuth 
et al 2010 
(202)  
Prospective  Vulval cancer Austria 93 GPS (0/1/2) _ _ 72 (77.4) 16 (17.2) 5 (5.4) Adjuvant 
treatment not 
specified  
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2.  Saijo et al 
2017 (203) 
 
Retrospectiv
e  
Endometrial cancer Japan  431  51 (11.8) 21 (4.9) 376 (87.2) 38 (8.8) 17 (4.0) Adjuvant 
chemotherapy in 
high risk patients 
3.  Liu et al 
2017 (204) 
 
Retrospectiv
e 
Ovarian cancer China 200 mGPS (0/1/2) 41 (20.5) 6 (3.0) 90 (45) 90 (45) 20 (10) 96% patients 
received 
chemotherapy  
Gynaecological 
cancer 
Inoperable 
            
1.  Xiao et al 
2015 (205) 
 
Retrospectiv
e  
Cervical cancer  China  238 mGPS (0/1/2) 107 (45.0) 29 (12.2) 138 (58.0) 71 (29.8) 29 (12.2) Chemo and 
radiotherapy  
2.  Roncolato 
et al 2018 
(206) 
 
Prospective  Endometrial cancer  Multinationa
l  
516 mGPS (0/1/2) _ _ 282 (54.7) 123 (23.8) 111 (21.5) Chemotherapy and 
best supportive 
care  
3.  Seebacher 
et al 2019 
(207) 
 
Retrospectiv
e  
Cervical cancer Austria  116 GPS _ _ 41 (35.3) 56 (48.3) 19 (16.4) Best supportive 
care for recurrent 
disease  
Combined Total     1594    999 (62.7) 394 (24.7) 201 (12.6)  
             
Prostate cancer 
Operable 
            
1.      _    _ _ _  
Total             
Prostate cancer 
Inoperable 
            
1.  Linton et al 
2013 (154)  
 
Prospective  Prostate cancer Multinationa
l  
112 mGPS (2 vs. 0) 
(1 vs. 0) 
 
 
>5: 36 
(32.1) 
27 (24.1) 76 (67.9) 17 (15.2) 19 (16.9) Docetaxel and 
prednisone 
treatment  
2.  Owari et al 
2018 (208) 
 
Retrospectiv
e  
Renal, prostate and 
urethral cancer 
Japan  111 mGPS (0/1/2) _ _ 82 (74) 26 (23) 3 (3)  84% treated with 
radiotherapy  
Combined Total     223    158 (70.9) 43 (19.3) 22 (9.9)  
             
Gastro-
oesophageal 
cancer Operable 
            
1.  Kobayashi 
et al 2008 
(209) 
Retrospectiv
e 
Oesophageal squamous 
cell carcinoma 
Japan 48 GPS (0/ 1 and 2) _ _ 27 (56.3) 16 (33.3) 5 (10.4) Neoadjuvant 
chemoradiotherap
y (nCRT) 
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2.  Kobayashi 
et al 2010 
(210) 
 
Retrospectiv
e 
Oesophageal  
Squamous Cell 
Carcinoma 
Japan 65 
 
GPS (0 and 1) 
  
_ _ 43 (66.2) 16 (24.6) 6 (9.2) 60% patients 
received 
neoadjuvant 
chemoradiotherap
y 
3.  Dutta et al 
2011 (211) 
 
Retrospectiv
e  
Oesophageal cancer  UK 112 GPS (0/1/2) _ _ 99 (88.4) 13 (11.6) 0 (0) 27.7% patients 
received 
neoadjuvant 
therapy and 12.5% 
received  adjuvant 
therapy 
4.  Dutta et al 
2011 (212) 
 
Retrospectiv
e  
Gastro-oesophageal 
cancer   
UK 121 GPS (0/1/2) _ _ 99 (81.8) 16 (13.2) 6 (5.0) 55.4% patients 
received 
neoadjuvant and 
15.7% received 
adjuvant therapy  
5.  Crumley et 
al 
2011(213)  
 
Retrospectiv
e  
Gastro-oesophageal 
cancer   
UK 100 GPS (0/1/2) _ _ 87 (87) 13 (13) 0 (0) Adjuvant and 
neoadjuvant 
therapy 
administered  
6.  Vashist et al 
2011 (214)  
 
Retrospectiv
e  
Oesophageal cancer Germany  495 GPS (0/1/2) _ _ 268 (54.1) 166 (33.5) 61 (12.3) No adjuvant or 
neoadjuvant 
therapy  
7.  Dutta et al 
2012 (215) 
  
Retrospectiv
e  
Oesophageal cancer UK 98 GPS (0/1/2)  _ _ 87 (88.8) 9 (9.2) 2 (2.0) 48.0% received 
neoadjuvant 
therapy and 18.4% 
received adjuvant 
therapy  
8.  Feng et al 
2014 (216)  
 
Retrospectiv
e  
Oesophageal cancer China 493 
 
GPS (0/1/2)  _ 
 
 
_ 316 (64.1) 121 (24.5) 56 (11.4) Adjuvant chemo 
and radiotherapy 
administered  
9.  Nakamura 
et al 2014 
(141) 
 
Retrospectiv
e  
Oesophageal cancer Japan  168 mGPS (0/1/2)  _ _ 137 (81.6) 19 (11.3) 12 (7.1) 7.7% received 
neoadjuvant 
therapy while 
36.9% received 
adjuvant therapy  
10.  Matsuda et 
al 2015 
(217) 
 
Retrospectiv
e  
Oesophageal cancer Japan 199 GPS (0/1/2)  10 (5.0) 12 (6.0) 108 (54.3) 68 (34.2) 23 (11.5) 49.8% patients 
received 
neoadjuvant 
chemo and 
radiotherapy  
11.  Arigami et 
al 2015 
(142) 
Retrospectiv
e  
Oesophageal cancer  Japan  238 mGPS (0/1/2)  _ _ 168 (70.6) 54 (22.7) 16 (6.7) Adjuvant therapy 
not specified  
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12.  Xu et al 
2015 (127) 
 
Retrospectiv
e 
Oesophageal SCC China 468 GPS/mGPS 
(0/1/2)  
108 (23) 89 (19) GPS: 336 
(71.8) 
 
mGPS: 360 
(76.9) 
GPS: 101 
(21.6) 
 
mGPS: 77 
(16.5) 
GPS: 31 
(6.6) 
 
 
mGPS: 31 
(6.6) 
41.9% patient 
received adjuvant 
chemo and 
radiotherapy  
13.  Hirahara et 
al 2015 
(218) 
 
Retrospectiv
e  
Oesophageal cancer Japan  141 GPS (0/1/2)  18 (12.8) 27 (19.1) 109 (77.3) 23 (16.3) 9 (6.4) Adjuvant therapy 
not specified  
14.  Walsh et al 
2016 (219) 
 
Retrospectiv
e 
Oesophageal cancer Ireland 223 mGPS (0 vs. 1/2)  _ _ 174 (78.0) _ mGPS 
1&2: 49 
(22.0) 
48.9% patients 
received 
neoadjuvant 
chemoradiotherap
y, 
29.6% patients 
received 
chemotherapy 
15.  Otowa et al 
2016 (220) 
 
Retrospectiv
e 
Oesophageal cancer Japan 100 Pre-NAC mGPS 
(0/1-2) 
 
Post-NAC mGPS 
(0/2) 
 
NAC=neoadjuva
nt chemotherapy  
_ _ Pre: 82 
(82.0) 
 
Post: 90 
(90.0) 
Pre: 7 (7.0) 
 
Post: 0 (0) 
Pre: 11 
(11.0) 
 
Post: 10 
(10.0) 
All patients 
received 
neoadjuvant 
chemotherapy  
16.  Toyokawa 
et al 2016 
(140)  
 
Retrospectiv
e 
Thoracic oesophageal 
squamous cell 
carcinoma 
Japan 185 GPS (0 vs 1/2)  _ _ 171 (92.5) 13 (7.0) 1 (0.5) 24.9% patients 
received 
neoadjuvant 
therapy  
17.  Nozoe et al 
2011 (221)  
 
Prospective  Gastric cancer Japan 232 GPS (0/1/2) 
mGPS (0/1/2) 
58 (25.0) 62 (26.7) 140 (60.3) 64 (27.6) 28 (12.1) Adjuvant therapy 
not specified  
18.  Kubota et al 
2012 (222) 
 
Retrospectiv
e  
Gastric cancer Japan  1017 GPS (0/1/2)  _ _ 956 (94.0) 40 (3.9) 21 (2.1) Adjuvant therapy 
not specified  
19.  Dutta et al 
2012 (223)  
 
Retrospectiv
e  
Gastric cancer UK 120 GPS (0/1/2)  _ _ 97 (80.8) 18 (15.0) 5 (4.2) Patients received 
both adjuvant and 
neoadjuvant 
therapy  
20.  Wang et al 
2012 (224) 
 
Retrospectiv
e  
Gastric cancer China 324 GPS (0/1/2)  62 (19.1) 32 (9.9) 248 (76.5) 58 (17.9) 18 (5.6) 64.8% patients 
received  adjuvant 
chemotherapy  
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21.  Jiang et al 
2012 (225)  
 
Retrospectiv
e  
Gastric cancer Japan  1710 mGPS (0/1/2) 145 (8.5) 162 (9.5) 1565 (91.5) 78 (4.6) 67 (3.9) Adjuvant therapy 
not specified 
22.  Takeno et al 
2014 (145) 
 
Retrospectiv
e  
Gastric cancer Japan  552 mGPS (0/1/2)  _ _ 494 (89.5) 24 (4.3) 34 (6.2) Adjuvant therapy 
not specified  
23.  Hirashima 
et al 2014 
(143) 
 
Retrospectiv
e  
Gastric cancer Japan  294 mGPS (0/1/2)  _ _ 174 (59.2) 84 (28.6) 36 (12.2) 3.1% patients 
received 
neoadjuvant 
chemotherapy  
24.  Aurello et 
al 2014 
(135)  
 
Retrospectiv
e 
Gastric cancer Italy 102 mGPS (0/1/2) 53 (51.9) 55 (53.9) 49 (48.0) 25 (24.5) 28 (27.5) 66.7% patients 
received adjuvant 
chemotherapy  
25.  Melling et 
al 2016 
(226)  
 
Retrospectiv
e 
Gastric cancer Germany 88 GPS (0/1/2)  _ _ 42 (47.7) 22 (25.0) 24 (27.3) Neoadjuvant and 
adjuvant therapy 
not specified 
Gastro-
oesophageal 
cancer 
Inoperable 
            
             
1.  Crumley et 
al 2006 
(227) 
 
Retrospectiv
e  
Gastro-oesophageal 
cancer 
UK 258 GPS (0/1/2) 
 
_ _ 92 (36) 121 (47) 45 (17) Palliative Chemo 
and radiotherapy  
2.  Crumley et 
al 2008 
(228) 
 
Retrospectiv
e  
Gastro-oesophageal 
cancer 
UK 65 GPS (0/1/2) _ _ 26 (40) 31 (48) 8 (12) Cisplatin based 
chemotherapy  
3.  Zhang et al 
2014 (229) 
 
Retrospectiv
e   
Oesophageal cancer   China  212 mGPS (0,1,2) 122 (57.6) 134 (63.3) 90 (42.5) 78 (36.8) 44 (20.8) Radiotherapy and 
cisplatin based 
chemo 
4.  Elahi et al 
2004 (230) 
Retrospectiv
e  
Gastric and colorectal 
cancer  
UK  Gastric: 66 GPS (0/1/2) 47 (71.2) 25 (37.9) Gastric: 17 
(25.8) 
Gastric: 26 
(39.4) 
Gastric: 23 
(34.8) 
Palliative Chemo 
and Supportive 
Care 
5.  Hwang et al 
2011 (231) 
 
Retrospectiv
e  
Gastric cancer   Korea 402 GPS: (1&2) 
 
140 (34.9) 77 (19.2) 238 (59.2) 111 (27.6) 53 (13.2) Cisplatin based 
chemotherapy  
6.  Jeong et al 
2012 (232) 
 
Retrospectiv
e  
Gastric cancer Korea  104 mGPS: (1 & 2) _ _ 58 (55.8) 29 (27.9) 17 (16.3) Palliative chemo 
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7.  Sachlova et 
al 2014 
(233) 
 
Retrospectiv
e  
Gastric cancer Czech Rep 91 Total 
 
64 (treated 
with chemo) 
GPS (1&2) _ _ 37 (41) 31 (34) 23 (25) Palliative platinum 
based 
chemotherapy  
8.  Namikawa 
et al 2016 
(234) 
 
Retrospectiv
e  
Gastric cancer Japan 244 GPS (0/1 or 2) 
 
mGPS (0/1 or 2) 
_ 
 
 
_ 
_ 
 
 
_ 
GPS: 
150 (61.5) 
 
mGPS:  
143 (58.6) 
GPS: _ 
 
 
mGPS: _ 
GPS: 1&2: 
94 (38.5) 
 
mGPS 
1&2: 101 
(41.4) 
Combination 
chemotherapy 
including 
trastuzmab  
9.  Arigami et 
al 2016 
(235) 
 
Retrospectiv
e 
Gastric cancer Japan 68 GPS: 1&2 _ _ 35 (51.5) 27 (39.7) 6 (8.8) Chemotherapy and 
chemoradiotherap
y  
10.  Hsieh et al 
2016 (236) 
 
Retrospectiv
e 
Gastric cancer  Taiwan  256 mGPS (>1) _ _ 66 (26) 100 (39) 90 (35) Combination 
Chemotherapy  
11.  Okuno et al 
2017 (152)  
Prospective Oesophageal cancer Japan  131 GPS (0/1/2) _ _ 56 (42.8) 48 (36.6) 27 (20.6) Radiotherapy and 
standard cisplatin 
vs. Radiotherapy 
and low dose 
cisplatin 
Combined Total     9590    6941 (72.4) 1670 (17.4) 979 (10.2)  
             
Haematological 
cancer 
Inoperable 
            
1.  Chou et al 
2015 (237) 
 
Retrospectiv
e  
Haematological cancer China 217 GPS: (1&2)  181 (83.4) 156 (71.9) 15 (6.9) 56 (30.9) 146 (62.2) Best supportive 
palliative care  
3.  Jung et al 
2015 (238)  
 
Retrospectiv
e  
B-cell Lymphoma Korea  213 L-GPS: 1&2 135 (63.4) 43 (20.2) 75 (35.2) 109 (51.2) 29 (13.6)  R-CHOP 
chemotherapy. 
Combined Total     430    90 (20.9) 165 (38.4) 175 (40.7)  
             
Renal cancer 
Operable 
            
1.  Qayyum et 
al 2012 
(239) 
 
Prospective  Renal cell cancer UK 79 GPS (0/1/2)  _ _ 57 (72.2) 19 (24.1) 3 (3.7) Adjuvant therapies 
not specified  
2.  Lamb et al 
2012 (240) 
 
Retrospectiv
e  
Renal cancer UK 169 GPS (0/1/2) _ _ 117 (69.2) 46 (27.2) 6 (3.6) Adjuvant therapies 
not specified 
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3.  Tsuijino et 
al 2017 
(241)  
 
Retrospectiv
e  
Renal cancer Japan  219 mGPS (0/1/2) _ _ 184 (84.0) 20 (9.1) 15 (6.9) Adjuvant therapies 
not specified 
4.  Fukuda et al 
2018 (242) 
 
Retrospectiv
e  
Renal cancer Japan  170 GPS (0/1/2) _ _ 56 (33)  67 (39) 47 (28) Chemo and 
immunotherapy as 
part of 
cryoreductive 
treatment  
5.  Inamoto et 
al 2017 
(243) 
 
Retrospectiv
e  
Urethral cancer Japan  574 GPS (0/1/2) _ _ 332 (57.8) 132 (23.0) 110 (19.2) Adjuvant therapies 
not specified 
6.  Son et al 
2018 (244) 
 
Retrospectiv
e  
Urethelial cancer South Korea 1137 mGPS (0/1/2) 219 (19.3) 158 (13.8) 918 (80.7) 148 (13.0) 71 (6.2) 30.6% treated with 
adjuvant 
chemotherapy  
7.  Owari et al 
2018 (208) 
 
Retrospectiv
e  
Renal and urethral 
cancer  
Japan  69 GPS (0/1/2) _ _ 36 (52.2) 19 (27.5) 14 (20.3) 56.5% treated with 
radiotherapy  
Renal cancer 
Inoperable 
            
1.  Ramsey et 
al 2007 (31) 
 
Retrospectiv
e  
Renal cell cancer 
 
UK  119 GPS: (0/1/2) 84 (71) 16 (14) 33 (28) 72 (60) 14 (12) Active 
Immunotherapy  
2.  Ramsey et 
al 2008 
(245) 
 
Prospective  Renal cell cancer  UK  23 GPS (0/1/2) _ _ 8 (35) 6 (26) 9 (39) Palliative 
immunotherapy  
Combined Total     2559    1741 (68.0) 529 (20.7) 289 (11.3)  
             
Colorectal 
Cancer 
Operable 
            
1.  Ishizuka et 
al 2007 
(246)  
 
Retrospectiv
e 
Colorectal cancer Japan 315 GPS (0/1/2)  76 (24.1) 100 (21.8) 183 (58.1) 89 (28.3) 43 (13.6) Neoadjuvant 
treatments not 
specified  
2.  McMillan et 
al 2007 
(118) 
 
Retrospectiv
e 
Colorectal cancer UK 316  mGPS (0/1/2)  101 (32.0) 54 (17.1) 185 (58.5) 93 (29.5) 38 (12.0) Adjuvant therapy 
not specified 
3.  Leitch et al 
2007 (247) 
 
Retrospectiv
e 
 
Colorectal cancer UK 149  mGPS (0/1/2)  61 (40.9) 14 (9.4) 88 (59.1) 48 (32.2) 13 (8.7) 47.7% of patients 
received adjuvant 
therapy  
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4.  Roxburgh et 
al 2009 
(248) 
 
Retrospectiv
e 
Colorectal cancer UK 287 mGPS (0/1/2)  _ _ 171 (60) 82 (28) 34 (12) Adjuvant therapy 
not specified 
5.  Ishizuka et 
al 2009 
(249) 
 
Retrospectiv
e 
Colorectal liver 
metastases 
Japan 93 GPS (0/1/2)  _ _ 63 (67.7) 24 (25.8) 6 (6.5) Neoadjuvant 
therapy not 
specified  
6.  Crozier et al 
2009 (250) 
 
Prospective Colon cancer UK 188 mGPS (0/1/2) _ _ 79 (42.0) 80 (42.6) 29 (15.4) 28.7% patients 
received adjuvant 
therapy 
 
7.  Roxburgh et 
al 2010 
(251) 
 
Retrospectiv
e 
Colon cancer UK 287 mGPS (0/1/2)  _ _ 143 (57) 102 (33) 42 (10) Adjuvant 
chemotherapy  
8.  Richards et 
al 2010 
(252)  
 
Prospective  Colorectal cancer UK 320 mGPS (0/1/2) _ _ 194 (61) 90 (28) 36 (11) 20.6% had 
adjuvant therapy  
9.  Kobayashi 
et al 2010  
(253) 
 
Retrospectiv
e 
Colorectal  liver 
metastases 
Japan 63 
 
GPS (0/ 1 and 2) _ _ 57 (90.5) 4 (6.3) 2 (3.2) 84.1% patients 
received adjuvant 
chemotherapy  
10.  Moug et al 
2011 (254)  
 
Retrospectiv
e  
Colorectal cancer UK 206 GPS (0/1/2) _ _ 113 (54.9) 53 (25.7) 40 (19.4) 4.4% received 
neoadjuvant and 
23.3% received  
adjuvant therapy  
11.  Roxburgh et 
al 2011 
(255) 
 
Retrospectiv
e  
Colorectal cancer  UK 302 GPS (0/1/2) 115 (38.1) 39 (12.9) 188 (62) 85 (28) 29 (10) 23.5% patients 
received adjuvant 
therapy  
12.  Roxburgh et 
al 2011 
(256) 
 
Retrospectiv
e 
Colon cancer UK 
 
76 mGPS (0/1 or 2) 42 (55.3) 31 (40.8) 34 (44.7) 33 (43.5) 9 (11.8) 100% patients 
received adjuvant 
chemotherapy 
13.  Richards et 
sl 2012 
(257) 
 
Retrospectiv
e  
Colorectal cancer UK 343 GPS (0/1/2)  _ _ 194 (56.6) 112 (32.7) 37 (10.7) Adjuvant therapies 
not specified 
14.  Suigimoto 
et al 2012 
(258)  
 
Retrospectiv
e  
Colorectal cancer  Japan  366 GPS (0/1/2)  _ _ mGPS 0/1: 
335 (91.5) 
_ 31 (8.5) Adjuvant 
chemotherapy 
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15.  Powell et al 
2012 (259) 
 
Prospective   Colorectal cancer  UK 411 mGPS (0/1/2)  181 (44.0) 74 (18.0) 243 (59.1) 125 (30.4) 43 (10.5) Adjuvant therapies 
not specified 
16.  Ishizuka et 
al 2012 
(260)  
 
Retrospectiv
e  
Colorectal cancer  Japan  271 GPS (0/1/2) _ _ 176 (64.9) _  mGPS 
1&2: 95 
(35.1) 
28.1% patients 
received adjuvant 
chemotherapy 
17.  Guthrie et 
al 2013 
(147)  
Retrospectiv
e  
Colorectal cancer  UK 206 mGPS (0/1/2)  _ _ 132 (64) 33 (16) 41 (20) 28.2% patients 
received adjuvant 
chemotherapy  
18.  Ishizuka et 
al 2013 
(261) 
 
Retrospectiv
e  
Colorectal stage IV 
cancer 
Japan  108 GPS 2 vs. 0,1 45 (41.7) 55 (50.9) 37 (34.2) 42 (38.9) 29 (26.9) Adjuvant 
chemotherapy  
19.  Ishizuka et 
al 2013 
(119) 
 
Retrospectiv
e  
Colorectal cancer Japan  480 GPS (0/1/2) _ _ 270 (56.3) 150 (31.2) 60 (12.5) Patients with stage 
IV received 
chemotherapy  
20.  Son et al 
2013 (262) 
 
Retrospectiv
e 
Colon cancer Korea 546 mGPS (2 vs. 0-1) _ _ 433 (80.0) 93 (17.0) 20 (3.0) 92.1% patients 
received 
chemotherapy 
21.  Nozoe et al 
2014 (263)   
 
Retrospectiv
e  
Colorectal cancer  Japan  272 GPS (0/1/2)  _ _ 179 (65.8) 62 (22.8) 31 (11.4) Adjuvant therapies 
not specified 
22.  Forrest et al 
2014 (264) 
 
Retrospectiv
e  
Colorectal cancer  UK 134 mGPS (0/1/2)  54 (40) _ 80 (60) 32 (24) 22 (16) Adjuvant therapies 
not specified 
23.  Sun et al 
2014 (265) 
 
Retrospectiv
e 
Colon cancer China 255 mGPS (0/1/2) _ _ 163 (63.9) 71 (27.8) 21 (8.3) Neoadjuvant or 
adjuvant not 
specified  
24.  Nakagawa 
et al 2014 
(266)  
 
Retrospectiv
e 
Colorectal liver 
metastases 
Japan 
 
343 mGPS (0/1/2) _ _ 295 (86.0) 33 (9.6) 15 (4.4) 20.1% patients 
received 
neoadjuvant 
chemotherapy and 
63.0% received 
adjuvant 
chemotherapy  
25.  Shibutani et 
al 2015 
(267) 
 
Retrospectiv
e  
Colorectal cancer  Japan  254 GPS (0/1/2)  _ _ 174 (68.5) 44 (17.3) 36 (14.2) Adjuvant 
chemotherapy  
26.  Ishizuka et 
al 2016 
(126) 
 
Retrospectiv
e 
Colorectal cancer Japan 627 GPS (2/0, 1) _ _ 346 (55.3) 177 (28.2) 104 (16.5) Adjuvant therapies 
not specified 
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27.  Park et al 
2016 (268) 
 
Retrospectiv
e  
Colorectal cancer UK 228 GPS (0/1/2)  _ _ 
 
131 (58) 71 (31) 26 (11) 57.5% received 
adjuvant therapy  
28.  Park et al 
2016 (7)  
 
Retrospectiv
e 
Colorectal cancer UK 1000 mGPS (0/1/2)  370 (37.0) 260 (26.0) 635 (63.5) 207 (20.7) 158 (15.8) 24.8% received 
adjuvant therapy 
and 9.8% received 
neoadjuvant 
therapy 
29.  Chan et al 
2016 (269) 
 
Retrospectiv
e 
Colorectal cancer Australia 386 mGPS (0/1/2)  _ _ 155 (40.2) 53 (13.7) 178 (46.1) Patients with high-
risk stage II and 
III colon cancer 
received adjuvant 
chemotherapy and 
those with stage II 
or III rectal 
cancers received 
neoadjuvant 
therapy  
             
Colorectal 
Cancer 
Inoperable 
            
1.  Elahi et al 
2004 (230) 
 
Retrospectiv
e  
Gastric and colorectal 
cancer 
UK  99 
 
GPS (0/1/2) 71 (71.7) 
 
 
26 (26.3) 
 
 
28 (28.3) 
 
 
 
45 (45.5) 
 
 
26 (26.2) 
 
 
Palliative 
chemotherapy and 
best supportive 
care 
2.  Read et al 
2006 (270) 
 
Prospective  Colorectal cancer  Australia  48 GPS (0/1/2) 48 (69) 14 (7) 15 (31) 26 (54) 7 (15) Palliative chemo 
and radiotherapy 
as well as 
supportive care 
3.  Leitch et al 
2007 (247) 
 
Retrospectiv
e  
Colorectal liver 
metastasis  
UK 84 GPS (0,1,2) _ _ 17 (20) 44 (52) 23 (28) Palliative 
chemotherapy  
4.  Ishizuka et 
al 2009 
(271) 
 
Retrospectiv
e  
Colorectal cancer Japan 112 mGPS: 1/2 40 (36) 79 (71) 72 (64) 4 (4) 36 (32) FOLFIRI and 
FOLFOX 
chemotherapy  
5.  Inoue et al 
2013 (272) 
 
Retrospectiv
e  
Colorectal cancer  Japan 245  
 
mGPS (1-2 vs.  
0) 
_ _ 133 (54.3) 78 (31.8)  34 (13.9) FOLFOX and 
FOLFIRI 
chemotherapy   
6.  Dreanic et 
al 2015 
(273) 
 
Retrospectiv
e  
Colorectal cancer  France 27 mGPS: 2 
Inverse mGPS: 2 
_ _ _ _ 27 (100) 5-fluorouracil-
based systemic 
chemotherapy and 
anti-VEGF 
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7.  Song et al 
2015 (274) 
 
Retrospectiv
e 
Colorectal cancer  Korea 177 mGPS: (0 vs. 1 or 
2) 
63 (35.6) 13 (7.3) 114 (64.4) 52 (29.4) 11 (6.2) Best supportive 
care  
8.  Thomsen et 
al 2016 
(162) 
 
Prospective  Colorectal cancer  Norway and 
Denmark  
374 mGPS (0/1/2) _ _ 165 (44.1) 166 (44.4) 43 (11.5) Cetuximab and 
FLOX vs. 
Cetuximab and 
intermittent FLOX 
Combined Total     9998     6020 (60.2) 2503 (25.0) 1475 (14.8)  
             
Head and Neck 
Operable 
            
1.  Farhan-
Alanie et al 
2015 (275)  
 
Retrospectiv
e  
Oral SCC UK 178 GPS (0/1/2)  _ _ 131 (74) 25 (14) 22 (12) 70 patients had 
adjuvant therapy  
Head and Nick 
Inoperable 
            
1.  Li et al 
2017 (276)  
 
Prospective  Nasopharyngeal cancer  China 249 GPS (0/1/2) - - 209 (83.9) 33 (13.3) 7 (2.8) 5.2% received 
radiotherapy and 
94.8% received 
chemoradiotherap
y 
2.  Chang et al 
2017 (277)  
 
Retrospectiv
e  
Head and neck cancer Taiwan  143 GPS (0/1/2) - - 39 (27.3) 72 (50.3) 32 (22.4) Concurrent 
chemoradiotherap
y  
3.  Chang et al 
2017 (278) 
 
Retrospectiv
e  
Head and neck cancer  Taiwan 139 GPS (0/1/2) - - 32 (23.0) 72 (51.8) 35 (25.2) All patients 
treated with 
concurrent 
chemoradiotherap
y  
Combined Total     709    411 (58.0) 202 (28.5) 96 (13.5)  
             
Hepatopancreati
cobiliary Cancer 
Operable 
            
1.  Jamieson et 
al 2011 
(279) 
 
Prospective  Pancreatic ductal 
cancer  
 
UK 135 GPS (0/1/2) _ _ 74 (54.8) 31 (23.0) 30 (22.2) 54.8% patients 
received adjuvant 
therapy  
2.  La Torre et 
al 2012 
(280) 
 
Retrospectiv
e  
Pancreatic cancer Italy  101 GPS (0/1/2)  _ _ 32 (31.7) 35 (34.7) 34 (33.6) 25.7% of patients 
received adjuvant 
chemo and 
radiotherapy  
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3.  Jamieson et 
al 2012 
(281) 
 
Retrospectiv
e 
Pancreatic ductal 
adenocarcinoma 
UK 173 mGPS (0/1/2) _ _ 95 (26.3) 37 (13.7) 41 (10.3) 38.7% patients 
received adjuvant 
chemotherapy 
4.  Stoz et al 
2013 (282) 
 
Retrospectiv
e  
Pancreatic cancer Austria  110 GPS (0/1/2)  _ _ 73 (66.7) 21 (19) 16 (14.3) 80.0% received 
chemotherapy  
5.  Wu et al 
2014 (283) 
 
Retrospectiv
e 
Gallbladder cancer China 85 GPS (0 vs 1/2)  >10: 43 
(50.6) 
<35: 14 
(16.5) 
38 (44.7)  GPS 1&2: 
47 (55.3) 
15.3% patients 
received adjuvant 
chemotherapy  
 
6.  Shiba et al 
2015 (284) 
 
Retrospectiv
e  
Gallbladder cancer Japan  51 GPS (0/1/2)  _ _ 38 (74.5) 8 (15.7) 5 (9.8) Neoadjuvant and 
adjuvant therapy 
not specified  
7.  Oshiro et al 
2013 (285)  
 
Retrospectiv
e  
Cholangiocarcinoma Japan  62 GPS (0/1/2)  _ _ 32 (50) 20 (34) 10 (16) Neoadjuvant and 
adjuvant therapy 
not specified  
8.  Shiba et al 
2013 (286) 
 
Retrospectiv
e  
Carcinoma of the 
ampulla of vater 
Japan  30 GPS (0/1/2)  _ _ 23 (76.7) 5 (16.7) 2 (6.6) Neoadjuvant and 
adjuvant therapy 
not specified  
9.  Ishizuka et 
al 2011 
(146)  
 
Retrospectiv
e  
HCC Japan  300 hGPS (0, 1/2) 
*CRP>0.3 mg/dl 
>3: 63 
(21.0) 
150 (50.0) 237 (79.0) 22 (7.3) 41 (13.7) Neoadjuvant and 
adjuvant therapy 
not specified  
10.  Ishizuka et 
al 2012 
(287) 
 
Retrospectiv
e 
HCC Japan 398 
 
GPS (0, 1/2) 263 (66.1) 238 (59.8) 156 (39.2) 214 (53.8) 28 (7.0) Neoadjuvant and 
adjuvant therapy 
not specified  
11.  Horino et al 
2013 (288)  
 
Retrospectiv
e 
HCC Japan  352 GPS (0/1/2)  26 (7.4) 61 (17.3) 280 (79.5) 57 (16.2) 15 (4.3) Neoadjuvant and 
adjuvant therapy 
not specified  
12.  Huang et al 
2014 (289)  
 
Prospective  HCC China  349 GPS (0/1/2)  19 (5.4)  10 (2.9) 278 (79.7) 61 (17.4) 10 (2.9) Neoadjuvant and 
adjuvant therapy 
not specified  
13.  Ni et al 
2015 (290) 
 
Retrospectiv
e  
HCC China 367 GPS (0/1/2) 
 
mGPS (0/1/2)  
_ _ GPS: 318 
(86.6) 
 
mGPS: 331 
(90.2) 
GPS: 45 
(12.3) 
 
 
mGPS: 32 
(8.7) 
GPS: 4 
(1.1) 
 
 
mGPS: 4 
(1.1) 
Neoadjuvant and 
adjuvant therapy 
not specified  
14.  Okamura et 
al 2015 
(291)  
 
Retrospectiv
e 
HCC Japan 256 GPS (0/1/2) _ _ 226 (88.3) 26 (10.2) 4 (1.5) Neoadjuvant and 
adjuvant therapy 
not specified  
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15.  Abe et al 
2016 (292)  
 
Retrospectiv
e 
HCC Japan 46 
 
GPS (0/ 1,2) 3 (6.5) 32 (69.6) 14 (30.4) _ mGPS 
1&2: 32 
(69.6) 
Neoadjuvant and 
adjuvant therapy 
not specified  
16.  Fu et al 
2016 (293) 
 
Retrospectiv
e 
HCC China Training: 
772 
 
 
GPS (0/1/2) 
 
mGPS (0/1/2) 
_  _ GPS 0: 672 
(87.0) 
 
mGPS 0: 
696 (90.2) 
GPS 1: 91 
(11.8) 
 
mGPS 1: 
68 (8.8) 
GPS 2: 9 
(1.2) 
 
 
mGPS 2: 8 
(1.0) 
Neoadjuvant and 
adjuvant therapy 
not specified  
             
Hepatopancreati
cobiliary Cancer 
Inoperable 
            
1.  Glen et al 
2006 (294) 
 
Retrospectiv
e  
Pancreatic cancer UK 187 GPS (0/1/2) 
 
 
120 (64) 62 (33) 56 (30) 80 (43) 51 (27) Palliative 
treatment with 
platinum based 
chemotherapy  
4.  Martin et al 
2014 (295)  
 
Retrospectiv
e   
Pancreatic cancer Australia  124 mGPS: (0,1,2) 
 
_ _ 46 (37) 26 (21)  52 (42) Chemotherapy for 
metastatic disease 
and radiotherapy 
for locally 
advanced disease  
5.  Kasuga et al 
2015 (296) 
 
Retrospectiv
e  
Pancreatic cancer Japan 61 mGPS: 2 17 (27.9) 22 (36.1) mGPS 0/1: 
49 (80.3) 
_ mGPS: 2 
12 (19.7) 
Gemcitabine 
and S-1 
combination 
therapy (FGS) as 
salvage 
chemotherapy 
6.  Mitsunaga 
et al 2016 
(297) 
 
Prospective  Pancreatic cancer Japan  280 
(Prospective
: 141) 
mGPS: 1 &2  
 
 
>5: 46 
(32.6) 
_ 79 (56.0) 39 (27.7) 23 (16.3) GEM 
chemotherapy  
7.  Moriwaki et 
al 2014 
(298) 
 
Retrospectiv
e  
Biliary tract cancer Japan  Total: 62 
 
Continuous: GPS 
(0 vs. 1/2) 
 
 
_ _ 19 (30.6) 17 (27.4) 26 (42.0) Chemotherapy 
with GEM and 
CDDP regimens 
 
8.  Zhou et al 
2015 (299) 
 
Prospective HCC China 224 GPS (0/1/2) 
 
mGPS 
(0/1/2) 
40 (18) 24 (11) GPS: 99 
(44.2) 
 
 
mGPS: 115 
(51.3) 
GPS: 101 
(45.1) 
 
mGPS: 85 
(38.0) 
GPS: 24 
(10.7) 
 
 
mGPS: 24 
(10.7) 
TRACE 
chemotherapy  
9.  Hurwitz et 
al 2015 
(153) 
Prospective Pancreatic cancer USA 121 mGPS (0/1/2) _ _ 51 (42.2) 34 (28.1) 36 (29.7_ Capecitabine vs 
Capecitabine and 
ruxolitinib 
 189 
 
Combined Total     4507    2985 (66.2) 970 (21.5) 552 (12.3)  
             
Pulmonary 
cancer operable 
            
1.  Pinato et al 
2014 (300) 
 
Retrospectiv
e  
Lung cancer UK Total:220 
mGPS: 199 
GPS (0/1/2)  66 (31)  65 (32) 131 (65.8) 39 (19.6) 29 (14.6) Adjuvant radio 
and chemotherapy  
2.  Miyazaki et 
al 2015 
(301) 
 
Retrospectiv
e  
NSCLC Japan  94 GPS (0/1/2)  _ _ 65 (67) 25 (25.8) 7 (7.2) Neoadjuvant and 
adjuvant therapy 
not specified  
3.  Kawashima 
et al 2015 
(144) 
 
Retrospectiv
e 
Lung cancer Japan 1043 GPS (0/1/2) 98 (9.4) 87 (8.3) 897 (86) 107 (10) 39 (4) Neoadjuvant and 
adjuvant therapy 
not specified  
4.  Fan et al 
2016 (302) 
 
Retrospectiv
e 
NSCLC China 1243 GPS (0/1/2) 
mGPS (0/1/2)  
379 (30.5) 154 (12.4) 813 (65.4) 327 (26.3) 103 (8.3) 55.0% patients 
received 
chemotherapyand 
17.7% patients 
received 
radiotherapy 
Pulmonary 
cancer 
Inoperable 
            
1.  Forrest et al 
2003 (303)  
 
Retrospectiv
e  
NSCLC UK  161 GPS (0/1/2)  132 (82) 22 (22) 27 (16.8) 101 (62.7) 33 (20.5) Chemotherapy 
mainly cisplatin 
and radical radio 
2.  Leung et al 
2012 (304) 
 
Retrospectiv
e  
Lung cancer  UK  261 mGPS (0/1/2) 149 (57) 41 (16) 59 (22.6) 163 (62.4) 39 (15.0) Chemotherapy 
(mainly platinum 
based) and/or 
radical 
radiotherapy 
3.  Gioulbasani
s et al 2012 
(305)  
 
Retrospectiv
e   
Lung cancer Greece 96 GPS (1&2) _ _ 68 (70.8) 18 (18.8) 10 (10.4) Platinum-based 
chemotherapy 
4.  Simmons et 
al 2015 
(306) 
 
Prospective  Lung cancer Greece 390 mGPS (0/1/2) 287 (73.6) _ 103 (26.4) 183 (46.9) 104 (26.7) Best supportive 
care  
 
5.  Zhou et al 
2015 (307) 
 
Retrospectiv
e  
Lung cancer China  359 mGPS 1&2 21 (33.7) 20 (5.6) 238 (66.3) 110 (30.6) 11 (3.1) Radiotherapy and 
chemotherapy 
 190 
(Irinotecan, 
Etoposide) 
6.  Jiang et al 
2015 (308) 
 
Prospective  Lung cancer China  138 GPS: 1&2 
 
 
_ _ 95 (68.8) 32 (23.2) 11 (8.0) Cisplatin based 
chemotherapy  
7.  Rinehart et 
al 2013 
(151) 
 
Prospective  Lung cancer USA 51 GPS (0/1/2) _ _ 9 32 10 Carboplatin and 
gemcitabine with 
or without 
dexamethasone  
 
Combined Total     4035    2502 (62.0) 1137 (28.2) 396 (9.8)  
             
Multiple 
Cancers 
Operable 
            
             
             
Multiple 
Cancers 
Inoperable 
            
1.  Chua et al 
2012 (163) 
 
Prospective  Multiple cancers Australia  68 mGPS (1&2) 
 
 
43 (63.2) 17 (25.0 21 (31) 34 (50) 13 (19) Single unit 
docetaxel 
treatment  
2.  Partridge et 
al 2012 
(309) 
 
Retrospectiv
e  
Multiple cancers UK 102 (GPS 
0/1/2) 
mGPS (1&2) 
 
_ _ 16 (15.7) 20 (19.6) 66 (64.7) Palliative best 
supportive care 
3.  Laird et al 
2013 (17) 
 
Prospective  
 
Multiple cancers UK  Total: 2456 
1825 (Test) 
631 
(Validation) 
mGPS: 1&2 Test: >10: 
1548 
(63.0) 
 
Validation
: >10: 345 
(54.7) 
Test: <35: 
1281 
(52.2) 
 
Validation
: <35: 463 
(73.4) 
 
 
 
Total: 563 
 
Test: 
277 (15.2) 
 
Validation:  
286 (45.3) 
Total: 712 
 
Test: 
544 (29.8) 
 
Validation: 
168 (26.6) 
Total: 1181 
 
Test: 
1004 (55.0) 
 
Validation: 
177 (28.1) 
Chemotherapy, 
radiotherapy and 
BSC 
4.  Anshushaug 
et al 2015 
(310) 
 
Retrospectiv
e  
Multiple cancers Norway Total: 723 
With 
mGPS: 521 
GPS (1 & 2) >10: 312 
(59.9) 
 209 (40.1) 131 (25.1) 181 (34.8) Palliative radio 
and chemotherapy  
5.  Miura et al 
2015 (311) 
 
Prospective  Multiple cancers Japan  1160 GPS 1&2 
 
_ _ 86 (7.4) 251 (21.6) 823 (70.9) Palliative best 
supportive care 
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6.  De Paula 
Pantano et 
al 2016 
(312) 
 
Prospective  Multiple cancers USA 459 mGPS 1&2 >10: 93 
(20.3) 
_ 366 (79.7) 31 (6.8) 62 (13.5) Palliative 
chemoptherapy 
and best 
supportive care 
7.  Tan et al 
2015 2015 
(313) 
 
Prospective  Multiple cancers Australia  Total: 114 
 
mGPS: 101 
mGPS: 1/2 >10: 51 
(50.5) 
_ 50 (49.5) _ mGPS 
1&2: 51 
(50.5) 
Chemotherapy  
Combined Total      4867    1311 (26.9) 1179 (24.2) 2377 (48.8)  
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Table 6.2:Summary of studies using GPS/mGPS to stratify patients undergoing operative and non-operative treatment for cancer.  
 
 
  
 Patients (n) GPS/mGPS 0 GPS/mGPS 1 GPS/mGPS 2 
Breast cancer  
181 100 (55.2) 61 (33.7) 20 (11.1) 
Bladder cancer  
2200 1443 (65.6) 613 (27.9) 144 (6.5) 
Gynaecological cancer  1594 999 (62.7) 394 (24.7) 201 (12.6) 
Prostate cancer  
223 158 (70.9) 43 (19.3) 22 (9.9) 
Gastro-oesophageal cancer 9590 6941 (72.4) 1670 (17.4) 979 (10.2) 
Haematological cancer  
430 90 (20.9) 165 (38.4) 175 (40.7) 
Renal cancer  
2559 1741 (68.0) 529 (20.7) 289 (11.3) 
Colorectal cancer  
9998 6020 (60.2) 2503 (25.0) 1475 (14.8) 
Head and Neck cancer  
709 411 (58.0) 202 (28.5) 96 (13.5) 
Hepatopancreaticobiliary cancer 
4507 2985 (66.2) 970 (21.5) 552 (12.3) 
Pulmonary cancer  
4035 2502 (62.0) 1137 (28.2) 396 (9.8) 
Multiple cancers  
4867 1311 (26.9) 1179 (24.2) 2377 (48.8) 
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Table 6.3: Summary of studies using mGPS to stratify patients undergoing operative and non-operative treatment for cancer. 
 Patients (n) GPS/mGPS 0 GPS/mGPS 1 GPS/mGPS 2 
Breast Cancer      
Operative _ _ _ _ 
Non-operative  181 100 (55.2) 61 (33.7) 20 (11.1) 
Bladder Cancer      
Operative  2133 1410 (66.1) 596 (27.9) 127 (6.0) 
Non-operative 67 33 (49.3) 17 (25.4) 17 (25.4) 
Gynaecological cancer      
Operative   724 538 (74.3) 144 (19.9) 42 (5.8) 
Non-operative 870 461 (53.0) 250 (28.7) 159 (18.3) 
Prostate Cancer      
Operative   _ _ _ _ 
Non-operative  223 158 (70.8) 43 (19.3) 22 (9.9) 
Gastro-oesophageal cancer     
Operative  7693 6076 (79.0) 1068 (13.9) 549 (7.1) 
Non-operative 1897 865 (45.6) 602 (31.7) 430 (22.7) 
Haematological cancer     
Operative   _ _ _ _ 
Non-operative  430 90 (20.9) 165 (38.4) 175 (40.7) 
Renal cancer      
Operative  2417 
 
1700 (70.3) 451 (18.7) 266 (11.0) 
Non-operative  142 41 (28.9) 78 (54.9) 23 (16.2) 
Colorectal cancer     
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Operative   8832 5476 (62.0) 2088 (23.6) 1268 (14.4) 
Non-operative  1166 544 (46.7) 415 (35.6) 207 (17.7) 
Head and neck cancer      
Operative   178 131 (74) 25 (14) 22 (12) 
Non-operative  531 280 (52.7) 177 (33.3) 74 (14.0) 
Hepatopancreaticobiliary  cancer     
Operative 3587 2586 (72.1) 673 (18.8) 328 (9.1) 
Non-operative  920 399 (43.4) 297 (32.3) 224 (24.3) 
Pulmonary cancer     
Operative   2579 1903 (73.8) 498 (19.3) 178 (6.9) 
Non-operative  1456 599 (41.1) 639 (43.9) 218 (15.0) 
Multiple cancers      
Operative   _ _ _ _ 
Non-operative  4867 1311 (26.9) 1179 (24.2) 2377 (48.8) 
Total Operative  28,143    
Total Non-operative  12,750    
Combined Total  40,893    
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7. THE PROGNOSTIC VALUE OF SYSTEMIC INFLAMMATION IN PATIENTS 
UNDERGOING SURGERY FOR COLON CANCER: COMPARISON OF 
COMPOSITE RATIOS AND CUMULATIVE SCORES 
 Introduction 
Colorectal cancer is the fourth most common cancer in the UK and the second most common 
cause of cancer death (314). Despite death rates from colorectal cancer falling by 
approximately 14% over the last decade, approximately 40% of those diagnosed will die 
from their colorectal cancer (314).  Surgery remains the primary modality of cure in these 
patients and therefore, there is a continuing interest in factors that will effectively identify 
patients at high risk of dying from their disease following potentially curative surgery. 
As discussed in sections 1.2-1.4 over the last decade or so it has become clear that markers 
of the systemic inflammatory response are clinically useful to identify patients at high risk 
of tumour progression in a variety of common solid tumours, in particular lung and 
gastrointestinal cancer (37, 38). These markers of the systemic inflammatory response are 
usually based around composite ratios or cumulative scores of different circulating white 
blood cells or acute phase proteins representing the systemic responses of two different 
organs, lymphoid/myeloid tissue and liver respectively (Table 7.1).  There have been two 
main approaches to the formation of these prognostic scores.  One approach is to take the 
ratio of different white blood cells and then apply a prognostic threshold to the ratio such 
that outcome is effectively stratified.  The most repeatedly validated example of this 
approach is the NLR based on the ratio of circulating neutrophil and lymphocyte counts 
(Table 7.1) (37, 38). Other validated examples are the PLR based on the ratio of circulating 
platelet and lymphocyte counts (Table 7.1) and the LMR based on the ratio of circulating 
lymphocyte and monocyte counts (Table 7.1) (37, 38). Also, recently a similar approach has 
been applied to the acute phase proteins, CRP and albumin to produce the CAR (Table 7.1) 
(37, 38). Although it is clear that the above ratios have prognostic value a disadvantage of 
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the ratio approach is that, depending on the threshold used, an abnormal ratio may be defined 
with one or both markers having a normal reference value. 
A simpler approach is the cumulative prognostic score, where markers of the systemic 
inflammatory response are defined as normal or as abnormal based on their laboratory 
reference ranges such that two markers with normal values score lowest and have the best 
outcomes and two markers with abnormal values score highest and have the poorest 
outcomes poorest. The most widely validated example of this approach is the GPS based on 
the acute phase proteins CRP and albumin (Table 7.1) (37, 38). Also, recently the Neutrophil 
Platelet Score (NPS) using neutrophils and platelets has been reported (39). Clearly, the 
cumulative score approach can also be applied to the ratios described above (Table 7.1) such 
as NLR (termed NLS), PLR (termed PLS) and LMR (termed LMS). 
Therefore, the aim of this Chapter was to compare the prognostic value of systemic 
inflammatory markers, in particular that of composite ratios and cumulative scores, in 
patients undergoing surgery for colon cancer. 
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 Patients and Methods 
Patients were identified from a prospectively collected and maintained database of colon 
cancer resections undertaken in a single surgical unit at Glasgow Royal Infirmary. 
Consecutive patients who met the following criteria were included: firstly, those who had 
preoperative measurement of serum CRP, albumin and differential blood cell counts within 
30 days before surgery; secondly, those who on the basis of preoperative abdominal 
computed tomography and laparotomy findings were considered to have undergone 
potentially curative resection for colonic cancer between January 1997 and June 2014. 
Patients with inflammatory bowel disease-related cancer, who underwent resection with 
palliative intent or local resection only, or had not had preoperative measurement of CRP or 
albumin, were excluded (7). Tumours were staged using the fifth edition of the TNM 
classification which was standard practice in Glasgow Royal Infirmary until January 2018, 
with additional data taken from pathological reports issued after resection (315). After 
surgery, all patients were discussed at a multidisciplinary meeting involving surgeons, 
oncologists, radiologists, and pathologists with special interest in colorectal cancer; patients 
with stage III or high-risk stage II disease and no significant comorbidities precluding 
chemotherapy use were offered primarily 5-fluorouracil-based adjuvant chemotherapy on 
the basis of current guidelines at the time.  
Preoperative serum CRP, albumin and differential blood cell counts were recorded 
prospectively. Neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), 
lymphocyte/monocyte ratio (LMR) and C-reactive protein/ albumin ratio (CAR) were all 
calculated by directly dividing the former by the latter (Table 7.1). The neutrophil 
lymphocyte score (NLS), platelet lymphocyte score (PLS), lymphocyte monocyte score 
(LMS), neutrophil platelet score (NPS) and mGPS were all constructed using normal 
reference ranges (Table 7.1).  
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Patients were routinely followed up for 5 years after surgery. Date and cause of death were 
crosschecked with the cancer registration system and the Registrar General (Scotland). 
Death records were complete until June 30th, 2017, which acted as the censor date. Cancer-
specific survival (CSS) was measured from date of surgery until date of death from recurrent 
or metastatic colonic cancer.  Overall survival (OS) was measured until the date of death 
from any cause. The West of Scotland Research Ethics Committee approved the study.  
Statistical Analysis  
The cut off values for individual ratios were examined using receiver operating characteristic 
(ROC) curve analyses. The threshold values of such characteristics were based on the most 
prominent point on the ROC curve for ‘‘sensitivity’’ and ‘‘1-specificity,’’ respectively. The 
optimal threshold values were defined using the Youden index (maximum (sensitivity + 
specificity - 1)) and these were compared with published validated values to determine the 
value used in the subsequent analysis (126, 316). The area under the ROC (AUROC) curve 
also was calculated. The relationship between NLR, PLR, LMR, CAR, NLS, PLS, LMS and 
mGPS and both cancer specific and overall survival was assessed using Cox proportional 
hazards regression to calculate hazard ratios (HRs) and 95% confidence intervals (95% CIs). 
The relationship between NLR, PLR, LMR, CAR, NLS, PLS, LMS and mGPS and patient 
clinicopathological characteristics was assessed using Pearson Chi-Square tests. In order to 
adjust for multiple comparisons during the correlation of composite ratios and cumulative 
scores and clinicopathological characteristics a p-value of <0.01 was considered significant. 
All analyses were performed using SPSS version 22.0 (IBM Corp, Armonk, NY).   
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 Results 
From the prospectively maintained database 801 patients undergoing potentially curative 
resection for colon cancer were examined (Table 7.2).  The majority of patients were over 
65 years of age (69%), were male (54%), were overweight or obese (57%) and were ASA 
grade 2 or greater (83%). The majority of patients presented electively (86%), had an open 
resection (85%) and did not receive adjuvant therapy (75%).  The majority of patients had 
either TNM stage II or III disease (86%) with moderate/well differentiated tumours (n=703, 
89%) and venous invasion (52%).  The majority of patients had no margin involvement 
(95%), peritoneal involvement (72%) or tumour perforation (97%) at time of resection.  On 
follow up there were 237 (28%) cancer related deaths and 437 (52%) deaths overall.  
The relationship between the composite ratios and cumulative scores and the 
clinicopathological characteristics of patients undergoing elective surgery for colon cancer 
is shown in Table 7.3 (n=689). There was statistically significant correlation between the 
majority of the composite ratios and cumulative scores and age (p<0.01), BMI (p<0.01), T-
stage (p<0.01), venous invasion (p<0.01) and peritoneal involvement (p<0.01). 
The relationship between composite ratios and cumulative scores and their component 
values in patients undergoing surgery for colon cancer is shown in Table 7.4 (n=801).   The 
majority were not assigned as systemically inflamed prior to surgery according to either 
ratios or scores (NLR>5 19%, NLS>0 47%, PLR>150 65%, PLS>0 48%, NPS>0 28%, 
CAR>0.22 49%, mGPS>0 41%).   
The median values for the components of the ratios and scores are shown in Table 7.4. An 
NLR 3-5 was associated with a median neutrophil count of 5.5 x109/l and a median 
lymphocyte count of 1.5 x109/l, both within the normal reference range. In contrast, an NLR 
>5 was associated with a median neutrophil count of 8.5 x109/l and a median lymphocyte 
count of 1.1 x109/l, both outside the normal reference range. A PLR>150 was associated 
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with a median platelet count of 325x109/l and a median lymphocyte count of 1.4x109/l, the 
platelet count being within the normal reference range.  An LMR<2.4 was associated with a 
median lymphocyte count of 1.3x109/l and a median monocyte count of 0.8x109/l, monocyte 
count being within the normal reference range.  A CAR>0.22 was associated with a median 
CRP concentration of 24mg/l and a median albumin concentration of 36g/l, albumin being 
within the normal reference range. 
The relationship between validated ratios, scores and 5 year cancer specific survival in 
patients undergoing surgery for colon cancer is shown in Table 7.5 and Figures 7.1-7.4. On 
ROC analysis using standard thresholds and cancer specific survival as an end-point the 
AUC for TNM stage was 0.649, NLR was 0.577, NLS was 0.566, PLR was 0.538, PLS was 
0.607, LMR was 0.613, LMS was 0.605, NPS was 0.580, CAR was 0.582 and mGPS was 
0.591. When adjusted for TNM stage, NLR>5 (p<0.001), NLS 1 and 2 (both p<0.01), PLS 
2 (p<0.001), LMR<2.4 (p<0.001), LMS 2 (p<0.001), NPS 2 (p<0.001), CAR> 0.22 
(p<0.001), mGPS 2 (p<0.001) were significantly associated with cancer specific survival.  
On ROC analysis using standard thresholds and 5 year overall survival as an end-point the 
following AUC for TNM stage was 0.569, NLR was 0.594, NLS was 0.586, PLR was 0.555, 
PLS was 0.620, LMR was 0.590, LMS was 0.585, NPS was 0.576, CAR was 0.603 and 
mGPS was 0.623. When adjusted for TNM stage, NLR>5 (p<0.001), NLS 1 and 2 (both 
p<0.01), PLS 2 (p<0.001), LMR<2.4 (p<0.001), LMS 2 (p<0.001), NPS 2 (p<0.01), CAR> 
0.22 (p<0.001), mGPS 2 (p<0.001) were all significantly associated with overall survival 
(Table 7.5 and Figures 7.1-7.4). 
The complementary prognostic value of the cumulative scores NPS and mGPS, markers of 
innate immune activation from two different organs, were examined in the context of TNM 
staging (Table 7.6).  Within TNM stage II disease the 5 year cancer specific survival rate 
was 82% and the 5 year cancer specific survival rate varied between 86% and 73% according 
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to the NPS and between 86% and 79% according to the mGPS. The 5 year overall survival 
rate was 57% and the 5 year overall survival rate varied between 61% and 47% according to 
the NPS and between 65% and 48% according to the mGPS.  
Within TNM stage III disease the 5 year cancer specific survival rate was 65% and the 5 
year cancer specific survival rate varied between 67% and 60% according to the NPS and 
between 69% and 59% according to the mGPS. The 5 year overall survival rate was 47% 
and the 5 year overall survival varied between 51% and 37% according to the NPS and 
between 53% and 38% according to the mGPS (Table 7.6).  
  
 202 
 Discussion 
The results of the present study directly compare, for the first time, the prognostic value of 
composite ratios and cumulative scores of the systemic inflammatory response.  These ratios 
and scores, whether composed of white cells from lymphoid/ myeloid tissue or from acute 
phase proteins from the liver, had prognostic value, independent of TNM stage, in patients 
with colon cancer. Moreover, systemic inflammation scores from different organs had 
similar prognostic value.  Taken together, the systemic inflammatory response represents an 
important prognostic domain to be monitored in patients with colon cancer. 
In the present study it was of interest that the ratio thresholds did not always differentiate 
normal from abnormal values of the composite values.  The discrepancy between the ratio 
threshold and the abnormal single component is shown in Figure 7.5.  In Figure 7.5, using 
the line of best fit, an NLR>5 was associated with a median neutrophil count of 
approximately 7.5, at the top of the normal reference range.  In contrast, an NLR>3 was 
associated with a neutrophil count of approximately 4.5, within in the normal reference 
range.  With reference to PLR>150 it was associated with a platelet count of approximately 
200, within the normal range (Figure 7.5). With reference to LMR<2.4 it was associated 
with a lymphocyte count of 1.5, at the bottom of the normal range (Figure 7.5).  Finally, with 
reference to CAR>0.22 was associated with a CRP of 10 well above the normal range 
(Figure 7.5).  Therefore, it is clear that a number of ratios (e.g. NLR>3 and PLR >150) do 
not describe components with abnormal values.  Moreover, the ratios, compared with scores, 
consistently assigned a higher proportion of patients to be systemically inflamed.  Given that 
scores based on abnormal value are simpler to construct and have similar and overlapping 
prognostic value, independent of TNM stage, compared with composite ratios (Table 7.5) 
the rationale for the continued use of such ratios is problematic.  Indeed, recent clinical 
calculators for survival in patients with metastatic colorectal cancer, based on data of more 
than 20,000 patients from randomised controlled trials (ARCAD database), has incorporated 
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the white cell count, neutrophil count, platelet count and albumin level as scores rather than 
derived ratios (168, 173). Furthermore  Dupré and Malik have argued that the variability of 
reported prognostic thresholds of NLR, PLR and LMR questions their reliability for routine 
clinical practice (166). 
Although it is presumed that composite ratios of lymphoid/ myeloid cells and acute phase 
proteins reflect similar aspects of the systemic inflammatory response, it is clear from the 
plot of NLR and CAR (Figure 2.5) that these ratios do not simply mirror one another.   In 
contrast, when cumulative scores such as NPS and mGPS, based on normal reference ranges, 
were compared there was better agreement in terms of systemic inflammatory response 
status and prognostic value (Table 7.6).  However it should be noted that although CRP and 
albumin are similar proteins components of a differential WCC such as neutrophil count are 
composed of a number of cell types (164). Irrespective the cumulative score approach, based 
on normal reference ranges, improves our understanding of aspects of the activation of the 
innate systemic inflammatory response.  The simplicity and consistency of this approach has 
much to commend it.  
The innate systemic inflammatory response in patients with cancer, as well as incorporating 
responses from lymphoid/ myeloid tissue and the liver, incorporates responses from other 
organs and tissues.  In particular, the response from the sympathetic nervous system is of 
interest since similar to that of NPS and mGPS it is intimately connected with immune 
responses (317).  Having established, in patients with cancer, the prognostic value of simple 
and objective markers of activation of lymphoid/ myeloid and liver tissue activation, it would 
be of considerable interest to examine the prognostic value of objective markers of activation 
of the sympathetic nervous system. 
In the present study there was a clear correlation between higher composite ratios and 
cumulative scores and increased age, BMI, advanced T-stage and the presence of both 
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venous and peritoneal invasion. These clinicopathological characterises are also directly 
associated with a poorer prognosis adding further weight to the prognostic ability of both 
composite ratios and cumulative score in patients with colonic cancer. 
Recently Park and co-workers reported that the mGPS provides complimentary prognostic 
information to current TNM-based staging (7). When TNM staging and mGPS were 
combined 5-year OS ranged from 92% (TNM 0, mGPS=0) to 26% (stage III, mGPS=2) and 
10-year OS ranged from 92% (TNM 0, mGPS=0) to 17% (TNM III, mGPS=2) (P<0.001) 
(7). This further highlights the prognostic ability of the mGPS which is complementary to 
the gold standard of TNM staging with both being routinely available worldwide (7). 
The present study has a number of possible limitations.  Although a relatively large 
prospective cohort there were small numbers of observations in some sub-group analysis.  
Furthermore, data relating to other factors that may have affected markers of the systemic 
inflammatory response such drugs taken prior to sampling were not available. Although the 
present study used the 5th rather than the 7th edition of the TNM staging system, this was 
recommended in the 2014 Colorectal Cancer Care Guidelines of the Royal College of 
Pathologists and as such is the basis for all current UK wide practice (6). Furthermore 
migration from the 5th to 7th edition would be expected to account for an upstaging from 
node negative to node positive disease in less than 3% of cases, with little subsequent effect 
on prognosis (6, 318, 319). 
A maximum of a 30-day interval between laboratory testing and surgery maybe considered 
to be too long. However this timescale has been widely reported in the literature and 
consistent with the chronic nature of the systemic inflammatory response in patients with 
cancer (37). Also, patients with inflammatory bowel disease related cancers were not 
included in the analysis. As such the patient confounding factors of active systemic 
inflammatory disease and acute changes in the inflammatory state have been minimised.   
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In summary, present study directly compares, for the first time, the prognostic value of 
composite ratios and cumulative scores of the systemic inflammatory response.  These ratios 
and scores, whether composed of white cells from lymphoid/ myeloid tissue or from acute 
phase proteins from the liver, had prognostic value, independent of TNM stage, in patients 
with colon cancer. However, cumulative scores, based on normal reference ranges, are 
simpler and more consistent for clinical use.   
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 Tables and Footnotes  
 Table 7.1: Systemic inflammation based prognostic ratios and scores 
  
Ratio/ Score Ratio/Score 
Neutrophil Lymphocyte Ratio (NLR):  
Neutrophil count: lymphocyte count ≤3 
Neutrophil count: lymphocyte count 3-5 
Neutrophil count: lymphocyte count >5 
Neutrophil Lymphocyte Score (NLS):  
Neutrophil Count ≤ 7.5 x 109/l and lymphocyte count ≥1.5 x 109/l 0 
Neutrophil Count > 7.5 x 109/l and lymphocyte count ≥1.5 x 109/l 1 
Neutrophil Count ≤ 7.5 x 109/l and lymphocyte count <1.5 x 109/l 1 
Neutrophil Count > 7.5 x 109/l and lymphocyte count <1.5 x 109/l 2 
Platelet Lymphocyte Ratio (PLR):  
Platelet count: lymphocyte count  ≤150 
Platelet count: lymphocyte count >150  
Platelet Lymphocyte Score (PLS):  
Platelet Count ≤ 400 x 109/l and lymphocyte count ≥1.5 x 109/l 0 
Platelet Count > 400 x 109/l and lymphocyte count ≥1.5 x 109/l 1 
Platelet Count ≤ 400 x 109/l and lymphocyte count <1.5 x 109/l 1 
Platelet Count > 400 x 109/l and lymphocyte count <1.5 x 109/l 2 
Lymphocyte Monocyte Ratio (LMR):  
Lymphocyte count: monocyte count ≥2.40 
Lymphocyte count: monocyte count <2.40 
 Lymphocyte Monocyte Score (LMS):  
Lymphocyte count ≥1.5 x 109/l and monocyte count ≤ 0.80 x 109/l 0 
Lymphocyte count <1.5 x 109/l and monocyte count ≤ 0.80 x 109/l 1 
Lymphocyte count ≥1.5 x 109/l and monocyte count > 0.80 x 109/l 1 
Lymphocyte count <1.5 x 109/l and monocyte count > 0.80 x 109/l 2 
Neutrophil Platelet Score (NPS):  
Neutrophil Count ≤ 7.5 x 109/l and platelet count < 400 x 109/l 0 
Neutrophil Count > 7.5 x 109/l and platelet count < 400 x 109/l  1 
Neutrophil Count ≤ 7.5 x 109/l and platelet count > 400 x 109/l  1 
Neutrophil Count > 7.5 x 109/l and platelet count > 400 x 109/l  2 
C-reactive protein Albumin Ratio (CAR):  
C-reactive protein: Albumin ≤0.22 
C-reactive protein: Albumin >0.22 
modified Glasgow Prognostic Score (mGPS):  
C-reactive protein ≤ 10mg/l and Albumin ≥35 g/l 0 
C-reactive protein > 10mg/l and Albumin ≥35 g/l 1 
C-reactive protein > 10mg/l and Albumin <35 g/l 2 
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Table 7.2: The clinicopathological characteristics of patients undergoing surgery for colon cancer (n=801). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a  
 
n=607, b n=575, c n=790, d n=778, e n=795, f n=799 
 Variables  n=801 (%) 
Age (years) <65 248 (31) 
 65-74 270 (34) 
 >75 283 (35) 
Sex Female 371 (46) 
 Male 430 (54) 
BMIa Underweight 72 (12) 
 Normal 190 (31) 
 Overweight 192 (32) 
 Obese 153 (25) 
ASA Gradeb 1 97 (17) 
 2 243 (42) 
 3 208 (36) 
 4 29 (5) 
Presentation Elective 689 (86) 
 Emergency 112 (14) 
Type of Surgery  Open 679 (85) 
 Laparoscopic 122 (15) 
Neoadjuvant therapyc No 782 (99) 
 Yes 8 (1) 
Adjuvant therapyd No 574 (75) 
 Yes 194 (25) 
T stage 1 52 (6) 
 2 76 (10) 
 3 418 (52) 
 4 255 (32) 
N stage 0 507 (63) 
 1 207 (26) 
 2 87 (11) 
TNM stage 1 116 (14) 
 2 391 (49) 
 3 294 (37) 
Differentiatione Mod/well 709 (89) 
 Poor 86 (11) 
Venous invasionf No  383 (48) 
 Yes 416 (52) 
Margin involvementf No  757 (95) 
 Yes 42 (5) 
Peritoneal involvementf No  578 (72) 
 Yes 221 (28) 
Tumour Perforationf No  772 (97) 
 Yes 27 (3) 
 208 
Table 7.3: The correlation between composite ratios and cumulative scores and clinicopathological characteristics of patients undergoing elective surgery for colon cancer (n=689). 
*p<0.01 considered significant  
 
 
 Age Sex BMI ASA 
Grade 
T-stage N-stage Differentiation Venous 
Invasion 
Margin 
Involvement  
Peritoneal 
Involvement  
Tumour 
Perforation 
Adjuvant 
Therapy  
NLR 0.009 0.398 <0.001 0.156 0.069 0.287 0.018 0.002 0.219 0.195 <0.001 0.063 
NLS 0.002 0.746 0.003 0.880 0.039 0.504 0.073 0.078 0.069 0.062 0.004 0.301 
PLR <0.001 0.391 <0.001 0.294 0.001 0.395 0.087 0.214 0.095 0.002 0.803 0.758 
PLS 0.008 0.827 <0.001 0.337 0.001 0.449 0.029 0.002 0.012 0.005 0.043 0.907 
LMR <0.001 0.004 0.030 0.705 0.063 0.948 0.557 0.133 0.750 0.085 0.041 0.067 
LMS <0.001 0.872 0.165 0.841 0.001 0.412 0.044 0.158 0.033 <0.001 0.184 0.097 
NPS 0.649 0.990 0.016 0.753 0.004 0.017 0.005 0.013 0.015 0.277 0.375 0.341 
CAR 0.008 0.618 0.027 0.009 <0.001 0.071 0.001 0.011 0.037 0.007 0.004 0.341 
mGPS 0.180 0.913 <0.001 0.294 <0.001 0.616 <0.001 0.006 0.005 0.003 0.001 0.422 
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Table 7.4: The relationship between composite ratios and cumulative scores and their component values in 
patients undergoing surgery for colon cancer (n=801). 
 
 
a n= 682, b n= 413 
 
   Median (range) Median (range) 
  n (%) Neutrophil Lymphocyte 
NLR  ≤3 388 (48.4) 4.2 (0.4-9.0) 2.0 (0.7-14.1) 
 3-5 260 (32.5) 5.5 (2.1-17.5) 1.5 (0.5-4.7) 
 >5 153 (19.1) 8.5 (2.2-21.3) 1.1 (0.3-2.5) 
NLS 0 421 (52.6) 4.8 (1.7-7.5) 2.0 (1.5-14.1) 
 1 325 (40.6) 5.1 (0.4-20.6) 1.3 (0.3-4.70) 
 2 55 (6.9) 9.9 (7.6-21.3) 1.1 (0.5-1.4) 
     
   Platelet Lymphocyte 
PLRa ≤150 237 (34.8) 248 (93-653) 2.1 (1.0-14.1) 
 >150 445 (65.2) 325 (119-814) 1.40 (0.30-4.70) 
PLSa 0 351 (51.5) 282 (94-396) 2.0 (1.5-14.1) 
 1 283 (41.5) 292 (93-814) 1.3 (0.3-11.0) 
 2 48 (7.0) 478 (406-698) 1.1 (0.6-1.4) 
     
   Lymphocyte Monocyte 
LMRb ≥2.4 252 (61.0) 1.9 (0.6 -14.1) 0.6 (0.1-1.3) 
 <2.4 161 (39.0) 1.3 (0.3-3.0) 0.8 (0.3-2.0) 
LMSb 0 214 (51.8) 2.0 (1.5-14.1) 0.6 (0.1-0.8) 
 1 169 (40.9) 1.3 (0.3-4.6) 0.7 (0.1-2.0) 
 2 30 (7.3) 1.2 (0.6-1.4) 1.0 (0.9-1.9) 
     
   Neutrophil Platelet 
NPSa 0 491 (72.0) 4.5 (0.4-7.50) 268 (93-400) 
 1 140 (20.5) 6.7 (2.3-18.8) 415 (96-811) 
 2 51 (7.5) 9.8 (7.6-20.60) 474 (406-814) 
     
   CRP Albumin 
CAR ≤0.22 412 (51.4) 5 (0.1-9)  38 (21-49) 
 >0.22 389 (48.6) 22 (6-339)  35 (15-47) 
mGPS 0 474 (59.2) 5 (0.1-10) 38 (21-49) 
 1 173 (21.6) 22 (11-220) 38 (35-47) 
 2 154 (19.2) 37 (11-339) 31 (15-34) 
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Table 7.5: The relationship between validated ratios, scores and survival in patients undergoing surgery for colon cancer (n=801)  
  Univariate  Multivariate 
Adjusted for TNM 
stage 
  Univariate  Multivariate 
Adjusted for TNM 
stage 
 
TNM stage AUC (95%CI) CSS 
HR (95%CI) 
p-value CSS 
HR (95%CI) 
p-value AUC (95%CI) OS 
HR (95%CI) 
p-value OS HR (95%CI) p-value 
I (n=116) 0.649 
(0.559-0.740) 
    0.569 
(0.477-0.661) 
    
II (n=391)  4.39 (1.78-10.85) 0.001    1.73 (1.16-2.57) 0.007   
III (n=294)  9.86 (4.02-24.17) <0.001    2.54 (1.70-3.79) <0.001   
NLR/ NLS           
NLR <3 (n=388) 0.577 
(0.529-0.624) 
    0.594 
(0.554-0.633) 
    
NLR 3-5 (n=260)  1.22 (0.87-1.72) 0.251 1.28 (0.91-1.80) 0.152  1.21 (0.95-1.53) 0.118 1.26 (0.99-1.59) 0.061 
NLR >5 (n=153)  2.06 (1.46-2.92) <0.001 2.11 (1.50-3.00) <0.001  1.85 (1.44-2.37) <0.001 1.88 (1.46-2.42) <0.001 
NLS 0 (n=421) 0.566 
(0.519-0.613) 
    0.586 
(0.546-0.626) 
    
NLS 1 (n=325)  1.49 (1.10-2.01) 0.010 1.57 (1.16-2.12) 0.003  1.45 (1.17-1.79) 0.001 1.49 (1.21-1.85) <0.001 
NLS 2 (n=55)  2.01 (1.22-3.30) 0.006 1.85 (1.12-3.05) 0.016  1.68 (1.15-2.46) 0.007 1.59 (1.09-2.33) 0.016 
PLR/ PLSa           
PLR≤150 (n=237) 0.538 
(0.486-0.589) 
    0.555 
(0.512-0.598) 
    
PLR >150 (n=445)  1.31 (0.92-1.86) 0.141 1.20 (0.84-1.70) 0.326  1.26 (0.98-1.63) 0.073 1.20 (0.93-1.55) 0.166 
PLS 0 (n=351) 0.578 (0.525-
0.631) 
    0.586 
(0.542-0.629) 
    
PLS 1 (n=283)  1.39 (0.98-1.96) 0.061 1.33 (0.94-1.88) 0.106  1.34 (1.05-1.70) 0.020 1.29 (1.01-1.65) 0.040 
PLS 2 (n=48)  2.77 (1.67-4.59) <0.001 2.42 (1.46-4.01) 0.001  2.16 (1.46-3.18) <0.001 1.94 (1.31-2.87) 0.001 
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LMR/ LMSb           
LMR ≥2.4 (n=161) 0.613 
(0.539-0.688) 
    0.590 (0.528-
0.652) 
    
LMR<2.4 (n=252)  2.62 (1.61-4.27) <0.001 2.49 (1.53-4.06) <0.001  2.08 (1.44-3.00) <0.001 1.99 (1.38-2.87) <0.001 
LMS 0 (n=214) 0.605 
(0.528-0.681) 
    0.585 
(0.522-0.648) 
    
LMS 1 (n=169)  1.69 (0.99-2.86) 0.051 1.65 (0.97-2.81) 0.064  1.47 (0.99-2.17) 0.058 1.41 (0.95-2.10) 0.088 
LMS 2 (n=30)  3.68 (1.81-7.49) <0.001 3.67 (1.80-7.49) <0.001  2.81 (1.59-4.95) <0.001 2.76 (1.56-4.88) <0.001 
NPSa           
NPS 0 (n=491) 0.580 
(0.526-0.634) 
    0.576 
(0.532-0.619) 
    
NPS 1 (n=140)  1.76 (1.22-2.55) 0.003 1.47 (1.02-2.13) 0.042  1.64 (1.26-2.14) <0.001 1.47 (1.12-1.92) 0.005 
NPS 2 (n=51)  2.50 (1.52-4.10) <0.001 2.14 (1.30-3.51) 0.003  1.83 (1.24-2.70) 0.002 1.65 (1.12-2.44) 0.011 
CAR/ mGPS           
CAR≤0.22 (n=412) 0.582 
(0.536-0.628) 
    0.603 
(0.563-0.642) 
    
CAR >0.22 (n=389)  1.88 (1.40-2.51) <0.001 1.76 (1.31-2.35) <0.001  1.88 (1.53-2.31) <0.001 1.84 (1.49-2.26) <0.001 
mGPS 0 (n=474) 0.591 
(0.544-0.639) 
    0.623 
(0.582-0.663) 
    
mGPS 1 (n=173)  1.35 (0.95-1.94) 0.099 1.22 (0.85-1.75) 0.282  1.49 (1.17-1.90) 0.001 1.44 (1.12-1.84) 0.004 
mGPS 2 (n=154)  2.47 (1.77-3.46)  <0.001 2.31 (1.65-3.25)  <0.001  2.32 (1.81-2.99) <0.001 2.28 (1.76-2.95) <0.001 
a n= 682, b n= 413 
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Table 7.6 The relationship between mGPS, NLS and 5 year cancer specific survival (CSS) and overall survival (OS) rates in patients undergoing potentially curative resection of TNM 
stage II (n=391) and III (n=294) colonic cancer.   
Values are expressed as % (standard error) survival not calculated if n<10. 
 
 Stage II 
(n=322) 
 
      Stage II 
(n=322) 
     
 mGPS    0  mGPS 1/2   mGPS 0-2  mGPS    0  mGPS 1/2   mGPS 0-2 
 n 5 year CSS (%) n 5 year CSS 
(%) 
n   n 5 year OS (%) n 5 year OS (%) n  
NPS 0 147 (85%) 88.4 (0.03) 78 (52%) 82.1 (0.04) 225 86.2 (0.02)  147 (85%) 66.7 (0.04) 78 (52%) 58.7 (0.06) 225 61.3 (0.03) 
NPS 1/2 26 (15%) 69.2 (0.09) 71 (48%) 74.6 (0.05) 97 73.2 (0.05)  26 (15%) 57.7 (0.10) 71 (48%) 43.7 (0.06) 97 47.4 (0.05) 
NPS 0-2 173 85.5 (0.03) 149 78.5 (0.03) 322 82.3 (0.02)  173 65.3 (0.04) 149 47.7 (0.04) 322 57.1 (0.03) 
 Stage III 
(n=254) 
      Stage III 
(n=254) 
     
NPS 0 120 (82%) 70.0 (0.04) 50 (46%) 60.0 (0.07) 170 67.1 (0.04)  120 (82%) 54.2 (0.05) 50 (46%) 44.0 (0.07) 170 51.2 (0.04) 
NPS 1/2 25 (18%) 64.0 (0.10) 59 (54%) 57.6 (0.07) 84 59.5 (0.05)  25 (18%) 48.0 (0.10) 59 (54%) 32.2 (0.06) 84 36.9 (0.05) 
NPS 0-2 145 69.0 (0.04) 109 58.7 (0.05) 254 64.6 (0.03)  145 53.1 (0.04) 109 37.6 (0.05) 254 46.5 (0.03) 
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 Figures and Legends  
 
 
 
 
 
Figure 7.1 a-d: The relationship between the NLR and NLS and both CSS and OS in patients undergoing 
surgery for colon cancer. NLR CSS (NLR<3-NLR3-5, p=0.216 and NLR3-5-NLR>5, p=0.005). NLR OS 
(NLR<3-NLR3-5, p=0.083 and NLR3-5-NLR>5, p=0.002). NLS CSS (NLS0-NLS1, p=0.007 and NLS1-
NLS2, p=0.249). NLS OS (NLS0-NLS1, p<0.001 and NLS1-NLS2, p=0.474). Number at risk depicts the 
number of patients alive or not censored entering each time period. 
Figure 7.1a:  
 
Figure 7.1b 
 
Figure 7.1c 
 
Figure 7.1d 
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Figure 7.2a-d: The relationship between the PLR and PLS and both CSS and OS in patients undergoing surgery 
for colon cancer. PLR CSS (PLR≤150-PLR>150, p=0.141). PLR OS (PLR≤150-PLR>150, p=0.061). PLS 
CSS (PLS0-PLS1, p=0.069 and PLS1-PLS2, p=0.006). PLS OS (PLS0-PLS1, p=0.016 and PLS1-PLS2, 
p=0.014). Number at risk depicts the number of patients alive or not censored entering each time period. 
Figure 7.2a  Figure 7.2b  
Figure 7.2c Figure 7.2d  
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Figure 7.3a-d: The relationship between the LMR and LMS and both CSS and OS in patients undergoing 
surgery for colon cancer. LMR CSS (LMR≥2.4-LMR<2.4, p<0.001). LMR OS (LMR≥2.4-LMR<2.4, 
p<0.001). LMS CSS (LMS0-LMS1, p=0.072 and LMS1-LMS2, p=0.023). LMS OS (LMS0-LMS1, p=0.067 
and LMS1-LMS2, p=0.020).  Number at risk depicts the number of patients alive or not censored entering each 
time period. 
Figure 7.3a  Figure 7.3b  
Figure 7.3c  Figure 7.3d 
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Figure 7.4a-d: The relationship between the CAR and mGPS and both CSS and OS in patients undergoing 
surgery for colon cancer. CAR CSS (CAR≥0.22-CAR<0.22, p<0.001). CAR OS (CAR≥0.22-CAR<0.22, 
p<0.001). mGPS CSS (mGPS0-mGPS1, p=0.113 and mGPS1-mGPS2, p=0.003). mGPS OS (mGPS0-mGPS1, 
p=0.002 and mGPS1-mGPS2, p=0.002). Number at risk depicts the number of patients alive or not censored 
entering each time period.
Figure 7.4a Figure 7.4b 
Figure 7.4c 
Figure 7.4d 
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Figure 7.5a: rs=0.653, p<0.001 
 
Figure 7.5b: rs=0.566, p<0.001 
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Figure 7.5c: rs=0.638, p<0.001 
 
Figure 7.5d: rs=0.992, p<0.001 
 219 
Figure 7.5e: rs=0.329, p<0.001 
 
Figure 7.5a-e: Plot of preoperative neutrophil count and NLR, platelet count and PLR, lymphocyte count and LMR, CRP and CAR, NLR and CAR in all patients undergoing surgical 
resection for colon cancer 
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8. AN EXPLORATORY STUDY EXAMINING THE RELATIONSHIP BETWEEN 
PERFORMANCE STATUS, SYSTEMIC INFLAMMATION AND CYTOKINE 
PROFILES IN PATIENTS WITH ADVANCED CANCER 
 Introduction 
As mentioned in Chapters 2 and 3 while a curative intent is the aim of any anti-cancer 
treatment, many patients go onto develop disseminated disease requiring systemic treatment 
with the aim of improving quality of life, while also improving survival (38). As a result, 
measures of Performance Status (PS) such as the Eastern Cooperative Oncology Group 
(ECOG) criteria gain increased clinical importance as they guide treatment as this has been 
consistently shown to predict survival.  
Clinical biomarkers of the systemic inflammatory response (CRP, albumin, neutrophils and 
platelets) have also become established as having prognostic accuracy in advanced cancer. 
To illustrate, the modified Glasgow Prognostic Score (mGPS – combining CRP and 
Albumin) (37, 38) and the Neutrophil Platelet Score (NPS) (37, 38, 40)  have been 
extensively validated as having prognostic value. Further, inflammation based prognostic 
scores have been combined with performance status in patients with advanced cancer to 
reliably stratify Quality of Life and survival (17, 25). These observations add to the firm role 
of systemic inflammation as the “seventh hallmark of cancer” and the “tip of the iceberg” in 
terms of cancer biology and treatment (117, 192, 193). Indeed, the activation of the systemic 
inflammatory response has been strongly implicated in tumorigenesis, aggressiveness of the 
disease and development of cachexia (7, 193, 194).  
Beneath the “tip of the iceberg”, cytokine activity plays an important part in the development 
of a systemic inflammatory response and symptoms of advanced disease (12). In patients 
with advanced cancer, pro-inflammatory cytokines become predominant leading to an up-
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regulation of IL -1, TNF-α, IL-6, IL-8, IL-10, IL-18, TGF-β and Macrophage Migration 
Inhibitory Factor (MIF) (193, 320). However, these cytokines have not been routinely 
measured in patients with advanced cancer due to the lack of international standardisation 
of analysis and validation of prognostic value. In contrast, routine measures of the systemic 
inflammatory response, such as the acute phase proteins CRP and albumin, are well 
standardised internationally and, combined in the mGPS, have validated prognostic value 
(37, 38). Alternatively, neutrophils and platelets have been combined in the Neutrophil 
Platelet Score (NPS) to improve the prediction of survival (37, 38, 40). Nevertheless, these 
cytokines are of increasing interest due to the expanding armamentarium of 
immunomodulatory agents in the oncology setting. 
Further, the relationship of these cytokines to established clinical factors (ECOG-PS) and 
mGPS is not understood. Understanding which cytokines are related to survival, 
performance status and clinical biomarkers of the inflammatory response may help inform 
potential treatment stratification in patients with advanced cancer (37, 38, 40). It is against 
this backdrop that a retrospective analysis of the results of a “Corticosteroids for Cancer 
Pain” trial was carried out (193, 321). Therefore, the primary aim of this Chapter was to 
examine the relationship between ECOG-PS, mGPS (and the validated prognostic 
framework ECOG-PS/ mGPS (17)), NPS and cytokine profiles in patients with advanced 
cancer.    
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 Patients and Methods 
This was a retrospective analysis of data already collected as part of a randomised double 
blind placebo control trial examining the analgesic effects of corticosteroids in patients with 
advanced cancer taking opioids (193). For the primary data collection, eligible patients met 
the following criteria: >18 years of age, a diagnosis of advanced cancer where curative 
treatment was not possible, taking opioids for moderate or severe cancer pain; pain level of 
4 (on a 0±10 Numerical Rating Scale (NRS)) at inclusion; expected survival > 4 weeks. 
Exclusion criteria included diabetes mellitus, peptic ulcer disease, and concurrent use of 
NSAIDs (193). As part of this trial the following inflammatory biomarkers were collected 
at trial baseline: CRP, albumin, neutrophils, platelets, erythrocyte sedimentation rate (ESR), 
IL-1β, IL-1ra, TNF-α, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12(p70), IL-18, interferon-γ, TGF-
β1, MIF, Macrophage Inflammatory Protein-1α (MIP-1α), Monocyte Chemoattractant 
Protein-1 (MCP-1) and soluble Tumour Necrosis Factor receptor-1 (sTNF-r1). sTNF-r1 was 
measured as it reflects TNF-α-activity, since TNF-α is among the most unstable cytokines 
(322, 323). The analytical methods are published previously (193). The cytokines were 
chosen on the basis of previous research on cancer related inflammation (110, 324, 325).  
Overall survival (OS) was measured until the date of death from any cause. Ethical approval 
for the original study was given by the Regional Committee for Medical Research Ethics 
Central Norway (4.2007.846) and the Norwegian Directorate of Health, and this included 
further analysis of biobanked data; Clinical trial information NCT00676936, EudraCT No 
2007-005617-19. Procedures were conducted in accordance with the Declaration of 
Helsinki, as revised in 1983.  
Statistical Analysis:  
Data are presented as medians, ranges, frequencies and percentages. The mGPS and the NPS 
were calculated according to methods previously described (39, 87). The relationship 
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between ECOG-PS, mGPS, NPS, and cytokine levels was examined using Independent 
Mann-Whitney U and Kruskal Wallis tests where appropriate. The IL-1ra and IL-6 
concentrations below the LLOQ are given as ≤21.7 ng/L and ≤2.33 ng/L respectively.  IL-
1ra and IL-6 were analysed as continuous and dichotomized variables (IL-1ra: ≤170 ng/L 
(326) and IL-6: ≤10ng/L (327)).  Given the explorative nature of this study, a significance 
level of <0.05 was considered significant. The time between the date of inclusion and the 
date of death of any cause was used to define overall survival (OS). Survival data were 
analysed using univariate Cox regression analysis. All statistical analysis was performed 
using SPSS version 22.0 (IBM Corp, Armonk, NY).  
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 Results 
The clinicopathological characteristics of patients are shown in Table 8.1.  Of the forty-nine 
patients previously reported, (193) nine patients were removed due to incomplete data 
leaving 40 patients to be included in the present analysis. The majority of patients were less 
than 65 years of age (58%), normal or underweight (73%), had good ECOG-PS (53%), had 
non-hormone dependent disease (63%), and no ongoing oncological treatment (73%). 
Metastatic disease was present in 98% of patients with the most common sites being the liver 
and bone.  The majority of patients had evidence of a systemic inflammatory response 
whether assessed by the mGPS (78%) or NPS (53%). All patients died on follow-up and the 
median survival was 91 days (4-933 days).  
The relationship between ECOG-PS, mGPS, NPS and cytokine profiles are shown in Table 
8.2. With increasing ECOG-PS (Table 8.2a - vis a vis deteriorating condition) there was a 
higher median value of IL-6 (p=0.016), ESR (p=0.002), CRP (p<0.01), albumin (p<0.01) 
and poorer survival (p<0.001).  With increasing mGPS (Table 8.2b - vis a vis increasing 
inflammation) there was a higher median value of IL-6 (p=0.016), MIF (p=0.010), ESR 
(p<0.01) and poorer survival (p<0.01). With increasing NPS 2 (Table 8.2c - vis a vis 
increasing inflammation) there was a higher median value of TGF-β (p<0.001).  
The relationship between ECOG-PS and mGPS framework and the cytokine profile is shown 
in Table 8.3.  When those patients with an ECOG-PS 0/1 and mGPS0 were compared with 
those patients with an ECOG-PS 2 and mGPS2 there was a higher median value of IL-6 
(p=0.017) and poorer survival (p<0.001). The majority of IL-1ra and IL-6 and concentrations 
were below the limit of detection. There was a clear increase in median IL-6 concentrations 
between mGPS 0/1 (2.33 ng/L) and mGPS 2 (21.1 ng/L). There was also a more progressive 
increase in IL-6 concentrations between NPS 1 (2.33 ng/L), NPS 2 (16.6 ng/L) and NPS 3 
(33.6 ng/L).  In addition, there was a clear increase in IL-6 concentrations between ECOG-
PS 0/1 (2.33 ng/L) and ECPG_PS 2 (20.4 ng/L). 
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When IL-1ra, as a continuous variable, was compared with ECOG-PS there was no 
significant association between IL-1ra and ECOG-PS (p=0.076). When IL-1ra, as a 
continuous variable, was compared with mGPS there was no significant association between 
IL-1ra and mGPS (p=0.633). On univariate Cox regression analysis IL-1ra, as a continuous 
variable, was significantly associated with poorer overall survival (HR 1.00, 95%CI 1.00-
1.01, p=0.007).  
When IL-1ra (≤170/>170 pg/ml), as a dichotomized variable, was compared with ECOG-PS 
there was no significant association between IL-1ra and ECOG-PS (p=0.258). When IL-1ra, 
as a dichotomised variable, was compared with mGPS there was no significant association 
between IL-1ra and mGPS (p=0.756). On univariate Cox regression analysis IL-1ra, as a 
dichotomized variable, was not significantly associated with poorer overall survival (HR 
1.68, 95%CI 0.73-3.86, p=0.253).  
When IL-6, as a continuous variable, was compared with ECOG-PS there was a significant 
association between IL-6 and ECOG-PS (p=0.010). When IL-6, as a continuous variable, 
was compared with mGPS there was a significant association between IL-6 and mGPS 
(p=0.016). On univariate Cox regression analysis IL-6, as a continuous variable, was 
significantly associated with poorer overall survival (HR 1.03, 95%CI 1.01-1.04, p<0.001).  
When IL-6 (≤10/>10 pg/ml), as a dichotomized variable, was compared with ECOG-PS 
there was a significant associations between IL-6 and ECOG-PS (p=0.034). When IL-6, as 
a dichotomised variable, was compared with mGPS there was a significant association 
between IL-6 and mGPS (p=0.022). On univariate Cox regression analysis IL-6, as a 
dichotomized variable, was significantly associated with poorer overall survival (HR 2.66, 
95%CI 1.34-5.27, p=0.005). 
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 Discussion  
The results of the present study show that, on examination of cytokine profiles, only IL-6 
was consistently associated with ECOG-PS and mGPS and their combination in patients 
with advanced cancer.  Given the extensively validated prognostic value of the ECOG-PS/ 
mGPS framework, it is clear that of the cytokines measured, IL-6 may represent a potentially 
useful therapeutic target to improve patient status in the context of this framework.   
Although the present study was carried out in a relatively small number of patients it does 
provide pilot data within the context of an established framework (ECOG-mGPS) that is 
known to effectively stratify quality of life (25, 206) and survival (17, 328) in patients with 
advanced cancer. The mGPS enables ready comparison between studies of different tumour 
types and stages of disease. Indeed, Kantola and colleagues in primary operable colorectal 
cancer (n=148) reported that the mGPS was associated with IL1-ra and IL-6 thus confirming 
the validity of the present results (329, 330). 
Furthermore, in addition to ECOG performance status the utility of the mGPS in the 
randomised clinical trial setting is now recognised (54). For example, in a recent RCT of an 
anti-inflammatory agent targeting the IL-6 JAK STAT pathway the mGPS was shown to 
effectively stratify survival (153).  
It has long been recognised that interleukin-6 is associated with pain, (331) weight loss, 
(332) and inflammatory responses in patients with cancer (333, 334). However, it is only in 
recent years that the systemic inflammatory response, in particular as measured by the 
mGPS, has become central to the symptoms associated with advanced cancer (25) and the 
repertoire of agents targeting IL-6 has been extensive enough to test this clinically in a robust 
manner (335).   
There is good evidence that pain may be associated with increased levels of inflammatory 
parameters (25). The patients recruited to this study had cancer related pain requiring strong 
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analgesia for relief. Therefore, it may be that the systemic inflammatory response was higher 
than that in an unselected cohort of patients with advanced cancer. In the present study 78% 
of patients had an elevated mGPS compared with 68% of patients in a large unselected cohort 
(25). This suggests that the systemic inflammatory response was indeed higher in patients 
within this study and associated with increased pain requirements. 
IL-6 is produced in a variety of cells including fibroblasts, endothelial cells, keratinocytes, 
macrophages, T-cells and mast cells. While it is true that cancer cells produce IL-6, the high 
circulating concentrations of IL-6 levels cannot be explained by tumour production alone. 
Indeed, recent studies have shown that monocytes produce significantly higher levels of IL-
6 in cachectic cancer patients than in healthy controls and in patients with advanced 
pancreatic cancer. In addition neutrophil activity has also been implicated in potentiating 
tumour growth through the activation of specific inflammatory cytokines particularly IL-1 
and IL-6 and via amino acid depletion (336) and promotes angiogenesis and the metastatic 
potential of cancer (336).  
In a recent systematic review by Lippitz and co-workers including 11,583 patients serum IL-
6 levels were found to correlate with survival in 82/101 studies comprising 85.6% of patients 
in 23 types of cancer (327). This percentage increased to 94.5% of reported patients when 
only dichotomized studies were included (327). Importantly, there was a significant 
correlation between higher serum IL-6 and tumour stage as described in 39/44 studies and 
91% of reported patients where clinical parameters had been specified (327). The average 
IL-6 threshold was approximately 10pg/ml (327). In the present study when this threshold 
was applied IL-6 was significantly associated with ECOG-PS, mGPS and survival.  
Therefore, the results of the present study are consistent with the literature which defines IL-
6 as a cancer-type-independent parameter for the progressive functional decline (ECOG-
PS), the systemic inflammatory response (mGPS) and survival in patients with advanced 
cancer (327).  
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There is now the possibility to target IL-6 upstream and downstream.  In terms of 
downstream signalling IL-6 is now recognised to be produced by multiple cell types in the 
tumour microenvironment including tumour cells, stromal cells and immune cells.  
Moreover, within these cell types IL-6 will activate the JAK/ STAT3 pathway and therefore 
has the potential not only to stimulate tumour cell growth but also reduce the efficacy of the 
immune cells to kill tumour cells (335). Therefore, although there are agents that can target 
IL-6 upstream and downstream, such complexity, and that most studies carried out have been 
pre-clinical, makes it difficult to predict the likely benefits of any particular agent in patients 
with advanced cancer. In this context, the results of the present study would suggest that 
such agents are target at patients with poor performance status and elevated systemic 
inflammatory response i.e.  ECOG-PS 2 and mGPS 2 for moderation of symptoms. 
To date the examination of agents targeting pro-inflammatory cytokines in the cancer setting 
has been limited. Infliximab and Etanercept (anti-TNF-α) have been studied and showed no 
benefit in muscle mass (a constitutional component of cancer cachexia) (337, 338). 
Clazakizumab, which targets IL-6, has also been examined in phase II trials and showed 
attenuation of muscle loss and improvements in anaemia, however no phase III trials are 
underway (339). It is of interest, however, that agents which target IL-1α, which is upstream 
of IL-6, have had beneficial effects on muscle mass and quality of life (340). The present 
work provides supporting evidence that agents targeting these cytokines are worthy of 
further exploration, however stratification using the ECOG-PS/mGPS framework should be 
incorporated into trial designs, to enable the effect of these agents to be optimised. Such an 
approach has been advocated recently (341) and demonstrated as being efficacious in similar 
settings (153). 
In terms of upstream signalling, it was of interest that of the cytokines measured only IL-1ra 
was significantly associated with IL-6 (rs 0.537, p<0.001), CRP  (rs 0.716, p<0.001) and 
neutrophil count (rs 0.606, p<0.001) (results not tabulated). There are also a number of 
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approaches to down regulate IL-1 signalling that look promising in patients with advanced 
cancer and worthy of clinical investigation (342). 
Although assays have been available for the measurement of IL-6 in the plasma for 
approximately 30 years there remain a number of obstacles to be overcome before IL-6 will 
become a routinely available clinical test in patients with cancer.  Until such time the ECOG-
PS/mGPS framework will continue to offer reliable risk stratification for patients with 
advanced cancer. 
While it should be noted that intractable pain and the associated physiological stress that this 
incurs has also been shown to lead to disease progression, long term opioid use is not without 
risk (343). Indeed, opioid administration, particularly long term administration has been 
shown to affect immune system function, angiogenesis, apoptosis, and invasion in a 
potentially deleterious manner (343, 344). Furthermore opioid administration can lead to 
suppression of the hypothalamic-pituitary-gonadal axis in both male and female patients 
leading to hypogonadism(343, 345). This suppresses anabolic activity and could potentiate 
secondary hypogonadism characteristics such as the loss of skeletal muscle mass which has 
a deleterious effect on both quality of life and outcomes in patients with cancer. 
The present study had some limitations. In particular, there were relatively small numbers 
of patient observations in some of the subgroup analysis. Given the exploratory nature of 
this study, no correction for multiple testing was performed. Also, the present results are a 
retrospective analysis of data obtained from a study examining the relationship between 
cytokine concentrations and symptoms in patients with advanced cancer taking 
opioids(193).  Prospective confirmation of the results obtained, and measurement of key 
cytokines would be important in future studies.   
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Given the previously validated prognostic value of the ECOG-PS/ mGPS framework (25), 
it is clear that of the cytokines measured, IL-6 may represent a potentially useful therapeutic 
target to improve patient status in the context of this framework. 
In summary, the results of the present study show that IL-6 was consistently associated with 
ECOG-PS and mGPS and their combination in patients with advanced cancer.  Moderation 
of circulating IL-6 concentrations should continue to be explored as a useful therapeutic 
treatment in these patients.   
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 Tables and Footnotes 
Table 8.1: Clinicopathological characteristics of patients within the “Corticosteroids and Cancer Pain” trial 
analysed as part of this study 
 Variables  n=40 (%) 
Age (years) <65 23 (57.5) 
 ≥65 17 (42.5) 
Sex Female 18 (45.9) 
 Male 22 (55.0) 
BMI* ≤25 29 (76.4) 
 >25 9 (23.6) 
ECOG-PS 0/1 21 (52.5) 
 2/3 19 (47.5) 
mGPS  0: CRP ⩽ 10 mg/l and albumin ⩾35 g/l 9 (22.5) 
 1: CRP >10 mg/l and albumin ⩾35 g/l 13 (32.5) 
 2: CRP >10 mg/l and albumin <35 g/l 18 (45.0) 
NPS 0: Neutrophils ≤ 7.5 x109/L and Platelets ≤400 x109/L 19 (47.5) 
 1: Neutrophils >7.5 x109/L or Platelets >400 x109/L 14 (35.0) 
 2: Neutrophils >7.5 x109/L and Platelets >400 x109/L 7 (17.5) 
Cancer Type Hormone Dependent  15 (37.5) 
 Non-Hormone Dependent  25 (62.5) 
Ongoing Oncological Treatment Yes 11 (27.5) 
 No 29 (72.5) 
Survival Alive 0 (0) 
 Dead 40 (100.0) 
Survival (Days) Median (Range) 91 (4-933) 
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Table 8.2a-c: The relationship between ECOG-PS (3.2a), mGPS (7.2b), and NPS (7.2c) and the cytokine profile 
 
  
Table 8.2a  ECOG-PS Median 
(range) 
   
Cytokines Normal Reference Range: 0/1 n=21 ≥2 n=19  p-value 
IL-1 ra <21.7 ng/L 21.7 (21.7-1641) 21.7 (21.7-4360)  0.357 
IL-6 <2.33 ng/L 2.33 (2.33-58.7) 20.4 (2.33-97.3)  0.016 
IL-18 <1.1 ng/L 99.5 (50.1-257) 107 (26.5-4588)  0.466 
MCP-1 <1.5 ng/L 61.4 (30.4-188) 81.0 (19.6-1235)  0.654 
MIF <4.8 ng/L 142 (45.1-722) 135 (40.9-745)  0.520 
sTNF-r1 <27.1 ng/L 10665 (813-24174) 12058 (3266-25934)  0.143 
TGF-β <1.2 ng/L 45124 (21856-
66224) 
50784 (26249-
103280) 
 0.330 
ESR M: 0-22 mm/h 
F: 0.29mm/h 
37 (3-136) 67 (18-109)  0.030 
CRP <3 mg/dl 20 (0.5-138) 64 (33-305)  0.002 
Albumin 35-50 g/L 39 (28-48) 31 (17-44)  0.001 
Neutrophil 2-7.5x109/L 3.7 (1.2-11) 6.4 (1-17.3)  0.040 
Platelet 150-400x109/L 316 (80-592) 422 (115-689)  0.209 
Survival (days)  200 (28-933) 50 (4-189)  <0.001 
Table 8.2b  mGPS Median 
(range) 
   
Cytokines Normal Reference 
Ranges: 
0 n=9 1 n=13 2 n=18 p-value 
IL-1 ra <21.7 ng/L 21.7 (21.7-179) 21.7 (21.7-1641) 21.7 (21.7-4360) 0.633 
IL-6 <2.33 ng/L 2.33 (2.33-39.9) 2.33 (2.33-58.7) 21.1 (2.33-118) 0.016 
IL-18 <1.1 ng/L 84.6 (57.5-257) 107 (52.4-226) 103 (26.5-4588) 0.523 
MCP-1 <1.5 ng/L 63.1 (43.7-164) 90.0 (30.4-188) 61.2 (19.6-1235) 0.254 
MIF <4.8 ng/L 85.4 (45.1-186) 329 (79.5-745) 127 (40.9-1348) 0.010 
TGF-β <27.1 ng/L 43279 (27144-
57458) 
47923 (21856-
66224) 
48293 (23402-
103280) 
0.430 
sTNF-r1 <1.2 ng/L 8459 (813-15257) 11734 (3723-24174) 10953 (3266-
33794) 
0.359 
ESR M: 0-22 mm/h 
F: 0.29mm/h 
16 (3-87) 40 (11-95) 72 (18-136) 0.002 
Neutrophil 2-7.5x109/L 3.5 (1.2-9.5) 5.7 (2.2-11) 6.45 (1-17.4) 0.060 
Platelet 150-400x109/L 316 (156-353) 400 (80-592) 406 (72-728) 0.516 
Survival (days)  511 (21-933) 117 (28-406) 51 (4-474) 0.003 
Table 8.2c  NPS Median 
(range) 
   
Cytokines Normal Reference 
Ranges: 
0 n=19 1 n=14 2 n=7 p-value 
IL-1 ra <21.7 ng/L 21.7 (21.7-1640) 21.7 (21.7-519) 21.7 (21.7-4360) 0.483 
IL-6 <2.33 ng/L 2.33 (2.33-58.7) 16.6 (2.33-105) 33.6 (2.33-118) 0.052 
IL-18 <1.1 ng/L 95.0 (52.4-257) 107 (26.5-191) 153 (74.2-4588) 0.247 
MCP-1 <1.5 ng/L 59.3 (19.6-164) 70.1 (36.5-188) 81 (36.4-1235) 0.863 
MIF <4.8 ng/L 126 (40.9-722) 126 (73.6-745) 338 (128-1348) 0.088 
TGF-β <27.1 ng/L 37694 (21856-
50694) 
51113 (23402-
103280) 
61194 (40449-
66224) 
<0.001 
sTNF-r1 <1.2 ng/L 9267 (813-25934) 11286 (3723-33794) 15257 (8459-
22060) 
0.170 
ESR M: 0-22 mm/h 
F: 0.29mm/h 
37 (3-102) 53.5 (6-136) 72 (15-109) 0.161 
CRP <3 mg/dl 33 (0.5-138) 47 (3.8-167) 138 (1.9-305) 0.020 
Albumin 35-50 g/L 36 (25-45) 33 (24-48) 31 (14-40) 0.173 
Survival (days)  132 (14-933) 77 (38-406) 37 (4-474) 0.154 
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Table 8.3: The relationship between combined ECOG-PS 0/1 and mGPS 0 and combined ECOG-PS 2 and 
mGPS 2 and cytokine levels  
n=19 LLOQ: ECOG-PS 0/1 & mGPS 
0 (n=7) Median (range)  
ECOG-PS 2 & mGPS 2 
(n=12) Median (range)  
p-value 
IL-1 ra <21.7 ng/L 21.7 (21.7-179) 21.7 (21.7-4360) 0.711 
IL-6 <2.33 ng/L 2.33 (2.33-2.33)  15.9 (2.33-97.3)  0.017 
IL-18 <1.1 ng/L 84.6 (57.5-257) 100 (26.5-4588) 0.711 
MCP-1 <1.5 ng/L 59.3 (43.7-164) 67.6 (19.6-1235) 0.902 
MIF <4.8 ng/L 85.4 (45.1-186) 107 (40.9-635) 0.432 
sTNF-r1 <27.1 ng/L 7618 (813-14901) 11064 (3266-25934) 0.167 
TGF-β <1.2 ng/L 37226 (27144-49734) 48293 (26249-103280) 0.068 
Survival (days)  638 (92-933) 60 (14-189) <0.001 
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9. THE RELATIONSHIP BETWEEN CT-DERIVED BODY COMPOSITION, 
THE SYSTEMIC INFLAMMATORY RESPONSE AND SURVIVAL IN 
PATIENTS UNDERGOING SURGERY FOR COLORECTAL CANCER 
 Introduction  
As mentioned above in section 1.4.2 in the past weight loss and BMI have been used as an 
indicator of nutritional decline and poor prognosis in patients with cancer (41, 346). 
However, due to the increased number of patients presenting in an overweight or obese state 
in the developed world the use of simple weight loss and BMI as a prognostic indicator has 
been questioned (66, 70, 347, 348). The ability to use routine CT scans to measure body 
composition, in particular skeletal muscle, has resulted in a marked increase in interest in 
using skeletal muscle index and skeletal muscle density to predict outcomes in patients with 
cancer, particularly in colorectal cancer (349). 
There is evidence supporting a disproportionate loss of skeletal muscle tissue to be an 
independent prognostic factor for both cancer-specific and overall survival in patients with 
colorectal cancer (350). Specifically muscle loss has been associated with poor treatment 
tolerance and efficacy (351), worse quality of life and increased morbidity (352). For 
example, in a large study Caan and co-workers reported that in patients with colorectal 
cancer there was a significant association between lower skeletal muscle index (SMI) and 
worse overall survival (353).  Also, Malietzis and co-workers reported that in patients with 
colorectal cancer there was a significant association between lower skeletal muscle density 
and worse overall survival (354).  
The importance of the systemic inflammatory response as a unifying mechanism for weight 
loss and loss of lean tissue in patients with cancer is increasingly recognised (81, 346, 355).  
Therefore, it is of interest that SMI and SMD have been repeatedly reported to be inversely 
associated with measures of the systemic inflammatory response such as the NLR and mGPS 
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(45, 71, 356-360), that are recognised to have prognostic value in their own right (38, 54). 
However, this relationship is not clear. It is possible that some patients with sarcopenia may 
have systemic inflammation and some patients with myosteatosis might similarly have 
systemic inflammation, but the coexistence of those three features is poorly understood. If 
the above association was due to the erosion of the SMI and SMD by an ongoing systemic 
inflammatory response it might be anticipated that the prognostic value of SMI and SMD 
was largely dependent on the presence of a systemic inflammatory response.  It might also 
be anticipated that low SMI and SMD would influence the relationship between the systemic 
inflammatory response and survival.  
To our knowledge, no study has comprehensively examined the relationship between CT 
derived body composition, systemic inflammatory response, as measured by the mGPS, and 
survival in patients with primary operable colorectal cancer. Therefore, the aim of this 
Chapter was to examine the above relationships in a prospectively maintained database of 
patients with colorectal cancer undergoing potentially curative resection.    
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 Patients and Methods 
Consecutive patients who underwent elective, potentially curative resection for colorectal 
cancer between March 2008 and June 2017 at a single centre were identified from a 
prospectively maintained database.  Those patients with a preoperative CT scan and a 
recorded height and weight were included.   
Patients were classified according to Body Mass Index (BMI) as underweight (BMI <18.5), 
normal weight (BMI 18.5–24.9), overweight (BMI 25.0–29.9) and obese (BMI ≥30) was 
recorded. All tumours were staged according to TNM 5th edition. Preoperative 
haematological and biochemical markers were recorded.   
The cause and date of death were confirmed with the Registrar General (Scotland) until 1st 
June 2017 that served as the censor date.  Informed consent was obtained from patients prior 
to surgery. Those with metastatic colorectal cancer and those who underwent emergency 
surgery or palliative surgery were excluded from the study.  Ethical approval was granted 
by the West of Scotland Research Ethics Committee, Glasgow.   
Methods: 
CT derived body composition analysis at the level of the third lumbar vertebra was carried 
out using NIH Image J version 1.47, http://rsbweb.nih.gov/ij/ as described in Chapter 2. A 
summary of all thresholds used can be found in (Table 9.1).  
Measurements were performed by two individuals and inter-rater reliability was assessed in 
a sample of 30 patient images using inter-class correlation coefficients (ICCC) (TFA ICCC 
= 1.000, SFA ICCC = 1.000, VFA ICCC = 1.000, SMA ICCC = 0.998, SMD ICCC = 0.972). 
Investigators were blind to patient’s demographic and clinico-pathological status. 
An autoanalyzer was used to measure serum CRP (mg/L) and albumin (g/L) concentrations 
(Architect; Abbot Diagnostics, Maidenhead, UK).  The mGPS, NLR and NPS were derived 
as previously described (99).  
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Statistical Analysis: 
Body composition measurements were presented as median and range and compared using 
Mann-Whitney or Kruskal-Wallis tests.  Categorical variables were analysed using χ2 test 
for linear-by-linear association, or χ2 test for 2 by 2 tables.   
Mortality within 30 days of the index procedure or during the index admission were excluded 
from subsequent survival analysis.  The time between the date of surgery and the date of 
death of any cause was used to define overall survival (OS).  Survival data were analysed 
using univariate and multivariate Cox regression.  Those variables associated to a degree of 
p<0.1 were entered into a backward conditional multivariate model.   
Missing data were excluded from analysis on a variable by variable basis.  Two tailed p 
values <0.05 were considered statistically significant.  Statistical analysis was performed 
using SPSS software (Version 21.0. SPSS Inc., Chicago, IL, USA). 
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 Results 
In total, 832 patients were identified as having undergone potentially curative surgery for 
colorectal cancer of these, 182 were excluded due to missing eligible CT scans, 
clinicopathological data or blood test results. A further five patients were excluded as they 
died in the immediate postoperative period. A total of 650 patients (354 males, 296 females) 
were included in final analyses.  
There have been a number of definitions of SMI using CT-scans. Nevertheless, it is clear 
that muscle mass varies in male and female patients and with BMI. SMI has been defined 
differently in male and female patients and according to BMI which are summarised Table 
9.1.  In the present study SMI (Dolan) thresholds were derived using ROC curve analysis to 
determine thresholds associated with overall survival in this population. This was also 
conducted using validated online biomarker cutoff optimization software (361). In male 
patients, the clinically significant cutoff for SMI with a BMI<25 was 45cm2/m2 and for male 
patients with a BMI≥25 was 53cm2/m2. The clinically significant cutoff for SMI in female 
patients with a BMI<25 was 39cm2/m2 and for female patients with a BMI≥25 was 
41cm2/m2. Given that these SMI threshold values (Dolan BMI>25) were similar to those of 
Martin (Table 9.1) and to facilitate comparison of studies the threshold values of Martin 
were used in the analysis. In addition, the association between sarcopenia (Martin) and 
sarcopenia (Dolan BMI>25) was strong (p<0.001). For example, when Martin and co-
workers thresholds were used 43.5% of patients had sarcopenia and when Dolan and co-
workers thresholds were used 42.9% of patients had sarcopenia (Table 9.1). 
In the present study in male patients, the clinically significant cutoff for SMI with a BMI<30 
was 45.6cm2/m2 and for male patients with a BMI≥30 was 56.8cm2/m2. The clinically 
significant cutoff for SMI in female patients with a BMI<25 was 39.1cm2/m2 and for female 
patients with a BMI≥30 was 44.6cm2/m2. Given that these SMI threshold values (Dolan 
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BMI>30) were not similar to those of Caan (Table 9.1) the threshold values of Caan were 
not used in the subsequent analysis.  
With reference to SMD Martin and colleagues in 1,473 patients with multistage lung and GI 
cancers defined SMD (myosteatosis) as an SMD <41HU in patients with BMI <25kg/m2 and 
<33HU in patients with BMI ≥25kg/m (66).  In contrast, Xiao and co-workers in 3,051 non-
metastatic stage I-III colorectal cancer defined myosteatosis according to sex as <35.5HU in 
males and <32.5HU in females (362). In the present study SMD (Dolan) thresholds were 
derived using ROC curve analysis to determine thresholds associated with overall survival 
in this population. This was also conducted using validated online biomarker cutoff 
optimization software (361).  The clinically significant cutoff for SMD in patients in the 
present cohort with a BMI<25 was 34 HU and for patients with a BMI≥25 was 32 HU. Given 
that these SMD threshold values (Dolan BMI>25) were not similar to Martin and were not 
used in the subsequent analysis.  
In the present study the clinically significant cutoff for SMD in male patients was 34.1 HU 
and in female patients was 34.4 HU.  Given that these SMD threshold values (Dolan 
Male/Female) were similar to Xiao and to facilitate comparison of studies the threshold vales 
of Xiao were used in the analysis. In addition, the association between SMD (Xiao) and 
SMD (Dolan Male/Female) was strong (p<0.001). For example, when Xiao and coworkers 
thresholds were used 47.5% of patients had myosteatosis and when Dolan and coworkers 
thresholds were used 46.8% of patients had myosteatosis. 
The relationship between clinicopathological characteristics, body composition and overall 
survival is shown in Table 9.2.  The majority of patients were over 65 years of age (64%), 
overweight or obese (68%), with some comorbidities (88%) and node negative disease 
(67%). The majority of tumours were located in the right colon (38%) and rectum (37%) and 
an open surgical approach was applied in 62% of cases.   A total of 528 patients were alive 
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at the censor date with a median survival was 44 months (range 1-110 months). Deaths by 
any cause occurred in 122 patients (18%); 71 (11%) of which were cancer specific.  On 
univariate survival analysis, age, ASA, TNM stage and the mGPS were significantly 
associated with overall survival (all p<0.001).  Of the body composition parameters BMI, 
SFI, VO, SMI (Martin, Dolan and Caan) and SMD (Martin, Dolan and Xiao) were 
significantly associated with overall survival (all p<0.05).  SMI and SMD were weakly 
associated (Figure 9.1).  On comparison of SMI (Martin) and SMD (Xiao), both SMI (HR 
1.68, 95%CI 1.17-2.41, p=0.005) and SMD (HR 1.47, 95%CI 1.02-2.11, p=0.040) were 
independently associated with overall survival. 
The relationship between SMI (Martin), SMD (Xiao) and mGPS and the clinicopathological 
characteristics are shown in Table 9.3, Table 9.4, and Table 9.5 respectively.   A low SMI 
(Martin) was significantly associated with older age, higher mGPS, lower BMI and lower 
SMD (Martin, Dolan and Xiao) (all p<0.001).  A low SMD (Xiao) was significantly 
associated with older age, female sex, higher ASA a right sided tumour, mGPS, lower BMI, 
SFI, VO and lower SMI (Martin, Dolan and Xiao) (all p<0.05). An elevated mGPS was 
significantly associated with a high ASA, TNM stage, tumour location, NLR, NPS, BMI>25, 
SMI (Martin, Dolan and Caan) and SMD (Martin and Dolan) (all p<0.05).  
The relationship between SMI (Martin) high/low groups, SMD (Xiao) high/low groups and 
mGPS high/low groups and overall survival are shown in Figure 9.2, Figure 9.3, Figure 9.4. 
On comparison of SMI (Martin), SMD (Xiao) and mGPS, SMI (Martin) (HR 1.50, 95%CI 
1.04-2.18, p=0.031), SMD (Xiao) (HR 1.42, 95%CI 0.98-2.05, p=0.061) and mGPS (HR 
1.44, 95%CI 1.15-1.79, p=0.001) were independently associated with overall survival  
(Table 9.6).  
In patients with a mGPS of 0, SMI (Martin) (HR 1.48, 95%CI 0.97-2.28, p=0.071 and SMD 
(Xiao) (HR 1.50, 95%CI 0.97-2.33, p=0.068) were weakly associated with overall survival 
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(Table 9.6). In patients with a mGPS of 1/2, SMI (Martin) (HR 2.02, 95%CI 0.98-4.18, 
p=0.058) was weakly associated with overall survival (Table 9.6).  
Low SMI (Martin) was present in 40% of patients with an mGPS of 0. In contrast, low SMI 
(Martin) was present in 66% of patients with an mGPS of 2.  Low SMD (Xiao) was present 
in 52% of patients with an mGPS of 0.  In contrast, SMD (Xiao) was present in 64% of 
patients with an mGPS of 2. A combination of Low SMI (Martin) and Low SMD (Xiao) was 
present with a mGPS 0 in 23.4% of patients. In contrast, a combination of Low SMI (Martin) 
and Low SMD (Martin) was present with a mGPS 2 in 45.5% of patients.  
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 Discussion 
The results of the present comprehensive study, in patients with colorectal cancer who were 
largely overweight, and using CT derived body composition analysis showed that sarcopenia 
(SMI) and myosteatosis (SMD) were significantly associated with survival.  Moreover, SMI 
and SMD were associated with the presence of a systemic inflammatory (in particular the 
mGPS) and had independent prognostic value.  Therefore, the present results support the 
routine measurement of the SMI, SMD and mGPS as part of the clinical and nutritional 
assessment in patients with cancer (52, 346, 363). 
Colorectal cancer has been extensively examined with reference to CT derived body 
composition and most studies have reported that either SMI or SMD are associated with 
survival.  In contrast, few studies have included a measurement of the systemic inflammatory 
response in their analysis.  In those studies that included a white cell measure of the systemic 
inflammatory response such as NLR, SMI and SMD were reported to be independently 
associated with survival (45, 360).  Irrespective, the systemic inflammatory response 
(however measured) is associated with lower SMI and SMD. These observations may have 
profound implications for the treatment of sarcopenia and myosteatosis in patients with 
colorectal cancer and, potentially, other common solid tumours.  
Such cross sectional data cannot determine whether a low SMI or SMD results in the 
presence of systemic inflammation or whether the presence of systemic inflammation results 
in low SMI or SMD. From the present results, it is clear that a low SMI, SMD or both can 
occur in the absence of systemic inflammation. However, the proportions of patients with a 
low SMI, SMD or both is substantially greater in the presence of systemic inflammation. It 
may be that in those patients that simply improving dietary intake and activity will improve 
SMI and SMD. In contrast, in those patients with a mGPS 1/2 it may be that moderation of 
the systemic inflammatory response is required in addition to improve SMI and SMD (355). 
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In order to better understand the nature of this relationship it will be important to carry out 
longitudinal and intervention studies.  
With reference to longitudinal studies Wallengren and colleagues reported that, in 471 
patients with advanced cancer, a CRP>10mg/L had  less muscle mass (using dual energy X-
ray absorptiometry) on study entry and lost muscle at an accelerated rate during follow-up 
(43). Mallietzis and co-workers reported that, in 856 patients with operable colorectal cancer, 
an NLR>3 was associated with lower muscle mass (CT scan) over time (44).  Both studies 
concluded that systemic inflammation was a risk factor for muscle loss and may be a useful 
marker of catabolic drive.  However, the loss of muscle quality has yet to be examined in 
this relationship. Therefore, further longitudinal studies are required if the relationship 
between skeletal muscle mass and quality, the systemic inflammatory response and survival 
is to be further elucidated. To our knowledge the above relationship has not been examined 
in interventional studies.  
It was of interest that, in the present study, approximately 50% of patients had a low SMI or 
SMD. Compared with other cohorts of patients with early stage colorectal cancer treated 
with surgical resection these figures appear high and similar to that reported in the terminal 
stage of the disease. Given that these percentages were similar using various thresholds of 
(Dolan, Martin, Caan and Xiao) for patients in this cohort, this may suggest that there is a 
baseline level of poor muscle quantity and quality within this population. This is perhaps not 
surprising given the deprivation levels of patients referred to Glasgow Royal Infirmary. 
Indeed, in Glasgow 190,000 or just under 32% of the city’s population resides in the 10% of 
the most deprived areas of the UK (so called “Glasgow effect”) (364).  This is associated 
with a poor diet and physical fitness and high levels of alcohol consumption and smoking 
which would have a direct effect on both muscle quantity and quality. Indeed, when direct 
comparisons are made with functional testing such as the ASA scoring in the present and 
other reported studies. For example, in the present study 33% of patients had an ASA score 
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of ≥3 (severe systemic disease) compared to a recent combined study of  2,100 UK and 
Canadian patients undergoing elective surgery for colorectal cancers where 20% had an ASA 
score of ≥3 (365). In addition, when the 763 UK based patients of this study were examined 
in isolation 11% had an ASA score of ≥3 (45). Therefore, it is clear that the present patient 
cohort had higher levels of comorbid disease and lower levels of physical function and this 
may account for, in part, the high percentage of patients with a low SMI and SMD.  
Indeed, it was of interest that in the present study ASA was significantly associated with 
SMD and not SMI. A similar relationship has recently been reported between SMD but not 
SMI and the Charleston comorbidity index (362). This confirms the clinical utility of SMD 
as there is increasing recognition that an increase in muscle mass is not necessarily 
associated with an increased in function (340, 366). It may be that an improvement in muscle 
quality rather than mass will result in an improvement in physical function.  
Limitations of the present study include its retrospective nature and that only patients with 
an electronically available CT scan were included. However, the study population was 
relatively large, well-documented in terms of clinicopathological characteristics and 
measures of the systemic inflammatory response and relatively mature follow-up.  
Furthermore, different validated threshold values were applied to the CT body composition 
parameters. 
In summary, the present study provides comprehensive evidence that both low skeletal 
muscle mass and quality has a significant relationship to the systemic inflammatory response 
and to survival in patients with operable colorectal cancer. This supports the incorporation 
of the SMI, SMD and mGPS as part of the clinical and nutritional assessment in patients 
with cancer.  This relationship also suggests potential therapeutic interventions.    
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 Tables and Footnotes  
Table 9.1: CT derived body composition measures and thresholds used 
Body Composition Measurement  Frequency n (%) 
High SFI (69):  
 Males>50.0 cm2m2 and Females>42.0 cm2m2  No: 116 (17.8%) 
Yes: 534 (82.2%) 
Visceral obesity (66, 70):   
VFA: Males >160 cm2 and Females >80 cm2 No: 177 (27.2%) 
Yes: 473 (72.8%) 
Sarcopenia   
SMI (Martin) (66):  
Males: BMI<25kg/m2 and SMI<43 cm2m2  or BMI≥25kg/m2 and SMI<53 cm2m2 
Females: BMI<5kg/m2 and SMI<41 cm2m2  or BMI≥25kg/m2 and SMI<41 cm2m2 
No: 367 (56.5%) 
Yes: 283 (43.5%) 
SMI (Dolan BMI>25): 
Males: BMI<25kg/m2 and SMI<45 cm2m2  or BMI≥25kg/m2 and SMI<53 cm2m2 
Females: BMI<25kg/m2 and SMI<39 cm2m2  or BMI≥25kg/m2 and SMI<41 cm2m2 
No: 371 (57.1%) 
Yes: 279 (42.9%) 
SMI (Caan) (353):   
Males: BMI<30kg/m2 and SMI<52.3 cm2m2 or BMI≥30kg/m2 and SMI<54.3 cm2m2 
Females: BMI<30kg/m2 and SMI<38.6 cm2m2  or BMI≥30kg/m2 and SMI<46.6 cm2m2 
No: 313 (48.2%) 
Yes: 337 (51.8%) 
SMI (Dolan BMI>30)  
Males: BMI<30kg/m2 and SMI<45.6cm2m2 or BMI≥30kg/m2 and SMI<56.8 cm2m2 
Females: BMI<30kg/m2 and SMI<39.1 cm2m2  or BMI≥30kg/m2 and SMI<44.6 cm2m2 
No: 386 (59.4%) 
Yes: 264 (40.6%) 
Myosteatosis   
SMD (Martin) (66):  
BMI<25kg/m2 and SMD<41 HU or BMI≥25kg/m2 and SMD<33HU  No: 258 (39.7%) 
Yes: 392 (60.3%) 
SMD (Dolan BMI>25)  
BMI<25kg/m2 and SMD<34 HU or BMI≥25kg/m2 and SMD<32HU No: 343 (52.8%) 
Yes: 307 (47.2%) 
SMD (Xiao) (362):  
Males<35.5HU and Females<32.5HU No: 309 (47.5%) 
Yes: 341 (52.5%) 
SMD (Dolan Male/Female)  
Males<34.1 HU and Females<HU 34.4 HU No: 304 (46.8%) 
Yes: 346 (53.2%) 
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Table 9.2: The relationship between clinicopathological characteristics, CT derived body composition and 
survival in patients undergoing elective surgery for colorectal cancer (n=650): univariate survival analysis  
Characteristic    
n= 650 (%) Overall Survival HR (95% CI) P-value 
 Clinico-pathological    
Age ≤65 234 (36.0) 1.64 (1.29-2.08) <0.001 
 65 - 74 251 (38.6)   
 >74 165 (25.4)   
Sex Female 296 (45.5) 1.19 (0.83-1.70) 0.351 
 Male 354 (54.5)   
ASA score 1 141 (21.7) 1.56 (1.23-1.97) <0.001 
 2 297 (45.7)   
 3 193 (29.7)   
 4 19 (2.9)   
Laparoscopic Surgery No 407 (62.6) 0.68 (0.45-1.03) 0.072 
 Yes 243 (37.4)   
TNM 0 14 (2.2) 1.67 (1.31-2.14) <0.001 
 I 155 (23.8)   
 II 263 (40.5)   
 III 218 (33.5)   
Venous Invasion No 266 (40.9) 1.26 (0.87-1.82) 0.217 
 Yes 384 (59.1)   
Tumour Location Right and Transverse 247 (38.0) 0.84 (0.58-1.23) 0.373 
 Left 145 (22.3)   
 Rectum 237 (36.5)   
 Total and Subtotal 21 (3.2)   
Adjuvant Chemotherapy No 463 (71.2) 0.70 (0.45-1.08) 0.102 
 Yes 187 (28.8)   
 Systemic inflammation    
mGPS 0 499 (76.8) 1.55 (1.25-1.91) <0.001 
 1 63 (9.7)   
 2 88 (13.5)   
NLR ≤3 369 (56.8) 1.40 (0.98-1.99) 0.066 
 >3 281 (43.2)   
NPS 0 568 (87.4) 1.66 (1.16-2.36) 0.005 
 1 67 (10.3)   
 2 15 (2.3)   
 Body composition    
BMI (kg/m2) <25 219 (33.7) 0.60 (0.39-0.91) 0.015 
 ≥25 431 (66.3)   
High SFI No 116 (17.8) 0.60 (0.40-0.89) 0.011 
 Yes 534 (82.2)   
Visceral obesity No 177 (27.2) 0.68 (0.47-0.98) 0.040 
 Yes 473 (72.8)   
Low SMI (Sarcopenia)     
SMI (Martin) No 367 (56.5) 1.74 (1.21-2.49) 0.003 
 Yes 283 (43.5)   
SMI (Dolan BMI>25) No 371 (57.1) 1.77 (1.24-1.54) 0.002 
 Yes 279 (42.9)   
SMI (Caan) No 313 (48.2) 1.58 (1.09-2.28) 0.016 
 Yes 337 (51.8)   
SMI (Dolan BMI>30) No 386 (59.4) 1.60 (1.12-2.28) 0.010 
 Yes 264 (40.6)   
Low SMD (Myosteatosis)     
SMD (Martin) No 258 (39.7) 1.84 (1.25-2.72) 0.002 
 Yes 392 (60.3)   
SMD (Dolan BMI>25) No 343 (52.8) 1.57 (1.10-2.25) 0.013 
 Yes 307 (47.2)   
SMD (Xiao) No 309 (47.5) 1.54 (1.07-2.22) 0.020 
 Yes 341 (52.5)   
SMD (Dolan Male/Female) No 304 (46.8) 1.58 (1.10-2.27) 0.014 
 Yes 346 (53.2)   
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Table 9.3: The relationship between Sarcopenia (Martin), clinicopathological characteristics, and systemic 
inflammation in patients undergoing elective surgery for colorectal cancer (n=650) 
Characteristic    
High SMI (No Sarcopenia 
n=367) 
Low SMI (Sarcopenia 
n=283) 
P-
value 
 Clinico-pathological    
Age ≤65 160 (43.6) 74 (26.1) <0.001 
 65 - 74 133 (36.2) 118 (41.7)  
 >74 74 (20.2) 91 (32.2)  
Sex Female 163 (44.4) 133 (47.0) 0.513 
 Male 204 (55.6) 150 (53.0)  
ASA score 1 81 (22.1) 60 (21.2) 0.159 
 2 167 (45.5) 130 (45.9)  
 3 113 (30.8) 80 (28.3)  
 4 6 (1.6) 13 (4.6)  
Laparoscopic Surgery No 220 (59.9) 187 (66.1) 0.109 
 Yes 147 (40.1) 96 (33.9)  
TNM 0 9 (2.5) 5 (1.8) 0.032 
 I 101 (27.5) 54 (19.1)  
 II 133 (36.2) 130 (45.9)  
 III 124 (33.8) 94 (33.2)  
Venous Invasion No 154 (42.0) 112 (39.6) 0.540 
 Yes 213 (58.0) 171 (60.4)  
Tumour Location Right and Transverse 138 (37.6) 109 (38.5) 0.293 
 Left 77 (21.0) 68 (24.0)  
 Rectum 143 (39.0) 94 (33.2)  
 Total and Subtotal 9 (2.5) 12 (4.2)  
Adjuvant Chemotherapy No 208 (56.7) 177 (62.5) 0.091 
 Yes 159 (43.3) 106 (37.5)  
 Systemic 
inflammation 
   
mGPS 0 298 (81.2) 201 (71.0) <0.001 
 1 39 (10.6) 24 (8.5)  
 2 30 (8.2) 58 (20.5)  
NLR ≤3 220 (59.9) 149 (52.7) 0.063 
 >3 147 (40.1) 134 (47.3)  
NPS 0 328 (89.4) 240 (84.8) 0.220 
 1 32 (8.7) 35 (12.4)  
 2 7 (1.9) 8 (2.8)  
 Body composition    
BMI (kg/m2) <25 103 (28.1 116 (41) 0.001 
 ≥25 264 (71.9) 167 (59)  
High SFI No 67 (18.3) 49 (17.3) 0.756 
 Yes 300 (81.7) 234 (82.7)  
Visceral obesity No 98 (26.7) 79 (27.9) 0.731 
 Yes 269 (73.3) 204 (72.1)  
Low SMI (Sarcopenia)     
SMI (Dolan BMI>25) No 356 (97.0) 15 (5.3) <0.001 
 Yes 11 (3.0) 268 (94.7)  
SMI (Caan) No 275 (74.9) 38 (13.4) <0.001 
 Yes 92 (25.1) 245 (86.6)  
SMI (Dolan BMI>30) No 315 (85.8) 71 (25.1) <0.001 
 Yes 52 (14.2) 212 (74.9)  
Low SMD (Myosteatosis)     
SMD (Martin) No 177 (48.2) 81 (28.6) <0.001 
 Yes 190 (51.8) 202 (71.4)  
SMD (Dolan BMI>25) No 224 (61.0) 119 (42.0) <0.001 
 Yes 143 (39.0) 164 (58.0)  
SMD (Xiao) No 196 (53.4) 113 (39.9) 0.001 
 Yes 171 (46.6) 170 (60.1)  
SMD (Dolan BMI 
Male/Female) 
No 197 (53.7) 107 (37.8) <0.001 
 Yes 170 (46.3) 176 (62.2)  
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Table 9.4: The relationship between SMD (Xiao), clinicopathological characteristics and systemic 
inflammation in patients undergoing surgery for colorectal cancer (n=650) 
Characteristic    
Low SMD (Xiao)   
 Clinico-pathological No (n=309) Yes (n=341) p-value 
Age ≤65 149 (48.2) 85 (24.9) <0.001 
 65 - 74 108 (35.0) 143 (41.9)  
 >75 52 (16.8) 113 (33.1)  
Sex Female 167 (54.0) 129 (37.8) <0.001 
 Male 142 (46.0) 212 (62.2)  
ASA score 1 91 (29.4) 50 (14.7) <0.001 
 2 140 (45.3) 157 (46.0)  
 3 72 (23.3) 121 (35.5)  
 4 6 (1.9) 13 (3.8)  
Laparoscopic Surgery No 195 (63.1) 212 (62.2) 0.805 
 Yes 114 (36.9) 129 (37.8)  
TNM 0 7 (2.3) 7 (2.1) 0.934 
 I 77 (24.9) 78 (22.9)  
 II 123 (39.8) 140 (41.1)  
 III 102 (33.0) 116 (34.0)  
T stage 0 7 (2.3) 7 (2.1) 0.327 
 1 34 (11.0) 45 (13.2)  
 2 59 (19.1) 45 (13.2)  
 3 160 (51.8) 184 (54.0)  
 4 49 (15.9) 60 (17.6)  
N stage 0 208 (67.3) 226 (66.3) 0.898 
 1 76 (24.6) 84 (24.6)  
 2 25 (8.1) 31 (9.1)  
Venous Invasion No 133 (43.0) 133 (39.0) 0.296 
 Yes 176 (57.0) 208 (61.0)  
Tumour Location Right and Transverse 108 (35.0) 139 (40.8) 0.041 
 Left 64 (20.7) 81 (23.8)  
 Rectum 127 (41.1) 110 (32.3)  
 Total and Subtotal 10 (3.2) 11 (3.2)  
Adjuvant Chemotherapy No 103 (33.3) 84 (24.6) 0.027 
 Yes 206 (66.7) 257 (75.4)  
 Systemic inflammation    
mGPS 0 242 (78.3) 257 (75.4) 0.045 
 1 35 (11.3) 28 (8.2)  
 2 32 (10.4) 56 (16.4)  
NLR ≤3 183 (59.2) 186 (54.5) 0.229 
 >3 126 (40.8) 155 (45.5)  
NPS 0 273 (88.3) 295 (86.5) 0.738 
 1 30 (9.7) 37 (10.9)  
 2 6 (1.9) 9 (2.6)  
 Body composition    
BMI (kg/m2) <25 136 (44.0) 83 (24.3) <0.001 
 ≥25 173 (56.0) 258 (75.7)  
High SFI No 76 (24.6) 40 (11.7) <0.001 
 Yes 233 (75.4) 301 (88.3)  
Visceral obesity No 126 (40.8) 51 (15.0) <0.001 
 Yes 183 (59.2) 290 (85.0)  
Sarcopenia     
Low SMI (Martin) No 196 (63.4) 171 (50.1) <0.001 
 Yes 113 (36.6) 170 (49.9)  
Low SM (Dolan BMI>25) No 204 (66.0) 167 (49.0) <0.001 
 Yes 105 (34.0) 174 (51.0)  
Low SMI (Caan) No 179 (57.9) 134 (39.3) <0.001 
 Yes 130 (42.1) 207 (60.7)  
Low SM (Dolan BMI>30) No 211 (68.3) 175 (51.3) <0.001 
 Yes 98 (31.7) 166 (48.7)  
Myosteatosis     
Low SMD (Martin) No 233 (75.4) 25 (7.3) <0.001 
 Yes 76 (24.6) 316 (92.7)  
Low SMD (Dolan BMI>25) No 303 (98.1) 40 (11.7) <0.001 
 Yes 6 (1.9) 301 (88.3)  
Low SMD (Dolan Male/Female) No 284 (91.8) 20 (5.9) <0.001 
 Yes 25 (8.1) 321 (94.1)  
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Table 9.5: The relationship between mGPS, clinicopathological characteristic and systemic inflammation in 
patients undergoing elective surgery for colorectal cancer (n=650) 
Characteristic    
mGPS 0 mGPS 1&2 (n=151) P-value 
 Clinico-pathological    
Age ≤65 185 (37.1) 49 (32.5) 0.410 
 65 - 74 193 (38.7) 58 (38.4)  
 >74 121 (24.2) 44 (29.1)  
Sex Female 228 (45.7) 68 (45.0) 0.887 
 Male 271 (54.3) 83 (55.0)  
ASA score 1 120 (24.0) 21 (13.9) 0.036 
 2 221 (44.3) 76 (50.3)  
 3 146 (29.3) 47 (31.1)  
 4 12 (2.4) 7 (4.6)  
Laparoscopic Surgery  No 303 (60.7) 104 (68.9) 0.070 
 Yes 196 (39.3) 47 (31.1)  
TNM 0 13 (2.6) 1 (0.7) <0.001 
 I 135 (27.1) 20 (13.2)  
 II 173 (34.7) 90 (59.6)  
 III 178 (35.7) 40 (26.5)  
Venous Invasion No 199 (39.9) 67 (44.4) 0.325 
 Yes 300 (60.1) 84 (55.6)  
Tumour Location Right and Transverse 175 (35.1) 72 (47.7) 0.014 
 Left 112 (22.4) 33 (21.9)  
 Rectum 197 (39.5) 40 (26.5)  
 Total and Subtotal 15 (3.0) 6 (4.0)  
Adjuvant Chemotherapy  No 293 (66.9) 92 (68.7) 0.704 
 Yes 206 (33.1) 59 (31.3)  
 Systemic inflammation    
NLR ≤3 308 (61.7) 61 (40.4) <0.001 
 >3 191 (38.3) 90 (59.6)  
NPS 0 459 (92.0) 109 (72.2) <0.001 
 1 38 (7.6) 29 (19.2)  
 2 2 (0.4) 13 (8.6)  
 Body composition    
BMI (kg/m2) <25 156 (31.3) 63 (41.7) 0.017 
 ≥25 343 (68.7) 88 (58.3)  
High SFI No 84 (16.8) 32 (21.2) 0.220 
 Yes 415 (83.2) 119 (78.8)  
Visceral obesity No 129 (25.9) 48 (31.8) 0.151 
 Yes 370 (74.1) 103 (68.2)  
Low SMI (Sarcopenia)     
SMI (Martin)   No 298 (59.7) 69 (45.7) 0.002 
 Yes 201 (40.3) 82 (54.3)  
SMI (Dolan BMI>25) No 299 (59.9) 72 (47.7) 0.008 
 Yes 200 (40.1) 79 (52.3)  
SMI (Caan) No 254 (50.9) 59 (39.1) 0.011 
 Yes 245 (49.1) 92 (60.9)  
SMI (Dolan BMI>30) No 309 (61.9) 77 (51.0) 0.017 
 Yes 190 (38.1) 74 (49.0)  
Low SMD (Myosteatosis)     
SMD (Martin)  No 214 (42.9) 44 (29.1) 0.002 
 Yes 285(57.1) 107 (70.9)  
SMD (Dolan BMI>25)  No 274 (54.9) 69 (45.7) 0.047 
 Yes 225 (45.1) 82 (54.3)  
SMD (Xiao)  No 242 (48.5) 67 (44.4) 0.374 
 Yes 257 (51.5) 84 (55.6)  
SMD (Dolan Male/Female)  No 241 (48.3) 63 (41.7) 0.156 
 Yes 258 (51.7) 88 (58.3)  
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Table 9.6: The relationship between SMI, SMD, mGPS, Sarcopenia and overall survival in patients undergoing 
elective surgery for colorectal cancer (n=650) 
 Independent, Mutually Adjusted Association HR (95% CI) p-value  
All Patients n=650    
mGPS 1.44 (1.15-1.79) 0.001 
Low SMI (Martin) 1.50 (1.04-2.18) 0.031 
Low SMD (Xiao) 1.42 (0.98-2.05) 0.061 
   
mGPS 0 n=499   
Low SMI (Martin) 1.48 (0.97-2.28) 0.071 
Low SMD (Xiao) 1.50 (0.97-2.33) 0.068 
   
mGPS 1/2 n=151   
Low SMI (Martin) 2.02 (0.98-4.18) 0.058 
Low SMD (Xiao) 1.30 (0.67-2.54) 0.438 
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 Figures and Legends  
 
Figure 9.1: The relationship between SMI and SMD in patients undergoing elective surgery for colorectal 
cancer (n=650) 
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Figure 9.2: The relationship between SMI (Martin) and overall survival (n=650, p=0.002) 
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Figure 9.3: The relationship between SMD (Xiao) and overall survival (n=650, p=0.019) 
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Figure 9.4: The relationship between mGPS and overall survival (n=650, p=0.010) 
  
  
 255 
10. COMPARISON OF THE PROGNOSTIC VALUE OF ECOG-PS, mGPS AND 
BMI/WL IN PATIENTS WITH ADVANCED CANCER: IMPLICATIONS FOR 
A CLINICALLY IMPORTANT FRAMEWORK FOR ASSESSMENT AND 
TREATMENT OF CANCER 
 Introduction  
The recognition of the poor prognosis associated with the syndrome of cachexia dates back 
to ancient Greece. These observations remain valid today as in patients with advanced 
cancer, progressive involuntary loss of body weight and lean tissue, anorexia, weakness and 
fatigue (cancer cachexia) are associated with poor survival (43).  Despite the clinical 
recognition of the syndrome of cancer cachexia, performance status remains the most useful 
clinical measure on which to base likely patient outcome to treatment and prognosis (25).   
There is now good evidence that the presence of a systemic inflammatory response, as 
evidenced by the mGPS is associated with the loss of lean tissue, anorexia, weakness and 
fatigue and poor survival in patients with advanced cancer (38, 367).  Moreover, in 
combination with ECOG-PS has been shown to effectively stratify the above measures of 
cachexia (17, 25). 
In contrast, Martin and colleagues (2015), in a large cohort study of more than 11,000 
patients with advanced cancer proposed that cachexia should be graded according to the 
concurrent Body Mass Index (BMI) and the degree of weight loss (WL) (368).  They showed 
that both had independent prognostic value and effectively stratified survival. However 
degree of WL may be limited due to its inaccurate and/or subjective reporting whilst BMI 
may be less useful as many patients with advanced cancer are overweight (368). 
Therefore, while ECOG-PS, mGPS and BMI/WL grade are all valid prognostic scores, and 
are related to cancer cachexia, to date, there has been no direct comparison of their 
prognostic value in patients with advanced cancer.  Such a comparison may inform clinical 
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practice as to which factors are associated with reduced survival and in turn inform the 
assessment and treatment of cancer cachexia.  Therefore, the aim of this Chapter was to carry 
out such a comparison in a prospective cohort of patients with advanced cancer.   
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 Patients and Methods  
Patients: 
An international database of patients with advanced cancer was analysed. All data were 
collected prospectively across 18 sites in the UK and Ireland (cancer centres, hospitals, and 
specialist palliative care units) over a five-year period (2011-2016). Eligible patients met the 
following criteria: >18 years of age; advanced cancer (defined as metastatic cancer 
[histological, cytological or radiological evidence], locally advanced or receiving anti-
cancer therapy with palliative intent); able to complete study questionnaires; provide a 
venous blood sample and with a recorded ECOG-PS. Patients were excluded if they had 
breast or prostate carcinoma with only bone metastases as their survival times could be many 
years and therefore an argument could be made that they did not in fact have advanced 
cancer. Patients who were undergoing active anti-cancer therapy or not, on both an inpatient 
and outpatient basis were included. The study had ethics committee approval in both the UK 
and Ireland and was conducted in accordance with the Declaration of Helsinki. All patients 
provided written informed consent. The study adhered to the STROBE guidelines for cohort 
studies. 
Individual centres were opened at staggered time points. Within each centre, patients who 
fulfilled the eligibility criteria were invited to participate and consented on a sequential basis 
therefore reducing selection bias. All assessments, including blood sampling, were 
performed on the day of consent. 
Prognostic markers 
Autobiographical and clinical data including the patient’s age, sex, ECOG-PS, mGPS, 
BMI/WL grade, underlying primary disease, and the presence of metastasis were recorded 
(6, 25, 369).   
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Bio-markers: CRP and albumin combined in the mGPS.  An autoanalyzer was used to 
measure serum CRP (mg/L) and albumin (g/L) concentrations (Architect; Abbot 
Diagnostics, Maidenhead, UK).  The mGPS and BMI/WL grade was derived as previously 
described (99, 369). 
Statistical Analysis: 
Categorical variables were analysed using χ2 test for linear-by-linear association, or χ2 test 
for 2 by 2 tables.  The time between the date of study entry and the date of death of any cause 
was used to define overall survival (OS). A survival time of 3 months or greater was used to 
define 3-month survival rate.  Survival data were analysed using univariate and multivariate 
Cox regression.  In addition to significant variables of interest on univariate analysis the 
predefined variables age, sex and cancer location were entered into a backward conditional 
multivariate model.  Cox Regression analysis was carried out for ECOG-PS, mGPS and 
BMI/WL grade to establish proportional Hazard Ratios.  
Two tailed p values <0.05 were considered statistically significant.  Statistical analysis was 
performed using SPSS software (Version 21.0. SPSS Inc., Chicago, IL, USA). 
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 Results  
A total of 730 patients (390 males, 340 females) met the eligibility criteria. The 
clinicopathological characteristics of the study population is shown in Table 10.1. The 
majority of patients were over 65 years of age (55.8%), had an ECOG-PS>0/1 (56.0%), 
mGPS>0 (55.5%), BMI≥25 (50.7%), <2.5% weight loss (56.8%) and had metastatic disease 
(85.8%). The majority of tumours were gastrointestinal (42.9%) and lung (28.2%) cancers.  
The median overall survival (OS) for the entire cohort was 7.3 months (95% CI: 1.0-73.63 
months). At the time of censoring, 182 patients (39.5%) were still alive. Median follow up 
time for these patients was 6.6 months (95% CI: 5.8-7.1 months).  
The relationship between ECOG-PS, mGPS and BMI/WL grade and overall survival in 
patients with advanced cancer is shown in Table 10.2a and Figures 10.1-10.3. On 
multivariate cox regression analysis ECOG-PS (HR 1.61 95%CI 1.42-1.83, p<0.001), mGPS 
(HR 1.53, 95%CI 1.39-1.69, p<0.001) and BMI/WL grade (HR 1.41, 95%CI 1.25-1.60, 
p<0.001) remained independently associated with overall survival.  
In patients with an ECOG-PS 0/1 the relationship between mGPS and BMI/WL grade and 
overall survival in patients with advanced cancer is shown in Table 10.2b. On multivariate 
cox regression analysis mGPS (HR 1.50, 95%CI 1.32-1.72, p<0.001) and BMI/WL Grade 
(HR 1.29, 95%CI 1.06-1.56, p=0.009) remained independently associated with overall 
survival.  
In patients with an ECOG-PS 2 the relationship between mGPS and BMI/WL grade and 
overall survival in patients with advanced cancer is shown in Table 10.2c. On multivariate 
cox regression analysis mGPS (HR 1.56, 95%CI 1.32-1.86, p<0.001) and BMI/WL Grade 
(HR 1.46, 95%CI 1.19-1.80, p<0.001) remained independently associated with overall 
survival.  
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In patients with an ECOG-PS 3/4 the relationship between mGPS and BMI/WL grade and 
overall survival in patients with advanced cancer is shown in Table 10.2d. On multivariate 
cox regression analysis mGPS (HR 1.55, 95%CI 1.12-2.15, p=0.009) and BMI/WL grade 
(HR 1.53, 95%CI 1.11-2.12, p=0.010) remained independently associated with overall 
survival.  
The relationship between ECOG-PS, mGPS and 3-month survival is shown in Table 10.3. 
In patients with an ECOG-PS of 0/1 there was a significant association between mGPS and 
3-months survival (p<0.001). In patients with an ECOG-PS of 2 there was a significant 
association between mGPS and 3-months survival (p<0.001). In patients with an ECOG-PS 
of 3/4 there was a non-significant association between mGPS and 3-months survival 
(p=0.102). In patients with an ECOG-PS of 0-4 there was a significant association between 
mGPS and 3-months survival (p<0.001).  
 In patients with an mGPS of 0 there was a significant association between ECOG-PS and 
3-months survival (p<0.001). In patients with an mGPS of 1 there was a significant 
association between ECOG-PS and 3-months survival (p=0.021). In patients with an mGPS 
of 2 there was a significant association between ECOG-PS and 3-months survival (p<0.001). 
In patients with an mGPS of 0-2 there was a significant association between ECOG-PS and 
3-months survival (p<0.001).        
The relationship between ECOG-PS, mGPS and 3-month survival in patients with a 
BMI/WL grade 0/1 is shown in Table 10.4. In patients with an ECOG-PS of 0/1 there was a 
significant association between mGPS and 3-months survival (p=0.001). In patients with an 
ECOG-PS of 2 there was a trend to a significant association between mGPS and 3-months 
survival (p=0.085). In patients with an ECOG-PS of 3/4 there was a non-significant 
association between mGPS and 3-months survival (p=0.741). In patients with an ECOG-PS 
of 0-4 there was a significant association between mGPS and 3-months survival (p<0.001).  
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 In patients with an mGPS of 0 there was a significant association between ECOG-PS and 
3-months survival (p=0.001). In patients with an mGPS of 1 there was a non-significant 
association between ECOG-PS and 3-months survival (p=0.343). In patients with an mGPS 
of 2 there was a significant association between ECOG-PS and 3-months survival (p=0.003). 
In patients with an mGPS of 0-2 there was a significant association between ECOG-PS and 
3-months survival (p<0.001).   
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 Discussion 
The results of the present study show that in a prospective cohort of patients with advanced 
cancer and a median survival of 7 months, the majority of patients had a good performance 
status and a low BMI/WL grade (minimal weight loss, normal BMI).  In contrast, the 
majority of patients had evidence of a systemic inflammatory response.  Although ECOG-
PS, mGPS and BMI/WL grade all effectively stratified overall survival when adjusted for 
age, sex and tumour type, both ECOG-PS and mGPS also stratified patient survival in those 
patients with a low BMI/WL grade. Therefore, the combination of ECOG-PS and mGPS 
reliably stratifies survival in patients with advanced cancer (17, 25, 331).  
The results of the present study are consistent with the work of Martin and colleagues who 
examined the relationship between weight loss grade, performance status and the GPS in 
more than 2,500 patients with advanced cancer and a median survival of 7.6 months (370).  
Unfortunately, to date this data has only been published in abstract form.  Nevertheless, the 
tabulated data in abstract is consistent with the present analysis and their conclusions that “a 
combination of BMI/ WL grades, PS and GPS consistently stratifies advanced cancer 
patients in to very different survival groups, and could be considered as diagnostic criteria 
for cachexia” have been confirmed and extended in the present study (370).     
The results of the present study indicate the importance of the systemic inflammatory 
response not only as a prognostic factor but also to inform the nutritional and functional 
decline associated with advanced cancer.  Indeed, in those patients who had both a good 
performance status and good BMI/WL grade (no obvious functional decline or weight loss), 
the mGPS effectively stratified median survival between 11.4 months and 7.5 months.  
Furthermore, in those patients 42%, had an elevated mGPS.  One interpretation of the 
findings is that obvious weight loss in patients with advanced cancer is a later event than 
functional decline, and that functional decline is a later event than the development of a 
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systemic inflammatory response (349).  Therefore, it may be that the mGPS should form the 
basis of stratification of likely survival in patients with advanced cancer.  Irrespective, 
greater prominence should be given to the assessment of the systemic inflammatory response 
(as evidenced by the mGPS) in patients with advanced cancer (38).  Moreover, the systemic 
inflammatory response, as evidenced by the mGPS, may be considered a cardinal feature of 
the syndrome of cancer cachexia (194, 355). If this proves to be the case then the systemic 
inflammatory response will become an important therapeutic target for cancer cachexia in 
the coming years (82). Indeed, targeting the inflammatory response to treat cancer cachexia 
has been proposed as a therapy with clinical trials now underway (371, 372). Trials have 
looked at this in the past but importantly patients were not entered into these trials on the 
basis of their inflammatory response.  
The present results support recent observations in the literature.  For example, with reference 
to cachexia Morley (2019) commented that although the cachexia score (CASCO) has been 
identified “as the best screening test available for cachexia, a quicker screen that may be 
equally effective is the Glasgow Prognostic Score” (373).  Indeed, this has been previously 
proposed  by Douglas and McMillan (2014) (355) and the importance of the systemic 
inflammatory response as a stratification factor randomised trials is now recognised (54).  
Therefore, it will be important that a direct comparison of the CASCO and ECOG-PS/mGPS 
tools is carried out in terms of body composition, quality of life and survival in patients with 
advanced cancer (374).  Moreover, such work is the basis of the rationalisation of the 
multiple tools developed to identify clinically important cachexia, sarcopenia and 
malnutrition. 
The present study had a number of limitations. The majority of patients were undergoing 
palliative care. As a result, it could be assumed that there had a high symptom burden which 
has been shown to be associated with worse outcomes. Furthermore, despite recruitment 
occurring across 18 sites, the patient cohort may not be completely representative of patients 
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with advanced cancer. However, they were well defined in terms of the components of know 
and validated prognostic scores which will allow for direct comparison with other 
populations in future studies. Finally, the method of patient recruitment/sampling strategy 
was opportunistic. However, the heterogeneity of the primary cancer types suggests that the 
recruitment process while being opportunistic was robust.   
In summary, while ECOG-PS, mGPS and BMI/WL grade are all valid prognostic scores the 
ECOG/mGPS framework is more robust and may form the basis of risk stratification of 
survival in patients with advanced cancer.  
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 Tables and Footnotes  
Table 10.1: Clinicopathological characteristics of patients with advanced cancer (n=730) 
Characteristic  
n=730 (%) 
 Clinico-pathological  
Age <65 323 (44.2) 
 65 - 74 225 (30.8) 
 >74 182 (24.9) 
Sex Male 390 (53.4) 
 Female 340 (46.6) 
Cancer Location  Lung 206 (28.2) 
 GI 313 (42.9) 
 Other 211 (28.9) 
Metastatic Disease No 104 (14.2) 
 Yes 626 (85.8) 
 Previous Ant-Cancer Therapy  
Chemotherapy No 148 (20.3) 
 Yes 582 (79.7) 
Radiotherapy No 572 (78.4) 
 Yes 158 (21.6) 
Hormones No 678 (92.9) 
 Yes 52 (7.1) 
 Performance status  
ECOG-PS 0/1 409 (56.0) 
 2 240 (32.9) 
 3/4 81 (11.1) 
 Systemic Inflammation  
mGPS 0 325 (44.5) 
 1 111 (15.2) 
 2 294 (40.3) 
 Body composition  
BMI ≤20.0 kg/m2 99 (13.6) 
 20-21.9 kg/m2 92 (12.6) 
 22-24.9 kg/m2 174 (23.4) 
 25-27.9 kg/m2 156 (21.4) 
 ≥28.0 kg/m2 209 (28.6) 
% Weight Loss <2.5 415 (56.8) 
 ≥2.5 315 (43.2) 
BMI/WL grade 0/1 404 (55.3) 
 2/3 241 (33.0) 
 4 85 (11.6) 
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Table 10.2: The relationship between ECOG, mGPS and BMI/WL grade and overall survival in patients with advanced cancer. 
Characteristics  Univariate p-value  Multivariate p-value Multivariate Adjusted 
 for Age, Sex and Cancer Location 
p-value 
Table 10.2a ECOG-PS  0/1-4 (n=730)       
ECOG-PS 1.85 (1.63-2.09) <0.001 1.61 (1.42-1.83) <0.001 1.64 (1.44-1.86) <0.001 
mGPS 1.63 (1.48-1.80) <0.001 1.53 (1.39-1.69) <0.001 1.49 (1.35-1.64) <0.001 
BMI/WL grade 1.48 (1.30-1.67) <0.001 1.41 (1.25-1.60) <0.001 1.39 (1.23-1.58) <0.001 
       
Table 10.2b ECOG-PS  0/1 (n=409)        
mGPS 1.51 (1.32-1.72) <0.001 1.50 (1.32-1.72) <0.001 1.44 (1.26-1.65) <0.001 
BMI/WL grade 1.29 (1.07-1.56) 0.007 1.29 (1.06-1.56) 0.009 1.25 (1.03-1.51) 0.024 
       
Table 10.2b ECOG-PS 2 (n=240)       
mGPS 1.59 (1.34-1.89) <0.001 1.56 (1.32-1.86) <0.001 1.53 (1.28-1.82) <0.001 
BMI/WL grade 1.50 (1.22-1.84) <0.001 1.46 (1.19-1.80) <0.001 1.43 (1.16-1.76) 0.001 
       
Table 10.2c ECOG-PS 3/4 (n=81)       
mGPS 1.42 (1.04-1.95) 0.029 1.55 (1.12-2.15) 0.009 1.54 (1.11-2.14) 0.009 
BMI/WL grade 1.37 (1.02-1.84) 0.039 1.53 (1.11-2.12) 0.010 1.58 (1.15-2.19) 0.005 
 267 
Table 10.3: The relationship between the ECOG-PS, mGPS and 3 month survival rate in patients with advanced cancer (n=730) 
ECOG-PS  mGPS=0 
 
mGPS=1 mGPS=2 mGPS 0-2  
  n (%) n (%) n (%) n (%) P-value 
0-1 N 226 56 127 409  
 Survival Rate at 3 months  218 (96.5%) 46 (82.1%) 105 (82.7%) 369 (90.26%) <0.001 
 Median Survival  10.9 7.0 7.0 9.1  
 95% CI 9.2-12.3 5.3-10.2 5.7-8.9 8.0-10.0  
2 N 87 42 111 240  
 Survival Rate at 3 months  76 (87.4%) 28 (66.7%) 62 (55.9%) 166 (69.2%) <0.001 
 Median Survival  7.3 5.0 3.5 5.2  
 95% CI 6.1-9.8 3.1-6.6 2.6-4.8 4.6-5.7  
3-4 N 12 13 56 81  
 Survival Rate at 3 months  8 (66.7%) 6 (46.2%) 19 (33.9%) 33 (40.7%) 0.102 
 Median Survival  5.9 2.6 1.9 2.5  
 95% CI 2.5-14.2 0.6-4.5 1.2-2.7 1.5-3.1  
ECOG-PS  0/1-4 N 325 111 294 730  
 Survival Rate at 3 months 302 (92.9%) 80 (72.1%) 186 (63.3%) 568 (77.8%) <0.001 
 Median Survival  9.6 5.3 4.2 6.6  
 95% CI 8.4-10.8 4.2-6.6 3.6-5.1 5.8-7.1  
P-value  <0.001 0.021 <0.001 <0.001  
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Table 10.4: The relationship between the ECOG-PS, mGPS and 3 month survival rate in patients with a BMI/WL grade 0/1 and advanced cancer (n=404) 
ECOG-PS  mGPS=0 
 
mGPS=1 mGPS=2 mGPS 0-2  
  n (%) n (%) n (%) n (%) P-value 
0-1 N 148 32 73 253  
 Survival Rate at 3 months  144 (97.3%) 26 (81.3%) 62 (84.9%) 232 (91.7%) 0.001 
 Median Survival  11.4 9.4 7.5 9.9  
 95% CI 9.2-14.4 4.0-17.8 6.1-9.9 8.7-11.4  
2 N 49 24 45 118  
 Survival Rate at 3 months  44 (89.8%) 21 (87.5%) 33 (73.3%) 98 (83.1%) 0.085 
 Median Survival  7.9 6.6 4.9 6.7  
 95% CI 6.8-10.7 5.0-8.9 3.7-6.6 5.2-7.6  
3-4 N 6 5 22 33  
 Survival Rate at 3 months  4 (66.7%) 3 (60%) 11 (50.0%) 18 (54.5%) 0.741 
 Median Survival  7.2 3.4 2.9 3.2  
 95% CI 1.0-73.2 0.6-8.4 1.2-5.0 1.8-5.0  
ECOG-PS  0/1-4 N 203 61 140 404  
 Survival Rate at 3 months 192 (94.6%) 50 (82.0%) 106 (75.7%) 348 (86.1%) <0.001 
 Median Survival  10.0 7.5 5.7 7.9  
 95% CI 8.9-11.7 5.8-8.9 4.8-7.1 7.3-8.9  
P-value  0.001 0.343 0.003 <0.001  
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 Figures and Legends   
 
 
Number at 
risk 
0  6   12   18   24   30   36   42  
ECOG 0/1 409  317 236 194 176 166 159 154 
ECOG 2 240  127 95 83 79 74 72 72 
ECOG 3/4 81  22 16 13 12 12 12 12 
Figure 10.1: The relationship between the ECOG-PS and OS in patients with advanced cancer (n=730, Log 
rank test: ECOG-PS 0/1-2: p<0.001, ECOG-PS 2-3/ 4:p<0.001, ECOG-PS 0/1-3/4: p<0.001). Number at risk 
depicts the number of patients alive or not censored entering each time period. 
 
 
 
 
 
 
 
ECOG 0/1 
ECOG 2 
ECOG 3/4 
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Number at 
risk 
0  6  12  18   24  30  36   42  
mGPS 0 325  270 207 180 166 158 152 150 
mGPS 1 111  66 50 42 41 39 37 35 
mGPS 2 294  130 90 68 61 55 64 53 
 
Figure 10.2: The relationship between the mGPS and OS in patients with advanced cancer (n=730, Log rank 
test: mGPS 0-1: p<0.001, mGPS1-2: 0.006, mGPS 0-2: p<0.001). Number at risk depicts the number of patients 
alive or not censored entering each time period. 
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Number at risk 0  6  12  18  24  30  36  42 
BMIWLGrade 0/1 404  300 224 187 171 160 152 148 
BMIWLGrade 2/3 241  131 99 82 77 73 72 71 
BMIWLGrade 4 85  35 24 21 20 19 19 19 
 
Figure 10.3: The relationship between the BMIWL grade and OS in patients with advanced cancer (n=730, 
Log rank test: BMIWL grade 0/1-2/3: p<0.001, BMIWL grade 2/3-4: p<0.001, ECOG-PS 0/1-4: p=0.010). 
Number at risk depicts the number of patients alive or not censored entering each time period. 
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BMIWLGrade 2/3 
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11. THE RELATIONSHIP BETWEEN THE ECOG-PS/mGPS FRAMEWORK, CT-
DERIVED BODY COMPOSITION, PHYSICAL FUNCTION TESTS AND 
SURVIVAL IN PATIENTS WITH ADVANCED CANCER 
 Introduction  
As mentioned in Chapters 3 and 5 there is now good evidence that measures of the systemic 
inflammatory response predict survival in patients with advanced cancer both in the 
observational (38) and randomised clinical trial setting (54).  In particular, the mGPS is a 
simple, objective clinically useful measure of the systemic inflammatory response since it 
has been extensively validated and its thresholds are well defined compared with other 
measures of the systemic inflammatory such as the NLR (166, 375).  In patients with 
advanced cancer it has been proposed that the mGPS is used with ECOG performance status 
(ECOG-PS), the so called ECOG-PS/ mGPS framework (17, 54, 206, 376).  This framework 
has more recently been shown to be associated with quality of life (25) and externally 
validated [12, 13, 14].  Therefore, with the increasing integration of oncology and palliative 
care, the ECOG-PS/ mGPS framework is a solid basis on which to examine the prognostic 
value of other measures (377).   
The use of the ECOG-PS has been criticised as being subjective, inaccurate and overly 
optimistic (378). As a result there has been an increased interest in the use of more objective 
measures of performance status in patients with advanced cancer. In patients with advanced 
cancer there is evidence supporting a disproportionate loss of skeletal muscle tissue, 
measured from a CT scan, to be an independent prognostic factor for both cancer-specific 
and overall survival (350). Specifically muscle loss has been associated with poor treatment 
tolerance and efficacy (351), poorer quality of life and increased morbidity (352).  
Alternatively, objective performance tests such as hand grip strength (HGS), the 2min walk 
test (2MWT) and the timed get up and go tests (TUG)  may be useful replacements for 
ECOG-PS.  However, it is not clear how this ECOG-PS/ mGPS framework is associated 
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with body composition and physical function tests.  Therefore, the aim of this Chapter was 
to examine the relationship between ECOG-PS/ mGPS framework, CT-derived body 
composition, physical function tests and survival in patients with advanced cancer. 
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 Patients and Methods  
Patients: 
A biobank of data from patients with advanced cancer was analysed. All data were collected 
prospectively across 9 sites in the UK and Ireland (cancer centres, hospitals, and specialist 
palliative care units) over a five-year period (2011-2016). Eligible patients provided written 
informed consent, were adults, had advanced cancer (defined as metastatic cancer 
[histological, cytological or radiological evidence], locally advanced or receiving anti-
cancer therapy with palliative intent), had the ability to comply with study procedures 
including provision of a venous blood sample (taken on the day of consent).  Patients were 
either inpatients or outpatients, undergoing anti-cancer therapy or not. The primary data 
collection studies had ethics appropriate ethics approval and were conducted in accordance 
with the Declaration of Helsinki. The study adhered to the STROBE guidelines for cohort 
studies. 
Prognostic markers 
Patient’s age, sex, and demographics were recorded, as were details of underlying disease 
including metastases. Validated prognostic tools/factors highlighted from a recent 
systematic review by Simmons and co-workers were included in the analysis (379).  
Bio-markers: CRP and albumin combined in the mGPS.  An autoanalyzer was used to 
measure serum CRP (mg/L) and albumin (g/L) concentrations (Architect; Abbot 
Diagnostics, Maidenhead, UK).  The mGPS was derived as previously described (99).  
Body composition:  CT images were obtained at the level of the third lumbar vertebra as 
previously described in Chapter 2. Patients whose scans were taken 3 months or more prior 
to study entry were excluded from the study. Scans with significant movement artefact or 
missing region of interest were not considered for inclusion. CT images were analysed as 
described in Chapter 2 using NIH Image J (version 1.47) or OsiriX software (version 4.1.1). 
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Both imaging software packages have been shown to provide excellent agreement for body 
composition measures (380). Thresholds were calculated as described in Chapter 2 and a 
summary of all thresholds used can be found in Table 11.1. 
Measurements were performed by two individuals and inter-rater reliability was assessed in 
a sample of 20 patient images using inter-class correlation coefficients (ICCC) (SMA ICCC 
= 0.986, SMD ICCC = 0.964). Investigators were blind to patient’s demographic and clinico-
pathological status. 
Physical function: ECOG-PS, 2MWT and TUG tests (measured in 186 patients in  UK) and 
HGS (measured in 103 patients in Ireland) and the presence of metastases and weight loss 
at study entry were assessed by either the treating clinician or clinical research staff. TUG 
and 2MWT test completion were recorded contemporaneously with completion being 
recorded as a test pass. A failure of TUG was classed as an inability to rise from a chair, 
walk three meters, turn around, walk back to the chair, and sit down. A failure of 2MWT 
was classed as an inability of an individual to walk without assistance for 2 minutes in total. 
A weak HGS was defined as <26 kg in men and <16kg in women (381). Patients who 
achieved HGS results below the above thresholds were deemed to have failed the HGS test. 
All objective measurements were then combined in the combined objective performance test 
(COPT) to give a pass/fail reading. 
Statistical Analysis: 
Body composition measurements were presented as median and range and compared using 
Mann-Whitney or Kruskal-Wallis tests.  Categorical variables were analysed using χ2 test 
for linear-by-linear association, or χ2 test for 2 by 2 tables.   
 The time between the date of study entry and the date of death of any cause was used to 
define OS.  Survival data were analysed using univariate and multivariate Cox regression 
analysis.  In addition to significant variables of interest on univariate analysis the predefined 
 276 
variables age, sex and cancer location were entered into a backward conditional multivariate 
model.  Kaplan Meier analysis was carried out for ECOG-PS and mGPS to establish 
proportional Hazard Ratios.  
Missing data were excluded from analysis on a variable by variable basis.  Two tailed p 
values <0.05 were considered statistically significant.  Statistical analysis was performed 
using SPSS software (Version 21.0. SPSS Inc., Chicago, IL, USA). 
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 Results 
A total of 289 patients (141 males, 148 females) met the eligibility criteria. The relationship 
between clinicopathological characteristics, body composition, physical function and overall 
survival is shown in Table 11.2. All objective functional tests were combined in the COPT 
in 289 patients in the UK and Ireland. The majority of patients were under 65 years of age 
(50.2%), BMI≤25 (50.9%) and had metastatic disease (86.9%). The majority of tumours 
were GI (33.6%) and lung (32.2%) cancers.  The median overall survival (OS) for the entire 
cohort was 6.7 months (95% CI: 8.9-11.0 months). At the time of censoring, 104 patients 
(36%) were still alive. Median follow up time for these patients was 11.7 months (95% CI: 
13.3-17.4 months). Correlation analysis showed a non-significant positive association 
between low SMI and TUG (rs: 0.091, p=0.215), 2MWT (rs: 0.096, p=0.191), HGS (rs: 
0.032, p=0.751) and COPT (rs: 0.067, p=0.258). In contrast correlation analysis showed a 
significant positive association between low SMD and TUG (rs: 0.167, p=0.023), 2MWT 
(rs: 0.184, p=0.012), HGS (rs: 0.223, p=0.024) and COPT (rs: 0.185, p=0.002).  On 
univariate survival analysis tumour location, previous chemotherapy, mGPS (Figure 11.2), 
ECOG-PS (Figure 11.1), SMI, SMD, TUG failure, 2MWT failure, HGS failure and COPT 
failure were associated with survival (all<0.05). 
The relationship between ECOG-PS and mGPS scoring and SMI in patients with advanced 
cancer is shown in Table 11.3a. There was a significant association between low SMI and 
ECOG-PS (p<0.05). There was no significant association between low SMI and mGPS. 
There was an increase in the percentage of patients having a low SMI from 43.4% in patients 
with an ECOG-PS≤1 and a mGPS=0 and to 58.8% in patients with an ECOG-PS=2 and a 
mGPS=2 (p=0.029). 
The relationship between ECOG-PS and mGPS scoring and SMD in patients with advanced 
cancer is shown in Table 11.3b. There was a significant association between a low SMD and 
ECOG-PS (p<0.001).  There was a significant association between a low SMD and mGPS 
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(p<0.05). There was an increase in the percentage of patients classified as having 
myosteatosis with a low SMD from 48.2% in patients with an ECOG-PS≤1 and a mGPS=0 
to 68.6% in patients with an ECOG-PS=2 and a mGPS=2 (p=0.011). 
The relationship between ECOG-PS and mGPS scoring and TUG test failure in patients with 
advanced cancer is shown in Table 11.3c.  There was a significant association between TUG 
test failure and ECOG-PS (p<0.001).  There was no significant association between TUG 
test failure and mGPS. There was an increase in the percentage of patients classified as 
having failed to complete TUG testing from 24.4% in patients with an ECOG-PS≤1 and a 
mGPS=0 to 36.8% in patients with an ECOG-PS=2 and mGPS=2 (p=0.329). 
The relationship between ECOG-PS and mGPS scoring and 2MWT failure in patients with 
advanced cancer is shown in Table 11.3d. There was a significant association between 2min 
walk failure and ECOG-PS (p<0.001).  There was no significant association between 2MWT 
failure and mGPS. There was an increase in the percentage of patients classified as having 
failed to complete 2min walk testing from 26.7% in patients with an ECOG-PS≤1 and a 
mGPS=0 to 36.8% in patients with an ECOG-PS=2 and a mGPS=2 (p=0.307). 
The relationship between ECOG-PS and mGPS scoring and HGS test failure in patients with 
advanced cancer is shown in Table 11.3e. There was no significant association between HGS 
failure and ECOG-PS. There was a significant association between HGS test failure and 
mGPS (p<0.01). There was an increase in the percentage of patients classified as having 
failed to complete HGS testing from 23.7% in patients with an ECOG-PS≤1 and a mGPS=0 
to 61.5% in patients with an ECOG-PS=2 and a mGPS=2 (p=0.362). 
The relationship between ECOG-PS and mGPS scoring and COPT failure in patients with 
advanced cancer is shown in Table 11.3f. There was a significant association between COPT 
failure and ECOG-PS (p<0.001). There was a significant association between COPT failure 
and mGPS (p<0.01). There was an increase in the percentage of patients classified as having 
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failed to complete COPT testing from 24.1% in patients with an ECOG-PS≤1 and a mGPS=0 
to 43.1% in patients with an ECOG-PS=2 and a mGPS=2 (p=0.183). 
The relationship between ECOG-PS, mGPS and SMI and overall survival in patients with 
advanced cancer is shown in Table 11.4a. On multivariate cox regression analysis ECOG-
PS (HR 1.90, 95%CI 1.51-2.39, p<0.001), mGPS (HR 1.71, 95%CI 1.45-2.02, p<0.001) and 
low SMI (HR 1.39, 95%CI 1.04-1.86, p=0.027) remained independently associated with 
overall survival.  
The relationship between ECOG-PS, mGPS and low SMD and overall survival in patients 
with advanced cancer is shown in Table 11.4b. On multivariate cox regression analysis 
ECOG-PS (HR 1.91, 95%CI 1.52-2.39, p<0.001) and mGPS (HR 1.70, 95%CI 1.44-2.00, 
p<0.001) remained independently associated with overall survival.  
The relationship between ECOG-PS, mGPS and TUG test failure and overall survival in 
patients with advanced cancer is shown in Table 11.4c. On multivariate cox regression 
analysis ECOG-PS (HR 2.18, 95%CI 1.61-2.94, p<0.001), mGPS (HR 1.89, 95%CI 1.51-
2.37, p<0.001) and TUG test failure (HR 1.82, 95%CI 1.22-2.72, p=0.003) remained 
independently associated with overall survival.  
The relationship between ECOG-PS, mGPS and 2MWT failure and overall survival in 
patients with advanced cancer is shown in Table 11.4d. On multivariate cox regression 
analysis ECOG-PS (HR 2.22, 95%CI 1.65-2.98, p<0.001), mGPS (HR 1.89, 95%CI 1.51-
2.37, p<0.001) and 2MWT failure (HR 1.83, 95%CI 1.24-2.73, p=0.003) remained 
independently associated with overall survival.  
The relationship between ECOG-PS, mGPS and HGS test failure and overall survival in 
patients with advanced cancer is shown in Table 11.4e. On multivariate cox regression 
analysis mGPS (HR 1.55, 95%CI 1.20-2.01, p=0.001) and HGS test failure (HR 1.63, 95%CI 
1.03-2.59, p=0.039) remained independently associated with overall survival.  
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The relationship between ECOG-PS, mGPS and COPT failure and overall survival in 
patients with advanced cancer is shown in Table 11.4f. On multivariate cox regression 
analysis ECOG-PS (HR 1.83, 95%CI 1.45-2.30, p<0.001), mGPS (HR 1.65, 95%CI 1.39-
1.95, p<0.001) and COPT failure (HR 1.63, 95%CI 1.21-2.19, p=0.001) remained 
independently associated with overall survival.  
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 Discussion 
The results of the present study show that ECOG-PS/ mGPS framework was associated with 
body composition parameters and physical function tests and these all had prognostic value.  
In particular, ECOG-PS was consistently associated with physical function tests. However, 
with the exception of handgrip strength, no body composition measure or physical function 
test displaced the prognostic value of ECOG-PS within the ECOG-PS/ mGPS framework.  
These results confirm the clinical reliability and prognostic importance of the ECOG-PS/ 
mGPS framework and suggest that physical function tests may further improve the objective 
nature of this framework in patients with advanced cancer. 
In the randomised clinical oncology trial setting performance status has become, through 
routine clinical use, an important established predictor of outcome and as a result an entry 
criteria for many trials.  Similarly, in this setting, it is becoming clear that markers of the 
systemic inflammatory response have prognostic value.  In particular, the mGPS through its 
established objective thresholds has recently been reported to predict response to treatment 
in a number of randomised trials (54). Therefore, it may be that the systemic inflammatory, 
as evidenced by the mGPS, will also become an important entry criteria for patients in 
randomised clinical trials.  On this basis the ECOG-PS/ mGPS framework has considerable 
potential to better select patients with advanced cancer for active oncological treatment. 
In the present study the quantity and quality of skeletal muscle and physical function tests 
were shown to have prognostic value.  These measures were also shown to be consistently 
associated with ECOG-PS.  Given the subjective nature of ECOG-PS it was of interest to 
examine whether any of these measures could replace ECOG-PS in the framework.  With 
survival as an endpoint, HGS appeared to be superior to SMI and SMD and was the only 
physical function test to displace ECOG-PS in the framework. However, HGS results were 
available in only 103 patients compared with 267 that had ECOG-PS data. In Table 11.2 the 
confidence intervals for HGS were wider than for ECOG-PS, despite broadly similar hazard 
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ratios. Therefore, while the results for HGS look more impressive they would seem to be 
less reliable in this model. HGS seems to offer a similar level of discrimination to ECOG-
PS however practically in an oncology outpatient context, ECOG-PS is far easier to measure.  
Therefore, the results of this study suggest that the ECOG-PS/mGPS framework should be 
the method of assessment of choice in patients with advanced cancer.  
In the present study it was of interest that SMD was significantly associated with both the 
ECOG-PS and mGPS. Furthermore, there was a significant positive association between 
SMD and TUG, 2MWT, HGS and COPT. One interpretation of the present cross-sectional 
results would be that the quality of skeletal muscle determines the strength and the 
performance status of the patient with advanced cancer patient. This interpretation would be 
consistent with the results of a recent study by Williams and co-workers who reported that 
SMD was related to physical function impairments including activities of daily living 
(ADL), climbing stairs, walking and TUG (382). Furthermore, that the presence of systemic 
inflammatory response degrades the quality of the skeletal muscle.  If this were to be the 
case then it might be anticipated that down regulation of the systemic inflammatory 
response, compared with placebo, would result in better preservation of muscle density, 
muscle strength and performance status. This hypothesis is the subject of a number of 
ongoing randomised clinical trials.  For example, there is a randomised placebo controlled 
phase III trial underway of a multimodal intervention (Exercise, nutrition, anti-inflammatory 
medication) in patients with advanced lung or pancreatic cancer undergoing anti-cancer 
therapy with palliative intent (NCT02330926) (371).   The aim of this trial is to prevent or 
attenuate loss of weight, muscle and physical function using a multimodal intervention 
which is anti-inflammatory. The findings from the associated phase II trial provide grounds 
for optimism for the ongoing phase III trial (383).   
It was of interest that a BMI>25, high SFI and the presence of visceral obesity was associated 
with better overall survival. There is evidence in the literature that high level of subcutaneous 
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and visceral fat were both associated with an increased risk of developing cancer, more post 
operative complications and worse outcomes (384). However there is also evidence in the 
literature that obesity can have a protective effect in patients with cancer, particularly those 
with advanced disease, termed the obesity paradox (385, 386).  
 
Lennon and co-workers in a recent review examined the obesity paradox in cancer (385). 
There are both host and tumour factors which could explain this phenomenon including 
detection bias (385).  Obese patients are at an increased risk of both diabetes and 
cardiovascular disease which are often diagnosed later in life (387). During their initial 
workup for these new diagnoses incidental, non-symptomatic early stage cancers can be 
picked up (385). Another potential explanation could be reverse causality which refers to the 
observation that some patients with a normal BMI at diagnosis were previously obese (388). 
These patients have more advanced disease which is driving their weight loss and leading to 
poorer outcomes (385). There is also evidence that some tumours in obese patients have less 
aggressive characteristics and are more susceptible to systemic treatment such as 
neoadjuvant chemotherapy (389-391). Finally, it may be that excess adipose tissue serves as 
a nutrient reserve and confers a survival advantage in times of stress, such as anti-cancer 
treatment (385, 392).”  
Limitations of the present study include that identical physical function test data was not 
available in all patients. In addition, 86.9% of patients had metastatic disease requiring 
regular opioid administration. Long term opioid use in particular has been shown to lead to 
hypogonadism in both men and women (343). This gonadal suppression can lead to reduced 
anabolic activity with decreased skeletal muscle mass and an associated reduction in quality 
of life and outcomes (343, 344).  However, the study population was relatively large, well-
documented in terms of clinicopathological characteristics and measures of the systemic 
inflammatory response and had relatively mature follow-up. 
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In summary, the ECOG-PS/ mGPS framework was associated with body composition 
parameters and physical function tests and these all had prognostic value. These results 
confirm the clinical reliability and prognostic importance of the ECOG-PS/ mGPS 
framework in patients with advanced cancer. 
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 Tables and Footnotes  
Table 11.1: CT derived body composition measures and thresholds used 
Body Composition Measurement  
Sarcopenia  
Low SMI (Martin) (66): 
Males: BMI<25kg/m2 and SMI<43 cm2m2  or BMI≥25kg/m2 and SMI<53 cm2m2 
Females: BMI<25kg/m2 and SMI<41 cm2m2  or BMI≥25kg/m2 and SMI<41 cm2m2 
Myosteatosis  
Low SMD (Martin) (66):  
BMI<25kg/m2 and SMD<41 HU or BMI≥25kg/m2 and SMD<33HU  
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Table 11.2: The relationship between clinicopathological characteristics, CT derived body composition, 
physical function and overall survival in patients with advanced cancer (n=289) 
Characteristic  Univariate  Multivariate Adjusted  
for Age, Sex and 
Cancer Location 
 
n=289 (%) Overall Survival HR 
(95% CI)  
P-value Overall Survival HR 
(95% CI)  
P-value 
 Clinico-
pathological 
     
Age <65 144 (49.8) 0.76 (0.97-1.17)   0.763 1.00 (0.83-1.20) 0.974 
 65 - 74 88 (30.4)     
 >74 57 (19.7)     
Sex Male 141 (48.8) 1.05 (0.78-1.40) 0.759 1.08 (0.81-1.44) 0.616 
 Female 148 (51.2)     
Cancer Location  Lung  93 (32.2) 1.29 (1.08-1.55)  0.006 1.29 (1.08-1.55) 0.006 
 GI 97 (33.6)     
 Other 99 (34.3)     
Metastatic 
Disease 
No 38 (13.1) 0.99 (0.62-1.58) 0.980 1.03 (0.64-1.63) 0.917 
 Yes 251 (86.9)     
 Previous Anti-
Cancer Therapy  
     
Chemotherapy˥ No 36 (14.8) 0.49 (0.32-0.75) 0.001 0.50 (0.33-0.76) 0.001 
 Yes 207 (85.2)     
Radiotherapy˥ No 167 (68.7) 1.13 (0.85-1.50) 0.411 1.16 (0.87-1.55) 0.319 
 Yes 76 (31.3)     
Hormones˦ No 208 (87.4) 1.01 (0.73-1.40) 0.937 1.13 (0.82-1.56) 0.471 
 Yes 30 (12.6)     
 Body composition      
Sarcopenia        
Low SMI 
(Martin)   
No 153 (52.9) 1.38 (1.03-1.84) 0.031 1.36 (1.02-1.82) 0.037 
 Yes 136 (47.1)     
Myosteatosis        
Low SMD 
(Martin)  
No 118 (40.8) 1.54 (1.14-2.07) 0.005 1.54 (1.14-2.09) 0.005 
 Yes 171 (59.2)     
 Systemic 
inflammation 
     
mGPS 0 124 (42.9) 1.79 (1.52-2.10) <0.001 1.79 (1.52-2.10) <0.001 
 1 43 (14.9)     
 2 122 (42.2)     
 Functional 
Testing 
     
ECOG-PS 0/1 162 (56.1) 2.17 (1.72-2.73) <0.001 2.31 (1.82-2.92) <0.001 
 2 105 (36.3)     
 3 22 (7.6)     
TUG Test 
Failure˨ 
No 118 (63.4)  2.31 (1.57-3.40) <0.001 2.43 (1.64-3.59) <0.001 
 Yes 68 (36.6)     
2MWT Failure˨ No 113 (60.8)  2.28 (1.54-3.36) <0.001 2.41 (1.63-3.57) <0.001 
 Yes 73 (39.2)     
HGS Test 
Failure˩ 
No 64 (62.1) 1.89 (1.20-2.98) 0.006 1.96 (1.24-3.09) 0.004 
 Yes 39 (37.9)     
COPT Failure No 182 (63.0) 2.06 (1.54-2.76) <0.001 2.14 (1.60-2.87) <0.001 
 Yes 107 (37.0)     
˥: 46 patients missing ˦: 51 patients missing ˧: 4 patients missing ˨: 103 patients missing ˩: 186 Patients missing 
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Table 11.3: The relationship between ECOG, mGPS and measures of body composition and objective 
performance status measurements in patients with advanced cancer (n=289) 
Table 
11.3a 
         
ECOG-
PS 
mGPS=0  mGPS=1  mGPS=2  All  P 
n=289 n Low SMI 
(Martin)  
n (%) 
n Low SMI 
(Martin) n 
(%) 
n Low SMI 
(Martin) n 
(%) 
n Low SMI 
(Martin) n 
(%) 
 
0-1 83 36 (43.4) 23 5 (21.7) 56 24 (42.9) 162 65 (40.1) 0.151 
2 39 21 (53.8) 15 6 (40.0) 51 30 (58.8) 105 57 (54.8) 0.436 
3 2 1 (50.0) 5 4 (80.0) 15 9 (60.0) 22 14 (63.6) 0.166 
All 124 58 (46.8) 43 15 (34.9) 122 63 (51.6) 289 136 (47.1) 0.285 
P  0.555  0.041  0.202  0.021  
Table 
11.3b 
         
ECOG-
PS 
mGPS=0  mGPS=1  mGPS=2  All  P 
n=289 n Low SMD 
(Martin) n 
(%) 
n Low SMD 
(Martin) n 
(%) 
n Low SMD 
(Martin) n 
(%) 
n Low SMD 
(Martin) n 
(%) 
 
0-1 83 40 (48.2) 23 11 (47.8) 56 34 (60.7) 162 85 (52.5) 0.311 
2 39 19 (48.7) 15 11 (73.3) 51 35 (68.6) 105 65 (61.9) 0.096 
3 2 2 (100.0) 5 5 (100.0) 15 14 (93.3) 22 21 (95.5) 0.783 
All 124 61 (49.2) 43 27 (62.8) 122 83 (68.0) 289 171 (59.2) 0.010 
P  0.350  0.053  0.055  <0.001  
Table 
11.3c 
         
ECOG-
PS 
mGPS=0  mGPS=1  mGPS=2  All  P 
n=186 n TUG test 
failure n (%)˨ 
n TUG test 
failure n (%)˨ 
n TUG test 
failure n (%)˨ 
n TUG test 
failure n (%)˨ 
 
0-1 45  11 (24.4) 13 3 (23.1) 33 8 (24.2) 91 22 (24.2) 0.995 
2 28  9 (32.1) 10 7 (70.0) 38 14 (36.8) 76 30 (39.5) 0.098 
3 2  2 (100.0) 5 5 (100.0) 12 9 (75.0) 19 16 (84.2) 0.354 
All 75 22 (29.3) 28 15 (53.6) 83 31 (37.3) 186 68 (36.6) 0.074 
P  0.066  0.006  0.008  <0.001  
Table 
11.3d 
         
ECOG-
PS 
mGPS=0  mGPS=1  mGPS=2  All  P 
n=186 n 2MWT failure 
n (%)˨ 
n 2MWT failure 
n (%)˨ 
n 2MWT failure 
n (%)˨ 
n 2MWT failure 
n (%)˨ ˨ 
 
0-1 45  12 (26.7) 13 3 (23.1) 33 11 (33.3) 91 26 (28.6) 0.727 
2 28  10 (35.7) 10 7 (70.0) 38 14 (36.8) 76 31 (40.8) 0.130 
3 2  2 (100.0) 5 5 (100.0) 12 9 (75.0) 19 16 (84.2) 0.354 
All 75 24 (32.0) 28 15 (53.6) 83 34 (41.0) 186 73 (39.2) 0.125 
P  0.081  0.006  0.033  <0.001  
Table 
11.3e 
         
ECOG-
PS 
mGPS=0  mGPS=1  mGPS=2  All  P 
n=103 n HGS test 
failure n (%)˩ 
n HGS test 
failure n (%)˩ 
n HGS test 
failure n (%)˩ 
n HGS test 
failure n (%)˩ 
 
0-1 38 9 (23.7) 10 3 (30.0) 23 11 (47.8) 71 23 (32.4) 0.146 
2 11  2 (18.2) 5 4 (80.0) 13 8 (61.5) 29 14 (48.3) 0.031 
3 0 0 (100.0) 0 0 (0) 3 2 (66.7) 3 2 (66.7) NA 
All 49 11 (22.4) 15 7 (46.7) 39 21 (53.8) 103 39 (37.9) 0.008 
P  0.700  0.067  0.656  0.192  
          
Table 
11.3f 
         
ECOG-
PS 
mGPS=0  mGPS=1  mGPS=2  All  P 
n-289 n COPT failure 
n (%) 
n COPT failure 
n (%) 
N COPT failure 
n (%) 
n COPT failure 
n (%) 
 
0-1 83 20 (24.1) 23 6 (26.1) 56 19 (33.9) 162 45 (27.8) 0.438 
2 39 11 (28.2) 15 11 (73.3) 51 22 (43.1) 105 44 (41.9) 0.010 
3 2 2 (100.0) 5 5 (100.0) 15 11 (73.3) 22 18 (81.8) 0.320 
All 124 33 (26.6) 43 22 (51.2) 122 52 (42.6) 289 107 (37.0) 0.004 
P  0.054  0.001  0.023  <0.001  
˥: 46 patients missing ˦: 51 patients missing ˧: 4 patients missing ˨: 103 patients missing ˩: 186 Patients missing
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Table 11.4: The relationship between ECOG-PS, mGPS, SMI, SMD and physical function and overall survival in patients with advanced cancer (n=289) 
 Table 11 4a       
Characteristics  Univariate p-value  Multivariate p-value Multivariate Adjusted 
 for Age, Sex and Cancer Location 
p-value 
ECOG-PS 2.17 (1.72-2.73) <0.001 1.90 (1.51-2.39) <0.001 2.03 (1.60-2.57) <0.001 
mGPS 1.79 (1.52-2.10) <0.001 1.71 (1.45-2.02) <0.001 1.65 (1.39-1.95) <0.001 
Low SMI (Martin)   1.38 (1.03-1.84) 0.032 1.39 (1.04-1.86) 0.027 1.36 (1.02-1.83) 0.037 
Table 11.4b       
Characteristics  Univariate p-value  Multivariate p-value Multivariate Adjusted 
 for Age, Sex and Cancer Location 
p-value 
ECOG-PS 2.17 (1.72-2.73) <0.001 1.91 (1.52-2.39) <0.001 2.04 (1.62-2.58) <0.001 
mGPS 1.79 (1.52-2.10) <0.001 1.70 (1.44-2.00) <0.001 1.63 (1.38-1.93) <0.001 
Low SMD (Martin)   1.54 (1.13-2.07) 0.005 ─ 0.363 ─ 0.185 
Table 11.4c       
Characteristics  Univariate p-value  Multivariate p-value Multivariate Adjusted 
 for Age, Sex and Cancer Location 
p-value 
ECOG-PS 2.17 (1.72-2.73) <0.001 2.18 (1.61-2.94) <0.001 2.18 (1.61-2.94) <0.001 
mGPS 1.79 (1.52-2.10) <0.001 1.89 (1.51-2.37) <0.001 1.89 (1.51-2.37) <0.001 
TUG Test Failure˨ 2.31 (1.57-3.40) <0.001 1.82 (1.22-2.72) 0.003 1.82 (1.22-2.72) 0.003 
Table 11.4d       
Characteristics  Univariate p-value  Multivariate p-value Multivariate Adjusted 
 for Age, Sex and Cancer Location 
p-value 
ECOG-PS 2.17 (1.72-2.73) <0.001 2.22 (1.65-2.98) <0.001 2.22 (1.65-2.98) <0.001 
mGPS 1.79 (1.52-2.10) <0.001 1.89 (1.51-2.37) <0.001 1.89 (1.51-2.37) <0.001 
2MWT Failure˨ 2.28 (1.54-3.36) <0.001 1.83 (1.24-2.73) 0.003 1.83 (1.24-2.73) 0.003 
Table 11.4e       
Characteristics  Univariate p-value  Multivariate p-value Multivariate Adjusted 
 for Age, Sex and Cancer Location 
p-value 
ECOG-PS 2.17 (1.72-2.73) <0.001 ─ 0.304 ─ 0.146 
mGPS 1.79 (1.52-2.10) <0.001 1.55 (1.20-2.01) 0.001 1.53 (1.18-1.98) 0.001 
HGS Test Failure˩ 1.89 (1.20-2.98) 0.006 1.63 (1.03-2.59) 0.039 1.68 (1.06-2.68) 0.029 
Table 11.4f Univariate p-value  Multivariate p-value Multivariate Adjusted 
 for Age, Sex and Cancer Location 
p-value 
ECOG-PS 2.17 (1.72-2.73) <0.001 1.83 (1.45-2.30) <0.001 1.93 (1.52-2.45) <0.001 
mGPS 1.79 (1.52-2.10) <0.001 1.65 (1.39-1.95) <0.001 1.59 (1.34-1.88) <0.001 
COPT Failure 2.06 (1.54-2.76) <0.001 1.63 (1.21-2.19) 0.001 1.68 (1.25-2.27) 0.001 
˥: 46 patients missing ˦: 51 patients missing ˧: 4 patients missing ˨: 103 patients missing ˩: 186 Patients missing
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 Figures and  Legends 
  
 
 
Number at risk 0  6   12   18   24   30   36   42  
ECOG 0/1 162 112 60 41 17 8 3 0 
ECOG 2 105  45 19 13 7 4 1 0 
ECOG 3/4 22 1 0 0 0 0 0 0 
Figure 11.1: The relationship between the ECOG-PS and OS in patients with advanced 
cancer. (Median Survival in months: ECOG-PS 0/1: 11.37, ECOG-PS 2: 5.58 ECOG-PS 
3: 2.13).  Number at risk depicts the number of patients alive or not censored entering each 
time period. 
 
Number at risk 0  6   12   18   24   30   36   42  
mGPS 0 124  92 51 39 15 8 2 0 
mGPS 1 43  24 12 8 5 2 1 0 
mGPS 2 122 43 15 9 6 2 1 0 
Figure 11.2: The relationship between the mGPS and OS in patients with advanced  
cancer. (Median Survival in months: mGPS 0: 18.86, mGPS 1: 10.03, mGPS 2: 4.94).  
Number at risk depicts the number of patients alive or not censored entering each time 
period. 
 
ECOG 0/1 
ECOG 2 
ECOG 3 
mGPS 0 
mGPS 1 
mGPS 2 
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12. THE RELATIONSHIP BETWEEN LONGITUDINAL CHANGES IN CT 
DERIVED BODY COMPOSITION AND OUTCOMES IN PATIENTS 
PREVIOUSLY TREATED WITH SURGERY FOR COLORECTAL CANCER 
 Introduction 
As mentioned in Chapter 9 patients with colorectal cancer in a similar pattern to other solid 
organ tumours disease progression is associated with a progressive nutritional and functional 
decline resulting in poor response to treatment and poor survival (41, 346).   
The relationship between weight loss and poor outcomes in patients with cancer has long 
been established. More recently, it has become clear that, through CT derived body 
composition analysis, this is in the main due to the loss of skeletal muscle mass (41, 346). 
This may be due poor treatment tolerance and efficacy (48, 351), worse quality of life and 
increased morbidity (352).  The basis of the relationship between a disproportionate loss of 
skeletal muscle mass and poor outcomes in patients with cancer is not clear.  There is 
evidence that there is a direct association between the magnitude of the systemic 
inflammatory response, as evidenced by systemic inflammation based scores such as the 
mGPS and NLR, and low SMI and low SMD in patients with colorectal cancer (44, 52, 356, 
360). However, whether this relationship is causal or merely associative is not known since 
few longitudinal and interventional studies have been published date. 
McMillan and coworkers reported that, in a longitudinal study of 18 male patients with 
advanced cancer, those patients with an elevated CRP concentration lost body cell mass 
(using a total body potassium counter) at a higher rate (20). Wallengren and colleagues 
reported that, in a longitudinal study of 471 patients with advanced cancer, those patients 
with an elevated CRP concentration had less muscle mass (using dual energy X-ray 
absorptiometry) on study entry and lost muscle mass at an accelerated rate during follow-
up, particularly in males (43). In addition, Malietzis and co-workers reported that, in 856 
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patients with operable colorectal cancer, those patients with an NLR>3 had lower muscle 
mass (using CT) on study entry and regained muscle mass at a lower rate following surgery 
(44).  These longitudinal studies suggest that systemic inflammation is a risk factor for 
muscle loss and that this may vary according to sex.  Moreover, given the differential 
relationship between muscle mass and physical function further longitudinal studies are 
required to examine these relationships. 
Therefore, the aim of this Chapter was to delineate the relationship between longitudinal 
changes in CT derived body composition, clinicopathological characteristics and the 
systemic inflammatory response in patients with colorectal cancer.  
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 Patients and Methods:  
Patients: 
Consecutive patients who underwent elective, potentially curative resection for colorectal 
cancer between March 2008 and June 2016 at a single centre were identified from a 
prospectively maintained database.  Those patients with a preoperative and follow-up CT 
scan and a recorded height and weight were included in the study.   
Patients were classified according to Body Mass Index (BMI) as underweight (BMI <18.5), 
normal weight (BMI 18.5–24.9), overweight (BMI 25.0–29.9) and obese (BMI >30). All 
tumours were staged according to TNM 5th edition. Preoperative haematological and 
biochemical markers were recorded.   
The cause and date of death were confirmed with the Registrar General (Scotland) until 1st 
June 2018 which served as the censor date.  Informed consent was obtained from patients 
prior to surgery. Those with metastatic colorectal cancer and those who underwent 
emergency surgery or palliative surgery were excluded from the study.  Ethical approval was 
granted by the West of Scotland Research Ethics Committee, Glasgow.   
Methods: 
Pre-operative and initial follow-up CT images were obtained at the level of the third lumbar 
vertebra as previously described (356) as part of their routine clinical follow up. The median 
time from pre-operative scan to follow up scan was 12 months (6-18 months). Scans with 
significant movement artefact or missing region of interest were excluded from study. Each 
image was analysed using a free-ware program (NIH Image J version 1.47, 
http://rsbweb.nih.gov/ij/) as described in Chapter 2. Thresholds were calculated as described 
in Chapter 2. 
High High SMI (Dolan Male/Female) was defined as patients with a high SMI in both the 
pre-op and follow up CT scans. High Low SMI (Dolan Male/Female) was defined as patients 
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with a high SMI in the pre-op and a low SMI in the follow up CT scans. Low High SMI 
(Dolan Male/Female) was defined as patients with a low SMI in the pre-op and a high SMI 
in the follow up CT scans. Low Low SMI (Dolan Male/Female) was defined as patients with 
a low SMI in both the pre-op and follow up CT scans. 
High High SMD (Dolan Male/Female) was defined as patients with a high SMD in both the 
pre-op and follow up CT scans. High Low SMD (Dolan Male/Female) was defined as 
patients with a high SMD in the pre-op and a low SMD in the follow up CT scans. Low High 
SMD (Dolan Male/Female) was defined as patients with a low SMD in the pre-op and a high 
SMD in the follow up CT scans. Low Low SMD (Dolan Male/Female) was defined as 
patients with a low SMI in both the pre-op and follow up CT scans. 
Measurements were performed by two individuals and inter-rater reliability was assessed in 
a sample of 30 patient images using inter-class correlation coefficients (ICCC) (TFA ICCC 
= 1.000, SFA ICCC = 1.000, VFA ICCC = 1.000, SMA ICCC = 0.998, SMD ICCC = 0.972). 
Investigators were blind to patient’s demographic and clinico-pathological status. 
An autoanalyzer was used to measure serum CRP (mg/L) and albumin (g/L) concentrations 
(Architect; Abbot Diagnostics, Maidenhead, UK).  The mGPS and NLR were derived as 
previously described (99). BMI measurements and bloods were not routinely carried out on 
follow up.    
Statistical Analysis: 
Body composition measurements were presented as median and ranges and compared using 
paired Wilcoxon tests.  Categorical variables were analysed using paired McNemar tests.  
Binary logistic regression was used to compare significant variables. 
Mortality within 30 days of the index procedure or during the index admission were excluded 
from subsequent survival analysis.  The time between the date of surgery and the date of 
death of any cause was used to define overall survival (OS).  Survival data were analysed 
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using univariate and multivariate Cox regression.  Those variables associated to a degree of 
p<0.1 were entered into a backward conditional multivariate model.   
Missing data were excluded from analysis on a variable by variable basis.  Two tailed p 
values <0.05 were considered statistically significant.  Statistical analysis was performed 
using SPSS software (Version 21.0. SPSS Inc., Chicago, IL, USA). 
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 Results 
In total, 704 patients were identified as having undergone potentially curative surgery for 
colorectal cancer with initial scans being available. Of these, 229 were excluded due to 
missing follow-up CT scans, clinicopathological data or blood test results. A further five 
patients were excluded as they died in the immediate postoperative period. A total of 470 
patients (258 males, 212 females) were included in final analyses.  
The majority of patients were over 65 years of age (62%), overweight or obese (67%), with 
some comorbidities (77%) and node negative disease (67%). The majority of tumours were 
located in the right colon (38%) and rectum (36%) and an open surgical approach was 
applied in 61% of cases.   A total of 373 patients were alive at the censor date and a median 
survival was 55 months (range 1-122 months). Deaths by any cause occurred in 97 patients 
(21%); 62 (13%) of which were cancer specific.  
Temporal changes in body composition are shown in Figures 12.1 and 12.2. The majority of 
patients did not change the SMI (81%) or SMD (72%) status on follow-up.  In male patients 
at the time of surgery 50.8% of patients had a high SMI (no sarcopenia) and 49.2% of 
patients had a low SMI (sarcopenia). On post-operative follow up scanning at a median of 
12 months 90.1% of those patients with an initial high SMI remained high. On post-operative 
follow up scanning at a median of 12 months 73.2% of those patients with an initial low SMI 
remained low. 
In female patients at the time of surgery 55.7% of patients had a high SMI (no sarcopenia) 
and 44.3% of patients had a low SMI (sarcopenia). On post-operative follow up scanning at 
a median of 12 months 90.7% of those patients with an initial high SMI remained high.  On 
post-operative follow up scanning at a median of 12 months 64.9% of those patients with an 
initial low SMI remained low (Figure 12.1). 
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In male patients at the time of surgery 47.7% of patients had a high SMD (no myosteatosis) 
while 52.3% of patients had a low SMI (myosteatosis). On post-operative follow up scanning 
at a median of 12 months 66.7% of those patients with an initial high SMD remained high. 
On post-operative follow up scanning at a median of 12 months 73.3% of those patients with 
an initial low SMD remained low (Figure 12.2). 
In female patients at the time of surgery 52.0% of patients had a high SMD (no myosteatosis) 
while 48.0% of patients had a low SMI (myosteatosis). On post-operative follow up scanning 
at a median of 12 months 62.7% of those patients with an initial high SMD remained high. 
On post-operative follow up scanning at a median of 12 months 86.3% of those patients with 
an initial low SMD remained low. 
The relationship between High High vs Low Low SMI (Dolan) and clinicopathological 
characteristics and survival in male patients is shown in Table 12.1. Compared with the High 
High SMI group, the Low Low SMI group were older (p<0.001), received less adjuvant 
chemotherapy (p<0.05), had a higher mGPS and NLR (both p<0.05) and had lower BMI≥25, 
pre-op SFI, follow up SFI, pre-op visceral obesity and follow up visceral obesity (all 
p<0.01). The Low Low SMI group also had a lower 3-year overall survival rate (p<0.01) 
The relationship between High High vs Low Low SMI (Dolan) and clinicopathological 
characteristics and survival in female patients is shown in Table 12.2. Compared with the 
High High SMI group, the Low Low SMI group were older (p<0.01), had more open surgery 
(p<0.05), had a higher mGPS (p<0.05) and had lower BMI≥25, follow up SFI, pre-op 
visceral obesity and follow up visceral obesity (all p<0.01). The Low Low SMI group also 
had a lower 3-year overall survival rate (p<0.01) 
The relationship between High High vs Low Low SMD (Dolan) and clinicopathological 
characteristics and survival in male patients is shown in Table 12.3. Compared with the High 
High SMD group, the Low Low SMD group were older (p<0.001), and had higher BMI≥25, 
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pre-op SFI, follow up SFI, pre-op visceral obesity and follow up visceral obesity (all 
p<0.01).  
The relationship between High High vs Low Low SMD (Dolan) and clinicopathological 
characteristics and survival in female patients is shown in Table 12.4. Compared with the 
High High SMD group, the Low Low SMD group were older (p<0.01), had a higher ASA 
(p<0.001), had a higher mGPS (p<0.10) and had higher BMI≥25, pre-op SFI, follow up SFI, 
pre-op visceral obesity and follow up visceral obesity (all p<0.001). The Low Low SMI 
group also had a lower 3-year overall survival rate (p<0.05) 
The relationship between longitudinal measurements in SMI (Dolan) and SMD (Dolan) in 
males and females combined are shown in Table 12.5.  On Cox-regression analysis, 
compared with the High High SMI group, the Low Low SMI group had poorer overall 
survival (HR 2.09, 95%CI 1.33-3.30, p≤0.001). Only 5% and 14% of patients were in the 
High Low SMI and the Low High SMI groups respectively. When this analysis was adjusted 
for pre-operative age, sex, TNM stage and mGPS (Table 12.5), age (HR 1.59, 95%CI 1.21-
2.09, p≤0.001), TNM (HR 1.70, 95%CI 1.27-2.29, p<0.001) and mGPS (HR 1.40, 95%CI 
1.10-1.79, p<0.01) remained independently associated with survival.  
 On Cox-regression analysis, compared with the High High SMD group, the Low Low SMD 
group had poorer overall survival (HR 1.91, 95%CI 1.16-3.14, p<0.05). Only 17% and 11% 
of patients were in the High Low SMD and the Low High SMD groups respectively.  When 
this analysis was adjusted for pre-operative age, sex, TNM stage and mGPS (Table 12.5), 
age (HR 1.59, 95%CI 1.21-2.09, p≤0.001), TNM (HR 1.70, 95%CI 1.27-2.29, p<0.001) and 
mGPS (HR 1.40, 95%CI 1.10-1.79, p<0.01) remained independently associated with 
survival. 
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 Discussion 
The results of the present longitudinal study show clearly that the majority of male and 
female patients did not change their SMI status (overall ~90% High High and ~65% Low 
Low) over the period of approximately 12 months following surgery for colorectal cancer.  
Furthermore, compared with High High SMI status, the Low Low SMI status was associated 
with greater prevalence of a pre-operative systemic inflammatory response (mGPS 17% and 
26% respectively) and poorer overall survival, but not TNM stage. Taken together the results 
of the present longitudinal study would indicate that low muscle mass is established early in 
the disease process, resistant to removal of the primary tumour and is associated with the 
presence of a systemic inflammatory response. 
The present observations are consistent with the few longitudinal studies in primary operable 
colorectal cancer.  Mallietz and coworkers (2016) using linear regression modelling 
compared longitudinal measurements at different time points in >800 patients and although 
it is not possible to derive the percentage of patients who had stable SMI it is clear that this 
was the majority of patients (44).  Furthermore, Brown and coworkers (2018) reported in a 
longitudinal study of 1924 patients that, over a period of approximately 14 months, the 
majority of patients had stable SMI and SMD (both ~60%) (393).  
There is now good evidence that both muscle mass and muscle quality predict overall 
survival in colorectal cancer and other common solid tumours.  In the present longitudinal 
study, there was a consistent association between skeletal muscle index and the systemic 
inflammatory response.  If these were causally linked, then it might be expected that changes 
in SMI status would be associated with changes in systemic inflammatory status.  However, 
it is clear that few patients changed their SMI status.  Moreover, in the present study 
longitudinal measurements of the systemic inflammatory response were not taken as part of 
patient follow-up.  It was of interest that more patients (almost three times as many) changed 
from Low SMI to High SMI than from High SMI to Low SMI.  This former group is of 
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particular interest since there appears to have been an improvement in their nutritional status 
and this subgroup warrants further investigation. 
These observations have a number of implications.  Firstly, they would suggest that, since 
SMI is relatively stable over at least 12 months, the die is cast at an early stage and it is likely 
that most of the prognostic value of SMI can be derived from the initial measurements in 
primary operable colorectal cancer.  Secondly, the consistent association in both cross 
sectional and now in a longitudinal study between a low SMI and the presence of a systemic 
inflammatory response may suggest that these are causally linked. Indeed, when adjusted for 
age, sex, TNM and mGPS changes in both SMI and SMD lost their significance.  Although 
there is abundant evidence that the systemic inflammatory response is associated with 
profound catabolism of skeletal muscle and may also block anabolism, few studies have 
attempted to target directly the systemic inflammatory response and monitor skeletal muscle 
mass in patients with either primary operable cancer or in advanced inoperable cancer. 
Furthermore, there is evidence that prehabilitation can improve outcomes in patients with 
cancer. Indeed, in a recent study combining three prehabilitation trials Trépanier and co-
workers showed that prehabilitation was associated with improved 5-year disease free 
survival in patients with stage III colorectal cancer (394). However, the effect of such 
prehabilitation on the modulation of the inflammatory response is not clear. It may be that 
such prehabilitation programs are better targeted at patients with less of a systemic 
inflammatory response.  
Future prospective longitudinal studies would be required to investigate this. However, the 
management of patient expectations will continue to be essential as the early onset of skeletal 
muscle loss found in the Chapter is unlikely to be reversed. As such it may be that the future 
aim of any prehabilitation regime is that it be multimodal targeting multiple aspects of the 
disease. 
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Limitations of the present study include its retrospective nature and that only patients with 
an electronically available CT scan were included in the analysis. However, the study 
population was relatively large, well-documented in terms of clinicopathological 
characteristics and measures of the systemic inflammatory response and relatively mature 
follow-up. 
In summary, the present longitudinal study provides new evidence that low skeletal muscle 
mass is established early in the disease course, maintained following resection of the primary 
tumour and associated with the presence of a systemic inflammatory response in patients 
with colorectal cancer.  Intervention studies are required to establish whether the relationship 
between low skeletal muscle mass and the systemic inflammatory response is causal in 
nature.  
 301 
 Tables and Footnotes 
Table 12.1: Relationship between changes in SMI and clinicopathological characteristics in male patients 
undergoing surgery for colorectal cancer (n= 211). 
 Characteristic High High 
SMI 
n=118 (%) 
Low Low 
SMI n=93 
(%) 
p-value  
 Clinico-pathological    
Age ≤65 59 (50.0) 23 (24.7) <0.001 
 65 - 74 49 (41.5) 37 (39.8)  
 >74 10 (8.5) 33 (35.5)  
ASA score 1 28 (23.7) 21 (22.6) 0.584 
 2 58 (49.2) 40 (43.0)  
 3 29 (24.6) 27 (29.0)  
 4 3 (2.5) 5 (5.4)  
Laparoscopic Surgery  No 70 (59.3) 56 (60.2) 0.896 
 Yes 48 (40.7) 37 (39.8)  
TNM 0 2 (1.7) 2 (2.2) 0.279 
 I 37 (31.4) 22 (23.7)  
 II 36 (30.5) 40 (43.0)  
 III 43 (36.4) 29 (31.2)  
Venous Invasion No 53 (44.9) 34 (36.6) 0.221 
 Yes 65 (55.1) 59 (63.4)  
Tumour Location Right and Transverse 44 (37.3) 28 (30.1) 0.406 
 Left  24 (20.3) 25 (26.9)  
 Rectum 47 (39.8) 35 (37.6)  
 Total and Subtotal  3 (2.5) 5 (5.4)  
Adjuvant Chemotherapy  No 65 (55.1) 63 (67.7) 0.026 
 Yes 53 (44.9) 30 (32.3)  
 Systemic inflammation    
mGPS 0 98 (83.1) 69 (74.2) 0.028 
 1 14 (11.9) 9 (9.7)  
 2 6 (5.1) 15 (16.1)  
NLR <3 70 (59.3) 44 (47.3) 0.016 
 3-5 37 (31.4) 27 (29.0)  
 >5 11 (9.3) 22 (23.7)  
 Body composition    
BMI (kg/m2) <25 12 (10.2) 57 (61.3) <0.001 
 ≥25 106 (89.8) 36 (38.7)  
Pre-op High SFI No 18 (15.3) 37 (39.8) <0.001 
 Yes 100 (84.7) 56 (60.2)  
Follow up High SFI No 17 (14.4) 30 (32.3) 0.002 
 Yes 101 (85.6) 63 (67.7)  
Pre-op Visceral Obesity No 20 (16.9) 40 (43.0) <0.001 
 Yes 98 (83.1) 53 (57.0)  
Follow up Visceral Obesity No 16 (13.6) 38 (40.9) <0.001 
 Yes 102 (86.4) 55 (59.1)  
Low SMD (Myosteatosis)     
 Pre-op SMD (Dolan Male/Female)  No 65 (55.1) 44 (47.3) 0.262 
 Yes 53 (44.9) 49 (52.7)  
 Follow up SMD (Dolan Male/Female)  No 58 (49.2) 38 (40.9) 0.230 
 Yes 60 (50.8) 55 (59.1)  
     
Overall 3-year survival rate (%)  101 (85.6) 66 (71.0) 0.009 
 302 
Table 12.2: Relationship between changes in SMI and clinicopathological characteristics in female patients 
undergoing surgery for colorectal cancer (n= 168) 
Characteristic High High SMI 
n= 107 (%) 
Low Low 
SMI n= 61 
(%) 
p-value  
 Clinico-pathological    
Age ≤65 47 (43.9) 14 (23.0) 0.018 
 65 - 74 35 (32.7) 31 (50.8)  
 >74 25 (23.4) 16 (26.2)  
ASA score 1 16 (15.0) 16 (26.2) 0.179 
 2 57 (53.3) 29 (47.5)  
 3 33 (30.8) 14 (23.0)  
 4 1 (0.9) 2 (3.3)  
Laparoscopic Surgery  No 58 (54.2) 45 (73.8) 0.012 
 Yes 49 (45.8) 16 (26.2)  
TNM 0 2 (1.9) 0 (0) 0.173 
 I 27 (25.2) 9 (14.8)  
 II 49 (45.8) 28 (45.9)  
 III 29 (27.1) 24 (39.3)  
Venous Invasion No 43 (40.2) 23 (37.7) 0.751 
 Yes 64 (59.8) 38 (62.3)  
Tumour Location Right and Transverse 46 (43.0) 29 (47.5) 0.090 
 Left  31 (29.0) 10 (16.4)  
 Rectum 30 (28.0) 20 (32.8)  
 Total and Subtotal  0 (0) 2 (3.3)  
Adjuvant Chemotherapy  No 58 (54.2) 38 (71.7) 0.147 
 Yes 49 (45.8) 23 (28.3)  
 Systemic inflammation    
mGPS 0 89 (83.2) 46 (75.4) 0.034 
 1 9 (8.4) 3 (3.3)  
 2 9 (8.4) 13 (21.3)  
NLR <3 60 (56.1) 37 (60.7) 0.845 
 3-5 35 (32.7) 18 (29.5)  
 >5 12 (11.2) 6 (9.8)  
 Body composition    
BMI (kg/m2) <25 15 (14.0) 35 (57.4) <0.001 
 ≥25 92 (86.0) 26 (42.6)  
Pre-op High SFI No 6 (5.6) 7 (11.5) 0.171 
 Yes 101 (94.4) 54 (88.5)  
Follow up High SFI No 3 (2.8) 10 (16.4) 0.002 
 Yes 104 (97.2) 51 (83.6)  
Pre-op Visceral Obesity No 16 (15.0) 23 (37.7) 0.001 
 Yes 91 (85.0) 38 (62.3)  
Follow up Visceral Obesity No 17 (15.9) 20 (32.8) 0.011 
 Yes 90 (84.1) 41 (67.2)  
Low SMD (Myosteatosis)     
 Pre-op SMD (Dolan Male/Female)  No 56 (52.3) 33 (54.1) 0.826 
 Yes 51 (47.7) 28 (45.9)  
 Follow up SMD (Dolan Male/Female)  No 42 (39.3) 24 (39.3) 0.991 
 Yes 65 (60.7) 37 (60.7)  
     
Overall 3-year survival rate (%)  93 (86.9) 42 (68.9) 0.005 
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Table 12.3: Relationship between changes in SMD and clinicopathological characteristics in male patients 
undergoing surgery for colorectal cancer (n= 181) 
Characteristic High High 
SMD 
n= 82 (%) 
Low Low 
SMD n=99 
(%) 
p-value  
 Clinico-pathological    
Age ≤65 50 (61.0) 19 (19.2) <0.001 
 65 – 74 24 (29.3) 45 (45.5)  
 >74 8 (9.8) 35 (35.4)  
ASA score 1 26 (31.7) 18 (18.2) 0.059 
 2 28 (34.1) 51 (51.5)  
 3 23 (28.0) 27 (27.3)  
 4 5 (6.1) 3 (3.0)  
Laparoscopic Surgery  No 54 (65.9) 57 (57.6) 0.255 
 Yes 28 (34.1) 42 (42.4)  
TNM 0 2 (2.4) 2 (2.0) 0.486 
 I 23 (28.0) 26 (26.3)  
 II 26 (31.7) 42 (42.4)  
 III 31 (37.8) 29 (29.3)  
Venous Invasion No 35 (42.7) 37 (37.4) 0.468 
 Yes 47 (57.3) 62 (62.6)  
Tumour Location Right and Transverse 25 (30.5) 40 (40.4) 0.267 
 Left  18 (22.0) 24 (24.2)  
 Rectum 37 (45.1) 31 (31.3)  
 Total and Subtotal  2 (2.4) 4 (4.0)  
Adjuvant Chemotherapy  No 46 (56.1) 65 (65.7) 
 
0.084 
 Yes 36 (43.9) 34 (34.3)  
 Systemic inflammation    
mGPS 0 67 (81.7) 75 (75.8) 0.208 
 1 10 (12.2) 10 (10.1)  
 2 5 (6.1) 14 (14.1)  
NLR <3 46 (56.1) 55 (55.6) 0.666 
 3-5 24 (29.3) 25 (25.3)  
 >5 12 (14.6) 19 (19.2)  
 Body composition    
BMI (kg/m2) <25 37 (45.1) 21 (21.2) 0.001 
 ≥25 45 (54.9) 78 (78.8)  
Pre-op High SFI No 35 (42.7) 12 (12.1) <0.001 
 Yes 47 (57.3) 87 (87.9)  
Follow up High SFI No 28 (34.1) 10 (10.1) <0.001 
 Yes 54 (65.9) 89 (89.9)  
Pre-op Visceral Obesity No 38 (46.3) 13 (13.1) <0.001 
 Yes 44 (53.7) 86 (86.9)  
Follow up Visceral Obesity No 36 (43.9) 11 (11.1) <0.001 
 Yes 46 (56.1) 88 (88.9)  
Low SMI (Sarcopenia)     
 Pre-op SMI (Dolan Male/Female)  No 48 (58.5) 43 (43.43) 0.043 
 Yes 34 (41.4) 56 (56.57)  
 Follow up SMI (Dolan Male/Female)  No 46 (56.1) 52 (52.52) 0.631 
 Yes 36 (43.9) 47 (47.48)  
     
Overall 3-year survival rate (%)  65 (79.3) 78 (78.8) 0.937 
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Table 12.4: Relationship between changes in SMD and clinicopathological characteristics in female patients 
undergoing surgery for colorectal cancer (n= 157) 
Characteristic High High 
SMD 
n= 69 (%) 
Low Low 
SMD n=88 
(%) 
p-value  
 Clinico-pathological    
Age ≤65 31 (44.9) 23 (26.1) 0.002 
 65 – 74 31 (44.9) 42 (42.0)  
 >74 7 (10.1) 28 (31.8)  
ASA score 1 28 (40.6) 6 (6.8) <0.001 
 2 30 (43.5) 49 (55.7)  
 3 11 (15.9) 29 (33.0)  
 4 0 (0) 4 (4.5)  
Laparoscopic Surgery  No 42 (60.9) 59 (67.0) 0.423 
 Yes 27 (39.1) 29 (33.0)  
TNM 0 1 (1.4) 1 (1.1) 0.953 
 I 14 (20.3) 15 (17.0)  
 II 33 (47.8) 45 (51.1)  
 III 21 (30.4) 27 (30.7)  
Venous Invasion No 26 (37.7) 33 (37.5) 0.981 
 Yes 43 (62.3) 55 (62.5)  
Tumour Location Right and Transverse 19 (27.5) 44 (50.0) 0.034 
 Left  20 (29.0) 18 (20.5)  
 Rectum 29 (42.0) 24 (27.3)  
 Total and Subtotal  1 (1.4) 2 (2.3)  
Adjuvant Chemotherapy  No 36 (52.2) 53 (60.2) 0.124 
 Yes 33 (47.8) 35 (39.8)  
 Systemic inflammation    
mGPS 0 56 (81.2) 66 (75.0) 0.054 
 1 8 (11.6) 5 (5.7)  
 2 5 (7.2) 17 (19.3)  
NLR <3 44 (63.8) 45 (51.1) 0.280 
 3-5 18 (26.1) 30 (34.1)  
 >5 7 (10.1) 13 (14.8)  
 Body composition    
BMI (kg/m2) <25 38 (55.1) 20 (22.7) <0.001 
 ≥25 31 (44.9) 68 (77.3)  
Pre-op High SFI No 13 (18.8) 2 (2.3) <0.001 
 Yes 56 (81.2) 86 (97.7)  
Follow up High SFI No 14 (20.3) 0 (0) <0.001 
 Yes 55 (79.7) 88 (100.0)  
Pre-op Visceral Obesity No 36 (52.2) 4 (4.5) <0.001 
 Yes 33 (47.8) 84 (95.5)  
Follow up Visceral Obesity No 36 (52.2) 3 (3.4) <0.001 
 Yes 33 (47.8) 85 (93.6)  
Low SMI (Sarcopenia)     
 Pre-op SMI (Dolan Male/Female)  No 35 (50.7) 49 (55.7) 0.537 
 Yes 34 (49.3) 39 (44.3)  
 Follow up SMI (Dolan Male/Female)  No 45 (65.2) 55 (62.5) 0.725 
 Yes 24 (34.8) 33 (37.5)  
     
Overall 3-year survival rate (%)  61 (88.4) 65 (73.9) 0.023 
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Table 12.5: The relationship between changes in SMI and SMD and overall survival in patients undergoing surgery for colorectal cancer & the relationship between changes in SMI and 
SMD and overall survival adjusted for age, sex, TNM and mGPS in patients undergoing surgery for colorectal cancer 
Characteristic  Follow-Up  
n= 470 (%) Overall Survival HR p-value  
All patients (n=470)      
Sarcopenia     
Low SMI (Dolan Male/Female) High High SMI (Dolan Male/Female)  225 (47.9)  Ref  
 High Low SMI (Dolan Male/Female) 24 (5.1) 1.93 (0.75-4.98) 0.172 
 Low High SMI (Dolan Male/Female) 67 (14.3)  1.62 (0.87-3.00) 0.126 
 Low Low SMI (Dolan Male/Female) 154 (32.8) 2.09 (1.33-3.30) 0.001 
Myosteatosis     
Low SMD (Dolan Male/Female) High High SMD (Dolan Male/Female) 151 (32.1)  Ref  
 High Low SMD (Dolan Male/Female) 82 (17.4) 1.40 (0.76-2.60) 0.283 
 Low High SMD (Dolan Male/Female) 50 (10.6)  1.41` (0.70-2.88) 0.338 
 Low Low SMD (Dolan Male/Female) 187 (39.8) 1.91 (1.16-3.14) 0.011 
     
Characteristic  Follow-Up  
n= 470 (%) Overall Survival HR adjusted for age, 
sex, TNM and mGPS 
p-value  
All patients (n=470)      
Sarcopenia     
Low SMI (Dolan Male/Female) High High SMI (Dolan Male/Female) 225 (47.9)  Ref  
 High Low SMI (Dolan Male/Female) 24 (5.1) 2.18 (0.84-5.62) 0.108 
 Low High SMI (Dolan Male/Female) 67 (14.3)  1.15 (0.61-2.18) 0.673 
 Low Low SMI (Dolan Male/Female) 154 (32.8) 1.57 (0.98-2.52) 0.062 
     
Myosteatosis     
Low SMD (Dolan Male/Female) High High SMD (Dolan Male/Female) 151 (32.1)  Ref  
 High Low SMD (Dolan Male/Female) 82 (17.4) 1.32 (0.71-2-46) 0.381 
 Low High SMD (Dolan Male/Female) 50 (10.6)  1.01 (0.49-2.09) 0.977 
 Low Low SMD (Dolan Male/Female) 187 (39.8) 1.36 (0.79-2.33) 0.262 
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 Figures and Legends  
 
Figure 12.1: Prisma diagram of changes SMI (Dolan) between initial staging and 12 month follow up CT scans 
in male (n=258) and female (n=212) patients undergoing surgery for colorectal cancer. 
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Figure 12.2: Prisma diagram of changes SMD (Dolan) between initial staging and 12 month follow up CT 
scans in male (n= 258) and female (n=212) patients undergoing surgery for colorectal cancer. 
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13. THE RELATIONSHIP BETWEEN GLUCOSE METABOLISM AND HOST 
SYSTEMIC INFLAMMATORY RESPONSE IN PATIENTS WITH CANCER: A 
SYSTEMATIC REVIEW 
 Introduction  
As mentioned in Chapters 3-5 four cancers- lung, colorectal, breast and prostate account for 
approximately half of all new cases and deaths (114). At a cellular level there are several 
traits of cancer that define its malignancy. These include genome instability, limitless 
replicative potential, self-sufficiency in growth signals, insensitivity to anti-growth signals, 
the ability to evade apoptosis, sustained angiogenesis, tissue invasion and metastasis, 
abnormal metabolic pathways, inflammation and evasion of the immune system (395, 396). 
All these hallmarks create what is known as the tumour microenvironment (TME, (268, 395, 
396)). The TME is composed of heterogeneous cell populations including tumour cells, 
immune cells, fibroblasts, adipocytes, blood vessels and the extracellular matrix. Therefore, 
there are interactions between malignant and non-transformed cells via a host of signalling 
molecules) (397). The tumour and its environment are constantly interacting, and this is an 
integral part of the tumour physiology, structure and function. The relationship between the 
tumour and its environment is essential to promote tumour cell growth and the development 
of metastasis (192).  
An important and long recognised characteristic of tumour cells is the dysregulated cellular 
energetics that results in the increased uptake of glucose (398). Warburg observed that 
tumour cells predominately produced adenosine 5′-triphosphate (ATP) via a high rate of 
glycolysis and consumption of glucose via the conversion of glucose to lactic acid.  He 
recognised that this was inefficient for the tumour cell to produce ATP when compared to 
normal oxidative phosphorylation (398, 399). Moreover, due to this anaerobic glycolysis 
and lactic acid formation the TME would become acidic allowing for the de-differentiation 
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of normal and malignant cells (400).   Warburg hypothesised that this metabolic defect was 
the basis of tumour formation.  In recent years it has been concluded that this metabolic 
defect is the result of genetic damage. Nevertheless, the impact of such dysregulated 
energetics of the tumour cell remains of considerable interest. 
The TME is likely to have a direct impact on the innate immune response and activation of 
the systemic inflammatory response. This can be evidenced by increases in the circulating 
acute phase proteins such as CRP and albumin and innate immune cells such as neutrophils 
and monocytes (7).  These immune cells are also metabolically active requiring large 
amounts of glucose.  
The prognostic value of the CRP, albumin and neutrophil counts in cancer has been well 
established in observational studies (85, 87).   In the last 15 years there has been a movement 
towards the use of combined prognostic scores such as the GPS/mGPS (CRP and albumin) 
and ratios such as the NLR (neutrophils and lymphocytes) to standardise and maximise 
prognostic value (37, 38).  
Therefore, it is of interest that imaging studies of the tumour have become an important 
element in the evaluation of detecting, staging and management of patients with cancer 
(401). Positron Emission Tomography (PET) is an established nuclear imaging technique 
based on the uptake of glucose that can examine the metabolism of tumours. However, PET 
provides relatively poor anatomical information whereas CT is commonly used in the initial 
diagnosis and staging of cancers.  
The recent routine clinical combination of PET and CT gives anatomic information with 
associated assessment of tumour physiological activity (49).  This provides better 
identification of metabolically active lesions improving the diagnostic accuracy and 
localisation of both the primary and metastatic lesions. In the oncological setting the tracer 
18F-2-fluoro-2-deoxy-D-glucose (18FDG) is commonly used due to its longer half-life which 
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aids in transportation and clinical application (76). However, a disadvantage of this tracer is 
that it is not tumour cell specific and can accumulate where there are metabolically active 
cells such as immune cells.  For example, it is recognised to accumulate in bone marrow, 
presumably due to formation of metabolically active immune cells. This additional 
variability that can occur with uptake parameters such as the standardized uptake value 
(SUV, which depends on appropriate calibration and reconstruction methods with inter-site 
variability, and dependence on lesion or organ segmentation) has resulted in normalising 
uptake to other metabolically active tissues. Interestingly, an elevated bone marrow to liver 
ratio has been reported to have prognostic value in a variety of common solid tumours and 
an increased cytokine load due to malignancy (402).  
Based on the above, it is hypothesised that glucose metabolism in both tumour and host 
inflammatory responses are related. This present review is timely given the rapidly 
expanding role of immune therapies (e.g. immune checkpoint inhibition and adoptive T-cell 
therapy) to treat patients with metastatic cancers. Therefore, the aim of this Chapter was to 
carry out a systematic review of the relationship between tumour and host inflammatory 
glucose metabolism using PETCT. A better understanding of these processes would be 
useful to inform therapeutic strategies for patients with cancer. 
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 Patients and Methods 
This systematic review of published literature was undertaken as outlined in Chapter 2. The 
primary outcome of interest of this systematic review was the relationship between tumour 
and host inflammatory glucose metabolism specifically using PETCT imaging in patients 
with cancer.  The secondary outcome of interest of this systematic review was the association 
between tumour and host inflammatory glucose metabolism as measured by PETCT imaging 
and survival in patients with cancer. Studies were identified via a literature search between 
1984 and 2018 using the following keywords:  cancer, malignancy, metastasis, 
inflammation, glucose, positron, CT and PETCT (last search update on 31st March 2018). 
To be eligible for inclusion, studies had to meet the following criteria.  (a) Patients with 
cancer (b) PETCT analysis the imaging modality used (c) Tumour (T), bone marrow (BM) 
and/or node (N) activity measured by either SUVmax, SUVmean, SUVpeak, bone marrow 
to liver ratio (BLR: mean BMSUV to mean Liver SUV ratio), metabolic tumour volume 
(MTV) and/or total lesion glycolysis (TLG: SUVmean × MTV). (d) markers of the systemic 
inflammatory response in the form of acute phase proteins (CRP and albumin) or 
components of the differential blood cell counts (neutrophils, leukocytes, monocytes and 
platelets) and their composite scores such as the mGPS, PLR and NLR. Exclusion criteria 
included (a) studies not carried out in patients with cancer (b) studies not using PETCT as 
the main imaging modality (c) studies not assessing tumour and bone marrow activity and 
(d) studies not including measurement of the systemic inflammatory response.  Due to the 
small number of studies and the heterogeneity of tumour type and tumour/bone marrow 
activity assessment, meta-analysis was not carried out.  
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 Results  
Study Selection Process  
The study selection process is summarised in Figure 13.1. Initial search strategy identified 
207 articles whose titles and abstracts were reviewed. Articles were excluded if they had not 
been carried out in humans (n=64), no full texts were available (n=12), those that were a 
systematic review/meta-analysis (n=32) and those not published in English (n=6). This led 
to a review of the full text of 93 articles. A further 83 articles were excluded as there was no 
direct comparison between the systemic inflammatory response and PET-CT output. The 
remaining 10 articles had their bibliographies reviewed in a systematic manner.  This 
identified a further 2 articles to be included in the final analysis leading to final figure of 12 
articles considered in the present systematic review (402-413).   
Overall Analysis 
The twelve included studies contained a total of 2,468 patients with the number of patients 
included in individual studies varying from 32 to 1,034 (Table 13.1). There was a wide 
variety in cancer anatomical locations including lung (n=4), oral (n=3), colorectal (n=2), 
gastric (n=1), head and neck (n=1) and multiple anatomical locations (n=1). Geographically 
studies were from Korea (n=5), China (n=2), Belgium (n=1), Taiwan (n=1), Canada (n-1), 
Japan (n=1) and the UK (n=1).   
The majority of studies showed a direct relationship between the host systemic inflammatory 
response and the indices of FDG accumulation as measured by BLR (n=5), BMSUVmax 
(n=4), TSUVmax (n=4), BMSUVmean (n=2), NSUVmax (n=2), SUVpeak (n=1), MTV 
(n=1) and TLG (n=1). In addition, the majority of studies showed a direct relationship 
between survival and indices of FDG accumulation BLR (n=3), TSUVmax (n=2), 
BMSUVmean (n=2), BMSUVmax (n=1), NSUVmax (n=1) and TLG (n=1).  
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All studies used the radioisotope 18F-FDG. There was some variation in the type of scanners 
used with the most common scanners being Siemens (n=5) and General Electric (n=4). In 
all studies patients were required to fast for minimum of 4-6 hours prior to the PET-CT study 
protocol being initiated and fasting blood glucose levels were measured prior to the 
administration of 18F-FDG. The majority of studies had a blood glucose threshold level of 
< 150.0 mg/dL for the injection of the radioisotope. There was some variation in the activity 
of 18F-FDG administered, however all studies used weight based protocols with 
administered activities ranging between 230-555 MBq. PET acquisition in the majority of 
studies was from base of skull to proximal thigh, using 6 – 8 bed positions, acquired 60 
minutes post FDG administration. All reconstructions involved CT attenuation correction 
and iterative reconstruction algorithms specific to the camera manufacturer’s software. 
Regions of interest (ROI) were either drawn freehand, using a minimum SUV cut off or by 
using isocontour software. The SUV parameters measured varied slightly although in 
general the maximum and mean SUV values were measured for the primary tumour 
(TSUVmax, TSUVmean), nodal disease (NSUVmax, NSUVmean) and bone marrow 
(BMSUVmax, BMSUVmean). The bone marrow to liver ratio (BLR) was defined using 
SUVmean measurements in the bone marrow, obtained mainly from vertebral bodies, and 
SUVmean from an ROI in the right lobe of liver.  
The majority of studies focused on patients with stage I-III disease who were treated with 
surgical resection with or without adjuvant chemoradiotherapy (n=8). In those studies where 
surgery was not the mainstay of treatment only one study had a majority of metastatic disease 
(79.2%) (406). Two studies were in Ear Nose and Throat (ENT) cancers with the treatment 
of choice being concurrent chemoradiotherapy and definitive radiotherapy (406, 408). One 
study was in patients with advanced Non-Small Cell Lung Cancer (NSCLC) not amenable 
to surgical resection and one study was in multiple cancer types again not amenable to 
surgical resection (402, 410). 
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The majority of studies use singular markers of the systemic inflammatory response 
including the WCC (n=9), CRP (n=7), haemoglobin (n=4), albumin (n=3), neutrophils 
(n=2), platelets (n=2), lymphocytes (n=1) and monocytes (n=1). In addition, composite 
ratios and scores were used in several studies including the NLR (n=7), PLR (n=5) and 
mGPS (n=1). Multiple markers of the systemic inflammatory response were used however 
there was considerable heterogeneity in the specific markers used.  
Therefore, a meta-analysis could not be meaningfully carried out due to the heterogeneity of 
tumour stage, tumour type and markers of the systemic inflammatory response.  
 
Relationship Between Tumour Glucose Metabolism using TSUVmax/mean, 
BMSUVmax/mean and BLR and Host Inflammatory Responses  
As can be seen in Table 13.1 the majority of studies would appear to be significantly 
association between activation of the systemic inflammatory response and increased tumour, 
bone marrow and nodal uptake in PET-CT. In particular, the largest study (n=1034) included 
in this review reported such a relationship (407). 
Jeong and coworkers compared the prognostic values of circulating blood cell-based 
parameters and tumour FDG uptake in patients with stage I NSCLC (407). In total 1034 
patients were included in this study. They were all newly diagnosed with NSCLC and 
underwent PET-CT scanning as part of their preoperative workup prior to undergoing 
surgical resection (407).  Biochemical and haematological measurements in the form of 
WCC, neutrophil, lymphocyte and platelet counts were taken (407). These were then used 
to calculate the composite ratios NLR and PLR. PET-CT scan analysis focused on tumour 
FDG uptake (407).  
The median age of the included patients was 61.6 years and 58.9% were male with 50.6% 
having never smoked (407). The majority of patients had adenocarcinomas (76.7%) and 
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were treated by lobectomy (87.1%) (407).  There were 144 recurrences and the median 
follow up was 29.5 months (407). Patients with a high TSUVmax had significantly higher 
WCC (p<0.001), neutrophil (p<0.001) and lymphocyte counts (p=0.002), and a greater NLR 
(p=0.016) (407). On univariate Cox regression analysis, WCC (p=0.028), TSUVmax 
(p<0.001), age (p<0.001), gender (p=0.003), smoking (p=0.002), cell type (p=0.001), and 
TNM stage (p<0.001) were significantly associated with disease specific survival (407). On 
multivariate analysis, TSUVmax (HR: 2.22 95% CI, 1.52–3.25; p<0.001), tumour stage 
(HR: 2.11 95% CI, 1.47–3.01; p<0.001), and old age (HR:1.03 95% CI, 1.01–1.05; p=0.002)  
remained independently prognostic in terms of disease specific survival (407).  
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 Discussion  
The results of the present systematic review showed that, in the majority of studies, there 
was a direct relationship between the tumour and bone marrow glucose uptake and host 
systemic inflammatory responses in patients with common solid tumours.    
Both tumour and nodal glucose uptake and bone marrow glucose uptake were associated 
with poor outcome in these patients. Although bone marrow FDG accumulation may mainly 
reflect inflammatory responses, tumour and nodal FDG accumulation reflect the malignant 
grade of the tumour cells in addition to the inflammatory responses. Therefore, it may be 
that the nature of their associations with survival will be different.    
Taken together the present review provides new insight into the interaction between tumour 
and host.  This may suggest new approaches to more optimal therapeutic targeting and 
monitoring strategies for patients with cancer. 
The basis of the relationship between tumour glucose uptake and markers of the systemic 
inflammatory response is not clear.  The importance of the tumour microenvironment is 
increasingly appreciated.  In addition to the tumour cells themselves stromal cells and 
inflammatory cells are now recognised to play a role in growth and progression of cancer. 
The predominant cells in the tumour stroma are the cancer-associated fibroblasts that have 
been shown to promote tumour progression and invasion through the production of growth 
factors, cytokines and metabolites and stimulate blood vessel formation (414). Such stromal 
cell activity is intimately linked to inflammatory cell activity and macrophages contribute to 
tumour progression and spread by the promotion of genetic instability, protection and 
nurturing of cancer stem cells, promotion of metastatic spread and the downregulation of the 
protective T-cell driven adaptive immune response (117, 415, 416).  In turn, such 
macrophage activity appears to be dependent on the tumour stage, tissue involvement and 
microbiota (415). The macrophage influence on tumour activity can be pro-inflammatory 
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and tumour growth promoting via the classical M1 pathway commonly upregulated by the 
inflammatory cytokines TNF-α and IL-6 (417). As well as anti-inflammatory and tumour 
growth reducing via the alternative M2 pathway commonly upregulated by the anti-
inflammatory cytokines IL-4 and IL-10 (417).   
The importance of neutrophil activity and infiltrate in cancer progression and metastasis has 
become an increasingly recognised prognostic domain. Neutrophil activity has been shown 
to increase tumour progression by facilitating and encouraging angiogenesis (336). 
Neutrophil activity has also been implicated in potentiating tumour growth through the 
activation of specific inflammatory cytokines particularly IL-1 and IL-6 and via amino acid 
depletion (336) and promotes angiogenesis and the metastatic potential of cancer (336). 
Neutrophils have also been shown to direct cancer cell growth towards endothelial cells 
which can lead to increased haematological spread promoting distant metastasis (336). 
Indeed in the pre-metastatic state in patients with advanced cancer neutrophil clusters or 
localised build-ups in distant organs has been shown to be predictive of eventual metastatic 
spread (336).    
Finally, it has also been postulated that cytokines produced by the tumour/stroma complex 
can lead to marrow mesenchymal cell recruitment as a thus providing a potential explanation 
for increased marrow activation seen in the present review (416).   
However, there is recognised uptake of 18FDG by both tumour and inflammatory cells and 
that the TME consists of both tumour and inflammatory cells (418). Therefore, part of the 
glucose uptake into the tumour may be due to the infiltration of inflammatory cells.  Indeed, 
Rosenberg and colleagues proposed caution when analysing PETCT scans as the marrow 
hypermetabolism shown may be due to inflammation and not necessarily where the tumour 
cells are located (419).   
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While bone marrow mesenchymal stem cells, monocyte or platelet progenitor cells are 
unregulated during the response to active malignancy an elevation of neutrophils which is 
quantitatively the most important cell type has been consistently seen in patients with active 
cancer as shown by the prognostic strength of neutrophils singularly and NLR (38, 40).”   
However, confirmation of this hypothesis will require careful histological examination of 
the areas of both tumour and bone marrow increased signal uptake.”  Irrespective, it is clear 
that both tumour and inflammatory cells display signs of the “Warburg effect” and it may be 
that both contribute to the increased lactate dehydrogenase and its prognostic value observed 
in patients with cancer (420, 421).  
In the present review it was confirmed that there was a relationship between tumour and 
bone marrow glucose uptake and poor outcome in patients with cancer confirming its clinical 
utility.  Given that two recent meta-analysis have established the prognostic strength of both 
singular and combined markers of the systemic inflammatory response in both operable and 
inoperable disease across multiple cancer types (37, 38) it remains to be determined whether 
the prognostic value of tumour and bone marrow glucose uptake is determined by the 
systemic inflammatory response or vice versa.    
While the majority of the above studies used singular markers of the systemic inflammatory 
response these have now been surpassed by the use of composite ratios and cumulative 
scores (37, 38). Furthermore in a recent study in operable colon cancer Dolan and co-workers 
showed that both composite ratios and cumulative scores had prognostic value, independent 
of TNM stage (40). However, cumulative scores, based on normal reference ranges, are 
simpler and more consistent for clinical use and should be used in future research to 
investigate the association between FDG-PET imaging and host inflammatory responses” 
The importance of the relationship between tumour and bone marrow glucose uptake and 
the systemic inflammatory response is of more than academic interest particularly in the era 
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of immunomodulatory therapy for patients with advanced cancer.  In particular, modulation 
of the innate and adaptive immune responses will shed new light on the nature of this 
relationship (422). Furthermore, while there was some heterogeneity in the results, there was 
a relationship between tumour and bone marrow glucose uptake and poor outcomes in five 
studies including 1,525 patients. 
To our knowledge this is the first systematic review to examine the relationship between 
tumour glucose metabolism using PETCT imaging and host inflammatory responses.  From 
the review there appeared to be a direct relationship between the tumour and bone marrow 
glucose uptake and host systemic inflammatory responses in patients with common solid 
tumours.   Furthermore, there was a relationship between tumour and bone marrow glucose 
uptake and poor outcome in these patients. 
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 Tables and Footnotes  
Table 13.1: Studies showing the relationship between tumour, bone marrow and nodal glucose metabolism and host systemic inflammatory responses in patients with cancer 
Author Date Country  (n) Type of Cancer Tracer  Measurements Readings Correlation Survival 
Prevost et al (403)  2006 Canada 120 Lung 18-FDG TSUVmean 
TSUVmax 
BMSUVmax 
BLR 
WCC, Hb, 
Platelets  
TSUVmean: 6.2 (1.4-23) 
BMSUVmax:1.5 (0.6-3.2) 
BLR: 1 (0.6-2.4)  
 
Spearman correlation  
TSUVmax 
BMSUVmax: (r=0.20 p<0.05) 
BLR: NS 
WCC (NS) 
Hb (NS) 
Platelets (NS) 
 
BMSUVmax  
BLR: (r=0.76 p<0.05) 
TSUVmax: (r=0.20 p<0.05) 
WCC (r=0.38 p<0.05) 
Hb (r=-0.30 p<0.05) 
Platelets (r=0.24 p<0.05) 
 
BLR 
BMSUVmax: 0.76 p<0.05) 
TSUVmax: NS 
WCC (r=0.49 p<0.05) 
Hb (NS) 
Platelets (r=0.30 p<0.05) 
 
 
Kaplan-Meir  
OS:  Median survival 
(95%CI) 
TSUVmax (weight 
adjusted) ≥10: 227 
(122-690) p=0.003 
BMSUVmax≥1.7: 151 
(83-690) p=0.00006 
BLR<1.5: 724 (553-
1,094) p=0.00004 
 
Multivariate Cox 
Regression 
OS: 
BMSUVmax: RR: 1.6 
95%CI 1.1-2.3 p=0.008 
Cicone et al (404) 2008 Belgium  35 SCC of head and neck 18-FDG TSUVmax 
TSUVmean 
BMSUVmax, 
BMSUVmean,  
Tumour size, 
Hb, WCC, 
Platelet, RBC 
TSUVmax: 10.4 (3.2-29.9)  
TSUVmean: 7.8 (2.6-24.6)  
BMSUVmean: 1.4 (0.7-
2.4) 
 
 
Pearson’s Correlation 
TSUVmax:  
No correlation with any blood 
parameters 
 
TSUVmean:  
WCC (r=0.44; p=0.011)  
 
BMSUVmean:   
No correlation with any blood 
parameters 
CSS: 
Multivariate Cox 
Regression 
BMSUVmean: p=0.04 
(No HR or CI given) 
 
OS:  
Multivariate Cox 
Regression 
BMSUVmean: p=0.03 
(No HR or CI given) 
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Inoue et al (402) 2009 Japan  32 Multiple 18-FDG BMSUVmean,  
LiverSUVmean, 
BLR, WCC, 
RBC, Platelet, 
CRP 
BMSUV mean: 1.4±0.3 
Liver SUV mean: 1.8±0.3  
BLR: 0.75±0.16 
 
Pearson’s Correlation 
BMSUVmean:  
WCC: (r=0.28 p=NS) 
RBC (r=0.42. p<0.05) 
Platelet (r=-0.06 p=NS) 
CRP (r=0.25 p=NS) 
 
BLR:  
WBC (r=0.35 p<0.05) 
RBC (r=0.12 p=NS) 
Platelet (r=0.06 p=NS) 
CRP (r=0.50 p<0.005) 
 
Not carried out for 
PET-CT markers 
Chang et al (405) 2013 Taiwan 151 Oral cavity squamous 
cell carcinoma 
 
18-FDG SUVmax, CRP TSUVmax≥19.3 Spearman Correlation 
TSUVmax: 
 CRP (r=Not given p<0.001) 
Not carried out for 
PET-CT markers 
Chen at al.(406) 2013 China 106 Pharyngo-laryngeal  
 
18-FDG TSUVmax, 
NSUVmax,  
CRP 
TSUVmax≥8.6mg/L 
NSUVmax≥5.7ng/ml 
Chi-squared test 
TSUVmax 
CRP (p=0.472) 
 
NSUVmax 
CRP (p=0.014) 
 
Not carried out for 
PET-CT markers 
Jeong et al (407) 
 
2016 South Korea 1034 Lung 18- FDG TSUVmax 
WBC, 
Neutrophil, 
Lymphocyte, 
NLE 
TSUV max>7.83 Linear Correlation: 
TSUVmax: 
WCC (r=0.208 p<0.001) 
Neutrophil (r=0.175 p<0.001) 
Lymphocyte (r=0.101 p=0.001) 
NLR (r=0.004 p=0.004) 
 
Multivariate Cox 
Regression: 
OS: 
TSUVmax>7.83: HR: 
2.222 95%CI 1.518-
3.254 p<0.001 
Zhong et al (408) 2017 China 121 Naso-pharyngeal 
carcinoma 
18- FDG TSUVmax, 
NSUVmax, 
Neutrophils, 
Monocytes, 
Leukocytes 
TSUVmax: >12.35 
NSUVmax >10.15 
Spearman’s Correlation 
TSUVmax: 
Leukocytes (r=0.203 p=0.025), 
neutrophils (r=0.238 p=0.009) 
monocytes (r=0.185 p=0.043) 
 
NSUVmax:   
Leukocytes (r=0.068 p=0.46), 
neutrophils (r=0.023 p=0.802) 
monocytes (p=0.024 p=0.024) 
 
Kaplan Meier 
PFS: 
TSUVmax>12.35: 
p=0.204 
NSUVmax>10.15 
p=0.004 
 
DMFS: 
TSUVmax>12.35: Not 
conducted 
NSUVmax>10.15 
p=0.003 
 
Multivariate Cox 
Regression: 
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PFS:  
NSUVmax>10.15: 
HR:2.572 95%CI 
1.121-5.898 p=0.026 
 
Multivariate Cox 
Regression: 
DMFS:  
NSUVmax>10.15: 
HR:3.065 95%CI 
1.145-8.201 p=0.026 
 
Lee et al (409) 2017 South Korea 110 Lung 18- FDG TSUVmax, 
MBSUVmax 
BLR 
Albumin, CRP 
NLR, PLR, 
WCC, Hb 
 
TSUVmax: 7.65 (0.80-
19.00) 
MBSUVmax: 1.47 (0.94-
2.63) 
BLR: 0.72 (0.46-1.40) 
 
Spearman Correlation 
BMSUVmax:  
Albumin (r=-0.062 p=0.50) 
CRP (r=0.279 p=0.003) 
NLR (r=0.236 p=0.01) 
PLR (r=0.137 p=0.20) 
WCC (r=-0.210 p=0.03) 
Hb (r=-0.038 p=0.70) 
 
BLR:  
Albumin (r=-0.227 p=0.02) 
CRP (r=0.437 p=0.001) 
NLR (r=0.305 p=0.001) 
PLR (r=0.318 p<0.01) 
WCC (r=0.278 p=0.03) 
Hb (r=-0.069 p=0.50) 
 
Multivariate Cox 
Regression:  
PFS: 
TSUVmax>6.5: 
HR:3.169 95%CI 1.43-
6.99 p=0.005 
BLR>0.8: HR: 2.49 
95%CI 1.25-4.94 
p=0.01 
 
OS: 
TSUVmax>6.5: 
HR:4.49 95%CI 1.05-
19.92 p=0.04 
BLR>0.8: HR: 2.15 
95%CI 0.69-7.87 
p=0.20 
Lee et al (410)  2017 South Korea 106 Lung 18- FDG TSUVmax,  
MTV 
TLG 
BMSUVmax 
BLR 
WCC, Hb, 
NLR, PLR, 
Albumin, CRP 
TSUVmax: 10.48 (1.40-
32.19) 
MTV: 20.97 (1.10-650.75) 
TLG: 138.47 (2.80-
3715.78) 
MBSUVmax: 1.57 (0.94-
2.22) 
BLR: 0.79 (0.45-1.50) 
 
Spearman Correlation 
BMSUVmax: 
WCC (r=0.294 p=0.002) 
Hb (r=-0.015 p=0.8) 
NLR (r=0.034 p=0.7) 
PLR (r=0.070 p=0.4) 
Albumin (r=-0.190 p=0.05) 
CRP (r=0.296 p=0.002) 
 
BLR:  
WCC (r=0.396 p<0.001) 
Hb (r=-0.114 p=0.2) 
NLR (r=0.281 p=0.06) 
PLR (r=0.070 p=0.5) 
Albumin (r=-0.349 p<0.001) 
CRP (r=0.428 p<0.001) 
Univariate Cox  
Regression:  
PFS: 
MTV: 1.00 (1.00-1.01) 
p=0.40 
TLG: 1.00 (0.99-1.01) 
p=0.50 
 
Multivariate Cox 
Regression 
PFS: 
TSUVmax: HR:0.99 
95%CI 0.92-1.04 p=0.5 
BMSUVmax: HR:0.73 
95%CI 0.18-3.05 
p=0.73 
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 BLR: HR: 14.44 
95%CI 2.60-80.28 
p=0.002 
 
Univariatee Cox 
Regression  
OS:  
BMSUVmax: HR: 2.01 
95%CI 0.53-7.65 
p=0.30 
 
Multivariate Cox 
Regression OS:  
TSUVmax: HR:1.00 
95%CI 0.99-1.01 p=0.9 
MTV: HR: 1.00 95%CI 
0.99-1.02 p=0.7 
TLG: HR: 1.08 (0.94-
1.22) p=0.07 
BLR: HR: 1.24 95%CI 
0.60-24.61 p=0.90 
Lee et al (411) 2017 South Korea 309 Gastric  18- FDG BMSUVmax 
BLR 
CRP, Albumin, 
Hb, NLR, PLR 
TSUVmax: 4.71 (2.62-
37.80) 
BMSUVmax: 1.45 (0.55-
2.66) 
BLR: 0.70 (0.28-1.35) 
Spearman correlation 
BMSUVmax 
TSUVmax: (r=0.093 p=0.104)  
WCC: (r=0.039 p=0.600) 
Hb (r=-0.117 p=0.039) 
NLR (r=0.121 p=0.033) 
PLR (r=0.158 p=0.005) 
Albumin (r=-0.041 p=0.474) 
CRP (r=0.100 p=0.079) 
 
BLR 
TSUVmax: (r=0.212 p=0.002) 
WCC: (r=0.003 p=0.563) 
Hb: (r=-0.172 p=0.002) 
NLR: (r=0.224 p=0.001) 
PLR: (r=0.250 p<0.001) 
Albumin (r=-0.168 p=0.003) 
CRP (r=0.094 p=0.100) 
 
Multivariate Cox 
Regression 
RFS:  
TSUVmax: HR: 1.33 
95%CI 0.70-2.39 
p=0.215 
BMSUVmax: HR: 0.94 
95%CI 0.38-2.33 
p=0.945 
BLR : HR : 6.42 
95%CI 2.07-19.84 
p=0.001 
 
OS :  
TSUVmax : HR : 2.89 
95%CI 0.96-8.72 
p=0.059 
BLR: HR: 10.39 
95%CI 1.34-80.33 
p=0.025 
 
 
McSorley et al 
(412) 
2017 United 
Kingdom 
103 Colorectal  18- FDG TSUVmax 
TSUVpeak  
TSUVmax: 11 (0-35) 
TSUVpeak: 8 (0-29) 
Categorical data: Chi squared 
test 
Univariate Cox 
Regression 
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MTV 
TLG 
 mGPS, NLR 
MTV: 4 (0-311) 
TLG: 28 (0-3124) 
Continuous data: Mann-
Whitney U test 
Pre-Op Scans (n=33): No 
association between 
TSUVmax, TSUVpeak, MTV, 
TLG, mGPS and NLR  
 
Post-Op Scans (n=70) 
NLR≥5: 
TSUVmax (20 vs 7 p=0.002) 
SUVpeak (14 vs 4 p<0.001) 
MTV (29mL vs 2mL p=0.001) 
TLG (338g vs 9g p<0.001) 
 
mGPS 1/2: 
TSUVmax (11 vs 6 p=0.048) 
SUVpeak (8 vs 4 p=0.046) 
MTV (13mL vs 2mL p=0.005) 
TLG (146g vs 10g p=0.004) 
 
Post op cohort (n=70) 
CSS: 
TSUVmax: HR: 2.02 
95%CI 0.82-4.98 
p=0.128 
MTV : HR : 1.68 
95%CI 0.66-4.22 
p=0.275 
 
Multivariate Cox 
Regression 
Post op cohortes 
(n=70) 
CSS: 
TSUVpeak:  HR: 2.39 
95%CI 0.95-5.99 
p=0.064 
TLG : HR :2.51 95%CI 
1.00-6.28  p=0.720 
 
Lee et al (413)  2017 South Korea 226 Colorectal  18-FDG  TSUVmax 
Tumour size 
BMSUVmean, 
WCC, CRP, 
NLR, PLR 
TSUVmax: 10.85 (2.54-
48.80) 
BMSUVmean: 1.67 (0.63-
3.12) 
Spearman’s correlation: 
BMSUVmean:   
TSUVmax: (r=0.266 p<0.001) 
Tumour size: (r=0.159 
p<0.017) 
WCC (r=0.160 p=0.016) 
CRP (r=0.252 p<0.001) 
NLR (r=0.223 p<0.001) 
PLR (r=-0.109 p=0.131)  
Univariate Cox 
Regression 
RFS : 
TSUVmax>10.50 :          
HR : 0.59 95%CI 0.29-
1.20 p=0.145 
BMSUVmean>1.90 : 
HR : 2.94 95%CI 1.30-
6.63 p=0.009 
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 Figures and Legends  
 
Figure 13.1: A PRISMA Flowchart demonstrating study selection process 
.
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14. THE USE OF CT AND PET-CT IMAGING TO MEASURE BODY 
COMPOSITION AND TUMOUR ACTIVITY IN PATIENTS WITH 
ADVANCED LUNG CANCER TREATED WITH RADIOTHERAPY 
 Introduction 
Globally, lung cancer is the most common cancer type and is responsible for 1.69 million 
deaths per year (79). In the UK lung cancer is the 3rd most common cancer accounting for 
13% of all new cancer cases (423). In Scotland lung cancer accounts for 16% of all new 
cancers with a 5 year survival below the UK average at 9.8%. 
The relationship between CT defined body composition and outcomes in patients with lung 
cancer has been widely reported (59). Differences in skeletal muscle quantity as measured 
by skeletal muscle index and quality as measured by skeletal muscle density have both been 
shown to directly relate to patient morbidity, response to treatment and survival (354, 360, 
424, 425).   
In two recent reviews, monitoring of the systemic inflammatory response was shown to be 
prognostic in both operable and advanced lung cancer (37, 38). In addition, the importance 
of the systemic inflammatory response as a unifying mechanism for weight loss, loss of lean 
tissue and poor outcomes in patients with cancer is increasingly recognized (81, 346, 355). 
Indeed, it has been reported that SMI and SMD are inversely associated with measures of 
the systemic inflammatory response such as the NLR and mGPS (45, 52, 356-360, 426). 
However, the role of tumour glucose uptake in the above relationship is not clear.   
Positron Emission Tomography (PET) is an established nuclear imaging technique based on 
the uptake of glucose that reflects the metabolic activity of tumours and combined with CT 
scanning gives both anatomic and metabolic assessment of the tumour and metastases (49), 
commonly using the tracer 18F-2-fluoro-2-deoxy-D-glucose (18FDG) (76). It is of interest 
therefore that in a systematic review there was a direct relationship between both tumor and 
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bone marrow 18FDG uptake and the systemic inflammatory response on PET-CT (53). In 
addition, the majority of the studies also showed a direct relationship between tumour 
glucose uptake and poor outcomes (53).  This suggests a potential mechanism of action for 
the multi-systemic effects of the systemic inflammatory response in patients with cancer 
(402).  
It may be hypothesised that high tumour glucose uptake causes loss of skeletal muscle 
directly and that this is related to patient outcomes. Therefore, the aim of the present Chapter 
was to examine the relationship between imaging derived tumour glucose uptake, body 
composition, the systemic inflammatory response and mortality in patients with lung cancer. 
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 Patients and Methods  
Patients: 
All patients with clinically confirmed non metastatic lung cancer treated with radical  
radiotherapy in North Glasgow between June 2008 and December 2012, who also underwent 
staging CT and 18F FDG-PETCT imaging prior to their treatment at the Beatson Oncology 
Centre, Glasgow were included in the study. Patients had routine blood sampling including 
a full blood count, serum CRP and albumin concentration at the time of their staging scan. 
Patients were followed up for 5 years or until death.  
Methods: 
Data were collected prospectively in a database, anonymised and subsequently analyzed 
including patient demographics, clinicopathological, oncological and radiological data. 
Body composition CT scan analysis and 18F FDG-PETCT scan analysis were performed 
retrospectively by clinicians blinded to clinical outcomes and markers of systemic 
inflammatory response as outlined in Chapter 2.  
An autoanalyzer was used to measure serum CRP (mg/L) and albumin (g/L) concentrations 
(Architect; Abbot Diagnostics, Maidenhead, UK).  The mGPS and NLR were derived as 
previously described (99). 
Body Composition CT Analysis:  
CT images were obtained, and analysis was carried out at the level of the third lumbar 
vertebra as previously described in Chapter 2. Patients whose scans were taken 3 months or 
more prior to commencing radiotherapy were excluded from the study. Scans with 
significant movement artefact or missing region of interest were not considered for inclusion. 
Each image was analysed using Image J (NIH version 1.47, http://rsbweb.nih.gov/ij/) shown 
to provide reliable measurements (356).  
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Measurements were performed by two individuals and inter-rater reliability was assessed in 
a sample of 30 patient images using inter-class correlation coefficients (ICCC) (TFA ICCC 
= 1.000, SFA ICCC = 1.000, VFA ICCC = 1.000, SMA ICCC = 0.986, SMD ICCC = 0.974). 
Investigators were blind to patient’s demographic and clinico-pathological status. 
18F FDG-PETCT: 
18F FDG-PETCT scanning was performed as outlined in Chapter 2.  
Statistical Analysis: 
ROC curve analysis determined the optimum thresholds for SUVmax, SUVmean, MTV and 
TLG. Body composition and PET-CT measurements were presented as median and range 
and compared using Mann-Whitney or Kruskal-Wallis tests.  Categorical variables were 
analysed using χ2 test for linear-by-linear association, or χ2 test for 2 by 2 tables.   
Univariate and multivariate survival data were analysed using Cox’s proportional hazards 
model.  Variables associated with overall survival at a significance level of p <0.1 on 
univariate analysis were included in multivariate modelling using backward conditional 
regression where a two-sided p value <0.05 was considered statistically significant. Overall 
survival was defined as time from date of 18F FDG-PETCT to date of death due to any 
cause. P values <0.05 were considered statistically significant.  Statistical analysis was 
performed using SPSS software (Version 21.0. SPSS Inc., Chicago, IL, USA). 
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 Results 
In total, 251 patients were identified as having undergone potentially curative radiotherapy 
for lung cancer. Of these, 61 were excluded due to scanning taking place more than 3 months 
before commencing radiotherapy. A further 71 patients were excluded due to absent markers 
of the systemic inflammatory response, CT derived body composition measurements and a 
histological diagnosis of small cell lung cancer (SCLC).  A total of 119 patients (57 males, 
62 females) were included in final analyses. The relationship between clinicopathological 
characteristics, tumour activity, body composition, markers of the systemic inflammatory 
response and overall survival are shown in Table 14.1.  The majority of patients were over 
65 years of age (86%), overweight (53%), with an ECOG-PS 0 or 1 (57%), node negative 
disease (54%) and an mGPS 1/2 (51%). All patients were treated with radiotherapy, six 
patients received additional chemotherapy and two received concurrent chemoradiotherapy.  
The majority of patients had an elevated TLG (61%) as determined by ROC curve analysis.  
On follow-up, 107 patients died, and the median survival was 22 months (range 3-91 
months). On univariate survival analysis, lung cancer stage (p<0.01), mGPS (p<0.05), NLR 
(p<0.01), Low SMD (p<0.05) and TLG (p<0.001) were associated with overall survival.  
The relationship between the TLG (<68.89/>68.89) and clinicopathological characteristics 
in patients lung cancer are shown in Table 14.2.  TLG (>68.89) was significantly associated 
with sex (p<0.05), TNM stage (p<0.001), mGPS (p<0.01) and SUVmax (p<0.001). 
The relationship between clinicopathological characteristics, tumour activity, body 
composition, markers of the systemic inflammatory response and overall survival in patients 
with lung cancer is shown in Table 14.3.  On multivariate survival analysis only TLG>68.89 
(HR:2.03, 95%CI 1.35-3.07, p<0.001) was independently associated with overall survival. 
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 Discussion 
The results of the present study show that, in a cohort of patients with lung cancer undergoing 
radical radiotherapy, there was a significant association between TLG (metabolic activity) 
and the mGPS (systemic inflammatory response).  These results are consistent with a recent 
systematic review which reported a relationship between markers of the systemic 
inflammatory response and PET-CT parameters (53).   However, there was not a significant 
association between TLG and SMI (skeletal muscle mass). This relationship has not, to our 
knowledge, been previously examined in cancer patients but it has long been thought that 
the metabolic activity of the tumour was insufficient, with perhaps the exception of a large 
metastatic burden, to account for the catabolic changes seen in patients with cancer (427).  
Therefore, given that only TLG was independently associated with survival the present 
results would suggest that tumour metabolic activity is indirectly associated with the loss of 
muscle mass in patients with lung cancer.  
The mechanism by which a metabolically active tumour evokes a systemic inflammatory 
response is not clear.  However, there are a number of plausible mechanisms.  Tumour 
hypoxia and necrosis and the production of lactate result in the local activation of innate 
immune cells and production of pro-inflammatory cytokines, including interleukin-6 (IL-6), 
stimulating production of CRP (428, 429). Circulating IL-6 levels are linked to tumour 
necrosis and both local and systemic inflammatory responses in patients undergoing 
resection for colorectal cancer (428).  An alternative hypothesis is that circulating tumour 
cells activate myeloid cells in the bone marrow to produce such pro-inflammatory cytokines, 
in particular IL-6 (429).  Indeed, there is some evidence from PET-CT studies there is 
increased uptake of glucose from the bone marrow and that the SUVmax from the bone 
marrow is also associated with markers of the systemic inflammatory response (53).  In the 
present study, glucose uptake was only examined in the tumour.  Irrespective, both of these 
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mechanisms would, in turn, result in a progressive catabolic state with subsequent 
breakdown of skeletal muscle resulting in a cachectic state.  
The results of the present study are also consistent with the proposal of McAllister and 
Weinberg that the systemic inflammatory response is the tip of the cancer iceberg reflecting 
cytokine activity, disordered metabolism and the development of cancer associated 
symptoms such as loss of appetite, fatigue and poor physical function (25, 192, 430). Given 
the present results and the increasing importance of the inflammatory responses in the 
assessment and treatment of lung cancer, it will be of considerable interest to better define 
the relationship between tumour metabolic activity and the components of the tumour 
microenvironment including tumour inflammatory cell infiltrate (9, 431), the tumour stroma 
(432, 433) and tumour mutational burden measured with circulating tumour DNA .  
The present study had a number of limitations including that the data was retrospectively 
analysed from a prospective audit of clinical practice, the majority of patients were treated 
with radiotherapy in isolation (97%).  Also, that histological tumour type was not determined 
in 21% of cases due to concurrent comorbidities and therefore the present cohort may be a 
relatively heterogeneous group.  However, the present study also has a number of strengths.  
To our knowledge, this is the first study to comprehensively examine the nature of the 
relationship between tumour metabolic activity, body composition, the systemic 
inflammatory response and survival in patients with cancer.  The measurements were carried 
out within one month of each other and the sample size compares favourably to previous 
studies in the field (53).  Indeed, given the routine clinical measurements used in the present 
study these results are readily validated and give a new insight into these relationships in 
patients with cancer.  
In summary, in patients treated with radical radiotherapy, tumour glucose uptake was 
associated with activation of systemic inflammatory response and mortality but not lower 
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skeletal muscle mass. These results provide new insight into the nature of skeletal muscle 
loss in patients with cancer and suggest that the loss of lean tissue is secondary and not to 
the direct metabolic activity of the tumour.  
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 Tables and Footnotes  
Table 14.1: The relationship between clinicopathological characteristics, tumour activity, body composition, 
markers of the systemic inflammatory response and overall survival in patients with lung cancer. 
Characteristics n=119 (%) Univariate Cox 
Regression Analysis OS 
p-value 
Sex    
Male 57 (47.9) 1.34 (0.91-1.97) 0.141 
Female  62 (52.1)   
Age    
<65 17 (14.3) 1.04 (0.79-1.37) 0.768 
65-74 54 (45.4)   
>75 48 (40.3)   
TNM    
I 42 (35.3) 1.40 (1.12-1.74) 0.003 
II 22 (18.5)   
III 55 (46.2)   
ECOG – PS    
0/1 68 (57.1) 0.74 (0.50-1.09) 0.126 
≥2 51 (42.9)   
Inflammatory Response     
mGPS     
0 58 (48.7) 1.30 (1.06-1.61) 0.014 
1 20 (16.8)   
2 41 (34.5)   
NLR    
<3 53 (44.5) 1.38 (1.09-1.76) 0.009 
3-5 35 (29.4)   
>5 31 (26.1)   
Body Composition:     
BMI kg/m2     
≤25 56 (47.1) 0.77 (0.54-1.13) 0.182 
>25  63 (52.9)   
Visceral Obesity   
VFA 134.23 (14.35-577.08) 1.00 (0.99-1.01) 0.780 
Visceral Obesity    
No 45 (37.8) 0.81 (0.55-1.20) 0.292 
Yes 74 (62.2)   
Sarcopenia   
SMI 44.23 (29.40-74.36) 1.00 (0.98-1.02) 0.899 
Low SMI    
No 61 (51.3) 0.98 (0.67-1.44) 0.930 
Yes 58 (48.7)   
Myosteatosis   
SMD 34.53 (9.58-51.24) 1.03 (1.00-1.05) 0.043 
 Low SMD    
No 45 (37.8) 0.66 (0.44-0.97) 0.035 
Yes 74 (62.2)   
   
PET-CT Analysis   
TLG 102.66 (3.47-2070.90) 1.01 (1.00-1.02) <0.001 
TLG > 68.89    
No 47 (29.5) 2.18 (1.46-3.26) <0.001 
Yes 72 (60.5)   
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Table 14.2: The relationship between TLG and clinicopathological characteristics in patients with lung cancer 
Characteristics  Low TLG (n=47) High TLG (n=72) p-value 
Sex    
Male 29 (61.7) 28 (38.9) 0.015 
Female  18 (38.3) 44 (61.1)  
Age    
<65 5 (10.60 12 (16.7) 0.578 
65-74 21 (44.7) 33 (45.8)  
>75 21 (44.7) 27 (37.5)  
TNM    
I 27 (57.4) 15 (20.8) <0.001 
II 8 (17.0) 14 (19.4)  
III 12 (25.5) 43 (59.7)  
ECOG – PS    
0/1 28 (59.6) 40 (55.6) 0.665 
≥2 19 (40.4) 32 (44.4)  
Inflammatory Response     
mGPS     
0 31 (66.0) 27 (37.5) 0.006 
1 7 (14.9) 13 (18.1)  
2 9 (19.1) 32 (44.4)  
NLR    
<3 26 (55.3) 27 (37.5) 0.146 
3-5 12 (25.5) 23 (31.9)  
>5 9 (19.1) 22 (30.6)  
Body Composition:     
BMI kg/m2     
≤25 19 (40.4) 37 (51.4) 0.241 
>25 28 (59.6) 35 (48.6)  
Visceral Obesity   
VFA 128.94 (15.33-577.08 140.19 (14.35-549.90) 0.683 
Visceral Obesity     
No 17 (36.2) 28 (38.9) 0.765 
Yes 30 (63.8) 44 (61.1)  
Sarcopenia   
SMI 43.34 (29.43-66.36) 45.35 (29.40-74.36) 0.350 
Low SMI    
No 24 (51.1) 37 (51.4) 0.972 
Yes 23 (48.9) 35 (48.6)  
Myosteatosis   
SMD 31.80 (9.58-48.04) 35.31 (13.98-51.24) 0.098 
Low SMD    
No 15 (31.9) 30 (41.7) 0.284 
Yes 32 (68.1) 42 (58.3)  
   
PET-CT Analysis    
SUV max 10.20 (3.1-23.7) 17.55 (4.00-36.90) <0.001 
SUVmax > 11.40    
No 28 (59.6) 16 (22.2) <0.001 
Yes 19 (40.4) 56 (77.8)  
Survival    
Survival rate (1 year)    
No 5 (10.6) 26 (36.1) 0.002 
Yes 42 (89.4) 46 (63.9)  
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Table 14.3: The relationship between clinicopathological characteristics, tumour activity, body composition, 
markers of the systemic inflammatory response and overall survival in patients with lung cancer:  Univariate 
and multivariate analysis. 
Characteristics n=119 (%) Univariate Cox 
Regression 
Analysis OS 
p-value Multivariate 
Cox Regression 
Analysis OS 
p-value 
Sex      
Male 57 (47.9) 1.34 (0.91-1.97) 0.141 ─ ─ 
Female  62 (52.1)     
Age      
<65 17 (14.3) 1.04 (0.79-1.37) 0.768 ─ ─ 
65-74 54 (45.4)     
>75 48 (40.3)     
TNM      
I 42 (35.3) 1.40 (1.12-1.74) 0.003 ─ 0.112 
II 22 (18.5)     
III 55 (46.2)     
ECOG – PS      
0/1 68 (57.1) 0.74 (0.50-1.09) 0.126 ─ ─ 
≥2 51 (42.9)     
Inflammatory 
Response  
     
mGPS       
0 58 (48.7) 1.30 (1.06-1.61) 0.014 ─ 0.097 
1 20 (16.8)     
2 41 (34.5)     
Body Composition:       
BMI kg/m2       
≤25 56 (47.1) 0.77 (0.54-1.13) 0.182 ─ ─ 
>25  63 (52.9)     
Visceral obesity      
No 45 (37.8) 0.81 (0.55-1.20) 0.292 ─ ─ 
Yes 74 (62.2)     
Sarcopenia     
Low SMI      
No 61 (51.3) 0.98 (0.67-1.44) 0.930 ─ ─ 
Yes 58 (48.7)     
Myosteatosis     
 Low SMD      
No 45 (37.8) 0.66 (0.44-0.97) 0.035 ─ 0.181 
Yes 74 (62.2)     
PET-CT Analysis     
TLG > 68.89      
No 47 (29.5) 2.18 (1.46-3.26) <0.001 2.03 (1.35-3.07) 0.001 
Yes 72 (60.5)     
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15. CONCLUSIONS 
 Overview of thesis 
It has been widely reported that patient outcomes are due to a complex and symbiotic 
relationship between tumour and host factors including the systemic inflammatory response 
(7). Body composition is increasingly recognised as an important prognostic domain in 
patients with cancer. There is evidence supporting a disproportionate loss of skeletal muscle 
tissue is associated with poor treatment tolerance and efficacy (351), worse quality of life, 
increased morbidity (352) and poorer survival in patients with cancer (350). Tumour 
metabolic activity has long been proposed as a driving force behind host factors including 
the systemic inflammatory response in patients with cancer. Recently the combination of 
PET and CT scanning has allowed for quantification of tumour metabolic activity as well as 
the identification of other metabolically active tissue in patients with cancer suggesting new 
mechanism connecting tumour activity, the systemic inflammatory response and body 
composition. Therefore, the aim of this thesis was to examine the relationship between the 
systemic inflammatory response, CT-derived body composition, tumour metabolic activity 
and outcomes in patients with cancer.  
The results of two large systematic reviews and meta-analysis of the relationship between 
the systemic inflammatory response and outcomes in patients with operable and inoperable 
cancer can be found in Chapter 3 and 4 respectively (37, 38). In these studies which 
contained 442 articles in total, a clear relationship between the systemic inflammatory 
response and both cancer specific and overall survival is demonstrated. These studies were 
mostly retrospective observational studies however in Chapter 5 a further systematic review 
containing 36 prospective randomised control trials adds to the weight of evidence behind 
the use of the systemic inflammatory response in patients with cancer (54).  Indeed, in 
Chapter 6, the systemic inflammatory response, as evidenced by the GPS/mGPS, was shown 
to be common in both primary operable and advanced inoperable cancers particularly in lung 
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and gastrointestinal cancers with 73.1% of patients being inflamed (Figure 15.1). Therefore, 
the systemic inflammation “iceberg” is in plain sight and should be factored into future 
treatment plans of patients with cancer.  These results will have profound implications for 
the future design of randomised control trials with monitoring of the systemic inflammatory 
response being incorporated into future trials in pancreatic cancer and potentially being used 
to aid with inclusion and exclusion criteria (167).  
The most common methods of assessing the systemic inflammatory response is with the use 
of composite ratios and cumulative scores constructed with different acute phase proteins or 
components of the differential white cell count (40). The two most commonly used 
composite ratios and cumulative scores would be NLR and the GPS/mGPS respectively (40). 
The results of Chapter 7 directly compare the prognostic value of composite ratios and 
cumulative scores in patients with colon cancer (Figure 15.1). Both ratios and scores, 
whether composed of white cells from lymphoid/ myeloid tissue or from acute phase proteins 
from the liver, had prognostic value, independent of TNM stage. However, cumulative 
scores, based on normal reference ranges, are simpler and more consistent for clinical use. 
This will have significant impact on future clinical practice particularly with the 
incorporation of monitoring of the systemic inflammatory response into clinical trial 
protocols. It also suggests that monitoring of the systemic inflammatory response should be 
incorporated into routine clinical practice to a greater extent to aid in clinical decision 
making and discharge planning (434). 
On a local level, monitoring of the systemic inflammatory response in the form of the mGPS 
has been incorporated into standard clinical practice at the multidisciplinary team level in 
patients with lung cancer where it aids in clinical decision making. In a surgical setting 
monitoring of the post operative inflammatory response also forms an important part of 
clinical decision making and helps guide post operative imaging and discharge planning. 
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The results of Chapter 8 suggest a relationship between the inflammatory cytokine IL-6 and 
the systemic inflammatory response as measured by mGPS and performance as measured 
by ECOG-PS and their combination in patients with advanced cancer. This suggests another 
potential therapeutic target aimed at moderation of circulating IL-6 concentrations in patients 
with cancer. With the  introduction of immunotherapies such as infliximab and clazakizumab 
which have been shown to be effective at modulating the inflammatory response in patients 
with cancer (337, 339) this modulation has become more effective and could be expanded 
to the majority of solid organ cancers (Figure 15.1).  
The use of CT-derived body composition analysis is an expanding area of clinical interest 
and has been shown to directly relate to both the inflammatory response and outcomes in 
patients with cancer particularly colorectal cancer (52, 354). The two most commonly used 
software packages for image analysis are ImageJ and Slice-O-Matic. The results of Chapter 
2 show that when directly compared ImageJ consistently gave higher values of different 
body composition parameters when compared to Slice-O-Matic (Figure 15.1). This led to 
more patients being diagnosed as viscerally obese and less being classified as sarcopenic. 
With the drive towards the incorporation of CT derived body composition analysis to 
standard clinical practice there must be a concurrent drive towards standardisation 
irrespective of the software package used (Figure 15.1). As a direct result of this a decision 
was made to calculate new thresholds for both sarcopenia and myosteatosis to be included 
in the remaining Chapters of this thesis (Figure 15.1).  
Skeletal muscle is a highly physiologically active tissue and both the mass and quality of 
skeletal muscle has been shown to effect the level of physiological reserve and outcomes in 
patients with cancer (48, 66, 369, 370). The results of Chapter 9 suggest a significant 
relationship between low skeletal muscle mass, skeletal muscle quality and survival in 
patients with operable colorectal cancer (Figure 15.1). This would support the incorporation 
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of the measurement of skeletal muscle mass and density as well as the systemic 
inflammatory response into the clinical and nutritional assessment of patients with operable 
cancers. It also suggests that moves should be made to modulate the inflammatory response 
prior to surgery either with systemic anti-inflammatories or with steroid administration at 
induction (435). 
The relationship between weight loss and outcomes has led to a number of studies using 
BMI/WLGrades to predict outcomes in patients with cancer particularly advanced disease. 
However, in Chapter 10 the use of the combined ECOG-PS/mGPS framework was shown 
to be more robust (Figure 15.1). As a result, it is suggested that the ECOG/mGPS framework 
form the basis for risk stratification of survival in patients with advanced cancer. The results 
of Chapter 11 show that both skeletal muscle mass and quality were associated with the 
systemic inflammatory response and measurements of physical function in patients with 
advanced cancer (Figure 15.1). Therefore, in the future CT-derived body composition 
analysis could add further weight to the widely used ECOG-PS/mGPS framework in patients 
with advanced cancer.  
Longitudinal changes in body composition have been shown to have significant impact on 
outcomes in patients with cancer (44). Indeed, a considerable amount of clinical research 
including several randomised control trials has looked at ways to reverse the changes in body 
composition associated with cancer. This can be through the use of targeted pharmacological 
treatments or both organised pre and post treatment exercise programs (383, 436). However, 
the results of Chapter 12 which suggest that changes in body composition occur early in the 
disease process and are maintained even after the resection of the primary tumour suggests 
that the die is already cast and that the effectiveness of interventions at altering body 
composition may be met with minimal results (Figure 15.1). This highlights the importance 
of screening programs which identify patients at an early stage before they become 
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symptomatic (437). In the future patient expectations will also need to be managed with the 
realisation that even after curative surgical or oncological treatment a return to pre-diagnosis 
physical performance is unlikely and that the aim of any systemic treatment should be to 
arrest any further decline in muscle quality and quality.  
There is evidence in the literature that chemotherapy can have a deleterious effect on 
outcomes particularly in inpatients with advanced cancers (438). Indeed Temel and co-
workers in a recent RCT suggested that patients treated with early best supportive care could 
have better outcomes when compared to those undergoing active systemic oncological 
treatments including chemotherapy (29, 438). The pathophysiology of this remains to be 
fully elicited however there is some evidence that chemotherapy induced loss of skeletal 
muscle may lead to reduced physiological reserves and poorer outcomes in patients with 
cancer (439, 440). This is particularly true in metastatic colorectal  cancer as can be seen by 
the results of two recent studies by Huemer and Köstek where chemotherapy was associated 
with a deterioration of skeletal muscle and poorer outcomes (439, 441). However, this 
reported association is not universal. Indeed, in a recent study in patients receiving palliative 
chemotherapy for advanced lung cancer Stene and co-workers found that approximately 
50% of patients maintained or increased their skeletal muscle mass (442).  
It would be of considerable interest to assess the effect of chemotherapy on body 
composition in patients with both operative and inoperative cancers. In this thesis this was 
not possible as CT scans often pre-dated the administration of chemotherapy in both 
operative and advanced cancers. However, future work particularly prospective work in 
pancreatic cancer with both pre and post chemotherapy scans being available will allow for 
this relationship to be better delineated. 
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The results of Chapter 13 examine the relationship between tumour physiology as measured 
but glucose metabolism and the host systemic inflammatory response (Figure 15.1). This 
systematic review suggests a direct relationship between the tumour and bone marrow 
glucose uptake and host systemic inflammatory responses in patients with common solid 
tumours. These results are confirmed in Chapter 14 which suggests that tumour metabolic 
activity as measured by tumour glucose uptake was associated with the systemic 
inflammatory response and mortality but not changes in body composition in patients with 
lung cancer (Figure 15.1). This suggests that the systemic effects of cancer including changes 
in body composition with their associated reduction in physical function and survival is 
mediated by the systemic inflammatory response activated through the bone marrow and not 
by the direct action of the tumour. This would provide further evidence that the early 
targeting of the systemic inflammatory response could provide a fruitful treatment strategy 
aimed at maintaining skeletal muscle mass and function while also improving quality of life 
and outcomes in patients with cancer.   
Finally, the systemic inflammatory response has a direct relationship with changes in body 
composition and outcomes in patients with cancer. Interestingly this association would seem 
to be independent of tumour metabolic activity and potentially tumour stage. Cancer related 
changes in body composition and their associated effect on performance status seem to be 
established early in the disease process and maintained despite treatments targeting the 
tumour specifically. The work presented in this thesis would suggest that new and novel 
treatment strategies utilising stratification and targeting of the systemic inflammatory 
response would be of benefit.  Such strategies could form part of an integrated treatment 
plan including prehabilitation in order to arrest any skeletal muscle loss and to improve 
outcomes in patients with cancer. 
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Figure 15.1: Schematic representation of relationships investigated in this theses and chapters relating to each 
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 Future work 
15.2.1 The relationship between the systemic inflammatory response, body composition, 
phenotypic subtyping and survival in patients with operable colorectal cancer 
Further investigation of the tumour metabolic activity, systemic inflammation and body 
composition trinity will be the focus of future work leading on from this thesis. To this end 
we are currently conducting a study examining the relationship between the systemic 
inflammatory response, body composition, histological tumour subtypes and survival in 
patients with operable colorectal cancer. This study will be directly relating the body 
composition and systemic inflammation data collected as part of this thesis to phenotypic 
tumour subtyping. This will be carried out on formalin fixed paraffin embedded tissue 
samples collected at the time of surgical resection. Three phenotypic characteristics will be 
examined; Ki67 proliferation index, Klintrup-Makinen (KM) grade for inflammatory 
infiltrate and stromal invasion using tumour stroma percentage (TSP). 
Immunohistochemical analysis for Ki67 will be performed using established protocols from 
the Institute of Cancer Sciences with appropriate positive and negative controls.  KM grade 
will be assessed by examining immune cell density at the invasive margin on hematoxylin 
and eosin (H&E) stained full sections of the tumour taken at the deepest point of invasion. 
Tumours will be graded as low if absent or patchy immune cell infiltrate and graded as high 
if immune cell infiltrate forms a thin band or florid cup. TSP will be carried out using H&E-
stained full sections taken at the deepest point of invasion. TSP will be calculated across the 
full section and graded as low if ≤50% stromal infiltration and high if >50% stromal 
infiltration. Patients will then be grouped into one of four phenotypic subtypes as shown in 
Table 15.1 below.  
This study will aid in identifying the driving force behind systemic inflammation. It may be 
that active tumour metabolism stimulates inflammation and this causes weight loss and loss 
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of function which leads to poor survival. Alternatively, it may be that cachectic muscle 
drives up the inflammatory response leading to reduced survival.  
A better understanding of this complex interaction will therefore allow us to better plan 
treatment interventions such as the use of non-steroidal anti-inflammatories or systemic 
steroids. Also, the ability to more accurately predict prognoses is of vital importance for 
patients with cancer. This could help with better counselling post-diagnosis improving the 
patient journey. This will help us achieve the aim of realistic medicine to support patient 
centred care, improve shared decision making and reduce unwarranted variation.  It will 
allow patients to make more informed decisions about the type of treatment they would like 
to embark on and the realistic likelihood of success. 
 
Table 15.1: Summary of phenotypic subtypes of patients undergoing surgical resection for colorectal cancer  
 Immune Proliferative Latent Stromal 
KM grade High Low Low Low 
Ki67 Any High Low Any 
TSP Any Low Low High 
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15.2.2 Investigating the relationship between molecular subtype, clinical outcomes and 
body composition in patients undergoing neoadjuvant therapy for Pancreatic Cancer. 
In addition to the above work in colorectal cancer additional future work will focus on 
relating body composition analysis to precision medicine in pancreatic cancer. Numerous 
studies have demonstrated the significant benefit of neoadjuvant treatment in both resectable 
and borderline resectable pancreatic cancers (443-445). However, recent studies have shown 
that only around 75% of patients complete the full neoadjuvant chemotherapy regime (445).  
Reasons for failure to complete neoadjuvant therapy include disease progression and 
deterioration in performance status. It has previously been reported in approximately 1200 
patients with resected pancreatic cancer that those with aggressive tumour biology 
particularly the aggressive squamous subtype are less likely to complete adjuvant 
chemotherapy and this is associated with poor performance status (446). This suggests that 
the differences in metabolic profiles of the particularly aggressive squamous subtype may 
predispose patients to cancer cachexia through metabolic effects in the cancer epithelial 
compartment.  
PRECISION-Panc is a therapeutic development platform that aims to integrate pre-clinical 
discovery with clinical trials in order to facilitate precision oncology in pancreatic cancer. 
Under the clinical development umbrella of PRECISION-Panc is PRIMUS (Pancreatic 
Cancer Individualised Multi-arm Umbrella Study), a clinical trial platform that is aimed at 
finding the right trial for the patient. By providing a portfolio of clinical trials, targeting 
different molecular sub-groups in different disease stages, will allow multiple novel 
therapeutic opportunities for patients. This will allow clinical testing in individually small, 
yet cumulatively large patient groups which is aimed both at early stage drug development 
and larger scale Phase II / III studies.  
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PRIMUS-002 is a Phase II study examining two neoadjuvant regimes, FOLFOX-A (Folinic 
Acid, Fluorouracil, Oxaliplatin and nab-Paclitaxel) and Gemcitabine-Abraxane 
(Gemcitabine with nab-Paclitaxel) focusing on biomarker and liquid biopsy development 
(Figure 15.2).  The aims of this study will be to investigate the impact of body composition 
on clinical outcomes in patients undergoing neoadjuvant therapy for pancreatic cancer in the 
PRIMUS-002 trial, to investigate the relationship between CT-derived body composition 
measurements, molecular subtypes and the systemic inflammatory response in patients with 
pancreatic cancer. Finally, to correlate molecular subtype and molecular pathways with 
sarcopenia and myosteatosis to identify pre-treatment biomarkers predicting deteriorating 
performance status whilst identifying novel therapeutic targets using a systems biology 
approach. 
Data will be prospectively collected through the PRECISION-Panc platform. All patients 
identified through PRECISION-Panc will enrol in the PRECISION-Panc master protocol 
(Figure 15.3) and undergo molecular profiling from endoscopic guided fine-needle core 
biopsy. Molecular assays performed will include the Glasgow Precision Oncology (GPOL) 
Clinical Cancer Genome, and transcriptomic analysis using gene expression arrays or RNA 
sequencing. Patients recruited to PRIMUS-002 will be allocated to either FOLFOX-A or 
Gemcitabine-Abraxane arm based on performance status and age and will have extensive 
clinical annotation as per clinical trial standards. Patients will undergo CT scans at diagnosis, 
after chemotherapy, and after radiotherapy (in selected cases) prior to surgery. Enabling a 
timeline of body composition analysis during the neoadjuvant treatment journey. Blood tests 
to determine mGPS will be taken prior to treatment start and at set intervals according to the 
trial protocol. Response to therapy will be determined by pathological regression score and 
radiology RECIST criteria. Body composition analysis will be carried out as outline in 
Chapter 2 using Slice-O-Matic.  
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Analysis into body composition will potentially enable clinicians to identify patients who 
may not tolerate treatment (resection or chemotherapy) due to poor nutritional status. Such 
patients may benefit from home nutritional support and/or a dedicated ‘prehabilitation’ 
programme (447) with the aim of optimising or at least arresting further physiological 
decline prior to intervention. Furthermore, patients predicted not to be able to tolerate 
systemic chemotherapy regimens can enter clinical trials with targeted therapies with less 
toxicity as they open in the PRECISION-Panc clinical trial portfolio. This study will for the 
first time combine CT-derived body composition with in depth genomic and transcriptomic 
analyses, and objective evidence of the systemic inflammatory response in patients with 
pancreatic cancer. Furthermore, as part of the PRECISION-Panc umbrella, prospectively 
collected clinico-pathological and patient follow-up/outcome data will be available allowing 
objective assessment of longitudinal changes in body composition to be assessed.   
  
 349 
 
Figure 15.2: PRIMUS-002 patient flow. Patients are allocated to either FOLFOX-A or AG arm based on 
performance status. Pre-treatment investigations included next generation sequencing (genome and 
transcriptome) of tumour biopsy, CT and PET-CT. This is repeated after chemo prior to surgery or radiotherapy 
(Phase 2 introduced after initial safety period). 
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Figure 15.3: The PRECISION-Panc Master Protocol. Patients are screened at time of diagnostic biopsy to 
allow additional samples for molecular profiling. This ensures rapid turn around from biopsy to recruitment .  
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17. APPENDIX 1 
 Tables and Footnotes: 
Table 17.1: Studies investigating the prognostic value of CRP in an unselected cohort of patients with advanced cancer  
No: 
CRP 
Study Type of 
Study 
Cancer Country  Patients 
(n) 
Measure of 
SIR 
Systemic Treatment  Cancer 
deaths 
(n) 
Overall 
deaths  
(n) 
Cancer 
Survival 
(HR, 95% CI) 
Overall 
survival 
(HR, 95% CI)  
Independent 
 Prognostic Factors 
1.  Ueno et al 
2000 (448)   
Retrospective   Prostate  Japan  103 CRP: ≥50mg/L Active Chemotherapy N/A 98 N/A Multivariate:  
3.140 (1.51–
6.55) p<0.010 
Performance Status, 
CA19-9 
2.  McMillan et al 
2001 (449)   
Retrospective  Multiple UK  772  CRP 
(Continuous per 
10-fold increase 
in CRP) 
Multiple treatments 
including platinum 
chemo and radio 
596 671 Multivariate:  
2.21 (1.92-2.56)  
P< 0.0001 
Multivariate:  
(Non-cancer 
survival) 
5.48 ( 3.55-
8.46) P < 
0.001 
Age, Albumin 
3.  Scott et al 
2002 (450)  
Retrospective  Lung UK 106 CRP>10mg/l 
 
CRP>100mg/l 
Palliative chemo with 
supportive treatment 
but no mention of 
either specifically  
N/A 106 N/A Multivariate:   
>10mg/l: 1.78 
(1.01-3.15) 
P=0.047 
Multivariate: 
>100mg/l: 
1.94 (1.41 – 
2.65) P<0.001 
Age, Tumour Type, 
Weight Loss, 
Karnofsky performance 
status, fatigue 
4.  Bromwich et al 
2004 (451)  
Retrospective  Renal  UK   58 CRP >10mg/l α-interferon treatment 
 
N/A 55 N/A Multivariate:   
2.03 (1.09-
3.80) P=0.026 
CRP Only 
5.  Elahi et al 
2005 (452)  
Retrospective  Lymphoma  UK 147 CRP (≤10/11-
100/>100mg/L) 
 
No mention of 
treatment but usually 
treated with chemo 
82 147  Multivariate:  
8.18 (4.80-
13.95) p<0.001 
Multivariate:  
2.11 (1.22-
3.64) P<0.001 
CRP Only 
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6.  Casamassima 
et al 2005 
(453)   
Retrospective  Renal  Italy   110 CRP: 8mg/L IL-2 plus gemcitabine 
and vinorelbine. 
N/A 38 N/A Multivariate:  
4.13 (1.68–
10.15) p=0.002 
DFI less vs. greater 
than 12  
7.  McArdle et al 
2006 (454)   
Prospective  Prostate UK  62 CRP>10mg/L Androgen Deprivation 
therapy +/- radio  
38 41 Multivariate: 
 1.97 (0.99-
3.92) p = 0.052 
N/A PSA 
8.  Sawaki et al 
2008 (455) 
 
Retrospective   Pancreatic  Japan 66 CRP: 10-
30mg/L 
 
>30mg/L 
Gemcitabine 1st line 
therapy  
N/A 56 N/A Multivariate:  
10–30mg/L:  
3.08 (1.18–
8.00) p=0.002 
 
>30mg/L  
5.99 (2.33–
15.45) p=0.002 
Location, diameter of 
tumour, Liver Mets 
9.  Al Murri et al 
2006 (197)   
Retrospective  Breast UK  96 CRP>10mg/l  
 
 
Chemotherapy and 
endocrine therapy  
51 N/A Multivariate: 
2.50 (1.40–4.48) 
p=0.002 
 
N/A GPS 
10.  Nakach et al 
2007 (456)   
Retrospective   Pancreatic Japan  74 CRP>50mg/L Second line palliative 
chemo 
71 74 N/A Multivariate: 
3.291 (1.681– 
6.444) p=0.001 
Performance Status, 
Peritoneal 
Dissemination 
11.  Ramsey et al 
2007 (31)  
Retrospective  Renal Cell  
 
UK  119 CRP: >10mg/L 
 
 
Active Immunotherapy  102 N/A Multivariate:  
2.85 (1.49-5.45) 
P = 0.002 
 
 
N/A MSKCC, MRCCPS, 
GPS, Calcium, 
Albumin  
12.  Tanaka et al 
2008 (457)  
Retrospective  Pancreatic Japan 264 CRP>50mg/L Single-agent 
gemcitabine therapy  
235 264 N/A (PFS given 
but not CSS) 
Multivariate: 
1.86 (1.22– 
2.85) p<0.001 
Karnofsky performance 
status, TNM stage, Hb, 
CA19-9 
13.  Beer et al 2008 
(458)   
Prospective  Prostate USA 160 CRP: 8mg/L Docetaxel-based 
chemotherapy 
N/A 63  N/A Multivariate: 
1.41 (1.20–
1.65)  
p<0.001 
CRP Only  
14.  Papadoniou et 
al 2008 (459)   
Retrospective  Pancreatic Greece  215 CRP-5-15mg/L  
 
>15mg/L 
Multiple treatments but 
all palliative 
N/A 215 N/A Univariate: 
5-15mg/l: 8.08 
(4.26-15.26) 
p<0.001 
Tumour location in tail, 
Lymph node spread, 
Treatment, 
Performance status, 
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Univariate: 
>15mg/l: 
18.69 (8.23-
42.40) p<0.001 
Weight loss, CEA and 
Jaundice  
15.  Yoshida et al 
2008 (460)   
Retrospective  Muscle-invasive 
bladder cancer 
Japan 88 CRP > 5mg/L  ChRT: External beam 
radio and two cycles of 
cisplatin  
23 N/A Multivariate:  
1.80 (1.01–2.97) 
p=0.046 
N/A T-stage 
16.  Koch et al 
2009 (461)   
Retrospective  NSCLC Sweden  289 CRP >10mg/L Palliative supportive 
care and platinum 
based chemo 
N/A 272 N/A Multivariate: 
1.50 (1.11–
2.02) p<0.010 
Stage, Performance 
Status, Smoking, Alb 
17.  Hashimoto et 
al 2009 (462)   
Retrospective  Pancreatic  Japan 326  CRP>10mg/L Gemcitabine treatment 
with palliative intent  
N/A 326 N/A Multivariate:  
0.56 (0.42–
0.75) p=0.001 
Inverse HR: 
1.79 (1.33-
2.38) 
KPS, Liver Mets, 
Peritoneal Mets, ALP, 
LDH  
18.  Zacharakis et 
al 2010 (463)   
Retrospective  Colorectal  Greece 541 CRP:  
5-15mg/l 
>15mg/l 
Combination 
Chemotherapy  
N/A 541 N/A Multivariate: 
5-15mg 
1.374 (1.051 
1.797) p=0.020 
 
>15mg: 
1.483 (1.077 
2.040) p=0.016 
low Hb, Low Alb, 
Fatigue, Blood 
transfusions, 
Combination Chemo, 
PS change 
19.  Iwasa et al 
2011 (464)   
Retrospective  Gastric cancer Japan  79 CRP≥20mg/L 5-FU based chemo N/A 79 N/A Multivariate:  
2.03 (1.25–
3.31) p<0.01 
ECOG, Ascites, Alb,  
20.  Falkensammer 
et al 2011 
(465)  
Retrospective  Renal Cell  Austria 86 CRP: >7mg/L Active Chemotherapy  N/A N/A (never 
given in text 
just HR) 
N/A Univariate:  
2.92 
(1.58–5.83) 
p=0.001 
Anaemia, 
Erythropoietin, LDH, 
Neopeterin 
21.  Masago et al 
2010 (466)   
Retrospective  Lung  Japan  79 CRP>10mg/L Gefitinib 
chemotherapy  
N/A 60 N/A Multivariate: 
1.48 (1.15–
1.95) p=0.0073 
EGFR 
22.  Shimoda et al 
2010 (467)  
 
Retrospective  Pancreatic Japan 83 CRP>10mg/L 
 
 
50 patients received 
single-agent treatment 
with gemcitabine 
(GEM), 9 patients 
GEM combined with 
N/A 83 N/A Univariate:  
CRP: 0.92 
(0.67–1.27) 
p=0.6099 
 
Albumin 
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radiotherapy (GEM+R) 
and 24 patients had 
best supportive care 
(BSC). 
Inverse HR: 
1.09 (0.79-
1.50) 
 
23.  Shinohara et al 
2013 (468)  
Retrospective  Renal Cell  Japan 407 CRP>3mg/L Multiple treatments 
including Cytokine 362 
77 IFN-α, IL-2, Chemo 
& mastectomy  
Generally poor 
outcome 
307 323 N/A Multivariate:  
2.1 (1.5–3.0) 
p<0.001 
Time from initial 
diagnosis to metastasis, 
Hb, corrected Ca, 
LDH, Liver metastasis, 
Bone Metastasis, 
Lymph Node 
Metastasis 
24.  Yi et al 2011 
(469)   
Retrospective  Pancreatic Korea  298 CRP>12mg/L 
 
Gemcitabine-based 
chemotherapy 
N/A 298 (Not 
specifically 
mentioned) 
N/A Multivariate:  
1.57: (1.07-
2.30)  
p= 0.021 
Metastasis to the liver, 
Ascites or 
carcinomatosis, 
Albumin 
25.  Kume et al 
2011 (470)   
Retrospective  Renal Cell  Japan  94 CRP>3mg/l Palliative chemo N/A 86 N/A Multivariate: 
2.11 (1.13–
3.93) p=0.018 
Sarcomatid 
differentiation, 
Vertebral Bone 
Involvement, 
Extraosseous 
metastasis, ALP 
26.  Lee et al 2011 
(471)   
Prospective  Multiple  Korea 126 CRP≥92mg/L Palliative symptomatic 
control and 
chemotherapy  
N/A 36  N/A Multivariate:  
2.44 (1.30- 
4.60) p=0.006  
Chemotherapy  
27.  Byström et al 
2012 (472)  
Retrospective  Colorectal  Sweden  106 CRP>5mg/L Active Chemotherapy  N/A 
 
 
60 N/A Univariate:  
1.46 (1.176-
1.822) p=0.001 
Multivariate: 
1.11 (0.86-
1.44) p=0.435 
TPA, TIMP  
28.  Ishioka et al 
2012 (473)   
Retrospective  Urothelial Japan  223 CRP: 
Continuous 
 
Palliative Chemo and 
radiotherapy for half 
with 45% treated with 
best supportive care 
184 184 N/A Multivariate: 
1.60 (1.19–
2.15) p=0.001 
Age, ECOG PS≥2, 
Haemoglobin, Log 
(LDH) Visceral 
Metastasis, Lymph 
Node Metastasis 
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29.  Prins et al 
2012 (474)   
Retrospective  Prostate USA 119 CRP: 
continuous, per 
each doubling 
of CRP) 
End of life symptom 
care and palliative 
chemo 
N/A 106 N/A Multivariate: 
1.11 (1.02–
1.20) p=0.013 
Alkaline phosphatase, 
Haemoglobin  
30.  Zeng et al 
2012 (475)   
Retrospective  Laryngeal  China 57 CRP>8mg/L Palliative chemo-
radiotherapy including 
platinum chemo 
29 N/A Multivariate: 
2.66 (1.22–5.82) 
p=0.014 
N/A Tumour site (glottic vs. 
supraglottic vs. 
subglottic) 
31.  Pond et al 
2012 (476)   
Retrospective  Prostate USA and 
Canada 
116 CRP: ≥8 mg/L Docetaxel-based 
chemotherapy 
N/A 108 N/A Multivariate: 
1.37 (1.13 – 
1.66) p=0.002 
PCWG-2 Subtype, 
Risk groups, Halabi 
nomogram, Smaletz 
nomogram 
32.  Kinoshita et al 
2012 (477)   
Prospective  HCC Japan  135 CRP>10mg/L Multimodal treatment 
including platinum 
chemo 
N/A 123 N/A Multivariate: 
3.31 (1.73–
6.32) p<0.001 
a-Fetoprotein level, 
Tumour Numbers, Alb, 
CRP 
33.  Morizane et al 
2012 (478)   
Retrospective   Urothelial  Japan  30 CRP>10mg/L Gemcitabine-cisplatin 
or carboplatin 
21 N/A Multivariate:  
4.61 (1.76-
12.05) 
p=0.002 
N/A CRP Only  
34.  Haas et al 
2013 (479)   
Retrospective  Pancreatic  Germany  291 CRP>10 mg/L 
but expressed as 
Log 80 
Palliative Chemo N/A 237 N/A Multivariate: 
1.32 (1.06–
1.63) p=0.011 
Stage of Disease, 
Tumour Grading, KPS, 
Log 
35.  Xia et al 2013 
(480)   
Prospective  Nasopharyngeal  China 335 CRP>2.46mg/L 
 
Chemo, Radio and 
combined therapies  
37 42 N/A Multivariate:  
2.114 (1.10- 
4.08) p=0.026 
Node classification  
36.  Yasuda et al 
2013 (481)   
Retrospective  RCC Japan  52 CRP≥8mg/l 31 and 21 patients were 
administered sunitinib 
and sorafenib, 
respectively 
20 22 N/A Multivariate: 
1.79 (1.15–
2.86) p=0.0099 
Neutrophils  
37.  Shirakawa et al 
2014 (482)   
Retrospective  Oesophageal Japan  163 CRP>10mg/L Palliative 
Chemotherapy, which 
is platinum, based 
N/A 163 N/A Multivariate:  
1.631 (1.119–
2.376) p=0.011 
Performance status, 
Number of Mets ≥3 
versus <3 
38.  Teishima et al 
2014 (483)  
Retrospective  Renal Cell  Japan   140 CRP>3mg/L Active Molecular 
Therapy  
70 73 N/A Multivariate: 
3.90 (2.06-
7.37) P<0.001 
Number of Mets, Prior 
nephrectomy 
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39.  Deberne et al 
2014 (484)  
Retrospective   Lung France  55 CRP>7mg/L Multiple treatments 
including 
chemotherapy, 
radiotherapy, and best 
supportive care some 
palliative surgery as 
well 
N/A 50  N/A Univariate:  
4.3 (2.38-7.8) 
p<0.001 
Leucocytes, 
Neutrophils, Hb, Alb, 
ALk P, Corrected Ca 
40.  Beuselinck et 
al 2014 (485)   
Retrospective  Renal Cell  Belgium  200 CRP>5mg/L Active sunitinib 
treatment  
   Univariate:  
3.17 (2.20-
4.68) 
p<0.001 
CRP Only  
41.  Xue et al 2014 
(486)   
Retrospective  Pancreatic  Japan 269 CRP<5mg/l 
 
Palliative 
Chemotherapy  
231 N/A N/A Multivariate:  
0.63 (0.41-
0.89) p=0.01 
Inverse HR: 
1.58 (1.12-
2.44) 
The status of initially 
unresectable/recurrent, 
Distant Mets, ECOG 
PS, CA19-9, CEA, 
LDH  
42.  Formica et al 
2014 (487)  
Retrospective  Colorectal  USA 106 CRP 
(Continuous)  
Fluorouracil, irinotecan 
and bevacizumab 
N/A 60 N/A Multivariate:  
1.01 (1.00-
1.02) p=0.0138 
NLR  
43.  Kim et al 2014 
(488)   
Prospective  Multiple Korea  141 CRP>10mg/L End of life best 
supportive care  
N/A 141 N/A Multivariate:  
1.64 (1.07–
2.52) p=0.023 
KPS, Time to terminal 
cancer<12 months, 
NLR>5  
 
 
44.  Xue-Feng et al 
2015 (489)   
Retrospective   Lung China  127 CRP>10mg/L Palliative 
Chemotherapy  
N/A 127 N/A Multivariate:   
1.80 (1.19-
2.71) p=0.005 
CEA, Lymph Node N2 
45.  Fiala et al 
2015 (490)   
Retrospective   NSCLC Czech Rep 595 CRP≥10mg/L Erlotinib N/A 395 N/A Multivariate:  
1.63 (1.30-
2.03) P<0.001 
EGFR Status, Stage, 
ECOG 
46.  Adams et al 
2015 (491)  
Retrospective  Diffuse large B 
cell lymphoma 
Netherlands 104 CRP>10mg/L Rituximab, 
Hydroxydaunorubicin, 
Oncovin, and 
prednisolone (R-
CHOP). 
N/A 34 N/A Univariate:   
2.60 (1.07-
6.30) 
p=0 .036 
NCCN-IPI  
47.  Ito et al 2011 
(492)   
Retrospective  
 
Prostate Japan 80 CRP>5mg/L Docetaxel and active 
chemotherapy  
37 38 N/A Multivariate:  
1.95 (1.33-
2.96) p<0.001 
Hb 
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48.  Li et al 2015 
(493)   
Retrospective  Osteosarcoma China  85 CRP>10mg/L Active Chemotherapy 
multiple types 
N/A N/A N/A Multivariate:  
2.39 (1.22–
4.67) p=0.01 
Tumour size, poor 
response to chemo, 
Metastatic disease 
49.  Tang et al 
2015 (494)  
Retrospective  Nasopharyngeal  China  1589 hs-CRP>1.96 
mg/L 
Chemoradiotherapy 
with chemo being 
platinum based 
N/A 153 N/A 
 
Multivariate:  
1.72 (1.24-
2.40) p=0.001 
Age, Tumour Stage, 
BMI, EBV DNA 
50.  Thurner et al 
2015 (495)   
Retrospective  Prostate Austria  261 CRP≥8.6mg/L  Confocal Radiotherapy 
with ADT therapy 
24 59 Multivariate:  
4.31 (1.22-15.1) 
p=0.023  
Multivariate: 
3.24 (1.84-
5.71) p<0.001 
PSA (10-20) 
51.  Zeng et al 
2015 (496)   
Retrospective  Nasopharyngeal  China  79 CRP>8mg/L Chemoradiotherapy 
with platinum-based 
chemo 
23 N/A Multivariate:   
3.04 (1.22-7.55) 
p=0.017 
N/A CRP Only  
52.  Xu et al 2015 
(497)  
Retrospective  Prostate China  135 CRP>10mg/L Palliative care 
treatment with no 
mention of type 
N/A 124 N/A Multivariate:   
2.39 (1.56-
3.69)  
p<0.001 
 Gleason Score 
53.  Go et al 2015 
(498)   
Retrospective  Lung  Korea 134 CRP≥19mg/L 
 
 
Palliative chemo in 
patients with advanced 
Lung Ca developing 
VTE 
N/A N/A 
(Probability 
of survival 
given in 
months) 
N/A Multivariate: 
1.596 (0.888-
2.865) p=0.118  
 
Stage, Alb, AMC 
54.  Martin et al 
2014 (295)  
Retrospective  Pancreatic  Australia  124 CRP>10mg/L 
 
Chemo for metastatic 
disease and radio for 
locally advanced 
N/A 114 N/A Multivariate:  
1.42 (0.89-
2.01) p=0.15 
 
 
CA19-9, ALC, ANC, 
Platelet, NLR, PLR, 
mGPS, Alb, ECOG 
55.  Mitsunaga et al 
2016 (297)  
Retrospective 
and 
Prospective  
Pancreas Japan  280 
(Prospective: 
141) 
CRP: 
Inter: >5-
20mg/L  
and  
High: >20mg/L 
 
 
GEM chemotherapy  N/A 280 (141 
prospective)  
N/A Retrospective 
Multivariate:  
Inter: 1.5 (1.1-
2.0) p=0.02 
High: 2.6 (1.9-
3.6) p<0.01 
Prospective 
Multivariate:  
Inter: 1.5 (0.8-
2.8) p=0.19 
High: 4.0 (1.6-
10.3) p<0.01 
Sex, Age, ECOG-PS, 
UICC stage, CA 19-9, 
mGPS, NLR 
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56.  Kim et al 2015 
(499)   
Retrospective  Pancreatic 
Ductal Ca 
Korea  343 (212 
underwent 
palliative 
chemo) 
CRP>10mg/L 
 
 
FOLFIRINOX and 
Gemcitabine based 
chemo  
N/A 343 N/A Multivariate: 
Whole Group: 
2.313 (1.658-
3.228) p<0.001  
Palliative 
Chemo: 
2.449 (1.635-
3.667) p<0.001  
ECOG, Alb, NLR 
Initial site of Mets, No 
initial chemotherapy 
57.  Yao et al 2105 
(500)  
Retrospective  Prostate Japan  57 CRP>18mg/L Docetaxel 
Chemotherapy  
N/A 55 N/A Multivariate:  
1.312 (0.428-
4.015) p=0.635 
 
Biopsy Gleason Score, 
PSA values, NLR 
58.  Wu et al 2015 
(501)  
Prospective  Lung  China 366 CRP>10.4mg/L Combination 
Chemotherapy  
N/A 366 N/A Multivariate: 
1.774 (1.270-
2.477) p=0.001 
Metastasis, NLR 
59.  Middleton et al 
2016 (502)   
Retrospective  Pancreatic 
Ductal Ca 
UK 38 CRP 
(Continuous) 
Combination 
gemcitabine and 
capecitabine chemo 
N/A 38 N/A Multivariate: 
1.55 (1.00-
2.39) p=0.049 
Log CA19-9 
60.  Casadei et al 
2016 (503)  
Prospective  Metastatic 
Colorectal Ca 
Italy  132 hs-CRP 
(Continuous) 
Combination 
chemotherapy 
including bevacizumab 
N/A 124 N/A Univariate:  
1.006 (1.004-
1.009) 
p<0.0001 
N/A 
 
61.  Sheng et al 
2016 (504)   
Retrospective  NSCLC China 144  CRP 
(Relatively High 
vs. Relatively 
Low) 
Combination 
Chemotherapy  
N/A 144 N/A Univariate  
1.43 (0.83-
2.47) p=0.204 
Current or ex-smoker, 
stage, ECOG-PS, PNI 
62.  Kou et al 2016 
(505)  
Retrospective  Pancreatic  Japan 306 CRP≥5mg/L Combination 
chemotherapy with 
palliative intent  
N/A 249 N/A Multivariate: 
1.24 (0.93-
1.65) p=0.15 
ECOG PS, Distant 
Metastasis, Initially 
unresectable, CEA, 
CA19-9, NLR 
63.  Ahn et al 2016 
(506)  
Retrospective  Multiple Cancer 
Types 
Korea 187 CRP≥8.4mg/L Best supportive care N/A 187 N/A Univariate: 
1.37 (1.03-
1.82) p=0.028 
ECOG PS≥3, High PPI 
score≥6, 
hyperbilirubinemia 
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Table 17.2: Studies investigating the prognostic value of Albumin in an unselected cohort of patients with advanced cancer 
No:  
Albumin  
Study Type of 
Study 
Cancer Country  Patients 
(n) 
Measure of SIR Systemic Treatment  Cancer 
deaths 
(n) 
Overall 
deaths  
(n) 
Cancer 
Survival 
(HR, 95% CI) 
Overall 
Survival 
(HR, 95% CI) 
Independent 
Prognostic Factors 
1.  Axdorph et 
al 2000 
(507)  
Retrospective  Hodgkin’s 
disease 
UK 145 Alb<40g/L 
 
 
Multiple treatments 
including MOPP 
chemo and radio  
48 57 Multivariate: 
2.56 (1.05-
6.25) p=0.037 
 
 
N/A IL-10, Hb<105g/dL 
2.  Viganó et al 
2000 (508) 
  
Retrospective Multiple 
palliative cancers 
Canada 227 Alb<35g/L 
 
 
Symptomatic 
palliative treatment  
N/A 208 N/A Univariate:  
1.9 (1.4-2.8) 
p<0.01 
 
  
Weight loss, 
Lymphocyte, Alk 
Phos, Karnofsky 
Performance status, 
ECOG 
3.  Maréchal et 
al 2007 
(509)  
Retrospective  Pancreatic 
Cancer  
Belgium  99 Alb<35g/L Gemcitabine based 
chemo as 2nd line 
N/A 90 N/A Multivariate: 
4.06 (1.88–
8.77) p<0.001  
CA19-9 
4.  Lam et al 
2007 (510)  
Prospective  Multiple Hong Kong 170 Alb (No 
threshold) 
 
 
Palliative supportive 
treatment  
N/A 167 N/A Multivariate:  
0.95 (0.92-
0.98) p=0.001 
 
Inverse HR: 
1.05 (1.02-
1.09) 
Age, Number of 
Mets, Karnofsky 
Performance Status, 
Edmonton Symptom 
Assessment System 
5.  Ramsey et al 
2007 (31)  
Retrospective  Renal Cell cancer  
 
Metastatic 
UK 119 Alb:<35g/L 
 
 
Active 
Immunotherapy  
102 N/A Multivariate:  
2.63 (1.38-
5.03)  
P=0.003 
 
N/A MSKCC, MRCCPS, 
GPS, Calcium, CRP 
6.  Paralkar et al 
2008 (511)  
Retrospective  NSCLC USA 172 Alb≤30g/L Palliative 
chemotherapy  
N/A 159 N/A Multivariate: 
1.7 (1.11-2.76) 
p=0.02 
ECOG PS, Number 
of Mets 
7.  Ngo et al 
2008 (512)   
Retrospective  B-cell lymphoma Singapore 183 Alb<37g/L CHOP 
(cyclophosphamide, 
doxorubicin, 
vincristine, and 
prednisolone) 
N/A 71 (2-year 
death rates)  
N/A Multivariate:  
2.29 (1.28–
4.10)  
p=0.005 
Age, LDH, Stage  
 414 
8.  Iwasa et al 
2011 (464)  
Retrospective   Disseminated 
gastric cancer 
Japan  79 Alb<30mg/L  5-FU based chemo N/A 79 N/A Multivariate 
1.69 (1.05-
2.73) p=0.03 
ECOG, Ascites, CRP 
9.  Shimoda et 
al 2010 
(467)  
 
Retrospective  Pancreatic Japan 83 Alb<35g/L 
 
 
50 patients received 
single-agent treatment 
with gemcitabine 
(GEM), 9 patients 
GEM combined with 
radiotherapy 
(GEM+R) and 24 
patients had best 
supportive care 
(BSC). 
N/A 83 N/A Univariate:  
7.15 (1.08–
47.43) 
P=0.042 
 
 
Albumin Only  
10.  Shim et al 
2011 (513)    
Retrospective   Gastric Cancer Korea 502 Alb<40g/L Taxanes and cisplatin 
as first line. 2nd line 
oral fluoropyrimidine 
monotherapy 
N/A 502 N/A Multivariate:  
1.82 (1.32-
2.53) 
 P < 0.001 
ECOG, Histological 
grade, PFS< 2.7 
months  
11.  Yi et al 2011 
(469)   
Retrospective  Pancreatic Korea  298 Alb<35mg/L Gemcitabine-based 
chemotherapy 
N/A 298  N/A Multivariate: 
1.701: (1.085-
2.667)  
p=0.021 
Metastasis to the 
liver, Ascites or 
carcinomatosis, CRP 
12.  Trédan et al 
2011 (514)   
Prospective  Multiple France  299 Alb<38 g/l 
 
 
Patients treated with 
palliative chemo but 
no specific mention of 
the type 
N/A 264 N/A Multivariate: 
1.47 (1.02-
2.11) p=0.0374 
 
 
ECOG, IL-6, LDH, 
Lymphocyte Count, 
Platelet Count 
13.  Lim et al 
2012 (515)   
Prospective  Biliary Tract 
Cancer 
Korea 50 Alb<35g/L iFAM chemotherapy 
in advanced biliary 
cancer 
N/A 49 N/A  Multivariate: 
2.11 (1.057–
4.22) p=0.034  
ECOG, Response to 
chemotherapy 
14.  Prakash et al 
2012 (516)  
Retrospective   B-cell lymphoma India 486 Alb<40g/L 
 
 
CHOP Chemo and 
IFRT chemo in 
resistant disease 
N/A 314 N/A Univariate: 
2.36 (1.32–
4.22) p=0.004 
 
 
Elevated LDH, LR: 
Not attained, Age≥60, 
PS (2,3,4), IPI: 
Intermediate and high 
risk, Cycles <6, 
Hb<10 
15.  Kang et al 
2014 (517)   
Retrospective  Biliary Tract Korea 168 Alb<35g/L Chemotherapy 
ultimately palliative. 
Chemo was platinum 
based 
N/A 168 N/A Multivariate: 
2.0 (1.0–3.8) 
p=0.036 
ECOG, Site of Mets 
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16.  Ulas et al 
2014 (518)   
Retrospective  Lung Cancer Turkey  462 Alb<30g/L  Platinum based 
chemotherapy as both 
1st and 2nd line treat 
N/A 391 N/A Multivariate: 
1.28 (0.98-
1.67) p=0.037 
LDH, ECOG, 
Calcium, Liver Mets, 
Malignant Pleural 
effusion, 
Chemotherapy, No of 
Mets, LPI 
17.  Imedio et al 
2014 (519)  
Retrospective  HCC Spain  62 ALB<35g/L TACE chemotherapy 
sorafenib, followed by 
second line erlotinib 
N/A 44 N/A Multivariate:  
2.99 (1.03–
8.66) P=0.044 
PS, Alcohol ethology 
18.  Malik et al 
2014 (520)  
Retrospective  Renal USA  70 Alb<34g/L Bio/chemo or 
combination therapy 
N/A 51 N/A Multivariate: 
2.82 (1.04-
7.65) p=0.042 
Age, Sex, ECOG, 
Mets, LDH 
19.  Tsai et al 
2014 (521)  
Prospective Multiple Taiwan  522 Alb<30g/L 
 
 
Palliative and 
supportive care 
N/A 479 N/A Multivariate: 
1.98 (1.01-
3.88) p<0.05 
AST 
20.  Stenman et 
al 2014 
(522)   
Retrospective  Renal Cell 
Cancer  
Sweden  84 Alb<30 g/L 
 
Chemotherapy, 
Radiotherapy and 
20% had Mastectomy  
N/A 84 N/A Multivariate: 
2.72 (1.22-
6.09) P=0.015 
 
Albumin Only  
21.  Koo et al 
2015 (523)   
Retrospective  Gastric Cancer Korea 3888 Alb<33g/L 
 
 
Palliative 
Chemotherapy  
N/A 3494 N/A Multivariate: 
1.32 (1.22-
1.44) p<0.001 
ECOG, No 
gastronomy, 
Peritoneal, Bone and 
Liver Mets, Bilirubin, 
ALP  
22.  Xue-Feng et 
al 2015 
(489)   
Retrospective   Lung China  127 Alb: Normal vs. 
Low 
Palliative 
Chemotherapy  
N/A 127 N/A Multivariate:  
0.928 (0.531-
1.622) p=0.793 
Inverse:  
1.078 (0.617-
1.883) 
CRP, CEA, Lymph 
Node N2 
23.  Kao et al 
2015 (524)  
Retrospective  Multiple  USA 143 Alb≥34g/L vs. 
24mg/L to 
33mg/L vs. 
<24mg/L 
Palliative 
Radiotherapy  
N/A 69 N/A Multivariate: 
2.09 (1.25-
3.48) p=0.005 
ECOG, Number of 
Active Tumours, 
Tumour site 
24.  Wild et al 
2015 (525)   
Retrospective  Pancreatic 
Adenocarcinoma 
USA  101 Baseline Alb: 
continuous  
 
  
Palliative 
chemoradiation  
86 88 N/A Multivariate:  
3.584 (1.832-
6.993) 
p=0.0002 
 
Lymph Node Count, 
Baseline Bun and 
platelets both 
continuous, PTV: 
continuous  
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25.  Helissey et 
al 2015 
(526)   
Retrospective  Breast Cancer France  56 Alb<35g/L 
 
CirCe01 phase III trial 
using platinum 
chemotherapy  
N/A 26 N/A  Multivariate: 
11.1 (3.6–34) 
p<0.001  
  
CTC >5, Receptor 
Status, Performance 
Status 
26.  
 
Narwani et 
al 2015 
(527)  
Retrospective  Multiple 
Myeloma 
UK  38 Alb<35g/L Chemo consists of 
oral 
cyclophosphamide 
500 mg once weekly: 
thalidomide 100 mg/d 
N/A 22 N/A Multivariate:  
9.34 (2.82-
30.92) p<0.001 
 
 
ALC, Age 
 
 
27.  Go et al 
2015 (498)  
Retrospective  Lung  Korea 134 Alb<35g/L 
 
 
Palliative chemo in 
patients with 
advanced Lung Ca 
developing VTE 
N/A N/A 
(Probability 
of survival 
given in 
months) 
N/A Multivariate: 
1.92 (1.07-
3.44) p=0.029 
Stage, AMC 
28.  Martin et al 
2015 (295)   
Retrospective   Pancreatic 
Cancer  
Australia  124 Alb<35g/L vs. 
>35g/L 
 
 
Chemo for metastatic 
disease and radio for 
locally advanced 
N/A 114 N/A Multivariate:  
0.47 (0.31-
0.72) p <0.001 
 
Inverse:  
2.12 (1.39-
3.23) 
 
CA19-9, ALC, ANC, 
Platelet, NLR, PLR, 
mGPS, ECOG 
29.  Kou et al 
2016 (505)  
Retrospective  Pancreatic 
Cancer  
Japan 306 Alb<35g/L Combination 
chemotherapy with 
palliative intent  
N/A 249 N/A Multivariate: 
0.80 (0.59-
1.09) p=0.15 
ECOG PS, Distant 
Metastasis, Initially 
unresectable, CEA, 
CA19-9, NLR 
30.  Moon et al 
2016 (528)  
Prospective  Neck Squamous 
Cell Ca 
Korea 153 Alb<33g/L Combination 
chemotherapy and 
chemoradiotherapy  
24 27 Multivariate:  
3.80 (1.57-
9.19) p=0.003 
N/A ECOG 1/0, BMI 
<18.5/others, NLR 
31.  Uemura et a 
2016 (529)  
Retrospective  Prostate Japan  41 Alb<39g/L Combination 
chemotherapy 
including docetaxel  
22 22 (All 
patients 
died of 
prostate Ca) 
Multivariate: 
3.776 (1.238-
11.516) p=0.02 
Multivariate: 
3.776 (1.238-
11.516) p=0.02 
BSI (>1% vs. ≤1%) 
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32.  Dorajoo et al 
2016 (530)  
Retrospective  Colorectal  Singapore  482 Alb<35g/L Combination chemo 
for Mets after 
previous resection of 
primary tumour 
N/A 480 N/A Multivariate:  
1.295 (1.039-
1.614) p=0.022 
Age≥65, Poorly 
differentiated Ca, Met 
site: Live r, Lung, 
Carcinomatosis, 
Bone, 
Carcinoembryonic 
antigen  
33.  Choi et al 
2016 (531)  
Retrospective  Pancreatic  Korea 396 Alb: Decreased  Palliative 
Chemotherapy  
N/A 396 N/A Univariate:  
1.380 (1.098-
1.735) p=0.006 
ECOG PS, CA19-9 
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Table 17.3: Studies investigating the prognostic value of WCC in an unselected cohort of patients with advanced cancer  
No:  
White 
Blood Cells 
Study Type of 
Study 
Cancer Country  Patients 
(n) 
Measure of SIR Systemic Treatment  Cancer 
deaths 
(n) 
Overall 
deaths 
(n) 
Cancer 
Survival 
(HR, 
95%CI) 
Overall 
survival 
(HR, 
95%CI)  
Independent 
Prognostic Factors 
1.  Mandreka et 
al 2006 (532)  
Retrospective  Lung  USA 1053 WCC> 
(>10.2x109 /L for 
males and 
>10.6x109 /L for 
females Low) 
 
Chemotherapy 
majority platinum 
based 
N/A 1011 N/A Multivariate: 
1.44 (1.23–
1.69) p=0.001 
ECOG, Stage, BMI 
Underweight, High 
Hb 
2.  Ramsey et al 
2007 (31)  
Retrospective  Renal Cell  
 
UK  119 WCC>11x109/L 
 
 
Active 
Immunotherapy  
102 N/A Multivariate:  
1.66 (1.17-
2.35) P = 
0.004 
 
 
N/A MSKCC, MRCCPS, 
GPS, Calcium, CRP, 
Albumin  
3.  Tibaldi et al 
2008 (533)  
Retrospective  Lung  Italy 320 WCC>10 (>10 x 
109/L) 
Chemo Active with 
cisplatin + 
gemcitabine or 
gemcitabine alone 
N/A 280 N/A Multivariate: 
1.79 (1.37–
2.33) 
p=0.0001 
Performance status, 
Histology, Brain 
metastasis 
4.  Partridge et al 
2012 (309)   
Retrospective  Multiple UK 101 (GPS 2) WCC>10x109/L Palliative end of life 
supportive care 
N/A 47 (4-week 
mortality) 
N/A Multivariate: 
1.015 (1.004-
1.026) 
p=0.005 
 
mGPS 2, Age, 
Primary cancer site: 
Breast 
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Table 17.4: Studies investigating the prognostic value of Neutrophils in an unselected cohort of patients with advanced cancer 
No: 
Neutrophils 
Study Type of 
Study 
Cancer Country  Patients 
(n) 
Measure of SIR Systemic Treatment  Cancer 
deaths  
(n) 
Overall 
deaths 
(n) 
Cancer 
survival 
(HR, 
95%CI) 
Overall 
survival 
(HR, 
95%CI)  
Independent 
Prognostic Factors 
1.  Lee et al 2011 
(534)   
Retrospective   Breast  Australia  693 Neutrophil (log 
scale) above 
baseline of 
≥7x109/L 
 
 
Active chemotherapy 
as part of two trials  
N/A 577 N/A Multivariate: 
1.34 (1.11–
1.62) p=0.003 
 
 
ECOG, ER Status, 
Number of visceral 
Mets, Age, Alk 
Phos, Hb 
2.  Kawashima et 
al 2012 (535)  
Retrospective  Renal Cell  Japan   87 Neutrophil>ULN 
 
 
Active 
Chemotherapy   
87 N/A Multivariate: 
3.597 (1.046–
12.364) 
P=0.042 
N/A Serum Sodium, CRP 
3.  Deberne et al 
2014 (484)  
Retrospective  Lung France  55 Neutrophil: >8000 
/mm3 
 
 
Multiple treatments 
including 
chemotherapy, 
radiotherapy, and 
best supportive care  
N/A 50  N/A Univariate:  
3.08 (1.36-7) 
p=0.0001 
 
 
Leucocytes, Hb, Alb, 
ALk P, Corrected 
Ca, CRP 
4.  Luo et al 2015 
(536)   
Retrospective  Nasopharyngeal  China 419 Absolute 
Neutrophil Count 
(ANC) >4.7x109L 
Chemotherapy which 
was active, and 
cisplatin based  
180 N/A Multivariate: 
2.780 (1.819-
4.247) 
p<0.001 
N/A Age, Stage III/IV, 
ANC, AER 
5.  Lacovelli et al 
2015 (537)  
Retrospective  Renal Cell  Italy  281 Neutrophils >ULN 
Hb<LLN 
Does not seem to 
mention specifics 
about chemo 
N/A 131 N/A Multivariate: 
1.99 (1.21-
3.27) p=0.006 
Mets at Diagnosis, 
ECOG, Hb, Liver 
Mets 
6.  Wu et al 2015 
(501)  
Prospective  Lung  China 366 Neutrophil 
>3.41x109cells/ml 
Combination 
Chemotherapy  
N/A 366 N/A Multivariate: 
1.020 (0.655-
1.586) 
p=0.931 
Metastasis, NLR, 
CRP 
7.  Ferrucci et al 
2016 (538)   
Prospective  Metastatic 
Melanoma 
Italy 720 ANC≥7500 Ipilimumab N/A 662 N/A Multivariate: 
3.38 (2.62-
4.36) 
p<0.0001 
ECOG, Brain Mets, 
Liver Mets 
 420 
8.  Bille et al 
2016 (539)  
Retrospective  Pleural 
Mesothelioma  
USA 191 Neutrophils >ULN First line 
combination 
chemotherapy  
N/A 191 N/A Multivariate: 
1.27 (0.82-
1.99) p=0.29 
Platelet count, 
Performance status, 
Histological 
diagnosis 
9.  Zaragoza et al 
2016 (540)  
Retrospective  Melanoma France 58 Neutrophils: 
continuous  
Neutrophils: 
≥7.5x109/L 
Chemotherapy 
including ipilimumab 
N/A 22 N/A Univariate:  
Continuous: 
1.34  (1.17-
1.53) 
p<0.0001 
 
≥7.5x109 /L : 
3.28 (1.38-
7.78) p=0.007 
LDH IU, 
Performance Status 
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Table 17.5: Studies investigating the prognostic value of Lymphocytes in an unselected cohort of patients with advanced cancer 
No: 
Lymphocytes 
Study Type of 
Study 
Cancer Country  Patients 
(n) 
Measure of SIR Systemic Treatment  Cancer 
deaths 
(n) 
Overall 
deaths  
(n) 
Cancer 
survival 
(HR,95%CI) 
Overall 
survival  
(HR,95%CI) 
Independent 
Prognostic Factors 
1.  Oki et al 
2008 (541)   
Retrospective    B-cell 
Lymphoma 
Japan 221 ALC<1x109/L Chemotherapy 
including Rituximab 
N/A N/A 
(percentage 
range given) 
N/A Multivariate: 
2.51 (1.38–
4.58) p=0.003 
IPI as a linear 
parameter 
2.  Trédan et al 
2011 (514)  
Prospective  Multiple France  299 lymphocyte count 
≤700/μL 
 
 
Patients treated with 
palliative chemo but 
no specific mention 
of the type 
N/A 264 N/A Multivariate: 
1.43 (1.04-
1.95) 
p=0.0268 
 
 
ECOG, IL-6, LDH, 
Alb, Platelet Count 
3.  Furukawa et 
al 2012 (542)   
Retrospective  Pancreatic   Japan  41 Lymph 
Count>2000/µl 
Nafamostat Mesilate 
Combined with 
Gemcitabine 
Chemotherapy 
N/A 41 N/A Multivariate: 
 24.016 
(5.003-
115.278) 
p<0.0001 
Jaundice, Ascites, 
CA19-9 
4.  Lin et al 2014 
(543)  
Retrospective  SCLC China 370 ALC≥0.45x109/L  Platinum based 
doublet 
chemotherapy 
N/A 370 N/A Multivariate: 
2.039 (1.488-
2.795) 
p<0.001 
LMR, Histology, 
ECOG 
5.  Lin et al 2014 
(544)  
Retrospective  Nasopharyngeal  China 281 ALC<2.25x109/L  Cisplatin based 
chemotherapy  
N/A 255 N/A Multivariate: 
0.59 (0.43-
0.81) p=0.001 
Age, LMR 
6.  Wild et al 
2015 (525)  
Retrospective  Pancreatic  USA  101 Lymph (<500 vs. 
≥500) 
 
  
Palliative 
chemoradiation  
86 88 N/A Multivariate:  
2.879  
(1.531-5.415) 
p=0.001  
 
 
Baseline Alb, 
Baseline Bun and 
platelets both 
continuous, PTV: 
continuous  
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7.  Bille et al 
2016 (539)  
Retrospective  Pleural 
Mesothelioma  
USA 191 lymphocyte (>1.4 
vs. ≤1.4)  
First line 
combination 
chemotherapy  
N/A 191 N/A Multivariate: 
0.78 (0.54-
1.12) P=0.17 
 
Inverse HR:  
1.282 (0.893-
1.852) 
Platelet count, 
Performance status, 
Histological 
diagnosis 
8.  Lin et al 2016 
(545)  
Retrospective  Metastatic 
Colorectal  
China  488 ALC ≥2.70x109/L FOLFOX 
chemotherapy  
N/A 479 N/A Multivariate:  
0.841 (0.676-
1.047) 
p=0.391 
 
Inverse HR:  
1.189 (0.955-
1.479) 
Gender, ECOG 
Performance, 
Tumour 
differentiation, Pre-
chemo AMC and 
LMR 
9.  Wu et al 2016 
(546)  
Retrospective  Cervical Cancer  US  71 TLC≥1000 
cells/mm3 
Platinum based 
chemoradiation  
N/A 42 N/A Multivariate: 
0.23 (0.05-
1.03) p=0.053 
 
Inverse HR:  
4.348 (0.971-
20) 
Stage III disease  
10.  Choi et al 
2016 (531)  
Retrospective  Pancreatic  Korea 396 Lymphocytes 
<2000 cells/mm3 
Palliative 
Chemotherapy  
N/A 396 N/A Univariate:  
1.410 (1.119-
1.777) 
p=0.004 
ECOG PS, CA19-9 
11.  Zaragoza et 
al 2016 (540)  
Retrospective  Melanoma France 58 Lymphocytes: 
continuous  
Chemotherapy 
including ipilimumab 
N/A 22 N/A Univariate; 
0.88 (0.50-
1.54) p<0.20 
 
Inverse HR:  
1.136 (0.649-
2) 
LDH IU, 
Performance Status 
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Table 17.6: Studies investigating the prognostic value of Monocytes in an unselected cohort of patients with advanced cancer 
No: 
Monocytes 
Study Type of 
Study 
Cancer Country  Patients 
(n) 
Measure of SIR Systemic Treatment  Cancer 
deaths 
(n) 
Overall 
deaths 
(n) 
Cancer 
survival 
(HR, 
95%CI) 
Overall 
survival  
(HR, 
95%CI) 
Independent 
Prognostic Factors 
1.  Bari et al 
2013 (547)  
Retrospective  T-cell lymphoma Italy 94 Mono>0.8x109/L Active chemo 
including vincristine 
N/A 48 N/A Multivariate: 
2.41, (1.19–
4.89)  
p =0.015 
PIT Score, 
Histopathology 
2.  Lin et al 
2014 (543)  
Retrospective  SCLC China 370 AMC≥0.45x109/L  Platinum based 
doublet 
chemotherapy 
N/A 370 N/A Multivariate: 
0.928 (0.686-
1.257) 
P=0.631 
LMR, Histology, 
ECOG 
3.  Lin et al 
2014 (544)  
Retrospective  Nasopharyngeal  China 281 AMC≥0.35x109/L  Cisplatin based 
chemotherapy  
N/A 255 N/A Multivariate: 
1.20 (0.85-
1.70) p=0.309 
Age, ALC, LMR 
4.  Go et al 
2015 (498)  
Retrospective  Lung  Korea 134 AMC≥640 cells/µL 
AMC= Absolute 
Mono Count 
Palliative chemo in 
patients with advanced 
Lung Ca developing 
VTE 
N/A N/A 
(Probability 
of survival 
given in 
months) 
N/A Multivariate: 
1.994 (1.137-
3.498) 
p=0.016 
 
 
Stage, Alb,  
5.  Lin et al 
2016 (545)  
Retrospective  Metastatic 
Colorectal  
China  488 AMC ≥0.55x109/L FOLFOX 
chemotherapy  
N/A 479 N/A Multivariate:  
1.514 (1.204-
1.903) 
p<0.001 
Gender, ECOG 
Performance, 
Tumour 
differentiation, Pre-
chemo LMR 
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Table 17.7: Studies investigating the prognostic value of Platelets in an unselected cohort of patients with advanced cancer 
No: 
Platelets 
Study Type of 
Study 
Cancer Country  Patients 
(n) 
Measure of SIR Systemic Treatment  Cancer 
deaths 
(n) 
Overall 
deaths 
(n) 
Cancer 
survival 
(HR, 95%CI) 
Overall 
survival 
(HR, 95%CI) 
Independent 
Prognostic Factors 
1.  Cho et al 
2008 (548)   
Retrospective  Renal Cell  Korea   197 Plate>450,000/mm3 Immunotherapy 
[interferon-α, 
interleukin-2 (IL-2), 
or a combination 
thereof with or 
without 5-
fluorouracil 
127 129 Multivariate: 
1.34 (0.74 – 
2.41) p=0.333 
N/A ECOG-PS, N-stage, 
Sarcomatoid 
differentiation, 
Number of Mets 
2.  Trédan et al 
2011 (514)   
Prospective  Multiple France  299 Plate <130g/L Patients treated with 
palliative chemo but 
no specific mention 
of the type 
N/A 264 N/A Multivariate: 
 1.70 (1.02-
2.81) 
p=0.0402 
ECOG, IL-6, LDH, 
Lymphocyte Count, 
Alb 
3.  Stenman et 
al 2014 (522)  
Retrospective  Renal Cell   Sweden  84 Plate: >360x 109/L Chemo, Radio and 
20% had 
Mastectomy  
N/A 84 N/A Multivariate: 
1.62 (0.79–
3.32) p=0.19 
Albumin Only  
4.  Chen et al 
2015 (549)  
Retrospective  Nasopharyngeal  China  2626 Plate>300×109 /L Active radio and 
chemo or 
combination  
N/A 774 N/A Multivariate:  
1.810 (1.531-
2.140) 
p<0.001 
Age, Sex, T-stage, 
N-stage 
5.  Wild et al 
2015 (525)  
Retrospective  Pancreatic  USA  101 Baseline Plate: 
continuous  
Palliative 
chemoradiation  
86 88 N/A Multivariate:  
1.004 (1.001-
1.007) 
p=0.005  
Baseline Alb, LN 
Count, Baseline Bil 
both continuous, 
PTV: continuous  
6.  Hong et al 
2015 (550)   
Retrospective Lung Cancer  China 919 Plate≥ULN  Chemotherapy and 
radiotherapy 
N/A 892 N/A Multivariate: 
1.016 (0.855-
1.208) 
p=0.856 
Stage, Response to 
treatment, LDH 
7.  Shoultz-
Henley et al 
2016 (551)  
Retrospective Oropharyngeal  USA 433 Plate: 350x109 /L Combined chemo 
and radiotherapy 
N/A Not 
mentioned 
only % 
given  
N/A Multivariate: 
1.9 (1.2-2.9) 
p<0.006 
Anaemia, Dahstrom-
Sturgis category, 
HPV status 
8.  Bille et al 
2016 (539)  
Retrospective  Pleural 
Mesothelioma  
USA 191 Plate>450,000 per 
mm3 
First line 
combination 
chemotherapy  
N/A 191 N/A Multivariate: 
2.09 (1.33-
3.35) p=0.002 
Performance status, 
Histological 
diagnosis 
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Table 17.8: Studies investigating the prognostic value of GPS/mGPS in an unselected cohort of patients with advanced cancer 
No: 
GPS/mGPS 
Study Type of 
Study 
Cancer Country  Patients 
(n) 
Measure of 
SIR 
Systemic 
Treatment  
Cancer 
deaths 
 (n) 
Overall 
deaths 
(n) 
Cancer 
survival 
(HR, 95%CI) 
Overall 
survival  
(HR, 95%CI) 
Independent 
Prognostic 
Factors 
1.  Forrest et al 
2003 (303)   
Retrospective  NSCLC UK  161 GPS (0/1/2)  Chemotherapy 
mainly cisplatin and 
radical radio 
N/A 118 N/A Multivariate:  
1.111(1.23–
2.35) 
P= 0.001 
Stage/ECOG score, 
CRP/Alb score 
2.  Elahi et al 
2004 (230)  
Retrospective  Gastric and 
colorectal  
UK  165 GPS (0/1/2) Palliative Chemo 
and Supportive Care 
N/A 165 N/A Univariate:  
Gastric: 
 1.71 (1.15–
2.25) 
 P = 0.002 
 
Colorectal:  
1.77 (1.51–
2.57) 
P < 0.001) 
Age, Tumour Type 
3.  Crumley et al 
2006 (227)  
Retrospective  Gastro-
oesophageal 
UK 258 GPS (0/1/2) 
 
Chemotherapy and 
radiotherapy with 
palliative intent  
202 211 Multivariate: 
1.51 (1.22-1.86) 
p<0.001 
N/A GPS Only  
4.  Al Murri et al 
2006 (197)  
Retrospective  Breast UK 96 GPS (0/1/2) Chemotherapy and 
endocrine therapy  
51 N/A Multivariate: 
2.26 (1.45-3.52) 
p<0.001 
N/A CRP, Alb  
5.  Glen et al 
2006 (294) 
 
Retrospective  Pancreatic UK 187 GPS (0/1/2) 
 
 
Palliative treatment 
with platinum based 
chemo  
N/A 181 N/A Multivariate:  
1.72 (1.40-
2.11) p< 0.001 
 
Age, TNM 
6.  Read et al 
2006 (270)  
Prospective  Colorectal  Australia  51 GPS (0/1/2) Chemo and 
Radiotherapy as well 
as supportive care 
N/A 32 
 
N/A Multivariate: 
 2.27 (1.09–
4.73) 
P = 0.028 
 
Type of treatment, 
PS, SAP 
 426 
7.  Ramsey et al 
2007 (31)  
Retrospective  Renal Cell   
 
UK  119 GPS: (0/1/2) Active 
Immunotherapy  
102 N/A Multivariate:  
2.35(1.51–3.67) 
P<0.001 
N/A MSKCC, 
MRCCPS, 
Calcium, CRP, 
Albumin  
8.  Leitch et al 
2007 (247)  
Retrospective  Colorectal Liver 
Mets 
UK 84 GPS (0,1,2) Palliative 
chemotherapy  
71 N/A Multivariate:  
1.44 (1.01–
2.04) 
P =0.043 
N/A Age, Single liver 
metastasis, Extra-
hepatic disease, 
chemotherapy 
treatment 
9.  Crumley et al 
2008 (228)  
Retrospective  Gastro-
oesophageal 
UK 65 GPS (0/1/2) Mostly cisplatin 
based chemotherapy  
58 59 Multivariate: 
1.69 (1.00-2.86) 
P=0.05 
N/A GPS Only  
10.  Ramsey et al 
2008 (245)  
Prospective  Renal Cell  UK  23 GPS (0/1/2) Palliative treatment 
with immunotherapy  
N/A 15 N/A Multivariate: 
2.23 (1.06-
4.57) p=0.029 
GPS Only  
11.  Ishizuka et al 
2009 (271) 
 
Retrospective  Colorectal  Japan 112 mGPS: 1/2 Active chemo in 
form of FOLFIRI 
and FOLFOX 
regimens 
44 N/A Multivariate: 
6.071 (1.625–
22.68) 
p=0.0073 
N/A mGPS only  
12.  Shimoda et al 
2010 (467) 
 
Retrospective  Pancreatic Japan 83 GPS (0 vs. 1 or 
2) 
50 patients received 
single-agent 
treatment with 
gemcitabine (GEM), 
9 patients GEM 
combined with 
radiotherapy 
(GEM+R) and 24 
patients had best 
supportive care 
(BSC). 
N/A 83 N/A Univariate:   
0.513 (0.047–
5.547) 
P=0.5825 
 
Inverse:  
1.949 (0.180-
21.277) 
Albumin 
13.  Hwang et al 
2011 (231) 
 
Retrospective  Gastric   Korea 402 GPS: (1&2) 
 
Mostly Cisplatin 
based chemotherapy 
general 1st line treat: 
taxanes and cisplatin 
N/A 402  N/A Multivariate:  
GPS 1: 1.75 
(1.37-2.26) 
p=0.001 
 
GPS 2: 1.79 
(1.29-2.47) 
p=0.001 
ECOG, Bone Mets 
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14.  Chua et al 
2012 (163)  
Prospective  Multiple Australia  68 mGPS (1&2) 
 
 
Single unit docetaxel 
treatment  
N/A 68 N/A Multivariate:  
1.111(2.2–7.7) 
p<0.0001 
 
NLR 
15.  Inoue et al 
2013 (272)  
Retrospective  Colorectal  Japan 164 (chemo 
only) 
mGPS (1-2 vs.  
0) 
FOLFOX and 
FOLFIRI chemo.  
N/A 
(HR 
given 
only) 
N/A Multivariate: 
1.858 (1.213-
2.846) 
p=0.0044 
N/A Age, CEA  
16.  Leung et al 
2012 (304)  
Retrospective  Lung  UK  261 mGPS (0/1/2) Chemotherapy 
(mainly platinum 
based) and/or radical 
radiotherapy 
246 248 Multivariate: 
1.67 (1.28-2.19) 
P<0.0001 
N/A Age, ECOG, 
Tumour stage 
(III/IV) 
17.  Jeong et al 
2012 (232)  
Retrospective  Gastric  Korea  104 mGPS: (1 & 2) Treated with 
palliative chemo 
N/A 94 N/A Multivariate: 
mGPS 1: 3.77 
(2.00–7.01) 
p<0.000 
 
mGPS 2: 2.29 
(1.21–4.32) 
p<0.010 
Histology, LN 
Mets, NLR 
18.  Partridge et al 
2012 (309)  
Retrospective  Multiple UK 101 (GPS 2) mGPS (1&2) 
 
Palliative end of life 
supportive care 
N/A 47  
(4-week 
mortality) 
N/A Multivariate: 
mGPS 1: 1.346 
(0.585-3.100) 
p=0.484 
 
mGPS 2: 2.712 
(1.252-5.875) 
p=0.011 
Age, Primary 
cancer site: Breast, 
WBC 
19.  Gioulbasanis 
et al 2012 
(305)   
Retrospective   Lung  Greece 96 GPS (1&2) Platinum-based 
chemotherapy 
N/A 89 N/A Multivariate:  
GPS 1: 1.20 
(0.68–2.13) 
p=0.529  
 
GPS 2: 2.63 
(1.29–5.34) 
p=0.008 
PS Only  
20.  Hwang et al 
2012 (201)  
Prospective  Bladder Korea 67 GPS (1&2) Treated with 
chemotherapy  
N/A 67 N/A Multivariate:  
GPS 1: 2.91 
(0.96-8.75) 
P=0.057 
 
GPS 2: 7.00 
(2.53-19.36) 
PS Only  
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P=0.001 
21.  Laird et al 
2013 (17)  
Prospective  
 
Multiple  UK  1825 (Test) 
631 
(Validation) 
GPS: 1&2 Chemo, radio and 
BSC 
N/A 1601(Test) 
 
471 
(Validation) 
N/A Multivariate: 
Test:  
mGPS 1: 1.62 
(1.35-1.93) 
p<0.001 
 
mGPS 2: 2.05 
(1.72-2.44) 
p<0.001 
 
Validation:  
mGPS 1: 1.58 
(1.25-2.01) 
p<0.001 
 
mGPS 2: 2.06 
(1.62-2.63) 
p<0.001 
Test: Dyspnoea, 
ECOG 
 
Validation: 
Quality of life, 
Physical Function, 
Pain, BMI, ECOG 
22.  Linton et al 
2013 (154)   
Prospective  Prostate Australia 112 mGPS (2 vs. 0) 
(1 vs. 0) 
 
 
Docetaxel and 
prednisone treatment  
N/A 84 N/A Univariate: 
mGPS 
Categorical (2 
vs. 0) 3.44 
(1.75-6.76) 
p <0.001 
 
(1.vs 0.) 
1.97 (1.01-
3.83) p=0.047 
 
mGPS only  
23.  Sachlova et al 
2014 (233)  
Retrospective  Gastric  Czech Rep 64 (treated 
with chemo) 
GPS (1&2) Palliative chemo 
mostly platinum 
based 
N/A 64 N/A Multivariate: 
GPS 1: 1.93 
(0.85-4.40) 
p=0.12 
 
GPS 2: 6.63 
(2.42-18.17) 
p<0.001 
OPNI  
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24.  Zhang et al 
2014 (229)  
Retrospective   Oesophageal   China  212 mGPS (0,1,2) Radiotherapy and 
cisplatin based 
chemo 
N/A 160 N/A  Multivariate: 
1.694 (1.350-
2.126) p<0.001 
Location, T&M, 
stage 
25.  Anshushaug et 
al 2015 (310)  
Retrospective  Multiple Norway 723 GPS (1 & 2) Palliative radio and 
chemo  
N/A 723 N/A Multivariate:  
Chemo: 
GPS: 
1: 1.69 (0.72-
4.00) p=0.23 
 
2: 3.00 (1.32-
6.80) p=0.009 
 
Radio: 
GPS 1: 2.90 
(0.97-8.67) 
p=0.06 
 
GPS 2: 3.98 
(1.52-10.42) 
p=0.005 
 
Age, Performance 
status, Referred to 
Palliative Care, 
Mets when 
diagnosed 
26.  Moriwaki et al 
2014 (298)  
Retrospective  Biliary Tract  Japan  218 Continuous: 
GPS (0 vs. 1/2) 
 
 
Chemo with GEM 
and CDDP regimens 
 
N/A 218 N/A Multivariate:  
0.60 (0.40-
0.90) P=0.012 
Inverse: 1.666 
(1.111-2.5) 
ALP, LDH, No of 
Mets, Liver, 
Peritoneal/Other 
Mets 
27.  Miura et al 
2015 (311)  
Prospective  Multiple Japan  1160 GPS 1&2 
 
Purely palliative 
care no active 
treatment  
N/A 1160 (All 
end of life 
care) 
N/A Multivariate:  
GPS 1: 1.07 
(0.78-1.49) 
P= 0.673 
 
GPS 2: 1.36 
(1.01-1.87) 
P= 0.046 
Performance 
status, Liver Mets,  
PP >6I, NLR≥4, 
Dyspnea, 
Oedem0.308a 
28.  de Paula 
Pantano et al 
2016 (312)  
Prospective  Multiple USA 459 mGPS 1&2 Predominantly 
supportive treatment 
but some still 
receiving chemo 
N/A 346 N/A Multivariate: 
GPS 1: 2.066 
(1.356-3.147) 
P= 0.001 
 
GPS 2: 2.664 
(1.929-2.680) 
P<0.001 
Sex, Hepatic Mets, 
CNS Mets, 
Treatment 
Palliative care 
only, KPS (0-
70%),  
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29.  Tan et al 2015 
(313)   
Prospective  Multiple  Australia  114 mGPS: 1/2 Chemotherapy but 
no specific mention 
of type 
N/A Followed up 
until the 
date of death 
or the date 
that data as 
last updated. 
N/A Multivariate: 
1.68 (1.03-
2.76) p=0.039 
 
 
PG-SGA C, 
Required dose 
reduction +/- 
transfusion  
30.  Jung et al 
2015 (238)   
Retrospective  B-cell Lymphoma Korea  213 L-GPS: 1&2  R-CHOP 
chemotherapy. 
50 58 N/A Multivariate  
GPS 1: 2.135 
(0.919-4.533) 
p=0.078 
 
GPS 2: 5.898 
(2.028-14.454) 
p=0.001 
ECOG  
31.  Xiao et al 
2015 (205)  
Retrospective  Cervical  China  238 mGPS (0/1/2) Chemo in the form 
of Cisplatin plus 5-
fluorouracil or 
cisplatin plus 
docetaxel. Also, 
treated with radio 
N/A 124 N/A Multivariate: 
1.820 (1.378-
2.404) 
p<0.001 
PS, FIGO Stage, 
LN status 
32.  Martin et al 
2014 (295)   
Retrospective   Pancreatic   Australia  124 mGPS: (0,1,2) 
 
Chemo for 
metastatic disease 
and radio for locally 
advanced 
N/A 114 N/A Multivariate:  
 mGPS 1.41 
(1.10-1.80) 
p=0.01 
 
 
 
CA19-9, ALC, 
ANC, Platelet, 
NLR, PLR, Alb, 
ECOG 
33.  Kasuga et al 
2015 (296)   
Retrospective  Pancreatic  Japan 61 mGPS: 2 Gemcitabine 
and S-1 
combination therapy 
(FGS) as salvage 
chemotherapy 
N/A 61 N/A Multivariate: 
6.605 (2.965–
14.709) 
p<0.001 
CA19-9 > 2,000 
ECOG>0 
34.  Simmons et al 
2015 (306)  
Prospective  Lung  Greece 390 mGPS (0/1/2) Best supportive care  
 
N/A 283 N/A Multivariate:  
1.67 (1.40-
2.00) p<0.001  
ECOG 
35.  Zhou et al 
2015 (307)  
Retrospective  Lung China  359 mGPS 1&2 Radiotherapy and 
chemotherapy 
(Irinotecan, 
Etoposide) 
N/A 180 N/A Multivariate: 
mGPS 1: 1.52 
(1.08-2.13) 
p=0.015  
 
mGPS 2: 5.23 
(2.36-11.58) 
p<0.001 
Adjusted for age, 
sex, disease stage, 
ECOG-PS. 
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36.  Chou et al 
2015 (237)  
Retrospective  Haematological  China 217 GPS: (1&2)  Palliative care no 
specific mention of 
chemo 
N/A 204 N/A Multivariate: 
GPS 1: 2.12 
(1.13–3.97) 
p=0.020 
 
GPS 2: 1.71 
(0.964–3.05) 
p=0.069 
PPI :> 4.5.  
37.  Jiang et al 
2015 (308)  
Prospective  Lung China  138 GPS: 1&2 
 
 
Cisplatin based 
chemo.  
N/A 138 Multivariate:  
GPS 1: 0.8 
(0.5-0.9) 
p=0.02 
 
GPS 2: 0.6 
(0.2-0.8) 
p=0.02 
 
Inverse: 
GPS 1: 1.25 
(1.111-2) 
 
GPS 2: 1.666 
(1.25-5) 
Multivariate:  
GPS 1: 0.8 
(0.4-0.9) 
p=0.02 
 
GPS 2: 0.5 
(0.2-0.9) 
P=0.02 
 
Inverse: 
GPS 1: 1.25 
(1.111-2.5) 
 
GPS 2: 
2 (1.111-5) 
CYFRA21-1, 
CEA, TPS 
38.  Dreanic et al 
2015 (273)  
Retrospective  Colorectal  France 27 mGPS: 2 
Inverse mGPS: 
2 
5-fluorouracil-based 
systemic 
chemotherapy and 
anti-VEGF 
N/A 27 N/A Univariate in 
anti-VEGF 
group:  
0.48 (0.18-
1.29) p=0.15 
 
Inverse: 2.083 
(0.775-5.555) 
 
GPS Only  
39.  Mitsunaga et 
al 2016 (297)  
Prospective  Pancreas Japan  280 
(Prospective: 
141) 
mGPS: 1 &2  
 
 
GEM chemotherapy  N/A 280 (141 
prospective)  
N/A Multivariate:  
mGPS: 1: 
0.9(0.4-1.9) 
p=0.76 
 
mGPS 2: 0.72 
(0.3-1.7) 
p=0.47 
 
Inverse: 
mGPS 1: 
1.111 (0.526-
2.5) 
Sex, Age, ECOG-
PS, UICC stage, 
CA 19-9, 
Prognostic CRP 
Classification, 
NLR 
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mGPS 2: 1.388 
(0.588-3.333) 
40.  Song et al 
2015 (274)  
Retrospective Colorectal  Korea 177 mGPS: (0 vs. 1 
or 2) 
Best supportive care 
and herbal therapy 
N/A  177 N/A Multivariate: 
0 vs 1: 1.135 
(0.717-1.797) 
p=0.588 
 
0 vs 2: 3.212 
(1.437-7.716) 
p=0.004 
LMR, CA19-9, 
AST, KM 
treatment 
41.  Zhou et al 
2015 (299)  
Prospective HCC China 244 GPS (0/1/2) TRACE 
chemotherapy  
N/A 198 N/A Multivariate: 
1.697 (1.325-
2.174)      p< 
0.001 
ALT, CLIP score  
42.  Namikawa et 
al 2016 (234)  
Retrospective  Gastric  Japan 224 GPS (0/1 or 2) 
 
mGPS (0/1 or 
2) 
Combination 
chemotherapy 
including trastuzmab  
N/A 223 N/A Multivariate: 
GPS: 1.297 
(0.667-2.552) 
p=0.444 
 
mGPS: 0.68 
(0.350-1.322) 
p=0.255 
Histological type, 
NLR  
43.  Arigami et al 
2016 (235)  
Retrospective Gastric  Japan 68 GPS: 1&2 Chemotherapy and 
chemoradiotherapy  
N/A 68 N/A Multivariate: 
GPS 1: 0.830 
(0.418-1.618) 
p=0.586 
 
GPS 2: 2.608 
(0.792-7.965) 
p=0.111 
F-NLR score 
(combined 
fibrinogen and 
NLR) 
44.  Hsieh et al 
2016 (236)  
Retrospective Gastric  Taiwan  256 mGPS (>1) Combination 
Chemotherapy  
N/A 248 N/A Multivariate: 
2.78 (1.60–
4.83) p<0.001 
Peritoneal Mets, 
NLR, mGPS, PG-
SGA 
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Table 17.9: Studies investigating the prognostic value of NLR in an unselected cohort of patients with advanced cancer 
No: NLR Study Type of Study Cancer Country  Patients 
(n) 
Measure of 
SIR 
Systemic 
Treatment  
Cancer 
deaths 
(n) 
Overall 
deaths 
(n) 
Cancer 
survival 
(HR, 
95%CI) 
Overall 
survival 
(HR, 
95%CI)  
Independent 
Prognostic Factors 
1.  Yamanaka et 
al 2008 (552)   
Prospective  Gastric  Japan  1220 NLR>2.5 
 
Patients receiving 
oral 
fluoropyrimidine 
N/A 984 N/A Multivariate:  
1.52 (1.32–
1.75) p=0.077 
Age, ECOG, 
Advanced Disease, 
Liver Mets, WBC 
9000-12000/mm3 
2.  Teramukai et 
al 2009 (553)   
Prospective  Lung   Japan 388 NLR≥4.744 Vinorelbine, 
gemcitabine, 
docetaxel, 
paclitaxel, 
carboplatin  
N/A 276 N/A Multivariate:  
1.56 (1.09–
2.24) p=0.015 
Neutrophil count 
3.  Kao et al 2010 
(554)  
Retrospective  Malignant 
mesothelioma  
Australia 173 NLR≥5 Platinum based 
chemotherapy  
N/A 131 N/A Multivariate:  
2.7 (1.8-3.9) 
p<0.001 
Histological subtype 
4.  An et al 2010 
(555)  
Retrospective  Pancreatic  China 95 NLR>5 Gemcitabine-based 
chemotherapy 
N/A 95 N/A Multivariate:  
4.489 (1.372–
14.692) 
p=0.013 
CA19-9  
5.  Chua et al 
2012 (163)  
Prospective  Multiple Australia  68 NLR>5 Single unit 
docetaxel treatment  
N/A 68 N/A Multivariate:  
2.0 (1.2–3.3) 
p=0.010 
GPS: 1&2 
6.  An et al 2011 
(556)  
Prospective  Nasopharyngeal  China 363 NLR>3.73 Local radio and 
cisplatin and/or 5-
FU-based 
neoadjuvant 
96 102 Multivariate: 
1.74 (1.15–
2.62) p=0.008 
N/A Age, sex and T-stage 
7.  Chua et al 
2011 (557)  
Retrospective  Colorectal  Australia 349 NLR≥5 Chemotherapy and 
best supportive care 
N/A 315 N/A Multivariate: 
1.7 (1.2-2.5) 
p=0.002 
ECOG>1 
8.  Wang et al 
2011 (558)  
Retrospective  Multiple  China  497 NLR>3 Multiple treatment 
modalities.  
N/A 464 N/A Multivariate:  
1.348 (1.062-
1.712) 
p=0.014 
Gender, Tumour 
Type, Surgery, Other 
Mets, Adjuvant 
treatment 
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9.  Jeong et al 
2012 (232)  
Retrospective  Gastric  Korea  104 NLR>3 
 
 
Treated with 
palliative chemo 
N/A 94 N/A Multivariate: 
1.65 (1.03–
2.64) 
p = 0.037 
Histology, LN Mets, 
mGPS 
10.  Lee et al 2012 
(169)  
Prospective  Lung 
adenocarcinoma 
Korea 199 NLR >2.18 Gefitinib with 
gemcitabine plus 
cisplatin as first-line 
therapy. 
N/A N/A 
(Expressed 
in months) 
N/A Multivariate: 
1.13 (1.06-
1.21) 
p<0.001 
ECOG 
11.  Kaneko et al 
2012 (559)  
Retrospective  Colorectal Japan  50 NLR ≥4 Palliative 
Oxaliplatin-based 
combination 
chemotherapy  
27 27 N/A Multivariate:  
4.39 (1.82-
10.7)  
p = 0.0013 
Platelets 
12.  Pinato et al 
2012 (560)  
Retrospective  HCC USA 112 NLR>5 Active platinum 
based chemo 
N/A 81 N/A Multivariate: 
2.06 (1.16-
3.66) p=0.013 
IBI, CLIP, BSC 
13.  He et al 2013 
(561)   
Retrospective  Colorectal  China 243 NLR≤3 
Inverted 
NLR 
NLR≥3 
Combination 
chemotherapy 
including 
Oxaliplatin and 
Irinotecan  
N/A 199 N/A Multivariate:  
0.678 
(0.479-.0961) 
p=0.029 
 
Inverted: 
1.475 (1.041-
2.088) 
CEA 
14.  Linton et al 
2013 (154)  
Prospective  Prostate Australia 112 NLR: 
Continuous 
Categorical: 
(≥5 vs. <5) 
Docetaxel and 
prednisone 
treatment  
N/A 84 N/A Univariate:  
NLR: Cont 
1.08 (0.83-
1.41) p=0.55 
 
NLR (≥5 vs. 
<5): 0.98 
(0.64-1.49) 
p=0.91 
mGPS 2 vs. 0 and 
mGPS 1 vs. 0 
15.  Unal et al 2013 
(562)  
Prospective   NSCLC Turkey  94 NLR (low or 
high) 
 
Chemoradiotherapy 
including platinum 
based treat  
N/A 81 N/A  Univariate: 
1.81 (1.16-
2.81) 
p=0.0008 
 
PLR, Response to 
chemoradiotherapy 
16.  Yao et al 2013 
(563)  
Prospective  Lung  China 182 NLR>2.68 
 
First-line platinum-
based 
chemotherapy. 
N/A 91 N/A Multivariate: 
1.761 (1.095-
–2.832) 
p=0.020 
 
Nodal spread N2, 
Metastasis M2. 
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17.  Fox et al 2013 
(180) 
 
Retrospective  Renal Cell  Australia 362 NLR>3 
 
Patients treated with 
Lapatinib or 
hormonal therapy 
after prior failure of 
immunotherapy in a 
randomised phase 
III trial 
N/A 357 N/A Multivariate: 
1.42 (1.10- 
1.84) p=0.008 
 
 
 
Neutrophils, 
Platelets, KPS, 
Corrected Calcium, 
Low Hb 
18.  Cetin et al 
2013 (564)  
Retrospective  Renal Cell  Turkey  100 NLR>3.04 Tyrosine Kinase 
Inhibitors 
N/A 54 N/A Multivariate: 
2.406 (1.327-
4.361) 
p=0.004 
Male, PFS 
19.  Jafri et al 2013 
(565)   
Retrospective  Lung  USA  173 NLR<5 
 
Treated with active 
chemotherapy 
multiple types 
 173  Univariate:   
0.57 (0.41-
0.79) 0.0008 
Inverted HR:  
1.754 (1.266-
2.439) 
PS (0-1/ 2–4), Mets 
(1-2/ >2), No 
chemotherapy, ALC 
<1, ALI < 18 
20.   Troppan et al 
2014 (566)  
Retrospective  B-cell Lymphoma Austria  290 NLR≥4  Standard rituximab, 
cyclophosphamide, 
doxorubicin, 
vincristine, and 
prednisone (R-
CHOP) regimen 
every 3 weeks for 
six to eight cycles 
N/A 92 N/A Multivariate: 
2.03 (1.17-
3.50) p=0.011 
Age ≥60, Clinical 
Stage III & IV, non-
GCB, dNLR≥4 
21.  Kim et al 2014 
(488)  
Prospective  Multiple Korea  141 NLR>5 
 
Best supportive care  N/A 141 N/A Multivariate:  
1.96 (1.17–
3.31) p=0.011 
 
KPS, Time to 
terminal cancer<12 
months, 
CRP≥10mg/dl 
22.  Kang et al 
2014 (567)  
Retrospective  Lung  UK  187 NLR≥4 
 
 
platinum-based 
chemotherapy 
N/A 187 N/A  Multivariate: 
1.465 (1.012-
2.119) 
p=0.043 
 
 
Extensive Disease, 
LDH 
23.  Cho et al 2014 
(30)  
Prospective  Gastric  Korea 268 NLR>3 Initial treatment 
with chest wall 
radiotherapy and 
FOLFOX and 
platinum based 
chemo 
N/A 268 N/A Multivariate: 
1.569 (1.227–
2.006) 
P<0.001 
Undifferentiated, 
Progressive disease 
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24.  Templeton et 
al 2014 (568)  
Retrospective  Prostate Canada  357 NLR>3 Docetaxel and 
platinum based 
chemo 
N/A 345 N/A Multivariate: 
1.89 (1.27-
2.82) p=0.002 
Liver Mets, Hb, Alb, 
Log (PSA, LDH, 
ALP) 
25.  Nuhn et al 
2014 (569)  
Retrospective  Prostate USA  238 NLR>3 
 
First line docetaxel N/A 237 N/A Multivariate: 
1.883 (1.248, 
2.842) 
p=0.002 
Number of chemo 
cycles, Hb, Alb, 
AST, Baseline PSA 
26.  Sonpavde et al 
2014 (570)  
Retrospective  Prostate  Multinational 
(US and 
Canada) 
784 NLR (Log 
transformed) 
Patients treated with 
Sunitinib and 
prednisolone and 
docetaxel-based 
chemotherapy 
N/A 516 N/A Multivariate: 
1.55 (1.32-
1.83) p<0.001 
Log (LDH), Hb, 
Organ Involvement 
27.  Keizmann et al 
2014 (571)  
Prospective  Renal cell  Multinational 
(USA and 
Israel)  
244 NLR>3 Sunitinib treatment N/A 203 N/A Multivariate: 
2.95 (2–4.34) 
p<0.001 
Sunitinib induced 
HTN, Pre-treatment, 
never having smoked 
28.  Li et al 2014 
(572)  
Retrospective  
 
HCC China 205 NLR>2.43 
 
Sorafenib based 
chemoembolization   
N/A 132 N/A Multivariate:   
1.104 (1.044–
1.167) 
p<0.001 
 
AFP, Tumour 
Morphology, Child-
Pugh Score, Platelets 
29.  Formica et al 
2014 (487)  
Retrospective  Colorectal  USA 106 NLR 
(Continuous) 
  
Fluorouracil, 
irinotecan and 
bevacizumab 
 
N/A 60 N/A Multivariate:  
1.8012 
(0.2833-
1.6048) 
p=0.0019 
CRP  
30.  Kacan et al 
2014 (573)  
Retrospective  Lung  Turkey  299 NLR≥5 Chemo and 
Radiotherapy no 
mention of surgery  
N/A 204 (2 
Year 
survival) 
N/A Multivariate: 
1.7 (1.0-2.7) 
p=0.017 
Age, Anaemia at 
diagnosis, Stage, 
ECOG PS 
31.  Lin et al 2014 
(574)  
Retrospective  Lung  China  81 NLR>3.5 EGFR-TKI 
treatment 
56 56 (All 
deaths Ca 
related) 
N/A Multivariate: 
3.29 (1.62–
6.71) p<0.001 
ECOG 
32.  Yoo et al 2014 
(575)  
Retrospective Lung Korea 138 NLR≥2 Concurrent 
chemoradiotherapy  
N/A 112 N/A Multivariate: 
2.115 (1.193-
3.749) 
p=0.010 
ECOG performance 
status 
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33.  Langsenlehner 
et al 2015 
(576)  
Retrospective  Prostate Austria 415 NLR≥5 Androgen 
deprivation therapy, 
Chemotherapy  
N/A 60 N/A Multivariate:  
2.16 (1.17-
3.99) p=0.013 
Intermediate risk 
group classification  
34.  Jiang et al 
2015 (577)  
Retrospective  Soft Tissue 
Sarcoma 
China  154 NLR>1 
 
Treated with active 
chemotherapy and 
Ipilimumab 
65 80 N/A Multivariate: 
2.477 (1.423-
4.311) 
P= 0.033 
Monocyte Ratio>1 
35.  Lorente et al 
2015 (178) 
2015  
Retrospective  
 
Prostate UK  755 NLR: 
Continuous 
 
NLR>3 
Patients treated with 
cabazitaxel (25 
mg/m2) versus 3-
weekly 
mitoxantrone (12 
mg/m2), both in 
combination with 
prednisone 10 mg 
daily 
N/A N/A (Does 
not give a 
figure) 
N/A Multivariate: 
Conti: 
1.91 (1.31-
2.79) p=0.001 
 
NLR>3: 
1.55 (1.3–
1.84),  
P < 0.001 
Measurable disease, 
Pain at baseline, 
Treatment arm 
36.  Luo et al 2015 
(578)  
Retrospective  Pancreatic  China  403 NLR: ≥3.1 74.9% underwent 
gemcitabine-based 
chemotherapy 
N/A 394 N/A Multivariate:  
1.42 (1.15-
1.74) p=0.001 
Age, CA19-9, 
Albumin, Tumour 
spread 
37.  Kim et al 2015 
(499)   
Retrospective  Pancreatic Ductal  Korea  343 (212 
palliative 
chemo) 
NLR>5 FOLFIRINOX and 
Gemcitabine based 
chemo  
N/A 343 N/A Multivariate:  
Whole 
Group: 
1.428 (1.014-
2.012) 
p=0.042  
 
Palliative 
Chemo: 
1.038 (0.654-
1.650) 
p=0.175  
ECOG, Alb, CRP, 
Initial site of Mets, 
No initial 
chemotherapy 
38.  Chen et al 
2015 (579)  
Retrospective  Colorectal  United States  166  NLR>5 
 
Best supportive care 
after failure of other 
treatment in 
palliative group and 
Panitumumab in 
active treatment 
group 
 
N/A N/A (No 
specific 
numbers of 
deaths) 
N/A Multivariate: 
1.73 (1.03-
2.89) p=0.039  
 
 
Metastatic Site 
numbers ≥1, 
LDH>ULN 
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39.  Santoni et al 
2015 (580)  
Retrospective  Renal Cell  Italy   151 NLR>3 Active treatment 
with VEGFR-TKI 
also treated with 
sunitinib, sorafenib, 
and pazopanib 
N/A 53 N/A Multivariate: 
2.21 (1.21–
4.04) p=0.010 
MSKCC Prognostic 
Group 
40.  Ho et al 2015 
(581) 
 
Retrospective  Large B Cell 
Lymphoma 
Taiwan  148 NLR>4.35 
 
Standard R-
chemotherapy. 
N/A 41 N/A Multivariate:  
1.624 (0.827-
3.189) 
p=0.159 
Age, B-symptoms, 
ECOG, ALC, AMC, 
ALC/AMC PS 
41.  Mitchell et al 
2015 (582)  
Prospective  Lung  Canada  1239 NLR>5 
 
Tecemotide in 
unresectable stage 
III non-small-cell 
lung cancer  
N/A 1239 N/A Univariate:  
0.81 (0.66–
0.99), P = 
0.0383 
Inverse HR: 
1.235 (1.01-
1.515) 
High sMUC1, High 
ANA 
 
42.  Martin et al 
2014 (295)  
Retrospective  Pancreatic   Australia  124 NLR≥5 
 
Chemo for 
metastatic disease 
and radio for locally 
advanced 
N/A 114 N/A Multivariate:  
1.60 (1.07-
2.40) p=0.02 
 
 
 
 
CA19-9, ALC, ANC, 
Platelet, PLR, mGPS, 
Alb, ECOG 
43.  Mitsunaga et 
al 2016 (297)  
Prospective  Pancreas Japan  280 
(Prospective: 
141) 
NLR≥5 GEM chemotherapy  N/A 280 (141 
prospective
)  
N/A Multivariate:  
1.3 (0.8-2.2) 
p=0.32 
 
Sex, Age, ECOG-PS, 
UICC stage, CA 19-
9, Prognostic CRP 
Classification, mGPS 
44.  Wu et al 2015 
(501)  
Prospective  Lung  China 366 NLR>2.68 Combination 
Chemotherapy  
N/A 366 N/A Multivariate: 
1.778 (1.157-
2.732) 
p=0.009 
Metastasis, CRP 
45.  Hong et al 
2015 (550)  
Retrospective Lung Cancer  China 919 NLR<5  
 
Inverse: 
 
NLR>5 
Chemotherapy and 
radiotherapy 
N/A 892 N/A Multivariate: 
0.908 (0.721-
1.144) 
p=0.413 
 
Inverse 
Multivariate:  
1.101 (0.874-
1.387) 
Stage, Response to 
treatment, LDH 
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46.  Yao et al 2015 
(500)  
Retrospective  Prostate Japan  57 NLR≥3.5 Docetaxel 
Chemotherapy  
N/A 55 N/A Multivariate:  
2.728 (1.050-
7.088) 
p=0.039 
 
Biopsy Gleason 
Score, PSA value 
47.  Wang et al 
2016 (583)  
Retrospective  Cervical  China 60 NLR<2 
 
Inverse: 
 
NLR>2 
Cisplatin-based 
chemoradiotherapy  
N/A 23 N/A Multivariate: 
0.268 (0.078-
0.924) 
p=0.037 
 
Inverse 
Multivariate: 
3.731 (1.082-
12.821) 
Nil  
48.  Beltran et al 
2016 (584)  
Retrospective  T-cell lymphoma  Peru 83 NLR≥4 Combined 
Chemotherapy, 
Radiotherapy and 
Chemoradiotherapy   
N/A 59 N/A Multivariate: 
4.73 (1.78-
12.6) p<0.01 
Performance Status 
49.  Ferrucci et al 
2016 (538)  
Prospective  Metastatic 
Melanoma 
Italy 720 NLR≥3 Ipilimumab N/A 662 N/A Multivariate: 
2.29 (1.86-
2.82) 
p<0.0001 
Sex, ECOG, Brain 
Mets, Liver Mets 
50.  Zhang et al 
2016 (585)  
Retrospective  RCC China 373 NLR≥2.2 Combined 
Chemotherapy 
including Sorafenib 
and Sunitinib  
N/A 373 N/A Multivariate: 
1.391 (1.022-
1.894) 
p=0.036 
Age, ECOG, IMDC 
Poor, Pathology, 
Fuhrman grade 
51.  Kou et al 2016 
(505)  
Retrospective  Pancreatic  Japan 306 NLR≥5 Combination 
chemotherapy with 
palliative intent  
N/A 249 N/A Multivariate: 
2.54 (1.75-
3.69) p<0.01 
ECOG PS, Distant 
Metastasis, Initially 
unresectable, CEA, 
CA19-9 
52.  Namikawa et 
al 2016 (234)  
Retrospective  Gastric  Japan 224 NLR≥4 Combination 
chemotherapy 
including 
trastuzmab  
N/A 223 N/A Multivariate: 
1.651 (1.187-
2.297) 
p=0.003 
Histological type 
53.  Moon et al 
2016 (528)  
Prospective  Neck Squamous 
Cell Ca 
Korea 153 NLR: 
Continuous  
Combination 
chemotherapy and 
chemoradiotherapy  
24 27 Multivariate:  
4.13 (1.57-
9.19) p=0.003 
Multivariate:  
3.22 (1.41-
7.09) p=0.005 
ECOG 1/0, BMI 
<18.5/others 
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54.  Lee et al 2016 
(586)  
Retrospective  Cholangiocarcinom
a 
Korea 221 NLR>5 Combination 
chemotherapy 
including 
Gemcitabine and 5-
Flurouracil based 
N/A 197 N/A Multivariate: 
1.87 (1.33-
2.62) p<0.001 
Carcinoembryonic 
antigen, carbohydrate 
antigen 19-9, stage 
cholangiocarcinoma, 
number of cycles of 
chemotherapy  
55.  Ahn et al 2016 
(506)  
Retrospective  Multiple Cancer 
Types 
Korea 205 NLR≥10 Best supportive care N/A 205 N/A Multivariate: 
1.54 (1.14-
2.07) p=0.005 
ECOG PS≥3, High 
PPI score≥6, 
hyperbilirubinemia 
56.  Choi et al 2016 
(531)  
Retrospective  Pancreatic  Korea 396 NLR: 2.5-4.4 
NLR: ≥4.5 
Palliative 
Chemotherapy  
N/A 396 N/A Multivariate: 
2.5-4.4: 1.659 
(1.306-2.108) 
p<0.001 
 
≥4.5: 2.926 
(2.181-3.927) 
p<0.001 
ECOG PS, CA19-9 
57.  Zaragoza et al 
2016 (540)  
Retrospective  Melanoma France 58 NLR week 1: 
continuous 
NLR week 1: 
≥4 
Chemotherapy 
including 
ipilimumab 
N/A 22 N/A Multivariate; 
Continuous: 
1.10 (1.01-
1.19) p=0.026 
 
≥4: 2.20 
(1.01-4.78) 
p=0.047 
LDH IU, 
Performance Status 
58.  Li et al 2016 
(587)   
Retrospective  Colorectal Ca Mets China 110 NLR≤5 
 
Inverse: 
 
NLR≥5 
Combination 
chemotherapy 
including XELOX, 
FOLFOX and 
FOLFIRI 
N/A 86 N/A Multivariate: 
0.99 (0.52-
1.91) p=0.98 
 
Inverse 
Multivariate: 
1.01 (0.524-
1.923) 
Age, ALP Level, 
Ascites, PLR 
59.  Hsieh et al 
2016 (236)   
Retrospective Gastric  Taiwan  256 NLR>3 Combination 
Chemotherapy  
N/A 248 N/A Multivariate: 
2.04 (1.22–
3.40) p=0.007 
Peritoneal Mets, 
NLR, mGPS, PG-
SGA 
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Table 17.10: Studies investigating the prognostic value of LMR in an unselected cohort of patients with advanced cancer 
No: LMR Study Type of 
Study 
Cancer Country  Patients 
(n) 
Measure of SIR Systemic 
Treatment  
Cancer 
deaths  
(n) 
Overall 
deaths 
(n) 
Cancer 
survival 
(HR, 
95%CI) 
Overall 
survival  
(HR, 95%CI) 
Independent 
Prognostic Factors 
1.  Li et al 2013 
(588)   
Retrospective  Nasopharyngeal  China 1547 LMR>5.220 Treatment with 
chemotherapy and 
radiotherapy  
1457 1465 Multivariate:   
0.669 
(0.535–
0.838) 
p=0.001 
Inverse: 
1.495 (1.193-
1.869) 
Multivariate:  
0.558 (0.417–
0.748) 
p=0.001 
Inverse: 
1.792 (1.337-
2.398) 
Sex, age, T stage, N 
stage, overall stage, 
treatment, prognostic 
measures. 
2.  Rambaldi et 
al 2013 (589)  
Retrospective  B-Cell Lymphoma Italy  700 LMR≤2.6 Systemic 
chemotherapy 
including rituximab 
N/A 392 (10 
Year 
survival) 
N/A Multivariate: 
1.88 (1.32–
2.70) p=0.001 
IPI>2 
3.  Lin et al 
2014 (543)  
Retrospective  SCLC China 370 LMR≥4.56 
Inverse: 
LMR≤4.56 
Platinum based 
doublet 
chemotherapy 
N/A 370 N/A Multivariate: 
0.530 (0.409-
2.795) 
p<0.001 
 
Inverse:  
1.887 (0.358-
2.445) 
ALC, Histology, 
ECOG 
4.  Lin et al 
2014 (544)  
Retrospective  Nasopharyngeal  China 281 LMR≥5.07 
Inverse: 
LMR≤5.07 
Cisplatin based 
chemotherapy  
N/A 255 N/A Multivariate: 
0.42 (0.30-
0.59) p<0.001 
 
Inverse:  
2.381 (1.695-
3.333) 
Age, ALC 
5.  Go et al 2014 
(590)  
Retrospective SCLC Korea 188 LMR: Low Platinum based 
chemotherapy  
N/A 152 N/A Multivariate: 
1.472 (1.029-
2.106) 
p=0.034 
Stage 
6.  Koh et al 
2015 (591)  
Retrospective  Hodgkin 
Lymphoma 
Korea 351 LMR<2.8 Active 
chemotherapy  
38 48 N/A  Multivariate:  
3.678 (1.008-
13.41) 
p=0.049  
LMR Only  
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7.  Jiang et al 
2015 (592)  
Retrospective  Nasopharyngeal  China   672 LMR (≥2.475 vs. 
<2.475) 
Active 
chemotherapy 
multiple modalities 
N/A 458 N/A Multivariate: 
0.50 (0.41-
0.60) p<0.001 
 
Inverse: 
2 (1.666-
2.439) 
N-stage, Number of 
metastatic lesions, 
Liver Mets 
8.  Ho et al 2015 
(581) 
 
Retrospective  Large B Cell 
Lymphoma 
Taiwan  148 LMR<2.11 
 
Standard R-
chemotherapy. 
N/A 41 N/A Multivariate:  
1.528 (0.751-
3.111) 
p=0.242 
Age, B-symptoms, 
ECOG, ALC, AMC, 
ALC/AMC PS 
9.  Song et al 
2015 (274)  
Retrospective Colorectal  Korea 177 LMR≤3.4 Best supportive care 
and herbal therapy 
N/A  177 N/A Multivariate: 
1.658 (1.092-
2.518) 
p=0.018 
mGPS, CA19-9, 
AST, KM treatment 
10.  Simon et al 
2016 (593)  
Retrospective  Hodgkin’s 
Lymphoma 
Hungary  121 LMR≤2.11 Combination of 
chemotherapy and 
radiotherapy  
N/A 13 N/A Multivariate: 
5.57 (1.53-
20.25) 
p=0.003 
PET 2 (positive)  
11.  Lin et al 
2016 (545)  
Retrospective  Metastatic 
Colorectal  
China  488 LMR≥3.11 
Inverse: 
LMR≤3.11 
FOLFOX 
chemotherapy  
N/A 479 N/A Multivariate:  
0.662 (0.501-
0.875) 
p=0.004 
 
Inverse:  
1.511(1.143-
1.996) 
Gender, ECOG 
Performance, 
Tumour 
differentiation, Pre-
chemo AMC  
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Table 17.11: Studies investigating the prognostic value of PLR in an unselected cohort of patients with advanced cancer 
No: PLR Study Type of 
Study 
Cancer Country  Patients 
(n) 
Measure of SIR Systemic Treatment  Cancer 
deaths 
(n) 
Overall 
deaths 
(n) 
Cancer 
survival 
(HR, 
95%CI) 
Overall 
survival  
(HR, 95%CI) 
Independent 
Prognostic Factors 
1.  Unal et al 2013 
(562)   
Prospective  Lung  Turkey  94 PLR>194 
 
Chemoradiotherapy 
including platinum 
based chemotherapy  
N/A 81 N/A  Multivariate:  
1.87 (1.20-
2.91) p=0.006  
 
 
Response to 
chemoradiotherapy, 
NLR  
2.  Liu et al 2013 
(594)  
Prospective  Lung  China  210 PLR≥152.6 First-line platinum-
based chemotherapy 
N/A 210 N/A Multivariate: 
2.025 (1.405-
2.919) 
p<0.0001 
Female sex, TNM 
stage IV, ECOG,  
3.  Martin et al 
2014 (295)   
Retrospective  Pancreatic   Australia  124 PLR≥200 
  
Chemo for metastatic 
disease and radio for 
locally advanced 
N/A 114 N/A Multivariate:  
1.58 (1.07-
2.33)  
p=0.02 
 
 
CA19-9, ALC, ANC, 
Platelet, NLR, 
mGPS, Alb, ECOG 
4.  Li et al 2015 
(595) 
 
Retrospective   HCC China  243 PLR>111.23 Multiple Palliative 
Chemo 
N/A 208 N/A Univariate:  
1.003 (1.002-
1.004) 
p=0.002 
 
 
White cell, 
Neutrophil, Platelets, 
NLR 
5.  Jiang et al  2015 
(596)   
Retrospective  
 
Nasopharyngeal  China  1261 PLR ≥153.64 Chemo and 
Radiotherapy 
137 125 Multivariate: 
1.84 (1.26-
2.67) 
p=0.001 
Multivariate: 
1.83 (1.28-
2.61) p=0.001 
Age, Sex, Histology, 
TNM, EBV DNA 
6.  Nakamura et al 
2015 (597)  
Retrospective  Cervical Japan  32 PLR>322.0 
 
All patients treated 
with external 
radiotherapy and 
concurrent cisplatin 
based chemo 
N/A 32 N/A Multivariate:  
4.204 (1.158-
15.268) 
p=0.029 
 
 
 2nd line 
chemotherapy, Pre-
treatment  
7.  Langsenehner et 
al 2015 (598)  
Retrospective  Prostate Austria  374 PLP≥190 Radiotherapy  18 65 Multivariate:  
3.99 (1.19-
13.4) 
p=0.025 
Multivariate: 
1.87 (1.02-
3.42) p=0.044 
Neoadjuvant ADT, 
Secondary ADT, 
Gleason score ≥7,  
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8.  Cannon et al 
2015 (599)   
Retrospective  Lung  USA  59 PLR>146 Stereotactic 
Radiation Therapy 
N/A 28 (17 
month 
follow up) 
N/A Multivariate:  
4.0 (1.5–11.0) 
p = 0.006 
PLR only  
9.  Hong et al 2015 
(550)  
Retrospective Lung Cancer  China 919 PLR≥250  Chemotherapy and 
radiotherapy 
N/A 892 N/A Multivariate: 
0.975 (0.783-
1.215) 
p=0.824 
Stage, Response to 
treatment, LDH 
10.  Wu et al 2015 
(501)  
Prospective  Lung  China 366 PLR>119.50 Combination 
Chemotherapy  
N/A 366 N/A Multivariate: 
1.079 (0.729-
1.596) 
p=0.705 
Metastasis, NLR, 
CRP 
11.  Kou et al 2016 
(505)  
Retrospective  Pancreatic  Japan 306 PLR≥150 Combination 
chemotherapy with 
palliative intent  
N/A 249 N/A Multivariate: 
0.96 (0.72-
1.28) p=0.78 
ECOG PS, Distant 
Metastasis, Initially 
unresectable, CEA, 
CA19-9, NLR 
12.  Li et al 2016 
(587)  
Retrospective  Colorectal Ca 
Mets 
China 110 PLR>162 Combination 
chemotherapy 
including XELOX, 
FOLFOX and 
FOLFIRI 
N/A 86 N/A Multivariate: 
2.27 (1.32-
4.03) p=0.003 
Age, ALP Level, 
Ascites  
 
  
 445 
Table 17.12: Studies investigating the prognostic value of other markers of the SIR in an unselected cohort of patients with advanced cancer 
No: 
Unassigned 
scores 
Study Type of 
Study 
Cancer Country  Patients 
(n) 
Measure of SIR Systemic 
Treatment  
Cancer 
deaths 
(n) 
Overall 
deaths 
(n) 
Cancer 
survival 
(HR, 
95%CI) 
Overall 
survival  
(HR, 95%CI) 
Independent 
Prognostic Factors 
1.  Yao et al 
2014 (91)  
Retrospective  Lung  China 316 GAR>0.58 Active platinum 
based chemo 
N/A 209 N/A Multivariate:  
1.65 (1.20-
2.26) p=0.002 
Albumin 
2.  Zhou et al 
2015 (88)  
Retrospective   Lung  China 367 CRP/Alb ratio 
(≥0.441) 
Etoposide-based 
chemotherapy  
N/A 258 N/A Multivariate: 
1.34 (1.04-
1.73) p=0.025 
Cancer stage, LDH 
level, PS 
3.  Shibutani et 
al 2015 (90) 
 
Retrospective  
 
Colorectal  Japan  66 AGR (>1.25) Active 
Chemotherapy 
including platinum 
chemo 
N/A N/A (Only 
HR 
reported) 
N/A Multivariate: 
2.247 (1.069-
4.722) 
p=0.033 
NLR 
4.  Chan et al 
2015 (92)  
Retrospective  HCC Hong Kong  425 AAPR (>0.68) Palliative chemo and 
radiotherapy  
N/A 418 N/A Multivariate:   
2.185 (1.780-
2.683) 
p<0.001 
AJCC, BCLC, 
CLIP, CUPI, JIS 
5.  Yamashita et 
al 2016 (89)  
Retrospective Prostate Ca Japan  79 CRP/Alb ratio 
(CAR) ≥7 
Docetaxel-based 
chemotherapy  
36 42 NA Multivariate:  
2.34 (0.91-
6.05) p=0.08 
 
ECOG PS≥1, PSA 
at docetaxel 
initiation, 
Hb≥12g/dL 
6.  Zhou et al 
2016 (88)  
Retrospective  SCLC China 276: Testing 
379: 
Validated  
CRP/Globulin 
Ratio ≥1.29 
Chemotherapy 
including etoposide 
based regimes as 
well as cranial 
radiotherapy  
N/A Testing: 
213 
Validated: 
205 
N/A Testing 
Multivariate: 
1.35 (1.61-
1.81) p=0.046 
 
Validated 
Multivariate:  
1.43 (1.05-
1.95) p=0.022 
ECOG-PS, Disease 
stage 
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18. APPENDIX 2 
 Tables and Footnotes:  
Table 18.1: Studies investigating the prognostic value of the GPS/mGPS in an unselected cohort of patients with operable cancer 
No: 
GPS/ 
mGPS 
Study Type of 
Study 
Cancer Country  Patients 
(n) 
Measure of 
Systemic 
Inflammatory 
Response (SIR) 
Additional 
Treatment  
Cancer deaths 
 (n) 
Overall deaths 
(n) 
Cancer survival 
(HR, 95%CI) 
Overall survival  
(HR, 95%CI) 
Independent 
Prognostic 
Factors 
1.  Ishizuka et al 
2007 (246)  
 
Retrospective Colorectal Japan 315 GPS (0/1/2)  No neoadjuvant 
treatments given  
66 144 N/A Multivariate: 
OR: 0.165 (0.037-0.732) 
p=0.0177 
 
Multivariate: 
Nil else 
2.  McMillan et al 
2007 (118) 
 
Retrospective Colorectal UK 316  mGPS (0/1/2)  Adjuvant therapy 
not specified 
70 117 Univariate:  
Colon:  p<0.0001 
 
Rectal: p<0.0001 
 
Multivariate: 
Dukes stage B  
1.74 (1.20-2.51) 
p=0.0032 
Univariate: 
Colon:  p<0.0001 
 
Rectal:  p<0.0001 
Multivariate:  
Age 
3. 0 Leitch et al 2007 
(247) 
 
Retrospective 
 
Colorectal UK 149  mGPS (0/1/2)  43 patients in the 
GPS 0, 24 patients 
in the GPS1 and 4 
patients in the GPS 
4 group underwent 
adjuvant treatment  
20 45 Multivariate: 
2.21 (1.11-4.41) 
p=0.024 
Multivariate: 
2.08 (1.32-3.28) 
p=0.002 
Multivariate: 
Age, TNM stage, 
monocyte count 
4.  Kobayashi et al 
2008 (209) 
 
Retrospective Oesophageal 
squamous 
cell 
carcinoma 
Japan 48 GPS (0/ 1 and 
2) 
Neoadjuvant 
chemoradiotherapy 
(nCRT) 
N/A 34 N/A Multivariate: 
OR: 0.17 (0.06-0.52) 
p=0.019 
 
 
Multivariate:  
Nil else 
5.  Roxburgh et al 
2009 (248) 
 
Retrospective Colorectal UK 287 mGPS (0/1/2)  Adjuvant therapy 
not specified 
67 116 Multivariate: 
2.65 (1.66-4.25) 
p<0.001 
N/A Multivariate: 
Age, Dukes stage, 
Klintrup criteria 
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6.  Ishizuka et al 
2009 (249) 
 
Retrospective Colorectal 
Liver 
Metastases 
Japan 93 GPS (0/1/2)  No patients had 
neoadjuvant 
chemotherapy  
48 51 Univariate: 
OR: 1.273 (0.269-
6.030) 
p=0.7612 
 
N/A Multivariate:  
Number of 
tumours, number 
of hepatectomies, 
synchronous lung 
metastasis, CRP 
7.  Crozier et al 
2009 (250) 
 
Prospective Colon 
cancer 
UK 188 mGPS (0/1/2) 54 patients received 
adjuvant therapy 
 
47 67 Multivariate: 
TNM stage 2 
patients (n=95) 
2.22 (1.04-4.74) 
p=0.0391 
N/A Multivariate: 
Presentation 
(elective/ 
emergency) 
8.  Roxburgh et al 
2010 (251) 
 
Retrospective Colon UK 287 mGPS (0/1/2)  Adjuvant 
chemotherapy  
80 125 
 
Multivariate: 
1.96 (1.19-3.21) 
p=0.008 
Multivariate: 
1.73 (1.18-2.25) 
p=0.005 
Multivariate:  
Dukes stage, 
vascular invasion 
9.  Richards et al 
2010 (252)  
 
Prospective  Colorectal  UK  320 mGPS (0/1/2) 66 had adjuvant 
therapy  
83 136 Multivariate: 
1.78 (1.32-2.41) 
p<0.001 
Multivariate: 
1.60 (1.26-2.02) p<0.001 
Multivariate:  
Age, Smoking, 
Dukes stage, 
POSSUM 
physiology score 
10.  Hefler-
Frischmuth et al 
2010 (202)  
 
Prospective  Vulval  Austria 93 GPS (0/1/2) No mention of 
adjuvant treatment 
23 27 N/A Multivariate: 
1.1 (0.5–2.4) p=0.8 
Multivariate:  
Tumour stage, 
Positive lymph 
node 
11.  Kobayashi et al 
2010 (210) 
 
Retrospective Esophageal 
Squamous 
Cell 
Carcinoma 
Japan 65 
 
GPS (0 and 1) 
  
39 patients received 
neoadjuvant 
chemoradiotherapy 
57 N/A Multivariate: 
GPS 0: 
0.071 (0.011-
0.470) p=0.0061 
 
GPS 1: 
0.367 (0.046-
2.927) p=0.3442 
N/A Multivariate: 
Number of lymph 
node metastases 
12.  Kobayashi et al 
2010 (253) 
 
Retrospective Colorectal 
Liver 
Metastases 
Japan 63 
 
GPS (0/ 1 and 
2) 
53 patients received 
chemotherapy after 
hepatectomy 
N/A 30 (5-year 
survival) 
N/A Multivariate: 
3.07 (1.18-7.98) 
p= 0.0217 
Multivariate: 
Liver metastases 
13.  Moug et al  2011 
(254)  
 
Retrospective  Colorectal  UK  206 GPS (0/1/2) 9 had neoadjuvant 
and 48 had adjuvant  
N/A 63 N/A Multivariate: 
1.56 (1.18-2.08) p=0.02 
Multivariate: 
pLNR 
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14.  Dutta et al 2011 
(211) 
 
Retrospective  Oesophageal  UK  112 GPS (0/1/2) 31 had neoadjuvant 
and 14 adjuvant 
therapy  
52 59 Multivariate: 
4.31 (2.20-8.45) 
p<0.001 
N/A Multivariate: 
Positive to total 
lymph node ratio 
(0/≤0.2/>0.2) 
15.  Dutta et al 2011 
(212) 
 
Retrospective  
Oesphagoga
stric   
UK  121 GPS (0/1/2) 67 patients have had 
neoadjuvant and 19 
adjuvant therapy  
39 44 Multivariate: 
1.96 (1.09–3.54) 
p= 0.025 
N/A Multivariate:  
TNM stage  
16.  Crumley et al 
2012 (213)  
 
Retrospective  Gastroesoph
ageal  
UK 100 GPS (0/1/2) Adjuvant and 
neoadjuvant therapy 
administered chemo 
and radiotherapy, 
but numbers not 
given 
51 55 Multivariate: 
3.99 (1.96-8.11) 
p<0.001 
N/A Multivariate: 
Number of 
positive LN, 
Tumour 
differentiation, 
Klintrup score, 
Ki-67 
17.  Jamieson et al 
2011 (279) 
 
Prospective  Pancreatic 
Ductal 
Cancer  
 
UK  135 GPS (0/1/2) 74 patients had 
adjuvant therapy  
107 109 
 
N/A Multivariate: 
2.26 (1.43-3.57) 
p=0.0001 
Multivariate: 
Tumour stage, 
tumour grade, 
margin involved, 
venous invasion, 
preoperative 
biliary drainage, 
adjuvant therapy 
18.  Roxburgh et al 
2011 (255) 
 
Retrospective  Colorectal  UK  302 GPS (0/1/2) 71 patients had 
adjuvant therapy  
85 135 Multivariate: 
1.81 (1.32-2.48) 
p<0.001 
Multivariate: 
1.60 (1.25-2.05) p<0.001 
Multivariate:  
Age, TNM, 
Peterson Index, 
Postoperative 
infective 
complications, 
ACE-27 
19.  Vashist et al 
2011 (214)  
Retrospective  Oesophageal  Germany  495 GPS (0/1/2) No adjuvant or 
neoadjuvant therapy  
N/A 71 N/A Multivariate: 
GPS 1: 1.7 (1.3–2.2) 
p<0.001 
 
GPS 2: 2.5 (1.7-3.6) 
p<0.001 
Multivariate: 
Tumour size, 
Node status, Mets, 
Cell type 
20.  Nozoe et al 2011 
(221)  
 
Prospective  Gastric  Japan 232 GPS (0/1/2) 
mGPS (0/1/2) 
No mention of 
adjuvant treatment 
N/A 184  N/A Multivariate: 
GPS: 3.425 (1.211–
9.709) p=0.020 
 
mGPS: 4.184 (1.792-
9.804) p=0.0009 
Multivariate: 
Tumour stage  
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21.  Ishizuka et al 
2011 (146)  
 
Retrospective  HCC Japan  300 hGPS (0, 1/2) 
*CRP>0.3 
mg/dl 
No mention of 
adjuvant treatment 
91 106 N/A Univariate: 
OR: 2.107 (1.061-4.185) 
p=0.033 
Univariate: 
CLIP score (0,1/ 
≥2) 
22.  Roxburgh et al 
2011 (256) 
 
Retrospective Colon 
Cancer 
UK 
 
76 mGPS (0/1 or 
2) 
All patients received 
adjuvant 
chemotherapy 
30 33 Multivariate: 
3.24 (1.45-7.27) 
p=0.004 
Multivariate: 
3.23 (1.49-7.01) 
p=0.003 
Multivariate: 
Petersen index, T 
category 
23.  Dutta et al 2012 
(215) 
  
Retrospective  Oesophageal 
Cancer 
UK  98 GPS (0/1/2)  47 underwent 
neoadjuvant therapy 
and 18 adjuvant  
60 68 Multivariate: 
2.91 (1.51-5.62) 
p=0.001 
N/A Multivariate: 
Age, Positive to 
total lymph node 
ratio, CD68 
tertials 
24.  Ishizuka et al 
2012 (287) 
 
Retrospective HCC Japan 398 
 
GPS (0, 1/2) No mention of 
neoadjuvant or 
adjuvant therapy  
112 130 N/A Multivariate: 
OR: 2.5 (1.124-5.561) 
p=0.025 
Multivariate: 
CLIP score (0, 1/ 
≥2) 
25.  Richards et al 
2012 (257) 
Retrospective  Colorectal 
Cancer 
UK  343 GPS (0/1/2)  No mention of 
adjuvant treatment  
85 N/A Multivariate: 
1.74 (1.27-2.39) 
p=0.001 
N/A Multivariate: 
GPS, Local 
Inflammatory Cell 
Infiltrate, TNM, 
Paterson Index 
26.  Qayyum et al 
2012 (239) 
Prospective  Renal Cell UK  79 GPS (0/1/2)  No mention of 
adjuvant therapies 
19 N/A Multivariate: 
8.64 (3.5–21.29) 
p<0.001 
N/A Multivariate: 
Nil else 
27.  Suigimoto et al 
2012 (258)  
 
Retrospective  Colorectal  Japan  366 GPS (0/1/2)  Adjuvant 
chemotherapy 
administered 
67 N/A Multivariate: 
3.09 (1.65-5.79) 
p=0.0004 
N/A Multivariate: 
Invasion Depth, 
Lymphatic 
Invasion, Lymph 
node metastasis  
28.  Kubota et al 
2012 (222) 
 
Retrospective  Gastric  Japan  1017 GPS (0/1/2)  No mention of 
adjuvant treatment 
66 92 Multivariate: 
GPS 1: 1.26 
(0.54-2.56) 
p=0.5702 
 
GPS 2: 5.07 
(1.94-11.41) 
p=0.0018 
Multivariate: 
GPS 1: 1.82 (1.00-3.11) 
p=0.0499 
 
GPS 2: 5.23 (2.30-10.37) 
p=0.0003 
Multivariate : 
Age≥75, Upper 
zone tumour, 
Lymph node mets, 
Surgical 
complications  
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29.  Powell et al 2012 
(259) 
 
Prospective   Colorectal  UK  411 mGPS (0/1/2)  Adjuvant therapy 
offered but no 
specific information 
on numbers given  
114 191 Multivariate: 
1.36 (1.03-1.79) 
p=0.028 
N/A Multivariate: 
Age, Lymph Node 
Ratio, Peterson 
Index, Klintrup 
score 
30.  La Torre et al 
2012 (280) 
 
Retrospective  Pancreatic  Italy  101 GPS (0/1/2)  26 underwent 
adjuvant treatment 
including 
chemotherapy and 
radiotherapy 
N/A 84 N/A Multivariate: 
1.7745 (1.1869-2.6532) 
p=0.005428 
Multivariate: 
LNR, Node status, 
Margin status  
31.  Dutta et al 2012 
(223)  
 
Retrospective  Gastric  UK  120 GPS (0/1/2)  Patients received 
both adjuvant and 
neoadjuvant therapy 
specific figures not 
given  
44 51 Multivariate: 
2.23 (1.40-3.54) 
p=0.001 
N/A Multivariate: 
Elevated lymph 
node ratio 
32.  Wang et al 2012 
(224) 
 
Retrospective  Gastric  China 324 GPS (0/1/2)  210 patients had 
adjuvant 
chemotherapy  
N/A 162 N/A Multivariate: 
1.397 (1.070-1.824) 
p=0.014 
Multivariate:  
The 7th TNM 
stage, Adjuvant 
chemotherapy  
33.  Lamb et al 2012 
(240) 
 
Retrospective  Renal  UK  169 GPS (0/1/2) No mention of 
adjuvant therapies 
35 59 Multivariate: 
6.65 (3.71 – 
11.93) p<0.001 
Multivariate: 
4.17 (2.48 – 7.03) 
p<0.001 
Multivariate:  
Fuhmann grade, 
Necrosis, UISS, 
Leibovich, 
SSIGN,  
34.  Ishizuka et al 
2012 (260)  
 
Retrospective  Colorectal  Japan  271 GPS (0/1/2) Adjuvant 
chemotherapy in 76 
cases 
42 59 Univariate: 
OR: 1.986 
(1.028-3.840) 
p=0.041 
Multivariate: 
OR: 2.023 (1.046-3.915) 
p=0.036 
Multivariate: 
Platelet Count  
35.  Jiang et al 2012 
(225)  
 
Retrospective  Gastric  Japan  1710 mGPS (0/1/2) No mention of 
adjuvant treatment 
N/A 562 N/A Multivariate: 
OR: 1.845 (1.184-2.875) 
p=0.007 
Multivariate:  
Age, Tumour 
stage  
36.  Jamieson et al 
2012 (281) 
 
Retrospective Pancreatic 
Ductal 
Adenocarcin
oma 
UK 173 mGPS (0/1/2) 67 patients received 
adjuvant 
chemotherapy 
N/A 173  N/A Multivariate: 
1.77 (1.19-2.62) 
p=0.005 
Multivariate: 
Tumour stage, 
resection margin 
status, venous 
invasion, 
inflammatory cell 
infiltrate, adjuvant 
therapy 
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37.  Stoz et al 2013 
(282) 
  
Retrospective  Pancreatic 
Cancer 
Austria  110 GPS (0/1/2)  88 Underwent 
chemotherapy  
N/A 110 N/A Univariate: 
1.095 (0.791-1.574) 
p=0.585 
Multivariate: 
Stage at diagnosis, 
NLR 
38.  Guthrie et al 
2013 (147)  
 
Retrospective  Colorectal  UK  206 mGPS (0/1/2)  58 patients had 
adjuvant 
chemotherapy  
29 41 Multivariate: 
Pre-Op: 1.97 
(1.16–3.34) 
P<0.05 
 
 
N/A Multivariate: 
Pre-Op NLR 
39.  Shiba et al  2013 
(286) 
 
Retrospective  Carcinoma 
of the 
ampulla of 
vater 
Japan  30 GPS (0/1/2)  No specific mention 
of adjuvant therapy  
N/A 25 N/A Multivariate: 
11.364 (1.017-126.9) 
p=0.048 
Multivariate:  
Lymph node 
metastasis  
40.  Oshiro et al 2013 
(285)  
 
Retrospective  Cholangioca
rcinoma 
Japan  62 GPS (0/1/2)  No mention of 
adjuvant treatment  
N/A 
 
46 N/A Multivariate: 
2.787 (1.153-6.735) 
p=0.022 
Multivariate:  
Nil Else 
41.  Horino et al 2013 
(288)  
 
Retrospective HCC Japan  352 GPS (0/1/2)  No mention of 
adjuvant treatment 
N/A 128 N/A Multivariate: 
3.796 (2.050–7.031) 
p<0.001 
Multivariate: 
Tumour size, 
Operation time, 
Vp 
42.  Ishizuka et al 
2013 (261) 
Retrospective  Colorectal 
Stage IV 
Japan  108 GPS 2 vs. 0,1 Majority had 
adjuvant 
chemotherapy  
72 79 N/A Multivariate: 
OR: 0.451 (0.271-0.753) 
p=0.002 
Multivariate: 
Pathology others, 
Subclass of stage 
IV 
43.  Ishizuka et al 
2013 (119) 
Retrospective  Colorectal  Japan  481 GPS (0/1/2) Patients with stage 
IV disease had 
chemotherapy  
120 150 Multivariate: 
OR: 2.604 (1.242-
5.456) p=0.011 
N/A Multivariate:  
Pathology, LN 
Mets, CRP, 
Albumin, CEA, 
COP-NLR 
44.  Son et al 2013 
(262)  
 
Retrospective Colon 
Cancer 
Korea 624 mGPS (2 vs. 0-
1) 
503 patients 
received 
chemotherapy 
N/A 55 (5 yr. 
survival) 
N/A Multivariate: 
2.217 (0.716-6.864) 
p=0.167 
Multivariate: 
Fibrinogen, stage, 
CEA 
45.  Nozoe et al 2014 
(263)   
 
Retrospective  Colorectal  Japan  272 GPS (0/1/2)  No mention of 
adjuvant treatment 
N/A 49 N/A Multivariate: 
OR: 7.41 (3.66-15.2) 
p<0.0001  
Multivariate: 
Tumour stage, 
venous invasion  
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46.  Takeno et al 
2014 (145) 
 
Retrospective  Gastric  Japan  552 mGPS (0/1/2)  No mention of 
adjuvant treatment 
N/A 215 N/A  Multivariate: 
1.2391 (0.9188-1.6787) 
p=0.1598 
Multivariate:  
HS-mGPS 
47.  Pinato et al 2014 
(300) 
 
Retrospective  Lung  UK  220 GPS (0/1/2)  Adjuvant radio and 
chemotherapy 
administered  
N/A 61 N/A Univariate:  
1.5 (1.0–2.0) p=0.02 
Multivariate: 
NLR, Pleural 
Effusion 
48.  Huang et al 2014 
(289)  
 
Prospective  HCC China  349 GPS (0/1/2)  No mention of 
adjuvant treatment 
N/A 153 N/A Multivariate: 
1.633 (1.226–2.174) 
p=0.001 
Multivariate: 
CLIP score, 
BCLC stage 
49.  Feng et al 2014 
(216)  
2014 
Retrospective  Oesophageal  China 493 GPS (0/1/2)  Adjuvant chemo and 
radiotherapy 
administered  
409 (1 year) N/A Univariate: 
1.907 (1.608-
2.262) p<0.001 
N/A Univariate: 
Tumour depth, 
Differentiation, 
Nodal Mets 
50.  Forrest et al 2014 
(264) 
 
Retrospective  Colorectal  UK  134 GPS (0/1/2)  No mention of 
Adjuvant treatment  
43 81 Univariate:  
2.12 (1.41-3.20) 
p<0.001 
N/A Univariate: 
T-stage, N-stage, 
TNM stage, 
Venous invasion, 
Peritoneal 
involvement, 
Margin 
involvement, 
Manual and 
Automatic 
Klintrup–Makinen 
grade 
51.  Wu et al 2014 
(283) 
 
Retrospective Gallbladder China 85 GPS (0 vs 1/2)  13 patients had post 
op chemotherapy  
 
N/A 75 N/A Multivariate: 
10.877 (2.496-47.398) 
p=0.001 
Multivariate: 
Tumour Invasion, 
Lymph node 
metastasis, 
Margin status 
52.  Hirashima et al 
2014 (143) 
 
Retrospective  Gastric  Japan  294 mGPS (0/1/2)  9 patients had 
neoadjuvant 
chemotherapy  
N/A 38 N/A Multivariate: 
<75 Years: (n=195) 
1.24 (0.41-3.75) p=0.70 
 
>75 Years: (n=99) 
2.26 (1.09-4.69) p=0.03 
 
Multivariate: 
Age, Total 
Gastrectomy, 
Peritoneal mets, 
Stage 
 453 
53.  Nakamura et al 
2014 (141) 
 
Retrospective  Oesophageal  Japan  168 mGPS (0/1/2)  13 had neoadjuvant 
treatment while 62 
had adjuvant 
treatment  
N/A 44 (3-year 
survival) 
N/A Multivariate: 
2.726 (1.021–7.112) 
p=0.0449 
Multivariate:  
N3: Lymph node, 
Residual Tumour  
54.  Sun et al 2014 
(265) 
 
Retrospective Colon 
cancer 
China 255 mGPS (0/1/2) No specific mention 
of neoadjuvant or 
adjuvant treatment  
N/A 94 N/A Multivariate: 
RR 2.968 (2.137-4.122) 
p=0.000 
Multivariate: 
AFP, 
CEA,fibrinogen, 
TNM 
55.  Nakagawa et al 
2014 (266)  
 
Retrospective Colorectal 
Liver 
Metastases 
Japan 
 
343 mGPS (0/1/2) 69 patients received 
neoadjuvant 
chemotherapy, 216 
received adjuvant 
chemotherapy  
86 94 Multivariate: 
1.595 (1.156-
2.201) 
p=0.004 
N/A Multivariate: 
CEA (<30/ ≥30 
ng/L) 
56.  Aurello et al 
2014 (135)  
 
Retrospective Gastric 
Cancer 
Italy 102 mGPS (0/1/2) 68 patients received 
adjuvant 
chemotherapy after 
surgery 
62 62 
 
N/A Multivariate: 
mGPS 1: 
1.70 (1.20-3.42) 
p=0.005 
 
mGPS 2: 
1.91 (1.38-3.18) 
p=0.008 
Multivariate: 
Prognostic index 
57.  Miyazaki et al 
2015 (301) 
 
Retrospective  Non Small 
Cell Lung 
Cancer 
(NSCLC) 
Japan  97 GPS (0/1/2)  No mention of 
adjuvant treatment 
29 44 N/A Multivariate: 
2.13 (1.036-4.393) 
p=0.04 
 
Multivariate: 
Patient factors, 
Inflammatory 
factors, stage 
factors  
58.  Matsuda et al 
2015 (217) 
 
Retrospective  Oesophageal 
Cancer 
Japan 199 GPS (0/1/2)  99 patients received 
neoadjuvant 
chemotherapy/ 
chemoradiotherapy 
N/A 72 N/A Multivariate: 
GPS 1: 
0.562 (0.229-1.377) 
p=0.208 
 
GPS 2: 
0.969 (0.123-7.668) 
p=0.976 
 
Multivariate: 
Clinical stage, 
fibrinogen and 
albumin score 
59.  Farhan-Alanie et 
al 2015 (275)  
 
Retrospective  Oral SCC UK  178 GPS (0/1/2)  70 patients had 
adjuvant therapy  
42 56 Multivariate: 
2.12 (1.49-3.00) 
p<0.001 
Multivariate: 
1.69 (1.23-2.31) p=0.001 
Multivariate: Male 
and AJCC stage 4 
60.  Ferro et al 2015 
(199) 
 
Retrospective  Bladder 
Cancer 
Italy 1037 mGPS (0/1/2)  799 received 
adjuvant 
chemotherapy 
426 430 Multivariate: 
mGPS 1: 0.87 
(0.54-1.40) 
p=0.565 
Multivariate: 
mGPS 1: 1.19 (0.84-
1.70) p=0.332 
Multivariate: 
 
Pathologic stage 
T4, Node positive 
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mGPS 2: 0.94 
(0.49-1.81 
p=0.853 
mGPS 2: 1.25 (0.74-
2.11) p=0.410 
and adjuvant 
Chemotherapy   
61.  Arigami et al 
2015 (142) 
 
Retrospective  Oesophageal 
Cancer  
Japan  238 mGPS (0/1/2)  No mention of 
adjuvant therapy  
N/A 98 N/A Multivariate: 
1.08 (0.49-2.19) p=0.830 
Multivariate:  
F-NLR Score, 
Lymph node mets, 
Depth of tumour 
invasion  
62.  Xu et al 2015 
(127) 
 
Retrospective Oesophageal 
SCC 
China 468 GPS/mGPS 
(0/1/2)  
196 patient received 
adjuvant chemo and 
radiotherapy  
N/A 259 N/A Univariate: 
GPS 1: 1.33 (0.99-1.78) 
p=0.057 
GPS 2: 1.83 (1.18-2.86) 
p=0.008 
 
mGPS 1: 1.39 (1.01-
1.91) p=0.046 
mGPS 2: 1.82 (1.17-
2.83) p=0.008 
Multivariate: 
Lymph Node 
Mets, 
Venous/lymphatic 
invasion, 
CRP/Alb Ratio 
63.  Ni et al 2015 
(290) 
 
Retrospective  HCC China 367 mGPS (0/1/2)  No mention of 
adjuvant treatment  
N/A 40 N/A Multivariate: 
4.356 (2.495-7.605) 
p<0.001 
Multivariate: 
GGT≥60, 
AFP≥400, CLIP 
Score, Vascular 
Invasion 
64.  Hirahara et al 
2015 (218) 
 
Retrospective  Oesophageal  Japan  141 GPS (0/1/2)  No mention of 
adjuvant treatment  
N/A 16 N/A Multivariate: 
2.045 (1.032-3.928) 
p=0.041 
Multivariate: 
p Stage  
65.  Shibutani et al 
2015 (267) 
 
Retrospective  Colorectal  Japan  254 GPS (0/1/2)  Adjuvant 
chemotherapy  
N/A 69 N/A Multivariate: 
7.238 (1.180-44.415) 
p=0.032 
Multivariate: 
NLR (Pre & Post 
op), Number of 
lymph node mets 
66.  Shiba et al 2015 
(284) 
 
Retrospective  Gallbladder 
Ca 
Japan  51 GPS (0/1/2)  No mention of 
adjuvant treatment 
N/A 16 N/A Multivariate: 
3.782 (1.119-12.786) 
p=0.032 
Multivariate: 
Lymph node 
metastasis 
67.  Kawashima et al 
2015 (144) 
 
Retrospective Lung Cancer Japan 1043 GPS (0/1/2) No mention of 
adjuvant treatment 
N/A 227 N/A Multivariate: 
GPS 1 
1.63 (1.09-2.42) 
p=0.02 
 
GPS 2 
1.44 (0.80-2.60) 
Multivariate: 
Age, smoking, 
preoperative co-
morbidity, CEA, 
pathological stage, 
histological 
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p=0.22 tumour type, LVI, 
surgical procedure 
68.  Watt et al 2015 
(600)  
 
Retrospective Colorectal 
cancer 
UK 508 mGPS (0/1/2) 108 patients had 
adjuvant 
chemotherapy 
following resection. 
172 292 Multivariate: 
1.54 (1.25-1.90) 
p< 0.001 
Multivariate: 
1.32 (1.12-1.56) 
p=0.001 
Multivariate: 
Age, site, TNM 
stage, margin 
involvement, 
peritoneal 
involvement, sex, 
venous invasion, 
tumour 
perforation 
69.  Okamura et al 
2015 (291)  
 
Retrospective HCC Japan 256 GPS (0/1/2) No mention of 
adjuvant treatment 
N/A 86 N/A Multivariate: 
1.71 (0.92-3.16) 
p=0.089 
Multivariate: 
AFP, des-gamma-
carboxy 
prothrombin, high 
NLR, low PNI. 
70.  Abe et al 2016 
(292)  
 
Retrospective HCC Japan 46 
 
GPS (0/ 1,2) No mention of 
adjuvant treatment 
N/A 17 N/A Multivariate: 
7.718 (1.710-34.840) 
p=0.008 
Multivariate: 
Milan criteria 
71.  Ishizuka et al 
2016 (126) 
 
Retrospective Colorectal 
Cancer 
Japan 627 GPS (2/0, 1) No mention of 
adjuvant treatment 
110 142 
  
N/A 
 
Multivariate: 
1.809 (1.181-2.772) 
p=0.006 
Multivariate: 
Pathological 
differentiation, 
CEA, stage, CAR, 
NLR 
72.  Park et al 2016 
(268) 
 
Retrospective  Colorectal 
Cancer 
UK  228 GPS (0/1/2)  131 received 
adjuvant therapy  
66 N/A Multivariate: 
1.59 (1.12–2.27) 
p=0.010 
N/A Multivariate: 
CD3 cancer cells 
nest density 
(low/high), NPS 
73.  Park et al 2016 
(7)  
 
Retrospective Colorectal  UK  1000 mGPS (0/1/2)  Adjuvant therapy: 
248 
Neoadjuvant 
therapy: 98 
242 435 Multivariate: 
1.28 (1.09-1.52) 
p=0.003 
Multivariate: 
1.28 (1.13-1.45) p<0.001 
Multivariate: 
Age, Adjuvant 
therapy, T stage, 
N stage, 
Differentiation, 
Margins involved 
74.  Fu et al 2016 
(293) 
 
Retrospective HCC China Training: 
772 
 
 
GPS (0/1/2) 
 
mGPS (0/1/2) 
No mention of 
adjuvant treatment 
N/A 377 (4-year 
survival) 
N/A Multivariate: 
Training cohort: 
mGPS 3.508 (1.384-
8.890) p=0.008 
Multivariate: 
AFP, GGT, IBS, 
PLR, PI, tumour 
size, tumour 
number, 
microscopic 
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vascular invasion, 
differentiation, 
BCLC. 
75.  Fan et al 2016 
(302) 
 
Retrospective Non-small 
Cell Lung 
Cancer 
China 1243 GPS (0/1/2) 
mGPS (0/1/2)  
684 patients 
received 
chemotherapy, 220 
patients received 
radiotherapy 
N/A 373  N/A Multivariate: 
GPS:  
2.228 (1.447-3.431) 
p< 0.0001 
 
mGPS: 
0.958 (0.633-1.452) 
p=0.841 
 
Multivariate: 
Gender, age, 
TNM stage, 
chemotherapy, 
radiotherapy 
76.  Chan et al 2016 
(269) 
 
Retrospective Colorectal 
Cancer 
Australia 386 mGPS (0/1/2)  Patients with high-
risk stage II and III 
colon cancer disease 
were generally 
offered standard 
adjuvant 
chemotherapy, 
whereas those with 
stage II or III rectal 
cancers were usually 
treated with 
neoadjuvant  
N/A 353 N/A Univariate: 
mGPS 1:  
1.552 (0.892-2.700) 
P=0.001 
 
mGPS 2: 
2.214 (1.454-3.369) 
p=0.001  
Multivariate: 
Age, T stage, 
grade, LMR 
77.  Walsh et al 2016 
(219) 
 
Retrospective Esophageal 
Cancer 
Ireland 223 mGPS (0 vs. 
1/2)  
109 patients 
received 
neoadjuvant 
chemoradiotherapy, 
66 patients received 
chemotherapy 
N/A 104 (5-year 
survival) 
N/A Multivariate: 
1.24 (0.69-2.22) 
p=0.47 
Multivariate: 
TNM stage, nodal 
status 
78.  Otowa et al 2016 
(220) 
 
Retrospective Oesophageal 
Cancer 
Japan 100 Pre-NAC 
mGPS (0/1-2) 
 
Post-NAC 
mGPS (0/2) 
 
NAC=neoadjuv
ant 
chemotherapy  
All patients 
underwent NAC 
followed by surgery 
N/A 36 N/A Multivariate: 
Pre-NAC mGPS: 
0.043 (0.001–1.311) 
p=0.067 
 
Post-NAC mGPS: 
0.020 (0.018–0.621) 
p=0.018 
 
Multivariate: 
Grade of response 
to chemotherapy 
79.  Melling et al 
2016 (226)  
 
Retrospective Gastric 
Cancer 
Germany 88 GPS (0/1/2)  Any 
neoadjuvant/adjuvan
t therapy was an 
exclusion criterion 
N/A 57 
 
N/A Multivariate: 
OR 1.6 (1.0-2.4) 
p=0.033 
Multivariate:  
Nil else 
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80.  Toyokawa et al 
2016 (140)  
 
Retrospective Thoracic 
Oesophageal 
Squamous 
Cell 
Carcinoma 
Japan 185 GPS (0 vs 1/2)  46 patients received 
neoadjuvant 
treatment (39 
chemotherapy, 6 
chemoradiotherapy, 
1 radiotherapy) 
N/A 77 
  
N/A 
 
Multivariate: 
1.021 (0.465-2.245) 
p=0.958 
Multivariate: 
Sex, performance 
status, America 
Society of 
Anaesthesiologist 
Physical Status 
Classification 
(ASA), cTNM 
stage, CONUT 
score 
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Table 18.2: Studies investigating the prognostic value of the NLR in an unselected cohort of patients with operable cancer 
No: 
NLR 
Study Type of 
Study 
Cancer Country  Patients 
(n) 
Measure of 
SIR 
Additional 
Treatment  
Cancer deaths 
(n) 
Overall deaths 
(n) 
Cancer survival 
(HR, 95%CI) 
Overall survival 
(HR, 95%CI)  
Independent 
Prognostic 
Factors 
1.  Halazun et al 2008 
(601)  
 
Retrospective Colorectal 
Liver 
Metastases 
UK 440 NLR >5 Adjuvant therapy of 
5-FU/folinic acid 
N/A 395 (5-year 
survival) 
N/A Multivariate: 
2.275 (1.654-3.129) 
p<0.0001 
Multivariate: 
Age, tumour 
number  
2.  Gomez et al 2008 
(602)    
 
Retrospective Intrahepatic 
cholangioca
rcinoma 
UK 27 NLR ≥5 No mention of 
adjuvant or 
neoadjuvant 
treatment  
N/A 21 N/A Multivariate: 
RR: 1.778 (0.558-5.668) 
p=0.331 
Multivariate:  
Nil else 
3.  Sarraf et al 2009 
(603)  
 
Retrospective Non-Small 
Cell Lung 
Cancer 
UK 177 NLR (tertiles) No mention of 
adjuvant or 
neoadjuvant 
treatment 
N/A 81 (5-year 
survival) 
N/A Multivariate: 
1.10 (1.03-1.17) 
p= 0.005 
Multivariate: 
Stage of disease 
4.  Kishi et al 2009 
(604) 
 
Retrospective Colorectal 
Liver 
Metastases 
US 200 NLR >5  Neoadjuvant 
chemotherapy 
N/A 118 (5-year 
survival) 
 
N/A Multivariate: 
2.0 (1.0-3.8) 
p= 0.048 
Multivariate: 
Postoperative 
factors namely 
concomitant 
radiofrequency 
ablation (RFA) 
and surgical 
margin 
5.  Cho et al 2009 
(605)  
 
Retrospective Epithelial 
Ovarian 
Cancer 
South 
Korea 
192 NLR >2.6  Adjuvant 
chemotherapy  
N/A 20 N/A Multivariate: 
8.42 (1.09-64.84) 
p=0.041 
Multivariate: 
Age, stage 
6.  Smith et al 2009 
(606)  
 
Retrospective Pancreatic 
Ductal 
Adenocarci
noma 
UK 110 NLR continuous 33 patients had 
adjuvant therapy  
N/A 106 N/A Univariate: 
1.047 (0.985-1.113) 
p=0.14 
Multivariate: 
Lymphocyte 
count, PLR 
7.  Halazun et al 2009 
(607) 
Retrospective HCC US 150 
 
NLR ≥5 116 patients 
received 
pretransplant tumour 
therapy 
N/A 61 N/A Multivariate: 
6.102 (2.286-16.290) 
p<0.0001 
Multivariate: 
Preoperative AFP 
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8.  Jagdev et al 2010 
(608) 
 
Retrospective Renal Cell 
Carcinoma 
UK 286 Log (NLR) No mention of 
adjuvant or 
neoadjuvant 
treatment 
63 (5-year 
survival) 
111 (5-year 
survival) 
Multivariate: 
4.2 (1.6-11) 
p=0.004 
Univariate: 
2.1 (1.5-2.8) 
p<0.001 
Multivariate: 
Log CRP, stage, 
grade, RBC, 
WBC, M stage, 
necrosis, micro 
vascular invasion 
9.  Ubukata et al 2010 
(609) 
 
Retrospective Gastric 
Cancer 
Japan 157 NLR ≥5 No neoadjuvant 
therapy. 
N/A 77 N/A Multivariate: 
RR: 5.779 (0.950-
35.170) p=0.0001 
Multivariate: 
Th1/ Th2 ratio, 
pathological stage, 
depth of invasion, 
tumour size, 
lymph node 
metastasis 
10.  Shimada et al 
2010 (610)   
 
Retrospective Gastric 
Cancer 
Japan 1028 NLR ≥4 No mention of 
adjuvant or 
neoadjuvant 
treatment 
128 147 N/A Multivariate: 
1.845 (1.236-2.747) 
p=0.003 
Multivariate: 
Tumour depth, N 
factor, distant/ 
peritoneal 
metastasis, 
histology, platelet 
count 
11.  Bhatti et al 2010 
(611) 
 
Retrospective Pancreatic 
ductal 
adenocarcin
oma 
UK 84 NLR 
(continuous) 
30 patients received 
adjuvant 
chemotherapy 
N/A 66 (3-year 
survival) 
N/A Multivariate: 
1.210 (1.010-1.449) 
p=0.039 
Multivariate: 
Lymphocyte 
count, resection 
margin 
12.  Mohri et al 2010 
(612) 
 
Retrospective Gastric 
Cancer 
Japan 357 NLR >2.2 No neoadjuvant 
therapy  
N/A 98 N/A Multivariate: 
2.78 (1.79-4.36) 
p<0.0001 
Multivariate: 
Tumour size, 
clinical T stage 
13.  Liu et al 2010 
(613)  
 
Retrospective Rectal 
carcinoma 
China 123 NLR >2 Stage II cancers 
received adjuvant 
chemotherapy 
N/A 
 
123 N/A Multivariate: 
2.615 (1.152-5.933) 
p=0.021  
Multivariate: 
Depth of invasion, 
tumour size, 
CA12-5 level, 
stage 
14.  Miyata et al 2011 
(128) 
 
Retrospective Oesophagea
l Cancer 
Japan 152 NLR ≥4 All patients received 
neoadjuvant 
chemotherapy 
N.A. 92 (5-year 
survival) 
N/A Multivariate: 
1.30 (0.76-2.22) 
p=0.3362 
Multivariate: 
Clinical response, 
SI score, number 
of metastatic 
lymph nodes, 
operative 
complication 
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15.  Dutta et al 2011 
(211) 
 
Retrospective  Oesophagus  UK  112 NLR (<2.5/ 2.5-
5/ >5) 
31 had neoadjuvant 
and 14 adjuvant 
therapy  
52 59 Univariate: 
1.08 (0.75-1.56) 
p=0.686 
N/A Multivariate: 
Positive to total 
lymph node ratio 
(0/≤0.2/>0.2), 
mGPS 
16.  Kao et al 2011 
(614) 
 
Retrospective Malignant 
pleural 
mesothelio
ma 
Australia 85 NLR ≥3 19 patients received 
neoadjuvant 
chemotherapy 
N/A 72 (5-year 
survival) 
N/A Multivariate: 
1.79 (1.04-3.07) 
p=0.04 
Multivariate: 
Gender, 
histological 
subtype, calretinin 
score, D2-40 score 
17.  Jung et al 2011 
(615) 
 
Retrospective Gastric 
cancer 
Korea 293 NLR ≥2 183 patients 
received adjuvant 
chemotherapy 
N/A 166 N/A Multivariate: 
1.462 (1.033-2.068) 
p=0.032 
Multivariate: 
Combined 
resection 
radicalism, Lauren 
classification, 
postoperative 
chemotherapy 
18.  Sharaiha et al 
2011 (616)  
 
Retrospective Esophageal 
cancer 
US 295 NLR ≥5 127 received 
neoadjuvant therapy 
(chemo/ 
radiotherapy) 
N/A 160 (5-year 
survival) 
N/A Multivariate: 
2.32 (1.53-3.50) 
p<0.0001 
Multivariate: 
Age, sex, stage, 
tumour 
differentiation, 
comorbidities 
19.  Tomita et al 2011 
(617) 
 
Retrospective Non-small 
Cell Lung 
Cancer 
Japan 284 NLR≥2.5 No mention of 
adjuvant or 
neoadjuvant 
treatment 
N/A 109 (5-year 
survival) 
N/A Multivariate: 
RR: 1.2863 (1.0462-
1.5738) 
p=0.0173 
Multivariate: 
Age, histology, 
pT, pN, pleural 
lavage cytology 
20.  Hung et al 2011 
(618) 
 
Retrospective Colon 
cancer 
Taiwan 1040 NLR ≥5 No neoadjuvant 
therapy administered 
122 334 N/A Multivariate: 
1.29 (1.07-1.80) 
p=0.012 
Multivariate: 
Age, CEA, 
examined lymph 
node no. <12, T 
stage, tumour 
obstruction/ 
perforation 
21.  Neal et al 2011 
(619) 
 
Retrospective Colorectal 
Liver 
Metastases 
UK 202 NLR ≥5 84 patients had 
systemic 
chemotherapy in the 
6 months before 
liver resection 
N/A 127 (5-year 
survival) 
N/A Univariate: 
2.51 (1.56-4.02) 
p<0.001 
Multivariate: 
Clinical risk score, 
neutrophil count, 
serum albumin 
22.  Asher et al 2011 
(620) 
 
Retrospective Ovarian 
Cancer 
UK 235 NLR>4 170 patients 
received 
chemotherapy 
N/A 169 (survival 
after 150 
months) 
N/A Multivariate: 
0.865 (0.521-1.437) 
p=0.575 
Multivariate: 
Age, stage, 
residual disease, 
PLR 
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23.  Wang et al 2011 
(621) 
 
Retrospective HCC China 101 NLR≥3 35 patients received 
pre-transplant 
tumour therapy 
N/A 51 N/A Multivariate: 
2.654 (1.419-4.964) 
p<0.001 
Multivariate: 
Tumour numbers, 
vascular invasion 
24.  Bertuzzo et al 
2011 (622) 
 
Retrospective HCC Italy 219 
 
NLR ≥5 159 patients 
received 
neoadjuvant 
treatments (TACE, 
PEI, RFA) 
27 61 N/A Multivariate: 
OR: 4.868 (2.473-9.582) 
p< 0.0001 
Multivariate: 
Microvascular 
invasion 
25.  Idowu et al 2012 
(623) 
 
Retrospective Soft Tissue 
Sarcoma 
UK 223 NLR ≥5 No mention of 
adjuvant or 
neoadjuvant 
treatment 
N/A 44 (5-year 
survival) 
N/A Multivariate: 
5.125 (1.245-21.086) 
p=0.024 
Multivariate: 
Grade, surgical 
margin. 
26.  Ishizuka et al 2012 
(624) 
 
Retrospective Colorectal 
Cancer 
Japan 169 NLR 
(continuous) 
Adjuvant 
chemotherapy in 
most patients 
86 96 N/A Multivariate: 
OR: 0.980 (0.870-1.106) 
p=0.747 
Multivariate: 
Tumour pathology 
27.  Wang et al 2012 
(224) 
 
Retrospective  Gastric  China 324 NLR >5  210 patients had 
adjuvant 
chemotherapy  
N/A 162 N/A Multivariate: 
1.866 (0.901-3.866) 
p=0.093 
Multivariate:  
The 7th TNM 
stage, adjuvant 
chemotherapy  
28.  Gondo et al 2012 
(625) 
 
Retrospective Bladder 
cancer 
Japan 189 NLR ≥2.5 38 received 
intravesical 
chemotherapy  
54 N/A  Multivariate: 
1.946 (1.035-
3.663) 
p=0.0387 
N/A Multivariate: 
Tumour size, Hb 
29.  Kwon et al 2012 
(626) 
 
Retrospective Colorectal 
cancer 
Korea 200 NLR ≥5 150 patients 
received adjuvant 
chemotherapy/ 
chemoradiation 
N/A 39 N/A Multivariate: 
1.520 (0.613-3.772) 
p=0.367 
Multivariate: 
Stage, CEA, PLR 
30.  Carruthers et al 
2012 (102) 
 
Retrospective Rectal 
cancer 
UK 115 NLR ≥5 Neoadjuvant 
chemoradiation 
N/A 43 N/A Multivariate: 
7.0 (2.6-19.2) 
p<0.001 
Multivariate: Total 
WBC, platelet 
count, R status, 
down staging 
31.  Dutta et al 2012 
(223)  
 
Retrospective  Gastric  UK  120 NLR (<2.5/ 2.5-
5/ >5) 
Patients received 
both adjuvant and 
neoadjuvant therapy 
specific figures not 
given  
44 51 Univariate: 
1.19 (0.76-1.87) 
p=0.454 
N/A Multivariate: 
Positive lymph 
node ratio 
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32.  Wang et al 2013 
(627) 
 
Retrospective Oesophagea
l 
Cacinosarc
oma 
China 33 NLR≥5 4 patients received 
adjuvant 
chemotherapy, 3 
received adjuvant 
radiotherapy 
N/A 14 N/A Multivariate: 
138.47 (6.772-2831.214) 
p=0.001 
Multivariate: 
Nil else 
33.  Choi et al 2014 
(628) 
 
Retrospective Soft Tissue 
Sarcoma 
Korea 162 NLR >2.5 7 patients received 
neoadjuvant 
chemotherapy, 72 
patients received 
adjuvant radiation, 
36 patients received 
adjuvant 
chemotherapy 
20 20 Multivariate: 
OR: 1.32 (0.55-
3.21) p=0.096 
N/A Multivariate: 
CRP, ESR, 
number of 
elevated markers 
34.  Szkandera et al 
2013 (629) 
 
Retrospective Soft Tissue 
Sarcoma 
Austria 260 NLR <3.58vs. 
≥3.58 
167 patients 
received adjuvant 
radiotherapy, 35 
received adjuvant 
chemotherapy 
N/A 86 N/A Multivariate: 
1.88 (1.14-3.12) 
P=0.014 
Multivariate: 
Sex, tumour 
necrosis, tumour 
stage 
35.  Krane et al 2013 
(630)  
 
Retrospective Bladder 
Cancer 
US 68 NLR >2.5 10 patients received 
neoadjuvant 
chemotherapy 
25 40 Multivariate: 
RR 2.68 (1.01-
8.59) 
 
Multivariate: 
RR 2.49 (1.14-6.09) 
 
Multivariate: 
Hypoalbuminaemi
a, pT3, nodal 
disease. 
36.  Pichler et al 2013 
(631) 
 
Retrospective Renal Cell 
Carcinoma 
Austria 678 NLR <3.3vs. 
≥3.3 
No mention of 
adjuvant or 
neoadjuvant 
treatment 
59 123 Multivariate: 
1.59 (0.84-2.99) 
P=0.148 
Multivariate: 
1.59 (1.10-2.31) 
P=0.014 
Multivariate: 
Age, T stage, 
tumour grade, 
presence of 
tumour necrosis 
37.  Jankova et al 2013 
(632)  
 
Retrospective Colorectal 
cancer 
Australia 322 NLR 
(continuous) 
7 patients received 
adjuvant 
radiotherapy, 197 
received adjuvant 
chemotherapy 
86 141 Multivariate: 
1.01 (0.92-1.12) 
P=0.782 
Multivariate: 
1.06 (1.01-1.12) 
P=0.013 
Multivariate:  
Age, direct spread 
beyond muscularis 
propria, nodes 
involvement, 
adjacent structure 
infiltrated, 
postoperative 
chemotherapy, sex 
38.  Fu et al 2013 
(633) 
 
Retrospective Hepatocellu
lar 
Carcinoma 
China 282 NLR>2 No mention of 
adjuvant or 
neoadjuvant 
treatment 
N/A 173 N/A Multivariate: 
1.434 (1.044-1.970) 
P=0.026 
Multivariate: 
Tumour size, 
tumour number, 
macroscopic 
vascular invasion, 
Child-Pugh class 
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39.  Shibutani et al 
2013 (634) 
 
Retrospective Colorectal 
Cancer 
Japan 674 NLR ≥2.5 No mention of 
adjuvant or 
neoadjuvant 
treatment 
136 177 Multivariate: 
1.609 (1.117-
2.319) 
P=0.011 
N/A Multivariate: 
Tumour diameter, 
lymph node 
metastasis, distant 
metastasis 
40.  Forget et al 2013 
(635) 
 
Retrospective Breast 
Cancer 
Belgium Centre 1: 
n=172 
 
Centre 2: 
n=162 
Centre 1: NLR. 
≥4 
 
Centre 2: NLR. 
≥3 
No mention of 
adjuvant or 
neoadjuvant 
treatment 
N/A Centre 1: 17 (at 
60 months) 
 
Centre 2: 8 (at 
24 months) 
N/A Centre 1:  
Univariate  
0.51 (0.35-8.58) 
P=0.47 
 
Centre 2: 
Univariate 
4.00 (1.12-14.3) 
P=0.03 
Univariate: 
Ketorolac or 
diclofenac use 
41.  Forget et al 2013 
(635) 
 
Retrospective NSCLC Belgium 255 NLR≥5 No mention of 
adjuvant or 
neoadjuvant 
treatment 
N/A 109 (at 60 
months) 
N/A Univariate: 
1.52 (1.07-2.17) P=0.02 
Multivariate: 
Pneumonectomy, 
Ketorolac (vs. no 
NSAIDS) 
42.  Forget et al 2013 
(635) 
 
Retrospective Kidney 
Cancer 
Belgium 227 NLR≥5 No mention of 
adjuvant or 
neoadjuvant 
treatment 
N/A 64 (at 60 
months) 
N/A Multivariate: 
1.67 (1.0-2.81) p=0.05 
Multivariate: 
Node status, stage, 
histological stage 
43.  Absenger et al 
2013 (636) 
 
Retrospective Colon 
Cancer 
Austria 372 dNLR (≤2.2 vs. 
>2.2) 
 
preoperative 
NLR   >4 
 
preoperative 
NLR ≥5 
230 patients 
received adjuvant 
chemotherapy 
N/A 72 N/A Multivariate: 
dNLR 
1.78 (1.07-2.97) p=0.026 
 
Preoperative NLR >4 
2.22 (1.36-3.62) p=0.002 
 
Preoperative NLR ≥5 
1.68 (1.03-2.73) p=0.037 
Multivariate: 
Clinical stage 
44.  Feng et al 2013 
(123) 
 
Retrospective Oesophagea
l Squamous 
Cell 
Carcinoma 
China 483 NLR >3.45  No mention of 
adjuvant or 
neoadjuvant 
treatment 
N/A 244 N/A Multivariate: 
1.310 (0.997-1.722) 
p=0.053 
Multivariate: 
Differentiation, 
depth of invasion, 
node metastasis, 
PLR, CNP 
45.  Mano et al 2013 
(637) 
 
Retrospective Hepatocellu
lar 
Carcinoma 
Japan 958 NLR ≥2.81 No mention of 
adjuvant or 
neoadjuvant 
treatment 
N/A 310 (5-year 
survival) 
N/A Multivariate: 
3.745 (1.027-1.088) 
p=0.0002 
Multivariate: 
Albumin, tumour 
size, portal vein 
thrombus, stage, 
multiple tumours 
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46.  Azuma et al 2013 
(638) 
 
Retrospective Upper 
Urinary 
Tract 
Urothelial 
Carcinoma 
Japan 137 NLR ≥2.5 No mention of 
adjuvant or 
neoadjuvant 
treatment 
54 (5-year 
survival) 
N/A Multivariate: 
3.06 (1.44-6.83) 
p=0.0035 
N/A Multivariate: 
pT stage, 
lymphovascular 
invasion 
47.  Dumitrascu et al 
2013 (639) 
 
Retrospective Hilar 
Cholangioc
arcinoma 
Romania 90 NLR <3.3 43 received adjuvant 
treatment 
(chemotherapy, 
radiotherapy or 
chemoradiotherapy) 
51 56 N/A Multivariate: 
RR 0.76 (0.57-1) 
p=0.053 
 
 
Multivariate: 
Adjuvant 
chemotherapy 
with gemcitabine, 
R0 resection, 
caudate lobe 
invasion 
48.  Perisanidis et al 
2013 (640) 
 
Retrospective Oral Cancer Austria 97 NLR >1.9 All patients treated 
with neoadjuvant 
chemoradiotherapy 
17 35 Multivariate: 
10.37 (1.28-84.08) 
p=0.029 
N/A Multivariate: 
ypTNM, 
perineural 
invasion 
49.  Noh et al 2013 
(641) 
 
Retrospective Breast 
Cancer 
Korea 442 NLR ≥2.5 Triple negative 
cancers are treated 
with chemotherapy  
25 (5-year 
survival) 
32 Multivariate: 
4.08 (1.62-10.28) 
p=0,003 
N/A Multivariate: 
Node status, ER 
status 
50.  Liao et al 2013 
(642) 
 
Retrospective Non-small 
Cell Lung 
Cancer 
China 59 NLR continuous  Patients who 
underwent 
neoadjuvant 
chemotherapy and/or 
radiotherapy were 
excluded 
N/A 23 (after 40 
months) 
N/A Multivariate: 
1.00 (0.40-2.49) 
p=0.98 
Multivariate: 
Tumour 
differentiation, 
FAP-α percentage/ 
grade. 
51.  Bambury et al 
2013 (643) 
 
Retrospective Glioblasto
ma 
multiforme 
Ireland 84 NLR >4  49 patients received 
complete Stupp 
protocol (using 
concurrent 
chemoradiotherapy 
followed by 
consolidation 
chemotherapy with 
temozolomide) 
N/A 82 N/A Multivariate: 
1.81 (1.08-3.01) 
p=0.025 
Multivariate: 
Age, gender, 
extent of 
resection, full 
Stupp protocol 
52.  Toiyama et al 
2013 (644) 
 
Retrospective Rectal 
Cancer 
Japan 84 NLR >3  All patients received 
neoadjuvant 
chemoradiotherapy 
N/A 37 (after 150 
months) 
N/A Multivariate: 
0.98 (0.37-2.56) 
p=0.96 
Multivariate: 
Pathological TNM 
stage, CRP 
53.  Son et al 2013 
(262) 
 
Retrospective Colon 
Cancer 
Korea 624 NLR ≥5 503 patients 
received 
chemotherapy 
N/A 55 (5 yr. 
survival) 
N/A Multivariate: 
1.841 (0.470-7.204) 
p=0.381 
Multivariate: 
Fibrinogen, stage, 
CEA 
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54.  Stoz et al 2013 
(282)  
 
Retrospective  Pancreatic 
Cancer 
Austria  110 NLR≥5 88 Underwent 
chemotherapy  
N/A 110 Multivariate: 
1.611 (1.024-
2.534) p=0.039 
N/A Multivariate: 
Stage at diagnosis, 
NLR 
55.  Guthrie et al 2013 
(147)  
 
Retrospective  Colorectal  UK  206 NLR>5  58 patients had 
adjuvant 
chemotherapy  
29 41 Multivariate 
Pre-Op:  
3.07 (1.23–7.63) 
P<0.05 
N/A Multivariate: 
Pre-Op and Post-
Op mGPS 
56.  Ishizuka et al 2013 
(119) 
 
Retrospective  Colorectal  Japan  481 NLR>3 Patients with stage 
IV disease had 
chemotherapy  
120 150 Univariate: 
OR: 0.961 (0.843-
1.096) p=0.554 
N/A Multivariate: 
Pathology, LN 
Mets, CRP, 
Albumin, CEA, 
GPS 
57.  Szkandera et al 
2014 (645) 
 
Retrospective Soft Tissue 
Sarcoma 
Austria 340 
Training 
set, 
n=170 
 
Validatio
n set, 
n=170 
NLR ≥5 Training set: 
16 received adjuvant 
chemotherapy, 102 
received adjuvant 
radiotherapy 
 
Validation set: 
22 received adjuvant 
chemotherapy, 107 
received adjuvant 
radiotherapy 
Training set: 30 
Validation set: 
22 
Training set: 53 
Validation set: 
51 
Univariate: 
Training set:  
2.14 (0.81-5.66) 
p=0.124 
 
Validation set: 
1.98 (0.77-5.08) 
p=0.153 
Multivariate: 
Training set: 
1.68 (0.75-3.76) p=0.201 
 
Validation set: 
2.84 (1.37-5.87) p=0.005 
Multivariate: 
Age, tumour 
grade, LMR, 
tumour size 
58.  Dalpiaz et al 2014 
(646) 
 
Retrospective Upper Tract 
Urothelial 
Carcinoma 
Austria 202 NLR ≥2.7 No mention of 
adjuvant or 
neoadjuvant 
treatment 
58 147 Multivariate: 
2.718 (1.246-
5.928) 
P=0.012 
Multivariate: 
2.480 (1.308-4.702) 
P=0.005 
Multivariate: 
pT stage 
 
59.  Luo et al 2014 
(647) 
 
Retrospective Upper 
Urinary 
Tract 
Urothelial 
Carcinoma 
Taiwan 234 NLR >3  Patients underwent 
RNU without 
neoadjuvant or 
adjuvant 
intervention. 
24 N/A Multivariate: 
6.38 (1.75-23.31) 
p=0.006 
N/A Multivariate: 
Pathological stage, 
age, smoking 
60.  Wu et al 2014 
(283) 
 
Retrospective Gallbladder China 85 NLR >2.3  13 patients had post 
op chemotherapy  
 
N/A 75 N/A Univariate: 
1.769 (1.111-2.818) 
p=0.016 
Multivariate: 
Tumour Invasion, 
Lymph node 
metastasis, Margin 
status 
61.  Zhang et al 2014 
(648) 
 
Retrospective Non-Small 
Cell Lung 
Cancer 
China 400 NLR <3.3vs. 
≥3.3 
Patients treated with 
neoadjuvant and 
adjuvant therapy 
were excluded 
86 N/A N/A Multivariate: 
2.075 (1.317-3.271) 
p=0.002 
Multivariate: 
Age, tumour size 
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62.  Ying et al 2014 
(649) 
 
Retrospective Colorectal 
Cancer 
China 205 NLR≥3.12 77 colon and 31 
rectal cancer patients 
underwent 
chemotherapy 
100 112 Multivariate: 
2.77 (1.72-4.46) 
p<0.001 
Multivariate: 
2.73 (1.74-4.29) 
p<0.001 
Multivariate: 
Grade (G3/G4), 
chemotherapy 
63.  Linton et al 2014 
(650) 
 
Retrospective Malignant 
Pleural 
Mesothelio
ma 
Australia 59 NLR. ≥5 64% received 
adjuvant 
radiotherapy, 33% 
received induction 
or adjuvant 
chemotherapy 
N/A 24 (survival >20 
months) 
N/A Survival after 4 months 
Univariate: 
 
NLR≥5 0.86 (0.40-1.82) 
p=0.69 
Multivariate: 
Nil else  
64.  Ishizuka et al 2014 
(120) 
 
Retrospective Gastric 
Cancer 
Japan 544 NLR (≤3 vs. >3) 343 patients 
received adjuvant 
chemotherapy 
55 108 N/A Univariate: 
1.990 (1.417-2.793) 
p<0.001 
Multivariate: 
Age, tumour type, 
lymph node 
metastasis, 
albumin, COP-
NLR 
65.  Kubo et al 2014 
(651) 
 
Retrospective Colorectal 
carcinoma 
Japan 524 NLR (high/low) Adjuvant 
chemotherapy in 156 
patients with stage 3 
cancer and 38 
patients with stage 2 
cancer 
74 104 Multivariate: 
1.71 (1.03-2.88) 
p=0.04 
N/A Multivariate: 
Cancer site, T 
stage, lymph node 
metastasis 
66.  Viers et al 2014 
(652) 
 
Retrospective Clear Cell 
Renal 
Carcinoma 
US 827 NLR 
(continuous) 
No mention of 
adjuvant or 
neoadjuvant 
treatment 
233 436 Multivariate: 
1.02 (1.01-1.04) 
p=0.009 
Multivariate: 
1.02 (1.01-1.03) 
p=0.004 
Multivariate: 
ECOG 
performance 
status, tumour 
size, constitutional 
symptoms, age 
67.  Koh et al 2014 
(653) 
 
Retrospective Breast 
Cancer 
South 
Korea 
157 NLR >2.25) All treated with 
neoadjuvant 
chemotherapy 
N/A 25 N/A Multivariate: 
24.87 (3.075-201.3) 
p=0.003 
Multivariate:  
Nil else 
68.  Hermanns et al 
2014 (654) 
 
Retrospective Bladder 
cancer 
Canada 424 NLR ≥3 29 patients received 
neo-adjuvant 
chemotherapy, 87 
received adjuvant 
chemotherapy, 55 
received salvage 
chemotherapy 
110 178 Multivariate: 
1.88 (1.39-2.54) 
p<0.001 
Multivariate: 
1.67 (1.17-2.39) 
p=0.005 
Multivariate: 
Charlson 
Comorbidity 
Index, Hb, 
platelets, N-stage, 
year of radical 
cystectomy, 
lymphovascular 
invasion 
 467 
69.  Tanaka et al 2014 
(655) 
 
Retrospective Upper Tract 
Urothelial 
Carcinoma 
Japan 665 NLR >3 129 patients 
received adjuvant 
chemotherapy 
129 N/A Multivariate: 
1.47 (1.03-2.11) 
p=0.036 
N/A Multivariate: 
Age, pathological 
T stage, 
lymphovascular 
invasion, lymph 
node involvement 
70.  Jiang et al 2014 
(656) 
 
Retrospective Gastric 
Cancer 
China 377 NLR <1.44 vs. 
≥1.44 
219 patients 
received adjuvant 
chemotherapy post 
gastrectomy 
N/A 223 N/A Multivariate: 
1.595 (1.045-2.435) 
p=0.030 
Multivariate: 
Tumour size, 
serosal invasion, 
lymph node 
metastasis, post 
complication 
71.  Yuan et al 2014 
(657) 
 
Retrospective Adenocarci
noma of 
Esophagoga
stric 
Junction 
China 327 NLR <5 vs. ≥5 18 patients received 
neoadjuvant 
chemotherapy, 59 
patients received 
adjuvant 
chemotherapy 
N/A 168 N/A Multivariate: 
2.551 (1.847-3.524) 
p<0.0001 
Multivariate: 
pTNM stage, 
adjuvant treatment 
72.  Ozdemir et al 
2014 (658) 
 
Retrospective Colorectal 
Cancer 
Turkey 281 NLR (≤2.2 vs. 
>2.2) 
Patients with lymph 
node invasion, 
vascular invasion, 
perineural invasion 
and high 
neoadjuvant CEA 
were given adjuvant 
chemotherapy 
N/A 134 N/A Multivariate: 
3.306 (1.713-6.378) 
p=0.005 
Multivariate: 
pN stage, pTNM 
stage. 
73.   Dalpiaz et al 2014 
(646) 
 
Retrospective Upper Tract 
Urothelial 
Carcinoma 
Austria 171 dNLR 
(continuous), 
No mention of 
adjuvant or 
neoadjuvant 
treatment 
54 79 Multivariate: 
1.16 (1.01-1.35) 
p=0.045 
Multivariate: 
1.21 (1.09-1.34) 
p<0.001 
Multivariate: 
Age at operation, 
pT-stage 
74.  Feng et al 2014 
(659) 
 
Retrospective Esophageal 
SCC 
China 483 NLR ≥3.5 No mention of 
adjuvant or 
neoadjuvant 
treatment 
N/A 244 N/A Multivariate: 
1.339 (1.015-1.768) 
p=0.039 
Multivariate: 
Differentiation, 
depth of invasion, 
nodal metastasis, 
PLR 
75.  Viers et al 2014 
(660) 
 
Retrospective Bladder 
Cancer 
USA 899 NLR 
(continuous) 
117 patients 
received adjuvant 
therapy (radiation or 
chemotherapy) 
345 615 Multivariate: 
1.04 (1.01-1.08) 
p=0.01 
Multivariate: 
1.03 (1.01-1.06) p=0.01 
Multivariate: 
Age at surgery, 
ECOG 
performance 
status, pathologic 
tumour stage, 
lymph node 
density, 
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lymphovascular 
invasion 
76.  McNamara et al 
2014 (661) 
 
Retrospective Biliary 
Tract 
Cancer 
Canada 326 NLR ≥3 90 received adjuvant 
chemotherapy 
N/A 199  N/A Multivariate: 
1.15 (0.87-1.53) p=0.33 
Multivariate: 
Site, stage, age 
77.  East et al 2014 
(133) 
 
Retrospective Colon 
Cancer 
UK 436 
 
Training 
set, 
n=386 
 
Test set, 
n=50 
NLR ≥3.4 26 patients received 
adjuvant 
chemotherapy  
N/A 27 N/A Multivariate: 
Training set: 1.43 (1.06-
1.94) p=0.02 
 
Test set: 3.40 (2.64-5.13) 
p<0.001 
Multivariate: 
N stage, R0 
resection, adjuvant 
treatment, T stage, 
WLR. 
78.  Malietzis et al 
2014 (662) 
 
Retrospective Colorectal 
Cancer 
UK 506 NLR >3 All patients with 
neoadjuvant or 
adjuvant therapy 
were excluded 
28 118 N/A Multivariate: 
OR: 1.23 (0.80-1.90) 
p=0.347 
Multivariate: 
Age at operation, 
T stage, N stage, 
surgical approach, 
ASA score, major 
complication 
79.   Grivas et al 2014 
(663) 
 
Retrospective Renal Cell 
Carcinoma 
Greece 114 NLR ≥2.7 No patients received 
adjuvant therapy  
10 14 N/A Multivariate: 
2.866  
p=0.034 
Multivariate:  
Hb level, Fuhrman 
grade 
80.  Shen et al 2014 
(664) 
 
Retrospective Rectal 
Cancer 
China 199 NLR ≥2.8 All patients treated 
with neoadjuvant 
chemoradiotherapy 
followed by surgery, 
184 patients 
received adjuvant 
chemotherapy. 
N/A 43 N/A Multivariate: 
2.123 (1.140-3.954) 
p=0.018 
Multivariate: 
ypTNM staging, 
adjuvant 
chemotherapy 
81.  Sun et al 2014 
(265) 
 
Retrospective Colon 
cancer 
China 255 NLR ≥5 No specific mention 
of neoadjuvant or 
adjuvant treatment 
N/A 94 N/A Multivariate: 
RR 1.541 (0.724-3.282) 
p=0.262 
Multivariate: 
AFP, CEA, 
fibrinogen, TNM, 
mGPS 
82.  Neofytou et al 
2014 (665) 
 
Retrospective Liver-only 
Colorectal 
Metastases 
UK 140 NLR >2.4 All patients received 
neoadjuvant 
chemotherapy 
N/A 59 (5-year 
survival) 
N/A Multivariate: 
1.52 (0.78-2.99) 
p=0.216 
Multivariate: 
No adjuvant 
chemotherapy 
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83.  Aurello et al 2014 
(135) 
 
Retrospective Gastric 
Cancer 
Italy 102 NLR ≥5 68 patients received 
adjuvant 
chemotherapy after 
surgery 
62 62 
 
N/A Multivariate: 
1.51 (0.69-3.28) 
p=0.29 
Multivariate: 
Prognostic index, 
mGPS, Tumour 
stage IV, PI 1&2 
84.  Pinato et al 2014 
(300) 
 
Retrospective  Lung  UK  220 NLR>5  Adjuvant radio and 
chemotherapy 
administered  
N/A 61 N/A Multivariate:  
3.8 (1.6 –8.9) p=0.002 
Multivariate: 
TNM stage, 
Pleural Effusion  
85.  Forrest et al 2014 
(264) 
 
Retrospective  Colorectal  UK  134 NLR>5 No mention of 
Adjuvant treatment  
43 81 Univariate: 
2.27 (0.99-5.19) 
p=0.052 
N/A Univariate: T-
stage, N-stage, 
TNM stage, 
Venous invasion, 
Peritoneal 
involvement, 
Margin 
involvement, 
Manual and 
Automatic 
Klintrup–Makinen 
grade 
86.  Song et al 2015 
(666) 
 
Retrospective Hypophary
ngeal SCC 
China 146 NLR ≥2.3 14 patients received 
adjuvant 
chemoradiotherapy 
 
94 received adjuvant 
radiotherapy 
N/A 75 (3-year 
survival) 
N/A Multivariate: 
2.36 (1.33-4.18) 
p0.003 
Multivariate: 
Treatment 
modalities 
87.  Xu et al 2015 
(127)  
 
Retrospective Oesophagea
l SCC 
China 468 NLR>2.40  196 patient received 
adjuvant chemo and 
radiotherapy  
N/A 259 N/A Univariate: 
1.50 (1.17-2.83) p=0.008 
Multivariate: 
Lymph Node 
Mets, 
Venous/lymphatic 
invasion, CRP/Alb 
Ration 
88.  Hirahara et al 
2015 (218) 
 
Retrospective  Oesophagea
l  
Japan  141 NLR≥2.5 No mention of 
adjuvant treatment  
N/A 16 N/A Univariate: 
1.164 (0.616-2.126) 
p=0.631 
Multivariate: 
pStage, GPS 
89.  Shibutani et al 
2015 (267) 
 
Retrospective  Colorectal  Japan  254 NLR>2.5  Adjuvant 
chemotherapy  
N/A 69 N/A Multivariate: 
6.599 (0.928-46.914) 
p=0.059 
Multivariate: 
NLR (Post op), 
Number of lymph 
node mets 
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90.  Takahashi et al 
2015 (667) 
 
Retrospective Non-small 
Cell Lung 
Cancer 
Japan 342 NLR ≥2.5 Patients who had 
received 
neoadjuvant 
chemotherapy or 
thoracic irradiation 
were not included. 
N/A 51 (5-year 
survival) 
N/A Multivariate: 
2.141 (1.306-3.515) 
p=0.003 
Multivariate: 
Smoking, CEA, 
nonadenocarcino
ma, pathological 
stage, presence of 
pleural invasion 
91.  Tu et al 2015 
(668) 
 
Retrospective Laryngeal 
Squamous 
Cell 
Carcinoma 
China 141 NLR >2.17 No mention of 
adjuvant treatment 
N/A 45 N/A Multivariate: 
2.177 (1.208-3.924) 
p=0.010 
Multivariate: 
T classification, 
lymph node 
metastasis 
92.  Shin et al 2015 
(669) 
 
Retrospective Colorectal 
Cancer 
Korea 269 NLR. ≥3 Patients treated with 
chemoradiation were 
excluded 
5 N/A Multivariate: 
6.190 (1.034-
37.047) 
p=0.046 
N/A Multivariate; 
Thrombocytosis 
93.  Que et al 2015 
(670) 
 
Retrospective Soft-tissue 
Sarcoma 
China 222 NLR ≥2.5 39 patients received 
adjuvant 
chemotherapy, 65 
patients received 
adjuvant 
radiotherapy 
N/A 82 (after 150 
months) 
N/A Multivariate: 
1.06 (0.52-2.16) 
p=0.881 
Multivariate: 
Tumour site, 
AJCC stage, PLR 
94.  Hsu et al 2015 
(671) 
 
Retrospective Gastric 
Cancer 
Taiwan 989 NLR >3.44 499 patients with 
stage 2 to 4 tumour 
received 
chemotherapy 
N/A 395 (5-year 
survival) 
N/A Multivariate: 
1.565 (1.198-2.044) 
p=0.001 
Multivariate: 
Resection margin, 
differentiation, T 
status, N status, 
LN ratio, M1 
status 
95.  Shimizu et al 2015 
(672) 
 
Retrospective Non-small 
Cell Lung 
Cancer 
Japan 334 NLR ≥2.5 Neither radiotherapy 
nor chemotherapy 
administered prior to 
the surgery 
N/A 95 (3-year 
survival) 
N/A Multivariate: 
1.60 (1.04-2.54) 
p=0.048 
Multivariate: 
Age, nodal 
metastasis, PNI 
96.  Han et al 2015 
(673) 
 
Retrospective Glioblasto
ma 
China 152 NLR ≥4 All patients received 
adjuvant radio-
chemotherapy 
N/A 118 (2-year 
survival) 
N/A Multivariate: 
1.050 (1.003-1.100) 
p=0.037 
Multivariate: 
KPS, resection, 
MGMT promoter, 
PLR 
97.  Liao et al 2015 
(674) 
 
Retrospective Hepatocellu
lar 
Carcinoma 
China 222 NLR >2.1 69 patients received 
transcatheter arterial 
chemoembolization 
(TACE) 1-month 
post surgery. 
N/A 77 (5-year 
survival) 
N/A Multivariate: 
3.013 (1.633-5.561) 
p=0.014 
Multivariate: 
Neutrophil count, 
postoperative 
TACE 
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98.  Aldemir et al 2015 
(675) 
 
Retrospective Gastric 
Cancer 
Turkey 53 NLR ≥2.75  No mention of 
adjuvant treatment 
N/A 19 N/A Univariate: 
p=0.88 
Univariate: 
ECOG 
performance 
status, platelet 
count 
99.  Kadota et al 2015 
(676) 
 
Retrospective Lung 
Squamous 
Cell 
Carcinoma 
US 485 
 
Training 
cohort 
n=331 
 
 
NLR >5.5 80% patients 
received adjuvant 
therapy 
N/A Training cohort 
n=188 
 
 
N/A In training cohort 
Univariate: 
1.82 (1.26-2.62) 
p=0.001 
Multivariate: 
Smoking pack-
year, pathological 
stage, 
CD10/CD20 risk 
index, age, 
lymphovascular 
invasion 
100.  Neofytou et al 
2015 (677) 
 
Retrospective Liver-Only 
Colorectal 
Metastases 
UK 140 NLR 
(continuous) 
All patients received 
neoadjuvant 
chemotherapy, 104 
received adjuvant 
chemotherapy. 
60 63 Univariate: 
 
1.20 (1.06-1.36) 
p=0.003 
N/A Multivariate: 
Adjuvant 
chemotherapy, 
preoperative 
LMR. 
101.  Bagante et al 2015 
(678) 
 
Retrospective Adrenocorti
cal 
Carcinoma 
US 84 NLR >5 51 patients received 
peri-operative 
systemic 
chemotherapy, 38 
patients received 
adjuvant mitotane 
50 (5-year  
CSS) 
N/A Multivariate: 
2.21 (1.10-4.43) 
p=0.025 
N/A Multivariate:  
AJCC tumour 
status and 
metastatic status 
102.  Wang et al 2015 
(679) 
 
Retrospective Hepatocellu
lar 
Carcinoma 
US 234 NLR >2.5 170 patients had 
antiviral treatment 
N/A 88 (5-year 
survival) 
N/A Multivariate: 
4.9 (1.8-13.2) 
p=0.002 
Multivariate: 
Tumour size 
103.  Pine et al 2015 
(680) 
 
Retrospective Colorectal 
Cancer 
UK 358 NLR ≥5 No mention of 
adjuvant treatment 
N/A 157 (after 4 
years)  
N/A Multivariate: 
1.819 (1.310-2.526) 
p<0.001 
Multivariate: 
Age, Dukes’ stage 
C and stage D 
104.  Li et al 2015 (681) 
 
Retrospective Endometria
l Cancer 
China 282 NLR ≥4.68 No mention of 
adjuvant treatment 
N/A 38 (5-year 
survival) 
N/A Multivariate: 
2.298 (0.679-7.781) 
p=0.181 
Multivariate: 
CRP, D-dimer,  
105.  Zhang et al 2015 
(682) 
 
Retrospective Non-small 
Cell Lung 
Cancer 
China 678 NLR >2.3 Adjuvant 
chemotherapy or/and 
radiotherapy 
N/A 367 N/A Multivariate: 
1.624 (1.304-2.022) 
p<0.001 
Multivariate: 
Pathological stage 
(I, II, IIIA) 
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106.  Zhang et al 2015 
(683) 
 
Retrospective Gallbladder 
Carcinoma 
China 145 NLR ≥1.94 No mention of 
adjuvant treatment 
N/A 117 (5-year 
survival) 
N/A Multivariate: 
RR 
2.059 (1.253-3.384) 
p=0.004 
Multivariate: 
Nevin stages, 
operation modes, 
Hb 
107.  Qu et al 2015 
(684) 
 
Retrospective Gastric 
Cancer 
China 1397 
Develop
ment set: 
n=1123 
 
Validatio
n set: 
n=274 
NLR >1.86 All patients 
underwent 
neoadjuvant 
chemotherapy or 
adjuvant 
radiotherapy 
N/A 3-year survival 
Development 
set: 307 
 
Validation set: 
60 
N/A Multivariate: 
1.379 (1.082-1.758) 
p=0.009 
Multivariate: 
Age, tumour size, 
Lauren type, depth 
of invasion, 
number of 
metastatic lymph 
node. 
108.  Zhang et al 2015 
(685) 
 
Retrospective Ovarian 
Cancer 
China 190 NLR >3.4) Surgery was 
followed by 
platinum-based 
chemotherapy 
N/A 170 (after 100-
month) 
N/A Univariate: 
2.172 (1.545-3.054) 
p<0.001 
Multivariate: 
Stage (FIGO), 
postoperative 
residual tumour 
mass, PLR 
109.  Yu et al 2015 
(686) 
 
Retrospective Gastric 
Cancer 
China 291 NLR <3.5  No mention of 
adjuvant treatment 
N/A 199 (5-year 
survival) 
N/A Multivariate: 
0.626 (0.460-0.852) 
p=0.003 
 
Multivariate: 
N staging, TNM 
staging 
110.  Sun et al 2015 
(136) 
 
Retrospective Gastric 
Cancer 
China 632 NLR. >1.83 395 patients 
received adjuvant 
chemotherapy 
N/A 448 N/A Multivariate: 
1.056 (0.830-1.343) 
p=0.656 
Multivariate: 
Age, 
respectability, 
distant metastasis, 
pathological stage, 
CEA, 
postoperative 
complications, 
PNI 
111.  Duan et al 2015 
(687) 
 
Retrospective Esophageal 
SCC 
China 371 NLR >3 No mention of 
adjuvant treatment 
192 N/A Multivariate:   
1.591 (1.132-
2.235) p=0.007 
N/A Multivariate: 
pN status  
112.  Wen et al 2015 
(688) 
 
Retrospective Renal Cell 
Carcinoma 
China 327 NLR ≥1.7 No mention of 
adjuvant treatment 
N/A 230 (after 80 
months) 
N/A Multivariate:             
1.674 (1.103-2.539)   
p=0.019 
Multivariate: 
Histological 
subtypes, pT stage 
113.  Zhang et al 2015 
(121) 
 
Retrospective Non-Small 
Cell Lung 
Cancer 
China 1238 NLR >2.3 Adjuvant treatments 
including 
chemotherapy, 
radiotherapy and 
N/A 686 N/A Univariate:                  
1.533 (1.458-1.785) 
p<0.001 
Multivariate: 
TNM stage, LDH, 
D-dimer, COP-
NLR 
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concurrent 
chemoradiotherapy 
114.  Choi et al 2015 
(689) 
 
Retrospective Colorectal 
Cancer 
Canada 549 NLR≥2.6 147 patients 
received adjuvant 
therapy: 
chemotherapy, 
radiation or both 
N/A  120 (5-year 
survival) 
N/A Multivariate:               
1.91 (1.26-2.9) p=0.002 
Multivariate:  
Age>75, lymph 
nodes positive, 
ASA status  
115.  Deng et al 2015 
(690) 
 
Retrospective Gastric 
Cancer 
China 389 NLR≥2.36 No mention of 
adjuvant treatment 
235 270 Multivariate:     
1.53 (1.11-2.11) 
p=0.010 
Multivariate:               
1.13 (0.68-1.87)   
p=0.648 
Multivariate: 
Age, tumour 
stage, lymph node, 
distant metastasis, 
dNLR 
116.  Spolverato et al 
2015 (691) 
 
Retrospective Hepato-
Pancreatico
-Biliary 
Malignanci
es 
US 452 NLR ≥5 189 patients 
received 
neoadjuvant 
chemotherapy. 
N/A 192 (5-year 
survival) 
N/A Multivariate:               
1.94 (1.03-3.64) p=0.040 
Multivariate: 
Age, 
complications. 
117.  Han et al 2015 
(692) 
 
Retrospective Esophageal 
SCC 
China 218 NLR< 2.60 Adjuvant treatment: 
17 received 
chemotherapy 
41 received 
radiotherapy 
24 received 
chemoradiotherapy 
N/A 138 N/A Multivariate:             
1.133 (0.762-1.685) 
p=0.538 
Multivariate: 
Tumour length, 
pTNM stage, 
LMR. 
118.  Kim et al 2015 
(693) 
 
Retrospective Gastric 
Cancer 
Korea 1986 NLR>2 No mention of 
adjuvant treatment 
N/A 323 (5-year 
survival) 
N/A Multivariate:             
1.403 (1.048-1.879) 
p=0.0230 
Multivariate: 
Age, approach 
method, depth of 
invasion, node 
status  
119.  Chan et al 2015 
(694) 
 
Retrospective Hepatocellu
lar 
Carcinoma 
Hong 
Kong 
324 NLR≥5 282 patients with 
chronic viral 
hepatitis received 
antiviral therapy 
N/A 79 (5-year 
survival) 
N/A Univariate:                 
1.587 (0.817-3.086) 
p=0.173 
Multivariate: 
Antiviral therapy, 
microvascular 
invasion, PNI. 
120.  Choi et al 2015 
(695) 
2015 
Retrospective Lung 
Cancer 
US 1139 NLR ≥5 Neoadjuvant: 
245 received 
chemotherapy 
18 received radiation 
 
Adjuvant: 
285 received 
chemotherapy 
N/A 752 (5-year 
survival) 
N/A Multivariate: 
Preoperative NLR      
1.686 (1.274-2.230) 
p=0.0003 
 
 
Multivariate: 
Age, stage, 
adjuvant radiation 
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170 received 
radiation 
121.  Lee et al (696) 
2015 
Retrospective Breast 
cancer 
South 
Korea 
3116 NLR ≥ 5.2 No mention of 
adjuvant treatment 
300 N/A Univariate:      
1.09 (0.94-1.26) 
p=0.516 
 
N/A Multivariate: 
Post op NLR 1-
week, Nuclear 
grade, AJCC 
stage, HR status. 
122.  Chen et al 2015 
(579) 
 
Retrospective Colorectal 
Cancer 
US 274 NLR >5 No mention of 
adjuvant treatment 
N/A 32 (3-year 
survival) 
N/A Univariate:                   
2.37 (1.10-5.10)   
p=0.023 
Multivariate: 
Metastatic site, 
LDH 
123.  Wuxiao et al 2015 
(697) 
 
Retrospective Colon 
Cancer 
China 548 NLR ≤3  All stage 3 patients 
received 5-
fluorouracil based 
adjuvant 
chemotherapy 
N/A 106 N/A Multivariate:                 
RR 0.384 (0.255-0.580) 
p<0.001 
Inverted: 2.60 (1.72-
3.92) 
Multivariate: 
Histological 
grade, 
preoperative CEA 
levels 
124.  Qing Chen et al 
2015 (698) 
 
Retrospective Intrahepatic 
cholangioca
rcinoma 
China 322 NLR ≥2.49 Patients treated with 
chemoradiotherapy 
are removed from 
this study  
N/A 204 (5-year 
survival) 
N/A Multivariate:             
1.600 (1.178-2.174) 
p=0.003 
Multivariate: 
CA199, tumour 
number, lymph 
node metastasis. 
125.  Kim et al 2015 
(699) 
 
Retrospective Upper 
Urinary 
Tract 
Urothelial 
Carcinoma 
South 
Korea 
277 NLR. ≥5:1 71 patients received 
adjuvant 
chemotherapy 
73 96 Univariate:      
1.179 (0.511-
2.718) p=0.700 
N/A Multivariate: 
Bladder cuff 
excision, 
pathologic T 
stage, 
lymphovascular 
invasion, derived 
NLR 
 
126.  Szkandera et al 
2015 (700) 
 
Retrospective Soft Tissue 
Sarcoma 
Austria 340 dNLR ≥2.39 No mention of 
adjuvant treatment 
N/A 98 N/A Multivariate:              
1.60 (1.07-2.40) p=0.022 
Multivariate: 
Tumour grade 
127.  Ben et al 2015 
(701) 
 
Retrospective Pancreatic 
Ductal 
Adenocarci
noma 
China 381 NLR ≥2 No mention of 
adjuvant treatment 
N/A 283 N/A Multivariate:               
1.51 (1.15-1.99) p=0.003 
Multivariate: 
lymphoid node 
involvement, poor 
tumour 
differentiation, 
edge positive. 
 475 
128.  Graziosi et al 2015 
(702) 
 
Retrospective Gastric 
Cancer 
Italy 156  NLR. ≥2.34 18 patients received 
neoadjuvant 
chemotherapy 
 
70 patients received 
adjuvant 
chemotherapy 
N/A 70 N/A Multivariate:              
1.70 (1.02-2.84) p<0.043 
Multivariate: 
Mixed-type 
Lauren 
classification 
129.  Takahashi et al 
2015 (703) 
 
Retrospective Endometria
l Cancer 
Japan 508 NLR >3  215 patients 
received adjuvant 
therapy 
50 55 N/A Univariate:                   
2.47 (1.45-4.24) 
p=0.0009 
Multivariate: 
Age, FIGO stage, 
LVSI, neutrophil 
count 
130.  Shirai et al 2015 
(704) 
 
Retrospective Pancreatic 
cancer 
Japan 131 NLR ≥5  No mention of 
adjuvant treatment 
N/A 103 (5-year 
survival) 
N/A Univariate:                 
0.984 (0.511-1.894) 
p=0.961 
Multivariate: 
Tumour size, 
resection margin 
status, tumour 
differentiation, 
PLR 
131.  Chen et al 2015 
(705) 
 
Retrospective Intrahepatic 
Cholangioc
arcinoma 
China 322 NLR 
(continuous) 
Adjuvant 
chemoradiotherapy 
used as well as 
radiofrequency 
ablation  
N/A 197 (5-year 
survival) 
N/A Multivariate:            
1.399 (1.006-1.947) 
p=0.046 
Multivariate: 
CA19-9, tumour 
number, lymph 
node metastasis, 
PLR 
132.  Neal et al 
2015(122) 
 
Retrospective Colorectal 
Liver 
Metastases 
UK 302 NLR ≥5  132 patients had 
systemic 
chemotherapy in the 
6 months prior to 
liver resection, 126 
patients received 
systemic 
chemotherapy 
following 
mastectomy 
204 (5-year 
survival) 
214 (5-year 
survival) 
Multivariate: 
1.927 (1.398-
2.655) p<0.001 
Multivariate:            
1.769 (1.302-2.403) 
p<0.001 
Multivariate: 
Clinical risk score 
133.  Kawashima et al 
2015 (144) 
 
Retrospective Lung 
Cancer 
Japan 1043 NLR >5  No mention of 
adjuvant treatment 
N/A 227 N/A Univariate: 
1.53 (1.00-2.34) 
p=0.05 
Multivariate: 
Age, smoking, 
preoperative co-
morbidity, CEA, 
pathological stage, 
histological 
tumour type, LVI, 
surgical procedure 
134.  Cummings et al 
2015 (124) 
 
Retrospective Endometria
l Cancer 
UK 605 NLR ≥2.4 33% of patients 
received adjuvant 
radiotherapy, 13% of 
patients received 
96 166 Multivariate: 
1.68 (1.03-2.76) 
p=0.04 
Multivariate: 
1.82 (1.27-2.62) 
p=0.001 
Multivariate: 
PLR, combined 
NLR + PLR, age, 
FIGO stage, 
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adjuvant 
chemotherapy 
grade, 
histopathological 
subtype, LVSI 
135.  Lian et al 2015 
(706) 
 
Retrospective Gastric 
Cancer 
China 162 NLR ≥4.02 No mention of 
adjuvant treatment 
N/A N/A (expressed 
in months) 
N/A Univariate: 
OR 2.58 (1.62-3.80) 
p=0.001 
Multivariate: 
Depth of invasion, 
lymph node 
metastasis, AJCC 
stage, PLR 
136.  Okamura et al 
2015 (291) 
 
Retrospective Hepatocellu
lar 
Carcinoma 
Japan 256 NLR ≥2.81 No mention of 
adjuvant treatment 
N/A 86 N/A Multivariate: 
2.41 (1.44-4.01) 
p=0.001 
 
Multivariate: 
AFP, des-gamma-
carboxy 
prothrombin, low 
PNI. 
137.  Xie et al 2016 
(707) 
 
Retrospective Oesophagea
l Squamous 
Cell Cancer 
China 317 NLR. >2.1 76 patients received 
adjuvant 
chemotherapy after 
surgery 
147 
 
152 Multivariate: 
1.196 (0.833-
1.719) 
p=0.332 
N/A Multivariate: 
PLR, TNM stage 
138.  Mohri et al 2016 
(708) 
 
Retrospective Gastric 
Cancer 
Japan 404 NLR >3  No mention of 
adjuvant treatment 
65 (5-year 
survival) 
82 (5-year 
survival) 
Multivariate: 
1.97 (1.08-3.58) 
p=0.03 
Multivariate: 
2.09 (1.10-3.94) 
p=0.02 
Multivariate:  
Age, gender, 
ASA, tumour size, 
p-stage 2 and 3, 
infectious 
complication 
139.  Ha et al 2016 
(129) 
 
Retrospective Ampulla of 
Vater 
Cancer 
South 
Korea 
227 NLR >1.78 Adjuvant treatments 
including 
chemotherapy, 
radiotherapy and 
concurrent 
chemoradiotherapy 
N/A 105 N/A Multivariate: 
1.280 (0.70-2.33) 
p=0.418 
Multivariate:  
Vascular invasion, 
CA19-9. 
140.  Li et al 2016 (137) 
 
Retrospective Colorectal 
Cancer 
China 5336 NLR (≤2.72 vs. 
>2.72) 
5-Fu based adjuvant 
chemotherapy for 
stage 2/3 patients 
588 611 N/A Multivariate: 
1.227 (1.003-1.501) 
p=0.047 
 
Multivariate:  
Age, T stage, N 
stage, 
differentiation, 
venous invasion, 
LMR, AGR 
141.  Takahashi et al 
2016 (709) 
 
Retrospective Lung 
adenocarcin
oma 
Japan 361 NLR ≥2.5 80 received adjuvant 
chemotherapy 
N/A 74 (5-year 
survival) 
N/A Multivariate: 
1.822 (1.133-2.931) 
p=0.013 
Multivariate: 
Gender, smoking 
history, 
pathological stage, 
lymphatic/ 
vascular/ pleural 
invasion 
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142.  Cheng et al 2016 
(710) 
 
Retrospective Upper Tract 
Urothelial 
Carcinoma 
Taiwan 195 NLR ≥2.7 35 patients received 
adjuvant 
chemotherapy and 
16 patients received 
adjuvant radiation 
therapy 
N/A 55 Multivariate: 
1.362 (0.652-
2.847) 
p=0.411 
Multivariate: 
1.611 (0.890-2.916) 
p=0.115 
Multivariate: 
WBC, pT stage, 
tumour grade, 
RDW 
143.  Turner et al 2016 
(711) 
 
Retrospective Colon 
Cancer 
Australia 396 NLR >5 Neoadjuvant 
chemotherapy was 
an exclusion criteria 
N/A 93 N/A Multivariate: 
1.75 (0.87-3.52) 
p=0.039 
Multivariate:   
Low CIC density, 
age, ASA score, 
T4 stage 
144.  Fu et al 2016 
(712) 
 
Retrospective Laryngeal 
Squamous 
Cell 
Carcinoma 
China 420 NLR ≥2.59 Patients needed to 
have no previous 
anti-cancer treatment 
to be included 
171 (5-year 
CSS) 
176 (5-year 
survival) 
Multivariate: 
1.42 (1.06-1.91) 
p=0.018 
Multivariate:               
1.31 (1.00-1.71) p=0.046 
Multivariate:  
Age, drinking, N 
stage, histological 
type 
145.  Lu et al 2016 
(713) 
 
Retrospective Hepatocellu
lar 
carcinoma 
China 963 NLR>2.81 No mention of 
adjuvant treatment 
N/A 553 (5-year 
survival) 
N/A Multivariate: 
1.296 (1.074-1.563) 
p=0.007 
Multivariate: 
Tumour number, 
incomplete 
capsule, serum 
albumin , ALT, 
macrovascular 
invasion 
146.  Chen et al 2016 
(714) 
 
Retrospective Esophageal 
Squamous 
Cell 
Carcinoma 
China 323 NLR >3.5 No mention of 
adjuvant treatment 
221 (5-year) N/A Multivariate: 
1.050 (0.740-
1.488) 
p=0.786 
N/A Multivariate: 
TNM stage, I 
stage 
 
147.  Wang et al 2016 
(715) 
 
Retrospective Gastroesop
hageal 
Junction 
and Gastric 
Adenocarci
noma 
US 1498 NLR 
(continuous) 
Neoadjuvant 
chemotherapy or 
radiotherapy 
588 (5-years) N/A Multivariate: 
1.10 (1.05-1.13) 
p<0.0001 
N/A Multivariate: 
T stage, N stage, 
tumour location 
148.  Hodek et al 2016 
(716) 
 
Retrospective Rectal 
Carcinoma 
Czech 
Republic 
173 NLR 
(continuous) 
All patients received 
neoadjuvant 
chemoradiotherapy 
N/A 22 N/A Univariate: 
RR 1.21 (1.03-1.43) 
p=0.02 
Univariate:     
WBC, RBC, Hb, 
platelet count, 
neutrophils, PLR 
149.  Christina et al 
2016 (138) 
 
Retrospective Oral cancer Austria 144 NLR> 1.9 All patients received 
neoadjuvant 
radiotherapy in 
combination with 
systemic cytotoxic 
therapy 
 
N/A 60 (5-year 
survival) 
N/A Univariate: 
1.16 (0.65-2.06) 
p=0.62 
Multivariate: 
Regression grade 
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150.  Morizawa et al 
2016 (717) 
 
Retrospective Bladder 
cancer 
Japan 110 NLR ≥2.6 37 patients received 
neoadjuvant 
chemotherapy 
32 42 Multivariate: 
2.6 (1.9-5.2) 
p=0.01 
Multivariate: 
2.8 (1.4-5.4) 
p=0.00 
Multivariate: 
ECOG-PS, lymph 
node metastasis, 
tumour growth 
pattern 
151.  Ishizuka et al 2016 
(126) 
 
Retrospective Colorectal 
Cancer 
Japan 627 NLR >2.9  No mention of 
adjuvant treatment 
110 142 
  
N/A 
 
Multivariate: 
1.811 (1.229-2.669) 
p=0.003 
 
Multivariate: 
Pathological 
differentiation, 
CEA, stage, CAR, 
GPS 
152.  Kosumi et al 2016 
(718) 
 
Retrospective Oesophagea
l Squamous 
Cell 
Carcinoma 
Japan 283 NLR ≥1.94 191 patients 
received adjuvant 
therapy; 10 patients 
received 
neoadjuvant 
chemoradiotherapy 
65 91 Multivariate:    
1.84 (1.07-3.21) 
p=0.028 
Multivariate:               
1.84 (1.17-2.93) 
p=0.0081 
Multivariate: 
Nil else  
153.  Kawahara et al 
2016 (719) 
 
Retrospective Bladder 
Cancer 
Japan 74 NLR ≥2.38 10 patients received 
neoadjuvant 
chemotherapy, 25 
patients received 
adjuvant 
chemotherapy 
N/A 29 (after 4000 
days) 
N/A Multivariate: 
4.62 (1.16-18.34) 
p=0.030 
Multivariate: 
CRP, pathological 
lymph node 
metastasis. 
154.  Wang et al 2016 
(139) 
 
Retrospective Ovarian 
Cancer 
China 143 NLR. >3.43) No mention of 
adjuvant treatment 
N/A 51 N/A Multivariate:               
3.37 (1.39-8.15) p=0.007 
Multivariate: 
Metastasis, 
prognostic 
inflammation 
score 
155.   Kang et al 2016 
(720) 
 
Retrospective Bladder 
Cancer 
Korea 385 Preop-NLR 
≥2.1 
96 patients received 
adjuvant 
chemotherapy 
85 116 Multivariate: 
1.16 (1.06-1.28) 
p=0.005 
Multivariate: 
1.13 (1.04-1.22) 
p=0.003 
Multivariate: 
Postop-NLR, pT 
stage, number of 
lymph nodes 
removed, lymph 
node status, age, 
surgical margin 
status 
156.  Chan et al 2016 
(269) 
 
Retrospective Colorectal 
Cancer 
Australia 1623 NLR. >3.19) Patients with high-
risk stage II and III 
colon cancer disease 
were generally 
offered standard 
adjuvant 
chemotherapy, 
whereas those with 
stage II or III rectal 
cancers were usually 
N/A 941 N/A Univariate: 
1.830 (1.539-2.176) 
p< 0.001 
Multivariate: 
Age, T stage, N 
stage, grade, LMR 
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treated with 
neoadjuvant 
chemoradiotherapy 
157.  Toyokawa et al 
2016 (140) 
 
Retrospective Thoracic 
Oesophagea
l Squamous 
Cell 
Carcinoma 
Japan 185 NLR >3.612  46 patients received 
neoadjuvant 
treatment (39 
chemotherapy, 6 
chemoradiotherapy, 
1 radiotherapy) 
N/A 77 
  
N/A 
 
Multivariate: 
1.194 (0.627-2.273) 
p=0.589 
Multivariate: 
Sex, performance 
status, ASA, 
cTNM stage, 
CONUT score 
158.  Bhindi et al 2016 
(721) 
 
Retrospective Bladder 
Cancer 
Canada 418 NLR (per 1-log 
unit) 
28 received neo-
adjuvant 
chemotherapy, 87 
received adjuvant 
chemotherapy, 54 
received salvage 
chemotherapy 
107 177 Multivariate: 
1.47 (1.20-1.80) 
p<0.001 
Multivariate: 
1.56 (1.16-2.10) 
p=0.004 
Multivariate: 
 T-stage, N-stage, 
haemoglobin, age, 
Charlson co-
morbidity index, 
lymphovascular 
invasion 
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Table 18.3: Studies investigating the prognostic value of the PLR in an unselected cohort of patients with operable cancer 
No: 
PLR 
Study Type of 
Study 
Cancer Country  Patients 
(n) 
Measure of 
SIR 
Additional 
Treatment  
Cancer deaths 
(n) 
Overall deaths 
(n) 
Cancer survival 
(HR, 95%CI) 
Overall survival  
(HR, 95%CI) 
Independent 
Prognostic 
Factors 
1.  Smith et al 2009 
(606) 
 
Retrospective Pancreatic 
Ductal 
Adenocarci
noma 
UK 110 PLR 
(continuous) 
33 patients had 
adjuvant therapy 
N/A 93 (48-month 
survival) 
N/A Multivariate: 
1.004 (1.002-1.006) 
p=0.0003 
Multivariate: 
Tumour size, 
Lymph node ratio 
2.  Bhatti et al 2010 
(611) 
 
Retrospective Pancreatic 
ductal 
adenocarcin
oma 
UK 84 PLR ≤100, 100-
200, >200 
30 patients received 
adjuvant 
chemotherapy 
N/A 66 (3-year 
survival) 
N/A Univariate: 
0.978 (0.899-1.075) 
0.642 
Multivariate:  
NLR, Resection 
margin status 
3.  Asher et al 2011 
(620) 
Retrospective Ovarian 
Cancer 
UK 235 PLR>300 170 patients 
received 
chemotherapy 
N/A 169 (survival 
after 150 
months) 
N/A Multivariate: 
1.698 (1.031-2.797) 
p=0.03 
Multivariate: 
Age, stage, 
residual disease 
4.  Dutta et al 2011 
(211) 
 
Retrospective  Oesophagus  UK  112 PLR (<150/ 
150-300/ >300) 
31 had neoadjuvant 
and 14 adjuvant 
therapy  
52 59 Univariate: 
0.94 (0.60-1.48) 
p=0.781 
N/A Multivariate: 
mGPS (0/1/2) 
lymph node ratio 
(0/≤0.2/>0.2) 
5.  Kwon et al 2012 
(626) 
 
Retrospective Colorectal 
cancer 
Korea 200 PLR <150, 150-
300, >300 
150 patients 
received adjuvant 
chemotherapy or 
chemoradiation 
N/A 39 N/A Multivariate: 
1.953 (1.161-3.284) 
p=0.012 
Multivariate: 
Stage, CEA 
6.  Dutta et al 2012 
(223)  
Retrospective  Gastric  UK  120 PLR (<150/ 
150-300/ >300) 
Patients received 
both adjuvant and 
neoadjuvant therapy 
specific figures not 
given  
44 51 Univariate: 
0.83 (0.49-1.40) 
p=0.483 
 
N/A Multivariate: 
Positive lymph 
node ratio, mGPS,  
7.  Carruthers et al  
2012 (102) 
 
Retrospective Rectal 
cancer 
UK 115 PLR<160 Neoadjuvant 
chemoradiation 
N/A 43 N/A Univariate: 
1.5 (0.8-2.7) 
p=0.192 
Multivariate:  
R status, NLR 
(<5) 
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8.  Raungkaewmanee 
et al 2012 (722) 
 
Retrospective Epithelial 
Ovarian 
Cancer 
Thailand 166 PLR ≥200 145 patients had 
adjuvant 
chemotherapy 
N/A 50 N/A Multivariate: 
1.41 (0.77-2.56) 
p=0.263 
Multivariate: 
Stage, surgical 
outcomes 
9.  Wang et al 2012 
(224) 
 
Retrospective  Gastric  China 324 PLR (<150/ 
150-300/ >300)  
210 patients had 
adjuvant 
chemotherapy  
N/A 162 N/A Univariate: 
0.867 (0.665-1.132) 
p=0.296 
Multivariate:  
The 7th TNM 
stage, Adjuvant 
chemotherapy, 
GPS 
10.  Feng et al 2013 
(123) 
 
Retrospective Oesophagea
l Squamous 
Cell 
Carcinoma 
China 483 PLR >166.5 No mention of 
adjuvant or 
neoadjuvant 
treatment 
N/A 244 N/A Multivariate: 
1.751 (1.345-2.280) 
p<0.001 
Multivariate: 
Differentiation, 
depth of invasion, 
node metastasis, 
CNP 
11.  Feng et al 2013 
(723) 
 
Retrospective Small Cell 
Carcinoma 
of 
Oesophagus 
China 43 PLR ≥150 26 patients received 
adjuvant 
chemoradiotherapy 
N/A 35 N/A Multivariate: 
2.272 (1.035-4.984) 
p=0.041 
 
Multivariate: 
Chemoradiotherap
y 
 
 
12.  Stoz et al 2013 
(282)  
 
Retrospective  Pancreatic 
Cancer 
Austria  110 PLR≥150 88 Underwent 
chemotherapy  
N/A 110 N/A Univariate: 
1.133 (0.815-1.574) 
p=0.458 
Multivariate:  
Stage at diagnosis, 
NLR 
13.  Toiyama et al 
2013 (644) 
 
Retrospective Rectal 
Cancer 
Japan 84 PLR >150  All patients received 
neoadjuvant 
chemoradiotherapy 
N/A 37 (after 150 
months) 
N/A Univariate: 
2.17 (0.90-5.21) 
p=0.08 
Multivariate: 
Pathological TNM 
stage, CRP 
14.  Son et al 2013 
(262) 
 
Retrospective Colon 
Cancer 
Korea 624 PLR>300 vs. 
<150/ 150-300 
503 patients 
received 
chemotherapy 
N/A 55 (5 yr. 
survival) 
N/A Multivariate: 
2.006 (0.530-7.589) 
p=0.305 
Multivariate: 
Fibrinogen, stage, 
CEA 
15.  Zhang et al 2014 
(648) 
 
Retrospective Non-Small 
Cell Lung 
Cancer 
China 400 PLR ≥171 Patients treated with 
neoadjuvant and 
adjuvant therapy 
were excluded 
86 129 N/A Univariate: 
1.985 (1.269-3.104) 
p=0.003 
Multivariate: 
Age, tumour size 
16.  Ying et al 2014 
(649) 
 
Retrospective Colorectal 
Cancer 
China 205 PLR≥176 77 colon and 31 
rectal cancer patients 
underwent 
chemotherapy 
100 112 Multivariate: 
1.15 (0.75-1.78) 
p=0.513 
Multivariate: 
1.15 (0.77-1.73) 
p=0.501 
Multivariate: 
Grade (G3/G4), 
chemotherapy 
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17.  Szkandera et al 
2014 (645) 
 
Retrospective Soft Tissue 
Sarcoma 
Austria 340 
 
Training 
set, 
n=170 
 
Validatio
n set, 
n=170 
PLR ≥200 Training set: 
16 received adjuvant 
chemotherapy, 102 
received adjuvant 
radiotherapy 
 
Validation set: 
22 received adjuvant 
chemotherapy, 107 
received adjuvant 
radiotherapy 
Training set: 30 
 
Validation set: 
22 
Training set: 53 
 
Validation set: 
51 
Univariate: 
Training set:  
2.43 (0.99-5.90) 
p=0.051 
 
Validation set: 
1.52 (0.66-3.54) 
p=0.320 
Univariate: 
Training set: 
3.02 (0.94-9.70) 
p=0.019 
 
Multivariate: 
Validation set: 
0.61 (0.30-1.25)  
p=0.175 
Multivariate: 
Age, tumour 
grade, LMR, 
tumour size 
18.  Baranyai et al 
2014 (724) 
 
Retrospective Colorectal 
Cancer 
Hungary 336 PLR >300  No mention of 
adjuvant or 
neoadjuvant 
treatment 
N/A 335 N/A Multivariate: 
3.5 (2.2-5.6) 
logrank P=3.6e-08 
(insignificant) 
 
Multivariate: 
Elevated platelet 
count 
19.  Jiang et al 2014 
(656) 
 
Retrospective Gastric 
Cancer 
China 377 PLR ≥184 219 patients 
received adjuvant 
chemotherapy post 
gastrectomy 
N/A 223 N/A Multivariate: 
1.068 (0.791-1.441) 
p=0.668 
Multivariate: 
Tumour size, 
serosal invasion, 
lymph node 
metastasis, post 
complication, 
NLR 
20.  Yuan et al 2014 
(657) 
 
Retrospective Adenocarci
noma of 
Esophagoga
stric 
Junction 
China 327 PLR <150, 150-
300, ≥300 
18 patients received 
neoadjuvant 
chemotherapy, 59 
patients received 
adjuvant 
chemotherapy 
N/A 185 N/A Univariate: 
PLR 150-300: 1.284 
(0.897-1.838) p=0.172 
 
PLR ≥300: 1.398 (0.872-
2.241) p=0.164 
 
Multivariate: 
pTNM stage, 
adjuvant treatment 
21.  Feng et al 2014 
(659) 
 
Retrospective Esophageal 
SCC 
China 483 PLR ≥150 No mention of 
adjuvant or 
neoadjuvant 
treatment 
N/A 244 N/A Multivariate: 
1.840 (1.407-2.407) 
p<0.001 
Multivariate: 
Differentiation, 
depth of invasion, 
nodal metastasis, 
NLR 
22.  Sun et al 2014 
(265) 
 
Retrospective Colon 
cancer 
China 255 PLR<150, 150-
300, >300 
No specific mention 
of neoadjuvant or 
adjuvant treatment 
N/A 94 N/A Multivariate: 
RR 0.825 (0.560-1.215) 
p=0.330 
Multivariate: 
AFP, CEA, 
fibrinogen, TNM, 
mGPS 
23.  Neofytou et al 
2014 (665) 
 
Retrospective Liver-only 
Colorectal 
Metastases 
UK 140 PLR >150 All patients received 
neoadjuvant 
chemotherapy 
N/A 59 (5-year 
survival) 
N/A Multivariate: 
2.17 (1.09-4.32) 
p=0.027 
Multivariate: 
No adjuvant 
chemotherapy 
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24.  Krenn-Pilko et al 
2014 (725) 
 
Retrospective Breast 
cancer 
Austria 793 PLR ≥292 712 patients 
received adjuvant 
radiotherapy, 93 
received adjuvant 
chemotherapy, 378 
received adjuvant 
hormonal treatment, 
and 202 received 
both adjuvant 
chemotherapy and 
hormonal therapy. 
136 136 Multivariate: 
2.03 (1.03-4.02) 
p=0.042 
Multivariate: 
1.92 (1.01-3.67) 
p=0.047 
Multivariate: 
Tumour stage, 
lymph node 
involvement 
25.  Szkandera et al 
2014 (726) 
 
Retrospective Colon 
Cancer 
Austria 372 PLR >225 No specific mention 
of neoadjuvant or 
adjuvant treatment 
N/A 91 N/A Multivariate: 
1.49 (0.92-2.40) 
p=0.107 
Multivariate:  
Nil else   
26.  Pinato et al 2014 
(300)  
 
Retrospective  Lung  UK  220 PLR>300 Adjuvant radio and 
chemotherapy 
administered  
N/A 61 N/A Univariate: 
1.6 (0.6–5.6) p=0.32 
Multivariate:  
TNM I/II/III, 
Pleural Effusion, 
NLR  
27.  Aurello et al 2014 
(135) 
 
Retrospective Gastric 
Cancer 
Italy 102 PLR <150, 150-
300, >300 (0,1,2 
respectively) 
68 patients received 
adjuvant 
chemotherapy after 
surgery 
62 62 
 
N/A Multivariate: 
PLR 1: 
0.43 (0.10-1.73) 
p=0.23 
 
PLR 2: 
1.13 (0.45-2.79) 
p=0.79 
 
Multivariate: 
Prognostic index, 
mGPS 
28.  Que et al 2015 
(670) 
 
Retrospective Soft-tissue 
Sarcoma 
China 222 PLR ≥133.915 39 patients received 
adjuvant 
chemotherapy; 65 
patients received 
adjuvant 
radiotherapy 
N/A 82 (after 150 
months) 
N/A Multivariate: 
2.60 (1.17-5.74) 
p=0.019 
Multivariate:  
Tumour site: 
Trunk & 
extremity, AJCC 
stage, PLR 
29.  Hsu et al 2015 
(671) 
 
Retrospective Gastric 
Cancer 
Taiwan 989 PLR >132 499 patients with 
stage 2 to 4 tumour 
received 
chemotherapy 
N/A 395 (5-year 
survival) 
N/A Multivariate: 
0.898 (0.696-1.159) 
p=0.41 
Multivariate: 
NLR, resection 
margins, 
differentiation, T 
status, N status, 
LN ratio, M1 
status 
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30.  Sheng Han et al 
2015 (673) 
 
Retrospective Glioblasto
ma 
China 152 PLR >135 All patients received 
adjuvant radio-
chemotherapy 
N/A 118 (2-year 
survival) 
N/A Multivariate: 
1.003 (0.999-1.007) 
p=0.152 
Multivariate: 
KPS, MGMT 
promoter, pre-
treatment NLR 
31.  Aldemir et al 2015 
(675) 
 
Retrospective Gastric 
Cancer 
Turkey 53 PLR <170 vs. 
≥170 
No mention of 
adjuvant treatment 
N/A 19 N/A Univariate: 
p=0.55 
Univariate: 
ECOG 
performance 
status, platelet 
count 
32.  Bagante et al 2015 
(678) 
 
Retrospective Adrenocorti
cal 
Carcinoma 
US 84 PLR >190 51 patients received 
peri-operative 
systemic 
chemotherapy, 38 
patients received 
adjuvant mitotane 
50 (5-year DSS) N/A Univariate: 
0.90 (0.47-1.73) 
p=0.757 
N/A Multivariate:  
AJCC tumour site, 
T stage III-IV, 
Metastasis, NLR 
33.  Wang et al 2015 
(679) 
 
Retrospective HCC US 234 PLR >118.5 170 patients had 
antiviral treatment 
N/A 88 (5-year 
survival) 
N/A Multivariate: 
1.6 (0.6-4.3) 
p=0.3 
Multivariate: 
Tumour size, NLR 
34.  Li et al 2015 (681) 
 
Retrospective Endometria
l Cancer 
China 282 PLR ≥250 No specific mention 
of neoadjuvant or 
adjuvant treatment 
N/A 38 (5-year 
survival) 
N/A Multivariate: 
0.993 (0.294-3.357) 
p=0.991 
Multivariate: 
CRP, D-dimer,  
35.  Zhang et al 2015 
(682) 
 
Retrospective Non-small 
Cell Lung 
Cancer 
China 678 PLR >106 Adjuvant 
chemotherapy or/and 
radiotherapy 
N/A 367 N/A Multivariate: 
0.966 (0.761-1.228) 
p=0.780 
Multivariate: 
Pathological stage 
(I, II, IIIA), NLR 
36.  Zhang et al 2015 
(683) 
 
Retrospective Gallbladder 
Carcinoma 
China 145 PLR ≥113.34 No specific mention 
of neoadjuvant or 
adjuvant treatment 
N/A 117 (5-year 
survival) 
N/A Univariate: 
RR 1.903 (1.309-2.767) 
p=0.001 
Multivariate: 
Nevin stages, 
operation modes, 
Hb, NLR 
37.  Qu et al 2015 
(684) 
 
Retrospective Gastric 
Cancer 
China 1397 
 
Develop
ment set: 
n=1123 
 
Validatio
n set: 
n=274 
PLR. >168 No specific mention 
of neoadjuvant or 
adjuvant treatment 
N/A 3-year survival 
 
Development 
set: 307 
 
Validation set: 
60 
N/A Univariate: 
1.762 (1.372-2.264) 
p<0.001 
Multivariate: 
Age, tumour size, 
Lauren type, depth 
of invasion, 
number of 
metastatic lymph 
node, NLR 
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38.  Zhang et al 2015 
(685) 
 
Retrospective Ovarian 
Cancer 
China 190 PLR >203 Surgery was 
followed by 
platinum-based 
chemotherapy 
N/A 170 (after 100-
month) 
N/A Multivariate: 
2.158 (1.468-3.171) 
p<0.001 
Multivariate: 
Stage (FIGO), 
postoperative 
residual tumour 
mass 
39.  Zhang et al 2015 
(727) 
 
Retrospective Bladder 
cancer 
China 124 PLR ≥140 No mention of 
adjuvant treatment 
N/A 55 (5-year 
survival) 
N/A Multivariate: 
1.161(0.605-2.226) 
p=0.654 
Multivariate: 
Diabetes, T 
staging, distant 
metastasis, LMR 
40.  Sun et al 2015 
(136) 
 
Retrospective Gastric 
Cancer 
China 632 PLR >140 395 patients 
received adjuvant 
chemotherapy 
N/A 448 N/A Multivariate: 
1.190 (0.960-1.475) 
p=0.113 
Multivariate: 
Age, 
respectability, 
distant metastasis, 
pathological stage, 
CEA, 
postoperative 
complications, 
PNI 
41.  Choi et al 2015 
(689) 
 
Retrospective Colorectal 
Cancer 
Canada 549 PLR≥295 147 patients 
received adjuvant 
therapy: 
chemotherapy, 
radiation or both 
N/A  120 (5-year 
survival) 
N/A Univariate:                  
1.81 (1.06-3.06) p=0.028 
Multivariate:  
Age>75, lymph 
nodes positive, 
ASA status, NLR  
42.  Deng et al 2015 
(690) 
 
Retrospective Gastric 
Cancer 
China 389 PLR≥132 No mention of 
adjuvant treatment 
235 270 Multivariate:    
0.96 (0.71-1.28) 
p=0.763 
Multivariate:               
1.03 (0.78-1.35) p=0.858 
Multivariate: 
Age, tumour 
stage, lymph node, 
distant metastasis, 
dNLR 
43.  Spolverato et al 
2015 (691) 
 
Retrospective Hepato-
Pancreatico
-Biliary 
Malignanci
es 
US 452 PLR ≥190 189 patients 
received 
neoadjuvant 
chemotherapy. 
N/A 192 (5-year 
survival) 
N/A Multivariate:               
1.79 (1.05-3.04) p=0.032 
Multivariate: 
Age, 
complications, 
NLR 
44.  Han et al 2015 
(692) 
 
Retrospective Esophageal 
SCC 
China 218 PLR<244 Adjuvant treatment: 
17 received 
chemotherapy 
41 received 
radiotherapy 
24 received 
chemoradiotherapy 
N/A 138 N/A Multivariate:             
1.014 (0.582-1.769) 
p=0.96 
Multivariate: 
Tumour length, 
pTNM stage, 
LMR. 
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45.  Kim et al 2015 
(693) 
 
Retrospective Gastric 
Cancer 
Korea 1986 PLR>126 No mention of 
adjuvant treatment 
N/A 323 (5-year 
survival) 
N/A Multivariate:             
1.035 (0.805-1.330) 
p=0.7888 
Multivariate: 
Age, approach 
method, depth of 
invasion, node 
status, NLR  
46.  Anthony et al 
2015 (694) 
 
Retrospective Hepatocellu
lar 
Carcinoma 
Hong 
Kong 
324 PLR≥150 282 patients with 
chronic viral 
hepatitis received 
antiviral therapy 
N/A 79 (5-year 
survival) 
N/A Univariate:                 
1.229 (0.756-1.998) 
p=0.405 
Multivariate: 
Antiviral therapy, 
microvascular 
invasion, PNI. 
47.  Kim et al 2015 
(699) 
 
Retrospective Upper 
Urinary 
Tract 
Urothelial 
Carcinoma 
South 
Korea 
277 PLR <150, 150-
300, >300 
71 patients received 
adjuvant 
chemotherapy 
73 96 Univariate:       
PLR 150-300 
1.460 (0.887-
2.405) p=0.137 
PLR >300 1.202 
(0.374-3.864) 
p=0.757 
N/A Multivariate: 
Bladder cuff 
excision, 
pathologic T 
stage, 
lymphovascular 
invasion, derived 
NLR 
 
48.  Neofytou et al 
2015 (677) 
 
Retrospective Liver-Only 
Colorectal 
Metastases 
UK 140 PLR 
(continuous 
variable) 
All patients received 
neoadjuvant 
chemotherapy, 104 
received adjuvant 
chemotherapy. 
60 63 Univariate: 
1.006 (1.002-
1.009) 
p<0.001 
N/A Multivariate: 
Adjuvant 
chemotherapy, 
neoadjuvant LMR. 
49.  Messager et al 
2015 (728) 
 
Retrospective Oesophagea
l and 
junctional 
carcinoma 
UK 153 PLR >192 36.6% of patients 
received adjuvant 
chemotherapy after 
surgery 
N/A  39 N/A Multivariate: 
2.47 (1.21-5.01) 
p=0.012 
Multivariate: 
Differentiation, 
resection margin, 
ypN 
50.  Pang et al 2015 
(729) 
 
Retrospective Gallbladder 
carcinoma 
China 316 PLR≥ 117.7 No mention of 
adjuvant or 
neoadjuvant 
treatment 
N/A 254 N/A Multivariate: 
2.021 (1.243-3.278) 
p=0.005 
Multivariate: 
CA-125, CA-199, 
TNM 
51.  Ozawa et al 2015 
(730) 
 
Retrospective Colorectal 
Cancer 
Japan 234 PLR ≥25.4 15 patients excluded 
as underwent 
adjuvant 
chemotherapy  
222 211 Multivariate: 
3.61 (1.08-12.64) 
p=0.038 
N/A Multivariate: 
Nil else  
52.  Shirai et al 2015 
(704) 
 
Retrospective Pancreatic 
cancer 
Japan 131 PLR ≥150  No mention of 
adjuvant treatment 
N/A 103 (5-year 
survival) 
N/A Multivariate:             
1.688 (1.045-2.726) 
p=0.032 
Multivariate: 
Tumour size, 
resection margin 
status, tumour 
differentiation 
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53.  Chen et al 2015 
(705) 
 
Retrospective Intrahepatic 
Cholangioc
arcinoma 
China 322 PLR ≥123 Adjuvant 
chemoradiotherapy 
used as well as 
radiofrequency 
ablation 
N/A 197 (5-year 
survival) 
N/A Multivariate:             
1.410 (1.026-1.938) 
p=0.034 
Multivariate: 
CA19-9, tumour 
number, lymph 
node metastasis, 
NLR 
54.  Neal et al 2015 
(122) 
 
Retrospective Colorectal 
Liver 
Metastases 
UK 302 PLR <150, 150-
300, >300 
132 patients had 
systemic 
chemotherapy in the 
6 months prior to 
liver resection, 126 
patients received 
systemic 
chemotherapy 
following 
mastectomy 
204 (5-year 
survival) 
214 (5-year 
survival) 
Univariate:      
1.244 (1.003-
1.542) p=0.047 
Univariate:                
1.244 (1.015-1.525) 
p=0.036 
Multivariate: 
Clinical risk score, 
NLR≥3 
55.  Xu et al 2015 
(127)  
 
Retrospective Oesophagea
l SCC 
China 468 PLR>147  196 patient received 
adjuvant chemo and 
radiotherapy  
N/A 259 N/A Univariate: 
1.12 (0.87-1.43) p=0.39 
Multivariate: 
Lymph Node 
Mets, 
Venous/lymphatic 
invasion, CRP/Alb 
Ratio 
56.  Kawashima et al 
2015 (144) 
 
Retrospective Lung 
Cancer 
Japan 1043 PLR >300  No mention of 
adjuvant treatment 
N/A 227 N/A Univariate: 
2.35 (1.45-3.82) 
p<0.01 
Multivariate: 
Age, smoking, 
neoadjuvant 
therapy,  co-
morbidity, CEA, 
pathological stage, 
histological 
tumour type, LVI, 
surgical procedure 
57.  Cummings et al 
2015 (124) 
 
Retrospective Endometria
l Cancer 
UK 605 PLR. ≥240 33% of patients 
received adjuvant 
radiotherapy, 13% of 
patients received 
adjuvant 
chemotherapy 
96 166 Multivariate: 
1.76 (1.09-2.87) 
p=0.022 
Multivariate: 
1.89 (1.30-2.75) 
p=0.001 
Multivariate: 
NLR, Combined 
NLR + PLR, age, 
FIGO stage, 
grade, 
histopathological 
subtype, LVSI 
58.  Lian et al 2015 
(706) 
 
Retrospective Gastric 
Cancer 
China 162 PLR ≥208 No mention of 
adjuvant treatment 
N/A N/A (expressed 
in months) 
N/A Multivariate: 
OR 2.55 (1.37-3.84) 
p=0.001 
Multivariate: 
Depth of invasion, 
lymph node 
metastasis, AJCC 
stage 
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59.  Saito et al 2016 
(731) 
 
Retrospective Perihilar 
cholangioca
rcinoma 
Japan 115 PLR >150 1 patient received 
neoadjuvant 
chemotherapy, 1 
patient received 
neoadjuvant  
radiation, 1 patient 
received 
neoadjuvant  
chemotherapy and 
radiation, 21 patients 
received adjuvant 
therapy 
N/A 59 (5-year 
survival) 
Multivariate:   
2.207 (1.200-
4.060) p=0.011 
N/A Multivariate: 
Preoperative 
factors (CEA, 
albumin, CRP), N 
category, portal 
vein invasion, 
surgical margin  
60.  Xie et al 2016 
(707) 
 
Retrospective Oesophagea
l Squamous 
Cell Cancer 
China 317 PLR >103 76 patients received 
adjuvant 
chemotherapy  
147 
 
152 Multivariate: 
1.776 (1.224-
2.578) 
p=0.003 
N/A Multivariate: 
TNM stage 
61.  Bhindi et al 2016 
(721) 
 
Retrospective Bladder 
Cancer 
Canada 418 PLR per 100 
units 
28 received neo-
adjuvant 
chemotherapy, 87 
received adjuvant 
chemotherapy, 54 
received salvage 
chemotherapy 
107 177 Univariate: 
1.21 (1.05-1.41) 
p=0.01 
Univariate: 
1.16 (1.02-1.33) 
p=0.03 
Multivariate:  
T-stage, N-stage, 
haemoglobin, 
NLR, age, 
Charlson co-
morbidity index, 
lymphovascular 
invasion 
62.  Ha et al 2016 
(129)  
 
Retrospective Ampulla of 
Vater 
Cancer 
South 
Korea 
227 PLR >192 Adjuvant treatments 
including 
chemotherapy, 
radiotherapy and 
concurrent 
chemoradiotherapy 
N/A 105 N/A Multivariate: 
0.686 (0.35-1.34) 
p=0.268 
Multivariate: 
Vascular invasion, 
CA19-9. 
63.  Li et al 2016 (137) 
 
Retrospective Colorectal 
Cancer 
China 5336 PLR >219 5-Fu based adjuvant 
chemotherapy for 
stage 2/3 patients 
588 611 N/A Multivariate: 
1.175 (0.946-1.460) 
p=0.144 
 
Multivariate: 
Age, T stage, N 
stage, 
differentiation, 
venous invasion, 
NLR, LMR, AGR 
64.  Chen et al 2016 
(714) 
 
Retrospective Esophageal 
Squamous 
Cell 
Carcinoma 
China 323 PLR >150 No mention of 
adjuvant treatment 
221 (5-year) N/A Multivariate: 
1.440 (0.978-
2.121) p=0.064 
N/A Multivariate: 
TNM stage, I 
stage 
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65.  Hodek et al 2016 
(716) 
 
Retrospective Rectal 
Carcinoma 
Czech 
Republic 
173 PLR 
(continuous) 
All patients received 
neoadjuvant 
chemoradiotherapy 
N/A 22 N/A Univariate: 
RR: 1.01 (1.00-1.01) 
p=0.02 
Univariate: 
Clinical T stage, 
circular vs semi-
circular, stenosing 
tumour, LVSI, 
angioinvasion, 
perineural 
invasion, R0 
resection, positive 
lymph nodes, 
tumour stage, 
WBC, RBC, Hb, 
platelet count, 
neutrophils, NLR 
66.  Wang et al 2016 
(139) 
 
Retrospective Ovarian 
Cancer 
China 143 PLR >201 No mention of 
adjuvant treatment 
N/A 51 N/A Univariate:                   
1.76 (1.02-3.06) p=0.043 
Multivariate: 
Metastasis, 
prognostic 
inflammation 
score 
67.  Chan et al 2016 
(269) 
 
Retrospective Colorectal 
Cancer 
Australia 1623 PLR >258 Patients with high-
risk stage II and III 
colon cancer disease 
received adjuvant 
chemotherapy.  
Stage II or III rectal 
cancers received 
neoadjuvant 
chemoradiotherapy 
N/A 941 N/A Univariate: 
1.592 (1.343-1.886) 
p< 0.001 
Multivariate: 
Age, T stage, N 
stage, grade, LMR 
68.  Toyokawa et al 
2016 (140) 
 
Retrospective Thoracic 
Oesophagea
l Squamous 
Cell 
Carcinoma 
Japan 185 PLR >193  46 patients received 
neoadjuvant 
treatment (39 
chemotherapy, 6 
chemoradiotherapy, 
1 radiotherapy) 
N/A 77 
  
N/A 
 
Multivariate: 
1.213 (0.696-2.115) 
p=0.496 
Multivariate: 
Sex, performance 
status, ASA, 
cTNM stage, 
CONUT score 
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Table 18.4: Studies investigating the prognostic value of the LMR in an unselected cohort of patients with operable cancer 
No: 
LMR 
Study Type of 
Study 
Cancer Country  Patients 
(n) 
Measure of 
SIR 
Additional 
Treatment  
Cancer deaths  
(n) 
Overall deaths 
(n) 
Cancer survival 
(HR, 95%CI) 
Overall survival  
(HR, 95%CI) 
Independent 
Prognostic 
Factors 
1.  Stotz et al 2014 
(732) 
 
Retrospective Colon 
Cancer 
Austria 372 LMR ≥ 2.14 230 patients 
received adjuvant 
chemotherapy 
N/A 72 N/A Multivariate: 
0.51 (0.31-0.83) 
p=0.007 
 
 
Multivariate: 
Tumour invasion 
depth, lymph node 
involvement, 
tumour stage 
2.  Szkandera et al 
2014 (645) 
 
Retrospective Soft Tissue 
Sarcoma 
Austria 340 
 
Training 
set, 
n=170 
 
Validatio
n set, 
n=170 
LMR ≥2.85 Training set: 
16 received adjuvant 
chemotherapy, 102 
received adjuvant 
radiotherapy 
 
Validation set: 
22 received adjuvant 
chemotherapy, 107 
received adjuvant 
radiotherapy 
Training set: 30 
Validation set: 
22 
Training set: 53 
Validation set: 
51 
Multivariate: 
Training set:  
0.41 (0.18-0.97) 
p=0.043 
 
Validation set: 
0.33 (0.12-0.90) 
p=0.030 
 
Multivariate: 
Training set: 
0.72 (0.34-1.52) 
p=0.390 
 
Validation set: 
0.35 (0.17-0.75) 
p=0.007 
 
Multivariate: 
Age, tumour 
grade, LMR, 
tumour size 
3.  Hu et al 2014 
(733) 
 
Retrospective Lung 
Cancer 
China 1453 LMR ≤3.68 No mention of 
adjuvant treatment 
N/A 509 N/A Multivariate: 
1.510 (1.265-1.803) 
p<0.001 
Multivariate: 
Age, TNM stage 
4.  Zhou et al 2014 
(734) 
 
Retrospective Gastric 
Cancer 
China 426 LMR ≥4.32  306 patients 
received adjuvant 
chemotherapy 
N/A 250 N/A Multivariate: 
0.688 (0.521-0.908) 
p=0.008 
 
 
Multivariate: 
Size, vascular/ 
nerve infiltration, 
TNM stage, 
adjuvant 
chemotherapy 
5.  Hutterer et al 2014 
(735) 
 
Retrospective Clear Cell 
Renal Cell 
Carcinoma 
Austria 678 LMR <3 No mention of 
adjuvant treatment 
68 123 Multivariate: 
2.332 (1.100-
4.942) p=0.027 
Multivariate: 
1.373 (0.929-2.031) 
p=0.112 
Multivariate: 
Age, pathologic T 
category, tumour 
grade, tumour 
necrosis 
6.  Zhang et al 2015 
(727) 
 
Retrospective Bladder 
cancer 
China 124 LMR ≥4 No mention of 
adjuvant treatment 
N/A 55 (5-year 
survival) 
N/A Multivariate: 
0.674 (0.412-0.890) 
p=0.003 
 
Multivariate: 
Diabetes, T 
staging, distant 
metastasis, PLR 
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7.  Han et al 2015 
(692) 
 
Retrospective Esophageal 
SCC 
China 218 LMR<2.57 Adjuvant treatment: 
17 received 
chemotherapy 
 
41 received 
radiotherapy 
 
24 received 
chemoradiotherapy 
N/A 138 N/A Multivariate:             
1.759 (1.201-2.576) 
p=0.004 
Multivariate: 
Tumour length, 
pTNM stage. 
8.  Deng et al 2015 
(690) 
 
Retrospective Gastric 
Cancer 
China 389 LMR≥4.95  No mention of 
adjuvant treatment 
235 270 Multivariate:    
1.00 (0.71-1.40) 
p=0.995 
Multivariate:              
1.00 (0.73-1.35) p=0.977 
 
Multivariate: 
Age, tumour 
stage, lymph node, 
distant metastasis, 
dNLR 
9.  Neofytou et al 
2015 (677) 
 
Retrospective Liver-Only 
Colorectal 
Metastases 
UK 140 Preoperative 
LMR ≤3 
All patients received 
neoadjuvant 
chemotherapy, 104 
received adjuvant 
chemotherapy. 
60 63 Multivariate: 
2.15 (1.13-4.10) 
p=0.020 
Multivariate: 
2.43 (1.32-4.48) 
p=0.004 
Multivariate: 
Adjuvant 
chemotherapy, 
preoperative  
10.  Neal et al 2015 
(122) 
 
Retrospective Colorectal 
Liver 
Metastases 
UK 302 LMR >2.35  132 patients had 
systemic 
chemotherapy in the 
6 months prior to 
liver resection, 126 
patients received 
systemic 
chemotherapy 
following 
mastectomy 
204 (5-year 
survival) 
214 (5-year 
survival) 
Univariate:     
0.624 (0.455-
0.855) p=0.003 
 
Univariate:                
0.638 (0.473-0.860) 
p=0.003 
 
Multivariate: 
Clinical risk score 
11.  Wen et al 2015 
(736) 
 
Retrospective Breast 
Cancer 
China 2000 LMR cut-off 
3.80 (low or 
high-LMR) 
No mention of 
adjuvant therapy but 
likely triple negative 
cancers had chemo  
N/A 326 N/A Multivariate:             
0.840 (0.629-1.121) 
p=0.236 
 
Multivariate: 
Menstrual status, 
tumour size, 
lymph node status 
ER, HER-2, 
monocyte count 
12.  Lin et al 2015 
(737) 
 
Retrospective HCC China 210 LMR >3.23  Antiviral therapy for 
all patients after 
surgery 
47 48 N/A Multivariate:             
0.398 (0.219-0.725) 
p=0.003 
 
Multivariate: 
Liver cirrhosis, 
ALP, 
microvascular 
invasion, 
histological 
differentiation, 
BCLC stage 
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13.  Yoshida et al 2015 
(738) 
 
Retrospective Bladder 
Cancer 
Japan 181 LMR <3.51 44 patients received 
adjuvant 
chemotherapy 
58 70 N/A Multivariate:               
3.77 (2.19-6.48) p<0.001 
Multivariate: 
pT-stage, pN-
stage, positive 
margin 
14.  Yamagishi et al 
2015 (739) 
 
Retrospective Malignant 
Pleural 
Mesothelio
ma 
Japan 44 LMR <2.74 Chemotherapy 
administered in 
57.3% of people  
N/A 28 N/A Multivariate:                
2.34 (1.58-3.47) 
p<0.0001 
Multivariate:  
Histological 
subtype, ECOG, 
Stage, Surgery 
15.  Ozawa et al 2015 
(740) 
 
Retrospective Colorectal 
Cancer 
Japan 117 LMR <3  53 patients received 
adjuvant 
chemotherapy 
24 (3-year death 
rate) 
N/A Multivariate:    
2.75 (1.40-5.44) 
p=0.004 
N/A Multivariate: 
Nil Else 
16.  Hutterer et al 2015 
(741) 
 
Retrospective Upper Tract 
Urothelial 
Carcinoma 
Austria 182 LMR ≥2 No mention of 
adjuvant treatment 
N/A 82 N/A Multivariate: 
0.56 (0.35-0.92) 
p=0.021 
 
Multivariate: 
Age, pathological 
T stage 
17.  Huang et al 2015 
(742) 
 
Retrospective Oesophagea
l Squamous 
Cell 
Carcinoma 
China 348 
 
LMR >2.93 105 patients 
received adjuvant 
therapy 
129 N/A Multivariate: 
0.600 (0.407-
0.885) 
p=0.010 
 
N/A Multivariate: 
Depth of invasion, 
nodal metastasis, 
lymphocyte count 
18.  Chen et al 2015 
(743) 
 
Retrospective Cervical 
Cancer 
China 485 LMR >2.87 63 patients received 
radiotherapy, 315 
received 
chemoradiotherapy 
N/A 64 N/A Multivariate: 
0.417 (0.244-0.714) 
p=0.001 
 
 
Multivariate: 
Lymph node 
metastasis 
19.  Bhindi et al 2016 
(721) 
 
Retrospective Bladder 
Cancer 
Canada 418 LMR per 1-log 
unit 
28 received neo-
adjuvant 
chemotherapy, 87 
received adjuvant 
chemotherapy, 54 
received salvage 
chemotherapy 
107 177 Univariate: 
0.69 (0.53-0.91) 
p=0.009 
 
 
Univariate: 
0.70 (0.55-0.88) 
p=0.002 
 
 
Multivariate: 
T-stage, N-stage, 
haemoglobin, 
NLR, age, 
Charlson co-
morbidity index, 
lymphovascular 
invasion 
20.  Li et al 2016 (137) 
 
Retrospective Colorectal 
Cancer 
China 5336 LMR >2.83 5-Fu based adjuvant 
chemotherapy for 
stage 2/3 patients 
588 611 N/A Multivariate: 
0.761 (0.621-0.932) 
p=0.008 
 
 
Multivariate:  
Age, T stage, N 
stage, 
differentiation, 
venous invasion, 
NLR, AGR 
 493 
21.  Chan et al 2016 
(269) 
 
Retrospective Colorectal 
Cancer 
Australia 1623 LMR >2.38 Patients with high-
risk stage II and III 
colon cancer disease 
were generally 
offered standard 
adjuvant 
chemotherapy, 
whereas those with 
stage II or III rectal 
cancers were usually 
treated with 
neoadjuvant 
chemoradiotherapy 
N/A 941 N/A Multivariate: 
0.569 (0.478-0.677) 
p< 0.001 
 
 
Multivariate: 
Age, T stage, N 
stage, grade 
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Table 18.5: Studies investigating the prognostic value of the other markers of inflammation in an unselected cohort of patients with operable cancer 
No: 
Other 
Study Type of 
Study 
Cancer Country  Patients 
(n) 
Measure of 
SIR 
Additional 
Treatment  
Cancer deaths 
(n) 
Overall deaths 
(n) 
Cancer survival 
(HR, 95%CI) 
Overall survival  
(HR, 95%CI) 
Independent 
Prognostic 
Factors 
1.  Miyata et al 2011 
(128) 
 
Retrospective Esophageal 
Cancer 
Japan 152 Systemic 
inflammation 
score (0-1 vs. 2-
3) involving 
leucocyte count, 
serum albumin 
and 
haemoglobin 
level 
All patients received 
pre-operative 
chemotherapy 
N. A 92 (5-year 
survival) 
N/A Multivariate: 
3.17 (1.74-5.78) 
p=0.0002 
Multivariate: 
Clinical response, 
number of 
metastatic lymph 
nodes, operative 
complication 
2.  Tomita et al 2012 
(130) 
 
Retrospective Non-Small 
Cell Lung 
Cancer 
Japan 301 NLR and CRP 
combined 
 
 
No mention of 
adjuvant treatment 
N/A N/A (expressed 
in %) 
N/A Multivariate: 
Both low/ both high  
Risk ratio 0.403 (0.240-
0.689) p=0.0012 
 
Either high/ both high  
Risk ratio 0.452 (0.225-
0.872) p=0.0177 
Multivariate: 
pT status, pN 
status, CEA. 
3.  Feng et al 2013 
(123) 
 
Retrospective Oesophagea
l Squamous 
Cell 
Carcinoma 
China 483 CNP (1-2 vs. 0) 
involving NLR 
and PLR 
No mention of 
adjuvant or 
neoadjuvant 
treatment 
N/A 244 N/A Multivariate: 
1.964 (1.371-2.814) 
p<0.001 
Multivariate: 
Differentiation, 
depth of invasion, 
node metastasis, 
PLR 
4.  Ishizuka et al 2013 
(119) 
 
Retrospective  Colorectal  Japan  481 COP-NLR (1, 
2/0) 
Patients with stage 
IV disease had 
chemotherapy  
120 150 Multivariate: 
OR: 0.464 (0.267-
0.807) p=0.007 
N/A Pathology, LN 
Mets, CRP, 
Albumin, CEA, 
GPS 
5.  Peng et al 2015 
(744) 
 
Retrospective HCC China 219 ∆PLR ≥2.875  No specific mention 
of neoadjuvant or 
adjuvant treatment 
N/A 40 N/A Multivariate: 
5.929 (2.823-12.448) 
p<0.001 
Multivariate: 
Vascular invasion 
6.  Peng et al 2014 
(745) 
 
Retrospective Small 
hepatocellul
ar 
carcinoma 
China 189 ∆NLR 
(postoperative 
minus 
preoperative 
NLR) 
68 patients received 
adjuvant therapy 
after operation 
(TACE, RFA, 
sorafenib) 
N/A 37 N/A Multivariate: 
2.637 (1.356-5.128) 
p=0.004 
Vascular invasion, 
postoperative 
NLR. 
7.  Ishizuka et al 2014 
(120) 
 
Retrospective Gastric 
Cancer 
Japan 544 COP-NLR (0, 
1/2) 
343 patients 
received adjuvant 
chemotherapy 
55 108 N/A Multivariate: 
1.781 (1.094-2.899) 
p=0.020 
Multivariate: 
Age, tumour type, 
lymph node 
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metastasis, 
albumin, COP-
NLR 
8.  Sung et al 2015 
(132) 
 
Retrospective Upper 
Urinary 
Tract 
Urothelial 
Carcinoma 
Korea 410 Inflammation 
risk score (none, 
I, II) involving 
NLR and ESR 
91 patients received 
adjuvant 
chemotherapy post 
operation 
67 118 Multivariate: 
Score I   2.785 
(1.343-5.776) 
p=0.006 
 
Score II   4.367 
(1.987-9.597) 
p<0.001 
Multivariate: 
Score I   2.513 (1.434-
4.405) 
p=0.001 
 
Score II   3.521 (1.888-
6.567) p<0.001 
Multivariate: 
Age, tumour 
stage, lymph node, 
margin, 
micropapillary 
variant 
9.  East et al 2014 
(133) 
 
Retrospective Colon 
Cancer 
UK 436 
Training 
set, 
n=386 
 
Test set, 
n=50 
White cell 
count/ 
lymphocyte 
ratio (WLR) 
≥3.4 
26 patients received 
adjuvant 
chemotherapy 
N/A 27 N/A Multivariate: 
Training set: 1.40 (1.04-
1.89) p=0.03 
 
Test set: 4.10 (3.13-7.42) 
p=0.03 
Multivariate: 
N stage, R0 
resection, adjuvant 
treatment, T stage, 
NLR. 
10.  Shen et al 2014 
(134) 
 
Retrospective HCC China 332 AST-platelet 
ratio index 
(APRI) <0.62 
vs. ≥0.62 
No mention of 
adjuvant or 
neoadjuvant 
treatment 
N/A 209 N/A Multivariate: 
1.508 (1.127-2.016) 
p=0.006 
Multivariate: 
APRI, tumour 
size, 
noncapsulation, 
tumour number 
11.  Aurello et al 2014 
(135) 
 
Retrospective Gastric 
Cancer 
Italy 102 Prognostic 
index (PI) 0/1/2 
involving CRP 
and white cell 
count 
 
Prognostic 
nutrition index 
(PNI) 0/1 
involving 
albumin and 
total 
lymphocyte 
count 
68 patients received 
adjuvant 
chemotherapy after 
surgery 
62 62 
 
N/A Multivariate: 
PI 1: 0.04 (0.01-0.20) 
p< 0.001 
 
PI 2: 0.37 (0.16-0.82) 
p=0.01 
 
Univariate: 
PNI 0/1: 0.52 (0.26-1.04) 
p=0.06 
Multivariate: 
mGPS 
12.  Takeno et al 2014 
(145) 
 
Retrospective  Gastric  Japan  552 HS-mGPS 
(0/1/2)  
No mention of 
adjuvant treatment 
N/A 215 N/A  Multivariate: 
1.6748 (1.2867-2.1314) 
p= 0.0002 
Multivariate:  
HS-mGPS 
13.  Cummings et al 
2015 (124) 
 
Retrospective Endometria
l Cancer 
UK 605 MLR <0.19 vs. 
≥0.19 
33% of patients 
received adjuvant 
radiotherapy, 13% of 
patients received 
96 166 Multivariate: 
1.26 (0.73-2.15) 
p=0.409 
Multivariate: 
1.23 (0.84-1.82) 
p=0.294 
Multivariate: 
PLR, combined 
NLR + PLR, age, 
FIGO stage, 
grade, 
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adjuvant 
chemotherapy 
histopathological 
subtype, LVSI 
14.  Shimizu et al 2015 
(672) 
 
Retrospective Non-small 
Cell Lung 
Cancer 
Japan 334 Prognostic 
nutritional index 
<50 vs. ≥50 
Neither radiotherapy 
nor chemotherapy 
administered prior to 
the surgery 
N/A 95 (3-year 
survival) 
N/A Multivariate: 
2.40 (1.39-4.14 
p=0.002 
Multivariate: 
Age, nodal 
metastasis, NLR 
15.  Wang et al 2015 
(679) 
 
Retrospective Hepatitis B-
Associated 
Hepatocellu
lar 
Carcinoma 
US 234 Prognostic 
nutritional index 
>50.5 
170 patients had 
antiviral treatment 
N/A 88 (5-year 
survival) 
N/A Multivariate: 
1.3 (0.5-3.4) 
p=0.5 
Multivariate: 
Tumour size, NLR 
16.  Sun et al 2015 
(136) 
 
Retrospective Gastric 
Cancer 
China 632 Prognostic 
nutritional index 
<48.2 vs. ≥48.2 
395 patients 
received adjuvant 
chemotherapy 
N/A 448 N/A Multivariate: 
1.668 (1.368-2.035) 
p=0.656 
Multivariate: 
Age, 
respectability, 
distant metastasis, 
pathological stage, 
CEA, 
postoperative 
complications 
17.  Sun et al 2015 
(136) 
 
Retrospective Gastric 
Cancer 
China 632 Canton score 
(0/1/2/3) 
395 patients 
received adjuvant 
chemotherapy 
N/A 448 N/A Multivariate: 
Canton score 1 
1.076 (0.796-1.454) 
p=0.633 
 
Canton score 2 
1.554 (1.151-2.097) 
p=0.004 
 
Canton score 3 
1.643 (1.142-2.364) 
p=0.007 
Multivariate: 
Resectability,  
18.  Zhang et al 2015 
(121) 
 
Retrospective Non-Small 
Cell Lung 
Cancer 
China 1238 Combination of 
neoadjuvant 
platelet count 
and neutrophil-
lymphocyte 
ratio 
COP-NLR 
(0/1/2) 
Adjuvant treatments 
including 
chemotherapy, 
radiotherapy and 
concurrent 
chemoradiotherapy 
N/A 686 N/A Multivariate:             
1.810 (1.587-2.056) 
p<0.001 
Multivariate: 
TNM stage, LDH, 
D-dimer, COP-
NLR 
19.  Chan et al 2015 
(694) 
 
Retrospective Hepatocellu
lar 
Carcinoma 
Hong 
Kong 
324 Prognostic 
nutritional index 
< 45 
282 patients with 
chronic viral 
hepatitis received 
antiviral therapy 
N/A 79 (5-year 
survival) 
N/A Multivariate:             
2.778 (1.630-4.813) 
p<0.001 
Multivariate: 
Antiviral therapy, 
microvascular 
invasion 
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20.  Kim et al 2015 
(699) 
 
Retrospective Upper 
Urinary 
Tract 
Urothelial 
Carcinoma 
South 
Korea 
277 PNI ≥45 vs. <45 71 patients received 
adjuvant 
chemotherapy 
73 96 Multivariate:  
0.947 (0.491-
1.826) p=0.870 
N/A Multivariate: 
Bladder cuff 
excision, 
pathologic T 
stage, 
lymphovascular 
invasion, derived 
NLR 
 
21.  Neal et al 2015 
(122) 
 
Retrospective Colorectal 
Liver 
Metastases 
UK 302 COP-NLR 
(2/1/0): 
Combination of 
platelet count 
and NLR 
132 patients had 
systemic 
chemotherapy in the 
6 months prior to 
liver resection, 126 
patients received 
systemic 
chemotherapy 
following 
mastectomy 
204 (5-year 
survival) 
214 (5-year 
survival) 
Univariate:     
1.243 (1.003-
1.541) p=0.047 
Univariate:                 
1.230 (1.005-1.505) 
p=0.045 
Multivariate: 
Clinical risk score 
22.  Neal et al 2015 
(122) 
 
Retrospective Colorectal 
Liver 
Metastases 
UK 302 Prognostic 
nutritional index 
(0/1) 
132 patients had 
systemic 
chemotherapy in the 
6 months prior to 
liver resection, 126 
patients received 
systemic 
chemotherapy 
following 
mastectomy 
204 (5-year 
survival) 
214 (5-year 
survival) 
Univariate:     
0.657 (0.437-
0.988) p=0.043 
Univariate:                
0.707 (0.475-1.053) 
p=0.088 
Multivariate: 
Clinical risk score 
23.  Cummings et al 
2015 (124) 
 
Retrospective Endometria
l Cancer 
UK 605 Combined NLR 
+ PLR 
 
(both low, either 
high, both high) 
33% of patients 
received adjuvant 
radiotherapy, 13% of 
patients received 
adjuvant 
chemotherapy 
96 166 Multivariate: 
Either high: 
1.46 (0.87-2.47) 
p=0.156 
 
Both high: 
2.26 (1.24-4.13) 
p=0.008 
Multivariate: 
Either high: 
1.59 (1.08-2.35) 
p=0.018 
 
Both high: 
2.54 (1.61-4.01) 
p<0.001 
Multivariate: 
Age, FIGO stage, 
grade, 
histopathological 
subtype, LVSI 
24.  Ishizuka et al 2016 
(126) 
 
Retrospective Colorectal 
Cancer 
Japan 627 CRP/ albumin 
ratio (CAR) 
>0.038 vs. 
≤0.038 
No mention of 
adjuvant treatment 
110 142 
  
N/A 
 
Multivariate: 
2.613 (1.621-4.212) 
p< 0.001 
Multivariate: 
Pathological 
differentiation, 
CEA, stage, GPS, 
NLR 
25.  Chen et al 2015 
(131) 
 
Retrospective Gastric 
Carcinoma 
China 1332 
 
Neoadjuvant 
haemoglobin, 
albumin, 
No mention of 
adjuvant treatment 
N/A 581 N/A Multivariate: 
Training set: 
0.782 (0.617-0.993) 
Multivariate: 
Age, longitudinal 
location, tumour 
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Training 
set: 888 
 
Validatio
n set: 444 
lymphocyte and 
platelet (HALP) 
<56.8 vs. ≥56.8 
p=0.043 
 
Validation set: 
0.700 (0.496-0.987) 
p=0.042 
size, N stage, M 
stage 
26.  Okamura et al 
2015 (291) 
 
Retrospective Hepatocellu
lar 
Carcinoma 
Japan 256 Prognostic 
nutritional index 
<48.5 vs. ≥48.5 
No mention of 
adjuvant treatment 
N/A 86 N/A Multivariate: 
1.96 (1.21-3.18) 
p=0.006 
Multivariate: 
AFP, des-gamma-
carboxy 
prothrombin, high 
NLR 
27.  Xu et al 2015 
(127)  
 
Retrospective Oesophagea
l SCC 
China 468 CRP/Albumin 
Ratio >0.50 
196 patient received 
adjuvant chemo and 
radiotherapy  
N/A 259 N/A Multivariate: 
2.44 (1.82-3.26) 
p<0.0001 
Multivariate: 
Lymph Node 
Mets, 
Venous/lymphatic 
invasion, CRP/Alb 
Ration 
28.  Chuan Li et al 
2015 (125) 
 
Retrospective Hepatocellu
lar 
Carcinoma 
China 236 Postoperative 
NLR-PLR 
(0/1/2) 
 
NLR> 2.3 and 
PLR>116 score 
2, either 1 score 
1, none score 0 
Antiviral drug 
(entecavir or 
lamivudine) were 
given to patients 
with positive HBV-
DNA 
N/A 41 N/A Multivariate: 
2.894 (1.992-4.2) 
p<0.001 
Multivariate: 
Microvascular 
invasion, 
transfusion 
29.  Arigami et al 2015 
(142) 
 
Retrospective Oesophagea
l Squamous 
Cell 
Carcinoma 
Japan 238 F-NLR (0-1/2) Patients who have 
undergone 
neoadjuvant 
treatment were 
excluded 
N/A 100 N/A Multivariate: 
1.94 (1.04-3.53) 
p=0.037 
 
Multivariate: 
Depth of tumour 
invasion, lymph 
node metastasis 
30.  Ha et al 2016 
(129) 
 
Retrospective Ampulla of 
Vater 
Cancer 
South 
Korea 
227 Systemic 
inflammatory 
index (≤780 vs. 
>780) 
Adjuvant treatments 
including 
chemotherapy, 
radiotherapy and 
concurrent 
chemoradiotherapy 
N/A 105 N/A Multivariate: 
0.924 (0.44-1.93) 
p=0.833 
Multivariate: 
Vascular invasion, 
CA19-9. 
31.  Li et al 2016 (137) 
 
Retrospective Colorectal 
Cancer 
China 5336 Albumin/ 
globulin ratio 
(<1.50 vs. 
≥1.50) 
5-Fu based adjuvant 
chemotherapy for 
stage 2/3 patients 
588 611 N/A Multivariate: 
0.646 (0.543-0.767) 
p<0.001 
 
Multivariate:  
Age, T stage, N 
stage, 
differentiation, 
venous invasion, 
LMR, NLR 
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32.  Christina et al 
2016 (138) 
 
Retrospective Oral cancer Austria 144 CRP/ 
Neutrophils 
(low/high) 
All patients received 
neoadjuvant 
radiotherapy in 
combination with 
systemic cytotoxic 
therapy 
 
N/A 60 (5-year 
survival) 
N/A Multivariate: 
2.7 (0.68-10.75) 
p=0.16 
Multivariate: 
Regression grade 
33.  Wang et al 2016 
(139) 
 
Retrospective Ovarian 
Cancer 
China 143 Prognostic 
Inflammation 
Score (0/1/2) 
involving NLR 
and serum 
albumin 
No mention of 
adjuvant treatment 
N/A 51 N/A Multivariate:                  
PIS 1: 0.33 (0.16-0.67) 
p=0.002 
PIS 2: 0.18 (0.09-0.38) 
p<0.001 
Multivariate:   
Metastasis, 
prognostic 
inflammation 
score 
34.  Toyokawa et al 
2016 (140) 
 
Retrospective Thoracic 
Oesophagea
l Squamous 
Cell 
Carcinoma 
Japan 185 CONUT score 
(≥3, ≤2) 
involving serum 
albumin 
concentration, 
total 
lymphocyte 
count, total 
cholesterol 
concentration  
46 patients received 
neoadjuvant 
treatment (39 
chemotherapy, 6 
chemoradiotherapy, 
1 radiotherapy) 
N/A 77 
  
N/A 
 
Multivariate: 
2.303 (1.191-4.455) 
p=0.013 
Multivariate: 
Sex, performance 
status, ASA, 
cTNM stage 
35.  Fu et al 2016 
(293) 
 
Retrospective Hepatocellu
lar 
Carcinoma 
China Training: 
772 
 
Validatio
n: 349 
 
Inflammation-
based score 
(IBS) 
No mention of 
adjuvant treatment 
N/A 377 (4-year 
survival) 
N/A Multivariate:  
Training 4.247 (2.786-
6.473) p<0.001 
Multivariate:    
GGT, mGPS, 
tumour number, 
microscopic 
vascular invasion, 
BCLC. 
 
